---
document_datetime: 2024-01-04 14:32:28
document_pages: 155
document_pathfilename: www.ema.europa.eu/en/documents/assessment-report/agamree-epar-public-assessment-report_en.pdf
document_name: agamree-epar-public-assessment-report_en.pdf
version: success
processing_time: 75.5980672
conversion_datetime: 2025-12-24 04:12:36.954281
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
<!-- image -->

12 October 2023 EMA/CHMP/487504/2023 Committee for Medicinal Products for Human Use (CHMP)

## Assessment report

## Agamree

International non-proprietary name: Vamorolone

Procedure No. EMEA/H/C/005679/0000

## Note

Assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted.

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Table of contents

| 1. Background information on the procedure                                                                              | ..............................................7                                                           |
|-------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------|
| 1.1. Submission of the dossier....................................................................................      | 7                                                                                                         |
| 1.2. Legal basis, dossier content.................................................................................      | 7                                                                                                         |
| 1.3. Information on Paediatric requirements.................................................................            | 7                                                                                                         |
| 1.4. Information relating to orphan market exclusivity                                                                  | ................................................... 7                                                     |
| 1.4.1. Similarity                                                                                                       | ....................................................................................................... 7 |
| 1.5. Applicant's request(s) for consideration                                                                           | ................................................................. 8                                       |
| 1.5.1. New active Substance status.............................................................................         | 8                                                                                                         |
| 1.6. Scientific Advice................................................................................................. | 8                                                                                                         |
| 1.7. Steps taken for the assessment of the product                                                                      | ....................................................... 8                                                 |
| 2. Scientific discussion                                                                                                | ..............................................................................10                          |
| 2.1. Problem statement...........................................................................................       | 10                                                                                                        |
| 2.1.1. Disease or condition.......................................................................................      | 10                                                                                                        |
| 2.1.2. Epidemiology                                                                                                     | ................................................................................................ 10       |
| 2.1.3. Aetiology and pathogenesis.............................................................................          | 10                                                                                                        |
| 2.1.4. Clinical presentation, diagnosis........................................................................         | 10                                                                                                        |
| 2.1.5. Management.................................................................................................      | 11                                                                                                        |
| 2.2. About the product ............................................................................................     | 12                                                                                                        |
| 2.3. Type of application and aspects on development...................................................                  | 12                                                                                                        |
| 2.4. Quality aspects                                                                                                    | ................................................................................................ 13       |
| 2.4.1. Introduction                                                                                                     | ................................................................................................. 13      |
| 2.4.2. Active Substance...........................................................................................      | 13                                                                                                        |
| 2.4.3. Finished Medicinal Product ..............................................................................        | 15                                                                                                        |
| 2.4.4. Discussion on chemical, pharmaceutical and biological aspects.............................                       | 18                                                                                                        |
| 2.4.5. Conclusions on the chemical, pharmaceutical and biological aspects .....................                         | 18                                                                                                        |
| 2.4.6. Recommendation(s) for future quality development............................................                     | 19                                                                                                        |
| 2.5. Non-clinical aspects..........................................................................................     | 19                                                                                                        |
| 2.5.1. Introduction .................................................................................................   | 19                                                                                                        |
| 2.5.2. Pharmacology...............................................................................................      | 19                                                                                                        |
| 2.5.3. Pharmacokinetics                                                                                                 | .......................................................................................... 21             |
| 2.5.4. Toxicology....................................................................................................   | 23                                                                                                        |
| 2.5.5. Ecotoxicity/environmental risk assessment........................................................                | 28                                                                                                        |
| 2.5.6. Discussion on non-clinical aspects....................................................................           | 28                                                                                                        |
| 2.5.7. Conclusion on the non-clinical aspects..............................................................             | 36                                                                                                        |
| 2.6. Clinical aspects                                                                                                   | ................................................................................................ 37       |
| 2.6.1. Introduction .................................................................................................   | 37                                                                                                        |
| 2.6.2. Clinical pharmacology                                                                                            | .................................................................................... 40                   |
| 2.6.3. Discussion on clinical pharmacology .................................................................            | 47                                                                                                        |
| 2.6.4. Conclusions on clinical pharmacology ...............................................................             | 47                                                                                                        |
| 2.6.5. Clinical efficacy                                                                                                | ............................................................................................. 47          |
| 2.6.6. Discussion on clinical efficacy ..........................................................................       | 79                                                                                                        |
| 2.6.7. Conclusions on the clinical efficacy...................................................................          | 94                                                                                                        |

<div style=\"page-break-after: always\"></div>

2.6.8. Clinical safety ............................................................................................... 95

2.6.9. Discussion on clinical safety ...........................................................................  121

2.6.10. Conclusions on the clinical safety ..................................................................  131

2.7. Risk Management Plan  .....................................................................................  132

2.7.1. Safety concerns ...........................................................................................  132

2.7.2. Pharmacovigilance plan  .................................................................................  132

2.7.3. Risk minimisation measures  ...........................................................................  133

2.7.4. Conclusion  ...................................................................................................  134

2.8. Pharmacovigilance...........................................................................................  134

2.8.1. Pharmacovigilance system  .............................................................................  134

2.8.2. Periodic Safety Update Reports submission requirements ...................................  134

2.9. Product information  .........................................................................................  134

2.9.1. User consultation..........................................................................................  134

2.9.2. Additional monitoring  ....................................................................................  135

3. Benefit-Risk Balance............................................................................  135

3.1. Therapeutic Context ........................................................................................  135

3.1.1. Disease or condition......................................................................................  135

3.1.2. Available therapies and unmet medical need ....................................................  135

3.1.3. Main clinical studies  ......................................................................................  135

3.2. Favourable effects  ...........................................................................................  136

3.3. Uncertainties and limitations about favourable effects ..........................................  137

3.4. Unfavourable effects  ........................................................................................  138

3.5. Uncertainties and limitations about unfavourable effects .......................................  142

3.6. Effects Table ..................................................................................................  145

3.7. Benefit-risk assessment and discussion ..............................................................  149

3.7.1. Importance of favourable and unfavourable effects ...........................................  149

3.7.2. Balance of benefits and risks  ..........................................................................  152

3.7.3. Additional considerations on the benefit-risk balance .........................................  153

3.8. Conclusions  ....................................................................................................  154

4. Recommendations ...............................................................................  154

<div style=\"page-break-after: always\"></div>

## List of abbreviations

| 6MWT       | 6-Minute Walk Test                                                                      |
|------------|-----------------------------------------------------------------------------------------|
| (11β -)HSD | (11β -)hydroxysteroid dehydrogenase                                                     |
| ACTH       | Adrenocorticotropic hormone                                                             |
| ADR        | Adverse drug reaction                                                                   |
| AE         | Adverse event                                                                           |
| AESI       | Adverse event of special interest                                                       |
| ALT        | Alanine aminotransferase                                                                |
| AST        | Aspartate aminotransferase                                                              |
| ALP        | Alkaline phosphatase                                                                    |
| AUC 0-24h  | Area under the drug concentration versus time curve from 0 to 24 hours                  |
| AUC 0-last | Area under the drug concentration to the last measurable concentration                  |
| AUC 0-inf  | Area under the plasma concentration time curve from time 0 to infinity                  |
| BCRP       | Breast cancer resistance protein                                                        |
| BMC        | Bone mineral content                                                                    |
| BMD        | Bone mineral density                                                                    |
| BMI        | Body mass index                                                                         |
| (D)(S)BP   | (Systolic) (Diastolic) blood pressure                                                   |
| BSEP       | Bile salt export pump                                                                   |
| CI         | Confidence interval                                                                     |
| CINRG-DNHS | Cooperative International Neuromuscular Research Group - Duchenne Natural History Study |
| C max      | Maximum drug concentration                                                              |
| CMQ        | Customised MedDRA query                                                                 |
| CL/F       | Oral clearance                                                                          |
| CUP        | Compassionate use programme                                                             |
| CYP        | Cytochrome P450                                                                         |
| DDI        | Drug drug interaction                                                                   |
| DMD        | Duchenne muscular dystrophy                                                             |
| DRF        | Dose range finding                                                                      |
| DSC        | Differential scanning calorimetry                                                       |
| DXA        | Dual-energy X-ray absorptiometry                                                        |
| EAE        | Experimental autoimmune encephalitis                                                    |
| EAIR       | Exposure adjusted incidence rate                                                        |
| EAP        | Expanded access programme                                                               |
| ECG        | Electrocardiogram                                                                       |
| E 50       | AUC value of vamorolone achieving 50% maximal effect                                    |
| E max      | Maximum effect                                                                          |
| ERA        | Environmental risk assessment                                                           |
| E-R        | Exposure-response                                                                       |
| FDA        | Food and Drug Administration                                                            |
| FAS        | Full analysis set                                                                       |
| FOR-DMD    | Finding the optimum regimen for DMD                                                     |
| FT-IR      | Fourrier transform infrared spectroscopy                                                |
| FVC        | Forced vital capacity                                                                   |
| GC         | Glucocorticoid                                                                          |

<div style=\"page-break-after: always\"></div>

| GLDH            | Glutamate dehydrogenase                                                                                               |
|-----------------|-----------------------------------------------------------------------------------------------------------------------|
| GI              | Gastrointestinal                                                                                                      |
| GMSS            | Bayley-III Gross Motor scale                                                                                          |
| (m)GR           | (membrane) Glucocorticoid receptor                                                                                    |
| GRE             | Glucocorticoid response element                                                                                       |
| HbA1c           | Hemoglobin A1c                                                                                                        |
| HDL cholesterol | High-density lipoprotein cholesterol                                                                                  |
| HI              | Hepatic impairment                                                                                                    |
| hERG            | Human ether-a-go-go -related gene                                                                                     |
| HPA             | Hypothalamic-pituitary-adrenal                                                                                        |
| HP- β CD        | Hydroxypropyl- β cyclodextrin                                                                                         |
| HPLC            | High performance liquid chromatography                                                                                |
| IC 50           | Half maximal inhibitory concentration                                                                                 |
| ICH             | International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use |
| ICP-MS          | Inductively coupled plasma mass spectrometry                                                                          |
| IR              | Infrared                                                                                                              |
| LDL cholesterol | Low-density lipoprotein cholesterol                                                                                   |
| LS-BMC          | Lumbar spine bone mineral content                                                                                     |
| LS-BMD          | Lumbar spine bone mineral density                                                                                     |
| LSM             | Least squares mean                                                                                                    |
| LTE             | Long-term extension                                                                                                   |
| MAD             | Multiple ascending dose                                                                                               |
| MATE            | Multidrug and toxin extrusion protein                                                                                 |
| MCIDs           | Minimally clinically important differences                                                                            |
| MEC             | Molar extinction coefficient                                                                                          |
| MedDRA          | Medical Dictionary for Regulatory Activities                                                                          |
| (m)ITT          | Modified intent-to-treat                                                                                              |
| MMRM            | Mixed model for repeated measures                                                                                     |
| MNAR            | Missing not at random                                                                                                 |
| MR              | Mineralocorticoid receptor                                                                                            |
| MRHD            | Maximum recommended human dose                                                                                        |
| MS              | Mass spectrometry                                                                                                     |
| NF- κB          | Nuclear factor kappa-light-chain-enhancer of activated B cells                                                        |
| NMR             | Nuclear magnetic resonance                                                                                            |
| NOAEL           | No-observed-adverse-effect level                                                                                      |
| NSAA            | North star ambulatory assessment                                                                                      |
| OAT             | Organic anion transporter                                                                                             |
| OATP            | Organic anion transporting polypeptide                                                                                |
| OCT             | Organic cation transporter                                                                                            |
| OOS             | Out of specification                                                                                                  |
| P1NP            | Procollagen 1 N-terminal propeptide                                                                                   |
| PBO             | Placebo                                                                                                               |
| PD              | Pharmacodynamic                                                                                                       |
| PDA             | Photo diode array                                                                                                     |
| PDN             | Prednisone                                                                                                            |
| P-gp            | P-glycoprotein                                                                                                        |
| Ph. Eur.        | European Pharmacopoeia                                                                                                |

<div style=\"page-break-after: always\"></div>

| PK         | Pharmacokinetic                                |
|------------|------------------------------------------------|
| PND        | Post-natal day                                 |
| PP         | Percentage point; Per protocol                 |
| PODCI      | Paediatric outcomes data collection instrument |
| PopK       | Population pharmacokinetic(s)                  |
| PRED       | Prednisone                                     |
| PT         | Preferred term                                 |
| QBD        | Quality by design                              |
| QD         | Once daily                                     |
| QMT        | Quantitative muscle testing                    |
| QTc        | QT interval corrected for heart rate           |
| QWBA       | Quantitative whole-body autoradiography        |
| RANKL      | Receptor activator of nuclear kappa-B ligand   |
| RBC        | Red blood cell                                 |
| REML       | Restricted maximum likelihood                  |
| RH         | Relative humidity                              |
| RMM(s)     | Risk minimisation measure(s)                   |
| RMP        | Risk management plan                           |
| ROS        | Route of synthesis                             |
| ROS1       | Clinical Formulation                           |
| ROS2/      | to be marketed formulation                     |
| SAD        | Single aAscending dose                         |
| SAE        | Serious adverse event                          |
| SCS        | Summary of clinical safety                     |
| (s-)CTX    | (Serum) Type 1 collagen C-telopeptides         |
| SD(s)      | Standard deviation (scores)                    |
| SE         | Standard error                                 |
| Sgk1       | Serum/glucocorticoid regulated kinase 1        |
| SmPC       | Summary of product characteristics             |
| SOC        | System organ class                             |
| TDAR       | T cell dependent antibody response             |
| TEAE       | Treatment emergent adverse event               |
| TGA        | Thermo-fravimetric analysis                    |
| t max      | Time to maximum drug concentration             |
| t 1/2      | half-life                                      |
| TSH        | Thyroid-stimulating hormone                    |
| TTCLIMB(V) | Time to climb 4 steps test (velocity)          |
| TTRW(V)    | Time to run/walk 10 metres test (velocity)     |
| TTSTAND(V) | Time to stand (velocity)                       |
| UGT        | Uridine 5′ -diphospho-glucuronosyltransferase  |
| ULN        | Upper limit of normal                          |
| UV         | Ultraviolet                                    |
| VAM        | Vamorolone                                     |
| V/F        | Oral volume of distribution                    |

<div style=\"page-break-after: always\"></div>

## 1. Background information on the procedure

## 1.1. Submission of the dossier

The  applicant  Santhera  Pharmaceuticals  (Deutschland)  GmbH  submitted  on  29  September  2022  an application for marketing authorisation to the European Medicines Agency (EMA) for Agamree, through the centralised procedure falling within the Article 3(1) and point 4 of Annex of Regulation (EC) No 726/2004. The eligibility to the centralised procedure was agreed upon by the EMA/CHMP on 25 June 2020.

Vamorolone was designated as an orphan medicinal product EU/3/14/1309 on 22 August 2014 in the following condition: Treatment of Duchenne muscular dystrophy.

Following the CHMP positive opinion on this marketing authorisation, the Committee for Orphan Medicinal Products (COMP) reviewed the designation of Agamree as an orphan medicinal product in the approved indication. More information on the COMP's review can be found in the orphan maintenance assessment report published under the 'Assessment history' tab on the Agency's website:

https://www.ema.europa.eu/en/medicines/human/EPAR/Agamree

The applicant applied for the following indication: Treatment of Duchenne muscular dystrophy (DMD) in patients aged 2 years and older.

## 1.2. Legal basis, dossier content

## The legal basis for this application refers to:

Article 8.3 of Directive 2001/83/EC - complete and independent application

The application submitted is composed of administrative information, complete quality data, non-clinical and clinical data based on applicants' own  tests and studies and/or bibliographic literature substituting/supporting certain test(s) or study(ies).

## 1.3. Information on Paediatric requirements

Pursuant to Article 7 of Regulation (EC) No 1901/2006, the application included an EMA Decision(s) P/0295/2022 on the agreement of a paediatric investigation plan (PIP).

At the time of submission of the application, the PIP P/0295/2022 was not yet completed as some measures were deferred.

## 1.4. Information relating to orphan market exclusivity

## 1.4.1. Similarity

Pursuant to Article 8 of Regulation (EC) No. 141/2000 and Article 3 of Commission Regulation (EC) No 847/2000, the applicant did submit a critical report addressing the possible similarity with authorised orphan medicinal products.

<div style=\"page-break-after: always\"></div>

## 1.5. Applicant's request(s) for consideration

## 1.5.1. New active Substance status

The applicant requested the active substance vamorolone contained in the above medicinal product to be considered as a new active substance, as the applicant claims that it is not a constituent of a medicinal product previously authorised within the European Union.

## 1.6. Scientific Advice

The applicant received the following scientific advice on the development relevant for the indication subject to the present application:

| Date             | Reference                 | SAWP co-ordinators                            |
|------------------|---------------------------|-----------------------------------------------|
| 22 January 2015  | EMA/CHMP/SAWP/47013/2015  | André Elferink, Mario Miguel Rosa             |
| 17 December 2015 | EMA/CHMP/SAWP/819793/2015 | Susan Morgan, André Elferink                  |
| 17 October 2019  | EMA/CHMP/SAWP/545127/2019 | Karl-Heinz Huemer, Fernando de Andrés Trelles |
| 29 January 2021  | EMA/SA/0000047033         | André Elferink, Stephan Lehr                  |

The scientific advice and protocol assistance pertained to the following quality, non-clinical, and clinical aspects:

- The quality characteristics of drug product and the choice of formulation; the proposed changes in formulation and use of the new formulation for the Phase 2a extension study and Phase 2b study; the justification for not conducting a BE study between the formulation #1 and formulation #2; the proposed justification for new active substance.
- The approach for reproductive, juvenile and chronic toxicology studies; the availability of chronic toxicology data prior to the initiation of the Phase 2a study; the approach for conducting MIST studies; adequacy of non-clinical package for MAA; the approach to perform the carcinogenicity studies post approval.
- Adequacy of the clinical pharmacology studies for MAA.
- The proposed doses, treatment times and extension study for the Phase 2a clinical study; the Phase 2a clinical study design regarding the proposed extension study clinical outcomes and pharmacodynamics biomarker outcomes for dose selection in the Phase 2b study.
- The design of the phase 2b clinical study and in particular the proposed doses, choice of age at treatment, primary clinical outcome measure, time of treatment, sample size; whether the proposed endpoint would be supportive for conditional approval; the proposed efficacy analysis and safety data package for conditional approval; the approach to convert conditional approval to full approval; the analysis approach for the confirmatory study VBP15-004 including estimand, primary, secondary and sensitivity analyses, additional efficacy data from concurrent external controls, and overall safety data including data from concurrent external controls.

## 1.7. Steps taken for the assessment of the product

The Rapporteur and Co-Rapporteur appointed by the CHMP were:

<div style=\"page-break-after: always\"></div>

| The application was received by the EMA on                                                                                                                                              | 29 September 2022   |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------|
| The procedure started on                                                                                                                                                                | 27 October 2022     |
| The CHMP Rapporteur's first Assessment Report was circulated to all CHMP and PRAC members on                                                                                            | 16 January 2023     |
| The CHMP Co-Rapporteur's first Assessment Report was circulated to all CHMP and PRAC members on                                                                                         | 01 February 2023    |
| The PRAC Rapporteur's first Assessment Report was circulated to all PRAC and CHMP members on                                                                                            | 31 January 2023     |
| The CHMP agreed on the consolidated List of Questions to be sent to the applicant during the meeting on                                                                                 | 23 February 2023    |
| The applicant submitted the responses to the CHMP consolidated List of Questions on                                                                                                     | 15 May 2023         |
| The CHMP Rapporteurs circulated the CHMP and PRAC Rapporteurs Joint Assessment Report on the responses to the List of Questions to all CHMP and PRAC members on                         | 26 June 2023        |
| The PRAC agreed on the PRAC Assessment Overview and Advice to CHMP during the meeting on                                                                                                | 06 July 2023        |
| The CHMP agreed on a list of outstanding issues in writing and/or in an oral explanation to be sent to the applicant on                                                                 | 20 July 2023        |
| The applicant submitted the responses to the CHMP List of Outstanding Issues on                                                                                                         | 11 September 2023   |
| The CHMP Rapporteurs circulated the CHMP and PRAC Rapporteurs Joint Assessment Report on the responses to the List of Outstanding Issues to all CHMP and PRAC members on                | 27 September 2023   |
| The CHMP, in the light of the overall data submitted and the scientific discussion within the Committee, issued a positive opinion for granting a marketing authorisation to Agamree on | 12 October 2023     |
| The CHMP adopted a report on similarity of Agamree with TRANSLARNA on (see Appendix on similarity)                                                                                      | 12 October 2023     |
| Furthermore, the CHMP adopted a report on New Active Substance (NAS) status of the active substance contained in the medicinal product (see Appendix on NAS)                            | 12 October 2023     |

<div style=\"page-break-after: always\"></div>

## 2. Scientific discussion

## 2.1. Problem statement

## 2.1.1. Disease or condition

In reference to the marketing authorisation application, vamorolone is intended for the treatment of Duchenne muscular dystrophy (DMD) in patients aged 4 years and older.

## 2.1.2. Epidemiology

DMD is a severe, progressive paediatric neuromuscular disorder that is ultimately lethal. It occurs almost exclusively in males (X-linked recessive disorder) with an estimated male birth prevalence of 1/3,5001/9,300. The estimated prevalence in the EU is approximately 15,000 cases.

## 2.1.3. Aetiology and pathogenesis

DMD is caused by several types of mutations in the gene for dystrophin located on chromosome Xp21. Most mutations are deletions, duplications and point mutations, which produce a shift in the open reading frame of the dystrophin mRNA leading to the absence of functional dystrophin protein.

Dystrophin  is  a  cytoplasmic  protein,  which  associates  with  other  proteins  to  form  the  dystrophinassociated protein complex that connects the actin cytoskeleton with the extracellular matrix. Functional dystrophin is critical for the structural stability of myofibers in skeletal, diaphragm and cardiac muscle and is also of importance for smooth muscles. In DMD, both dystrophin and the dystrophin-associated protein  complex  proteins  are  missing,  leading  to  excessive  membrane  fragility  and  permeability, dysregulation of calcium homeostasis, oxidative damage. These factors play a crucial role in muscle cell necrosis. During the progression of the disease, the regenerative capacity of the muscles appears to be exhausted, and connective and adipose tissue gradually replaces muscle fibers.

## 2.1.4. Clinical presentation, diagnosis

The  onset  of  DMD  occurs  in  early  childhood  and  initial  findings  may  include  delays  in  reaching developmental milestones  such  as  sitting  or  standing  without  assistance,  toe  walking,  unusual  gait, difficulty climbing stairs or rising from a sitting position (Gower's sign) and repeated falling leading to an increased incidence of fractures in ambulatory subjects. Weakness is more pronounced in proximal than distal muscles and the lower limb more than the upper limb. Affected boys may show a delay in walking (after  18  months  of  age)  accompanied  with  speech  and/or  global  developmental  delay.  Autism  and behavioural problems, such as attention deficit hyperactivity disorder, anxiety, obsessive-compulsive disorder, are relatively common. Untreated children with DMD rarely achieve the ability to run or jump. Loss of independent ambulation occurs between the ages of 6 and 13 years, the average being 9.5 years in non-steroid treated patients. Once ambulation is lost, joint contractures and scoliosis develop rapidly, which leads to an impaired pulmonary function. There is gradual loss of upper limb, trunk, and neck function, severely affecting patient quality of life, as well as that of caregivers and families (Bendixen 2012; Magliano 2014; Uzark 2012). Complications from this loss of ambulation have a major cascading effect, including scoliosis.

<div style=\"page-break-after: always\"></div>

Children with DMD have reduced bone density and an increased risk of developing fractures of certain bones, such as hips and spine. Many affected individuals will display mild to moderate degrees of nonprogressive intellectual impairment and learning disabilities.

Symptoms of cardiomyopathy (persistent tachycardia and heart failure) can develop in early teens and are  present  in  almost  all  patients  in  their  twenties.  In  affected  patients,  dilated  cardiomyopathy  is characterised  by  extensive  fibrosis  of  the  posterobasal  left  the  ventricular  wall.  As  the  disease progresses, fibrosis can spread to the lateral free wall of the left ventricle. With the involvement of the posterior papillary muscle, significant mitral regurgitation can occur. Inter- and intraatrial conduction abnormalities, possibly involving the AV node, can be seen. Arrhythmias, particularly supraventricular arrhythmias, are also associated with the developing cardiomyopathy (Venugopal, 2022).

Another serious complication associated with DMD is weakness and deterioration of muscles in the rib cage. This can result in an increased susceptibility to respiratory infections (e.g., pneumonia), difficulty coughing, and, ultimately, respiratory failure.

Without physical therapy treatment, leg braces may be needed by the age 8-9 to assist walking in affected individuals. Most affected individuals require a wheelchair between 10 and 12 years of age. Untreated patients die during late teens to early twenties from respiratory failure and or cardiomyopathy.

Achieving a timely and accurate diagnosis of DMD is a crucial aspect of care. Most recent data indicate the mean [median] ages in years of diagnostic milestones as follows: first signs, 2.7 [2.0]; first creatine kinase (CK), 4.6 [4.6]; DNA/muscle biopsy testing, 4.9 [4.8]; and time from first signs to diagnostic confirmation, 2.2 [1.4] (Thomas et al. 2022). The method for diagnosing DMD has not changed during the last decade. The diagnostic process typically begins in early childhood after suggestive signs and symptoms. Diagnosis is  suspected on the basis of the clinical  picture,  family  history  and  laboratory findings (serum creatine kinase (CK) is 100-200 times the normal level). Genetic testing is the gold standard and involves multiplex-ligation dependent probe amplification (MLPA) for detection of deletions and duplications of exon (s) and full gene sequencing for detecting small deletions and duplications and non-sense or point mutations. Given the value of information provided by genetic analysis muscle biopsy is now recommended when genetic analysis in inconclusive. Genetic testing is therefore a critical tool in the accurate diagnosis of DMD.

## 2.1.5. Management

No medical cure exists for DMD, and the disease has a poor prognosis. The main aim of DMD treatment is the modification of the natural course of the disease or prolonging survival. Treatment is centred on glucocorticoid therapy, prevention of contractures, and medical care of cardiomyopathy and respiratory compromise (Shimizu-Motohashi 2019; McMillan 2019). Glucocorticoids should be continued after loss of ambulation according to current guideline recommendations (Birkrant et al. 2018) and have been shown to improve strength and motor function, delay loss of ambulation by 2 to 3 years, preserve upper limb and respiratory function, avoid scoliosis surgery, and delay the onset of cardiomyopathy.

Recent studies confirm the benefits of starting glucocorticoids in younger children, before significant physical decline (Merlini 2012; Lamb 2016). Complications of corticosteroid therapy must be managed and  include:  weight  management,  gastric  protection,  monitoring  and  treatment  of  osteoporosis, ophthalmic assessment for cataracts and glaucoma. The two common corticosteroid drugs used to treat individuals  with  DMD  are  prednisone  and  deflazacort.  Prednisone  is  recommended  at  a  dosage  of 0.75 mg/kg per day, and deflazacort at 0.9 mg/kg/day.

Deflazacort was approved by the FDA in 2017 for the treatment of DMD in patients aged 5 years and older. In 2019, the indication was extended to include patients 2 years of age and older. Prednisone is

<div style=\"page-break-after: always\"></div>

available and widely used in the US and in the European Union but is not specifically indicated for DMD. Thus, neither prednisone nor deflazacort are approved for the treatment of DMD in Europe.

For a subpopulation of DMD patients, in which mutation created a nonsense stop codon in the dystrophin mRNA resulting in premature termination of translation and, hence, a truncated, non-functional protein, ataluren  (Translarna)  was  granted  a  conditional  marketing  authorisation  in  the  EU  on  31  July  2014 (EMEA/H/C/2720) for the treatment of patients aged 5 years and above, which has been extended to ambulatory patients aged 2 years and older.

Thus, there is an unmet medical need for mutation-independent treatments similar to glucocorticoids with an acceptable benefit-risk profile.

## 2.2. About the product

Vamorolone is a synthetic corticosteroid analogue that structurally diverges from other members of the class of glucocorticoid agents. Vamorolone contains a double bond between carbon atoms 9 and 11 of the steroid C ring. It also lacks the hydroxyl group at carbon 11, which prevents the respective formation of hydrogen bonds at the glucocorticoid receptor (GR) and mineralocorticoid receptor (MR). Compared to other glucocorticoid drugs, this different binding of vamorolone is thought to 1) retain the established transcriptional repression at the GR with concomitantly reduced gene trans-activating characteristics and 2) entail  MR  antagonism  contrary  to  the  MR  agonistic  action  of  other  corticosteroids.  In  addition, vamorolone- is supposed to have membrane stabilizing properties and does not serve as a substrate for 11β -hydroxysteroid dehydrogenase 1 and 2 (11β -HSD 1 and 2), whose enzymatic activities have been linked  to  the  adverse  effects  of  standard  glucocorticoid  therapy  (muscle  atrophy,  bone  loss,  insulin resistance, hypertension and weight gain).

The indication for vamorolone as initially proposed by the applicant was:

' Treatment of Duchenne muscular dystrophy (DMD) in patients aged 2 years and older .'

The indication for vamorolone as finally approved by the CHMP is:

' Treatment of Duchenne muscular dystrophy (DMD) in patients aged 4 years and older .'

The recommended dose of vamorolone in patients 4 years and older is 6 mg/kg once daily in patients weighing less than 40 kg.

In patients weighing 40 kg and above, the recommended dose of vamorolone is 240 mg once daily.

The daily dose may be down-titrated to 4 mg/kg/day or 2mg/kg/day based on individual tolerability. Patients should be maintained at the highest tolerated dose within the dose range.

## 2.3. Type of application and aspects on development

The  vamorolone  clinical  development  programme  for  DMD  includes  10  clinical  studies:  6  clinical pharmacology studies in healthy subjects and subjects with hepatic impairment (HI), and 4 studies in boys with DMD (a pivotal phase 2b study VBP15-004, a phase 2a open-label study VBP-002, a phase 2 open-label study VBP15-003, and a phase 2 open-label study VBP-LTE).

The quality, pre-clinical and clinical development of vamorolone were discussed within several centralised scientific advice (see above).

<div style=\"page-break-after: always\"></div>

## 2.4. Quality aspects

## 2.4.1. Introduction

The  finished  product  is  presented  as  oral  suspension  containing  40  mg/ml  of  vamorolone  as  active substance.

Other ingredients are: citric acid (monohydrate) (E 330), disodium phosphate (E 339), glycerol (E 422), orange flavour,  purified  water,  sodium  benzoate  (E  211),  sucralose  (E  955),  xanthan  gum  (E  415), hydrochloric acid (for pH adjustment).

The product is available in an amber glass bottle containing 100 ml of the suspension as described in section 6.5 of the SmPC. Two 8 ml oral dosage syringes graduated in 0.1 ml increments and a press-in bottle adapter are included.

## 2.4.2. Active Substance

## 2.4.2.1. General information

The chemical name of vamorolone is (8S,10S,13S,14S,16R,17R)-17-hydroxy-17-(2-hydroxyacetyl)10,13,16-trimethyl-7,8,12,14,15,16-hexahydro-6H-cyclopenta[a]phenanthren-3-one corresponding to the molecular formula C22H28O4. It has a relative molecular mass of 356.46 g/mol and the following structure:

Figure 1: Active substance structure

<!-- image -->

The chemical structure of vamorolone was elucidated by a combination of elemental analysis, UV, FT-IR, 1H-NMR, 13C-NMR, and MS. The solid state properties of the active substance were measured by XRPD, DSC and TGA.

The active substance is a slightly hygroscopic micronised powder, it has poor aqueous solubility across the physiological pH range.

Vamorolone exhibits stereoisomerism due to the presence of six chiral centres. These centres originate in  the  starting  material  and  are  controlled  in  the  specifications  of  the  starting  material  and  active substance by specific optical rotation.

Only one stable polymorph of vamorolone has been observed. The manufacturing process has been demonstrated to produce the stable polymorphic form. Testing via XRPD during stability studies has shown that micronisation and storage do not impact the polymorphic form. Therefore, the polymorphic form is not tested routinely at release.

<div style=\"page-break-after: always\"></div>

## 2.4.2.2. Manufacture, characterisation and process controls

Detailed information on the manufacturing of the active substance has been provided and was considered satisfactory. Vamorolone is synthesised in seven main steps using well defined starting materials with acceptable specifications.

During the procedure, an MO was raised on the absence of sufficient information on the control strategy and impurity profile of a proposed starting material. This was resolved by the provision of sufficient information on the impurity profile and the justification provided for the associated control strategy in the response. The starting material was therefore considered acceptable.

Reprocessing  procedures  have  been  described  for  certain  steps  to  be  performed  in  case  of  out  of specification results. The manufacturing steps will be repeated and no other solvents or raw materials are used.

Critical  process  parameters  of  the  manufacturing  process  of  vamorolone  have  been  identified  and controls established. Adequate in-process controls are applied during the synthesis. The specifications and control methods for intermediate products, starting materials and reagents have been presented.

The characterisation of the active substance and its impurities are in accordance with the EU guideline on chemistry of new active substances.

Potential  and  actual  impurities  were  well  discussed  with  regards  to  their  origin  and  characterised, including potential mutagenic impurities.

The commercial manufacturing process for the active substance was developed in parallel with the clinical development programme. Changes introduced have been presented in sufficient detail and have been justified. An initial route of synthesis (ROS1) was developed for vamorolone active substance and was used during development for the finished product. It differs from the proposed commercial route of synthesis (ROS2) used. Batches of vamorolone active substance manufactured with the ROS1 synthetic route were used for clinical studies. A commercially suitable route of synthesis ROS2 has been developed. Active substance manufactured by ROS2 was evaluated in the PK study (VBP15-PK-FORM) comparing the proposed to be marketed formulation to the earlier clinical formulations using ROS1.

The active substance is micronised. The particle size of the active substance impacts both the in-vitro dissolution and the in-vivo pharmacokinetics as outlined in study VBP15-PK-FORM. Further information on the pharmacokinetic studies conducted can be found in the clinical section of the report.

The active substance is packaged in bags which comply with EC 10/2011 as amended, and Ph. Eur. requirements. The bags are placed into drums.

## 2.4.2.3. Specification

The active substance specification includes tests for: appearance, identity (IR), assay (HPLC), related substances  (HPLC),  residual  solvents  (Gas  Chromatography),  water  content  (Ph.  Eur.),  residue  on ignition (Ph. Eur.), particle size distribution (laser light diffraction), specific optical rotation (Ph. Eur.) and microbiological quality (Ph. Eur.)

Impurities present at higher than the qualification threshold according to ICH Q3A (0.15%) were qualified by toxicological and clinical studies, and appropriate specifications have been set. The limits for unqualified impurities are set in accordance with ICH Q3A requirements.

The analytical methods used have been adequately described and non-compendial methods appropriately validated in accordance with the ICH guidelines. Satisfactory information regarding the reference standards used for assay and impurities testing has been presented.

<div style=\"page-break-after: always\"></div>

The particle size limits for the micronised active substance are set in line with those used in the finished product batches investigated in the PK studies.

Batch analysis data (13 batches, 10 at commercial scale) of the active substance are provided. The analysis includes both micronised and non-micronised active substance produced using the commercial route of synthesis (ROS2). The results are within the specifications and consistent from batch to batch.

## 2.4.2.4. Stability

Stability data from three batches of micronised active substance, one at commercial scale and two at pilot scale from the proposed manufacturer stored in a container closure system representative of that intended for the market for up to 24 months (one batch) and 12 months (two batches) under long term conditions (25ºC / 60% RH) and for up to 6 months under accelerated conditions (40ºC / 75% RH) according to the ICH guidelines were provided. In addition to this, supportive stability results of four commercial  batches  of  non-micronised  active  substance  were  provided  for  24  months  at  the  same conditions. Photostability testing following the ICH Q1B guideline was performed on one batch. Results on stress conditions in both the solid and liquid phase were also provide on one batch. Stress testing conditions included heat, humidity, acidic, neutral, alkaline, light, and oxidation.

The following parameters were tested : appearance, assay (HPLC), related substances (HPLC), specific optical rotation (Ph. Eur.), water content (KF), polymorphic form (XRPD), particle size distribution (laser light  diffraction)  and  microbiological  quality  (Ph.  Eur.). The  analytical  methods  used  were  stability indicating.

At long term and accelerated storage conditions no significant changes are seen in any of the parameters investigated, all results remain within specification.

The  stability  results  indicate  that  the  active  substance  manufactured  by  the  proposed  supplier  is sufficiently stable. The stability results justify the proposed retest period of 24 months in the proposed container. The stability results do not indicate a need for a temperature storage condition, however the applicant's self-imposed storage condition is acceptable. The proposed storage conditions of an active substance do not impact the patient or healthcare professionals.

With respect to ongoing stability studies any confirmed out-of-specification result, or significant negative trend, should be reported to the Rapporteur and EMA.

## 2.4.3. Finished Medicinal Product

## 2.4.3.1. Description of the product and pharmaceutical development

Vamorolone  oral  suspension  is  a  40  mg/mL  (4.0%  w/v)  orange  flavoured  suspension  for  oral administration.

All  excipients are well known pharmaceutical ingredients and their quality is compliant with Ph. Eur. standards,  with  the  exception  of  the  in-house  orange  flavouring.  The  composition  of  the  in-house flavouring  was  suitably  described.  Excipients  were  appropriately  justified  in  line  with  the  proposed paediatric patient population. The levels of the preservative selected were suitably justified, the applicant demonstrated that the lowest effective levels for antimicrobial preservation were selected. The list of excipients is included in section 6.1 of the SmPC.

<div style=\"page-break-after: always\"></div>

The product was formulated as a multi-dose oral suspension containing 40 mg/mL of vamorolone. The formulation was developed and altered throughout the clinical phases, and an optimised to be marketed formulation was selected based on improved stability, manufacturability, and palatability.

The different clinical formulations demonstrated similar in vitro -dissolution profiles. Vamorolone is a BCS Class II compound displaying poor aqueous solubility across the physiological pH range. Only one stable polymorph is known and the active substance manufacturer has been shown to reproducibly manufacture this form. The particle size of the active substance is important to finished product performance (i.e. bioavailability), and micronisation of the active substance also improves physical stability of the product and palatability. The commercial formulation was compared to the earlier clinical formulations in PK studies.  Overall  the  to-be-marketed  formulation  was  considered  acceptable,  for  further  information please refer to the clinical section.

It is foreseen that administration via enteral feeding tubes may be relevant for some patients receiving this product. In the course of the assessment the applicant was requested to provide information on the administration via enteral feeding tubes. The applicant indicated that further investigations were required in  order to provide this information which would take additional time. A recommendation for further quality  development is  therefore  raised,  requesting  that  these  investigations  are  performed  and  the outcome of this recorded in the product information (REC1).

A  dissolution  method  was  developed,  the  selected  method  was  demonstrated  to  be  suitably discriminating  with  respect  to  particle  size  of  the  active  substance.  Viscosity  was  also  identified  as important to ensure dosage uniformity.

The manufacturing process has been developed using elements of QbD such as risk assessment, and potential critical material attributes and critical process parameters were identified.

The primary packaging is an amber glass bottle. The material complies with Ph. Eur. requirements. The choice of the container closure system has been validated by stability data and is adequate for the intended use of the product. Evidence of relevant CE marks were provided for the oral dosing devices.

## 2.4.3.2. Manufacture of the product and process controls

The  finished  product  is  manufactured  at  one  manufacturing  site.  The  process  is  considered  to  be  a standard manufacturing process.

The manufacturing process and dosage form are considered standard. The applicant has committed to perform process validation on the first three full-scale batches. An acceptable process validation protocol was  provided.  The  in-process  controls  are  adequate  for  this  type  of  manufacturing  process  and pharmaceutical form.

## 2.4.3.3. Product specification

The finished product specifications include appropriate tests for this kind of dosage form; appearance (visual &amp; odour), viscosity (Ph. Eur.), re-dispersibility (in-house), pH (Ph. Eur.), identification of active substance (HPLC, PDA), identification of preservative (HPLC), assay of active substance (HPLC), assay of preservative (HPLC), related substance (HPLC), particle size (laser light diffraction), dissolution (USP paddle / HPLC), deliverable volume (USP), uniformity of dosage units (Ph. Eur.) and microbiological quality (Ph. Eur.).

The limits for impurities have been set in line with the relevant ICH guidance, the specification limit for an impurity exceeds the ICH qualification threshold. Sufficient data has been provided to qualify and justify the impurity at the level proposed.

<div style=\"page-break-after: always\"></div>

During the procedure, the applicant tightened the dissolution limit and the proposed limit is considered acceptable. It was noted that it may be possible for the limit for dissolution to be set tighter in line with the clinical batch performance. Considering this a recommendation for further quality development to re-evaluate the dissolution limits was noted (REC2).

The potential presence of elemental impurities in the finished product has been assessed following a riskbased approach in line with the ICH Q3D Guideline for Elemental Impurities. Batch analysis data on three  batches  using  a  ICP-MS  method  was  provided,  demonstrating  that  each  relevant  elemental impurity was not detected above 30% of the respective PDE. Based on the risk assessment and the presented batch data it can be concluded that it is not necessary to include any elemental impurity controls. The information on the control of elemental impurities is satisfactory.

A risk assessment concerning the potential presence of nitrosamine impurities in the finished product has been performed considering all suspected and actual root causes in line with the 'Questions and answers  for  marketing  authorisation  holders/applicants  on  the  CHMP  Opinion  for  the  Article  5(3)  of Regulation  (EC)  No  726/2004  referral  on  nitrosamine  impurities  in  human  medicinal  products' (EMA/409815/2020) and the 'Assessment report- Procedure under Article 5(3) of Regulation EC (No) 726/2004- Nitrosamine  impurities  in  human  medicinal  products'  (EMA/369136/2020).  Based  on  the information provided, it is accepted that there is no risk of nitrosamine impurities in the active substance or the finished product. Therefore, no specific control measures for nitrosamine impurities are deemed necessary.

The analytical methods used have been adequately described and appropriately validated in accordance with the ICH guidelines. Satisfactory information regarding the reference standards used for assay and impurities testing has been presented.

Batch analysis results are provided for three commercial sized batches confirming the consistency of the manufacturing process and its ability to manufacture to the intended product specification.

## 2.4.3.4. Stability of the product

Stability data from three commercial scale batches of finished product stored for up to 24 months under long term conditions (25ºC / 60% RH) and for up to 6 months under accelerated conditions (40ºC / 75% RH) according to the ICH guidelines were provided. The batches are identical to those proposed for marketing and were packed in the primary packaging proposed for marketing. In addition to this, data from supportive stability studies on earlier formulations was provided. The applicant initially had not submitted sufficient data to support their request for a 24-month shelf life, as the available time-points were not sufficient to enable an extrapolation of the magnitude requested. A major objection was raised regarding this point, and in response the applicant submitted further data which supported the requested shelf life.

Samples were tested for appearance (visual &amp; odor), viscosity (Ph. Eur.), re-dispersibility (in-house), pH (Ph. Eur.), assay of active substance and the preservative (HPLC), related substances (HPLC), particle size  (laser  light  diffraction),  dissolution  (in-house),  microbiological  quality  (Ph.  Eur.).  The  analytical procedures used are stability indicating.

The tested parameters are generally stable over time at all testing points and at both long-term as well as accelerated storage conditions. Viscosity values show a decrease over time, but values remain within the validated range. Dissolution data show some variability; however the results indicate no significant trends and no OOS are reported. The results for batch 5149662 were out of specification for the particle size at certain time-points. The OOS results related to issues with the method of analysis used at that

<div style=\"page-break-after: always\"></div>

time which was further amended, all results with the amended method are compliant as demonstrated during stability studies.

With respect to ongoing stability studies. In accordance with EU GMP guidelines, any confirmed out-ofspecification result, or significant negative trend, should be reported to the Rapporteur and EMA.

In addition, one batch was exposed to light as defined in the ICH Guideline on Photostability Testing of New Drug Substances and Products.

Based on available stability data, the proposed shelf-life of 24 months with no specific storage condition as stated in the SmPC (section 6.3) for the un-opened product are acceptable.

In-use stability was investigated on two commercial scale batches at 45, 90, and 140 days, when stored at  2-8°C.  With  respect  to  the  140  day  time-point,  OOS  results  for  assay  (decreased  values)  were observed, therefore it is not possible to set longer in-use shelf life than 90 days. The latest age of the batches available to conduct the testing were from the 14 month time-point. Considering this point the applicant is also recommended to conduct further in-use stability testing with a batch closer to the 24 month  time-point,  and  a  relevant  commitment  by  the  applicant  was  provided  (REC3).  Overall  the available data confirm the appropriate shelf life for the opened product is 3 months when stored upright within a refrigerator (2-8°C).

## 2.4.3.5. Adventitious agents

No excipients derived from animal or human origin have been used.

## 2.4.4. Discussion on chemical, pharmaceutical and biological aspects

Information on development, manufacture and control of the active substance and finished product has been presented in a satisfactory manner. During the procedure, two major objections were raised on the choice  of  active  substance  starting  material  and  its  impurity  control,  and  on  the  extent  of  stability extrapolation to support the claimed finished product shelf life. Further information was provided to justify the proposed control strategy for the starting material of the active substance and further stability data was provided to support the proposed finished product shelf-life. The MOs were considered to be resolved. The results of tests carried out indicate consistency and uniformity of important product quality characteristics, and these in turn lead to the conclusion that the product should have a satisfactory and uniform performance in clinical use.

At the time of the CHMP opinion, there were a number of minor unresolved quality issues having no impact on the Benefit/Risk ratio of the product, these concern the finished product and relate to the feasibility of administration via enteral feeding tubes, potential re-evaluation of the limit for dissolution in light of further batch data, and performing additional in-use stability testing at the end of shelf life. These points are put forward and agreed as recommendations for future quality development.

## 2.4.5. Conclusions on the chemical, pharmaceutical and biological aspects

The quality of this product is considered to be acceptable when used in accordance with the conditions defined in the SmPC. Physicochemical and biological aspects relevant to the uniform clinical performance of the product have been investigated and are controlled in a satisfactory way.

<div style=\"page-break-after: always\"></div>

## 2.4.6. Recommendation(s) for future quality development

In the context of the obligation of the MAHs to take due account of technical and scientific progress, the CHMP recommends the following points for investigation:

1. The applicant is recommended to investigate the feasibility of the administration of the product via enteral feeding tubes in line with the Quality of medicines questions and answers: Part 2, and  update  the  product  information  based  on  the  outcome  of  this  investigation.  It  is recommended that the results and updated Product Information be submitted.
2. The  applicant  is  recommended  to  re-evaluate  the  proposed  dissolution  limit  for  the  finished product when results from the process validation batches are available. It is recommended that the results and supporting updated documentation be submitted.
3. The applicant is recommended to perform further in-use stability testing at the end of the shelf life of the finished product. It is recommended that such testing is conducted on at least one batch close to 24 months in age and that the results be submitted.

## 2.5. Non-clinical aspects

## 2.5.1. Introduction

Vamorolone  was  identified  in  a  screen  for  corticosteroid  analogues  with  retained  anti-inflammatory transrepression  activity  but  reduced  transactivation  properties  at  the  GR.  The  21-aminosteroids ( 'lazaroids' , e.g., tirilazad) and anecortave had served as prototypes for these analogues and contain a double bond between carbon atoms 9 and 11 of the steroid C-ring instead of the 11 β -hydroxyl or carbonyl moiety of known members of the glucocorticoid class (Baudy et al ., 2012).

## 2.5.2. Pharmacology

## 2.5.2.1. Primary pharmacodynamic studies

## Primary pharmacodynamics in vitro

Vamorolone was profiled against other corticosteroid candidates by its effective inhibition of nuclear factor kappa-light-chain-enhancer of activated B cells (NFΚ b) inflammatory target genes, which was similar to prednisolone in myoblasts and myotubes in vitro (IC50 of 2.16-2.76×10 -8  M vs. 1.44-9.91×10 -7  M,  respectively).  This  anti-inflammatory  activity  of  vamorolone  was  dependent  on nuclear translocation of the GR and consequently abolished in mutant fibroblasts lacking a functional GR. Contrary to prednisolone and dexamethasone, however, the interaction of vamorolone with the GR does not seem to efficiently stimulate GRE-driven transcriptional activation and repression based on lower induction of serum/glucocorticoid regulated kinase 1 (Sgk1) and receptor activator of nuclear kappa-B ligand  (RANKL)  as  well  as  lesser  downregulation  of  adrenocorticotropic  hormone  (ACTH)  secretion in vitro .

X-ray crystallography of the ligand-binding domain of the GR indicates that the structural difference at carbon 11 of the steroid C ring of vamorolone might account for its distinct pharmacodynamic (PD) activity compared to other glucocorticoids. The absence of the hydroxyl group at carbon 11 could also result in the antagonism of vamorolone at the MR, because this hydroxyl group is required for effective hydrogen  bond  formation  with  the  ligand-binding  domain  of  the  MR  and  therefore  present  in  other

<div style=\"page-break-after: always\"></div>

members of the glucocorticoid class that act as MR agonists. In fact, vamorolone was unable to activate the MR like deflazacort in a cellular reporter assay, but rather demonstrated comparable MR antagonist potency like eplerenone.

In  cultures  of  either  wildtype  myotubes  or  myoblasts  from  a  patient  with  limb  girdle  muscular dystrophy 3B, 1 to 100 µM vamorolone concentration-dependently appeared to alleviate laser- or glass bead-induced experimental membrane damage, while the enhanced intracellular flurorescent dye influx after prednisolone incubation indicated significantly deteriorated damage of myotubes.

## Primary pharmacodynamics in vivo

Primary  PD in vivo investigations  compared  the  activity  vamorolone  with  prednisolone,  the  active metabolite of the glucocorticoid prednisone, in the well-established mdx mouse model of human DMD. Due to the age-dependently different severity of the muscle phenotype of mdx mice, this comparison was performed in mdx mice starting from either post-natal day (PND) 15 for 6 weeks and from adulthood for 4 months. Prednisolone and vamorolone decreased the body weight of young (-18 % vs. -9 to -11%) and at lower magnitude also adult mdx mice indicating a catabolic effect (-10 % vs. -9 %). Owing to the more severe dystrophic phenotype of younger mdx mice, both vamorolone and prednisolone similarly increased grip strength, particularly in the forelimb of these animals, whereas grip strength was not improved after prolonged administration of the two glucocorticoids in older mdx mice. The separate in vitro investigation  of  the extensor  digitorum  longus muscle  prepared  from  vamorolone  and prednisolone treated animals did not suggest relevant differences in the functional improvement between the two age groups. Vamorolone also effectively diminished cellular Cathepsin B protease activity in mdx mice,  which  was  comparable  to  prednisolone  at  the  30 mg/kg/day  vamorolone  high  dose.  The Cathepsin B  decrease  was  less  prominent  in  older  mdx  mice  for  both  glucocorticoids.  Histologically, vamorolone doses ≥15 mg/kg/day effectively reduced diaphragm inflammations in both age groups of mdx mice. A similar reduction was only detected following prednisolone administration of older mdx mice.

Prednisolone further caused degenerations in gastrocnemius muscle of young mdx mice and induced cardiac hypertrophy as well as cardiac fibrosis at the two age levels. Vamorolone did not evoke cardiac hypertrophy  and  mild  signs  of  cardiac  fibrosis  were  restricted  to  young  mdx  mice.  In  addition, vamorolone did not adversely affect bone development of PND 12 wildtype and young mdx mice, which coincides with the lack of relevant in vitro induction of the bone resorption marker RANKL. In contrast, prednisolone significantly activated RANKL expression resulting in shortened body and tibia length in the young mdx mice, which was associated with lower trabecular thickness of the animals.

The  immunosuppressive  activity  of  vamorolone  and  prednisolone  resulted  in  dose-dependent  and significant reductions of spleen weight and peripheral blood leukocytes counts in young mdx mice. Still, splenocytes were significantly decreased only by prednisolone. Lymphocyte phenotyping unravelled that prednisolone  reduced  B  cells,  naïve  and  regulatory  T  cells,  whereas  only  high  dose  vamorolone diminished naïve T cells. These data coincide with the outcome of a T cell dependent antibody response (TDAR) study in mice (see below).

The  general  anti-inflammatory  effect  of  vamorolone  has  been  substantiated  in  the  experimental autoimmune  encephalitis  (EAE)  model  of  human  multiple  sclerosis  in  mice.  Daily  doses  of  either 30 mg/kg vamorolone or 15 mg/kg prednisolone were orally administered one day before EAE induction until study termination on day 20. Vamorolone significantly reduced EAE severity, but not as efficient as prednisolone, which additionally seemed to delay EAE onset. Nevertheless, the number of inflammatory foci in the spinal cord of animals treated with vamorolone or prednisolone was comparable. The low number of just 7 mice per group might have interfered with more meaningful results.

<div style=\"page-break-after: always\"></div>

## 2.5.2.2. Secondary pharmacodynamic studies

Vamorolone only showed significant agonistic activity at the GR and antagonism at the MR in vitro but unveiled no relevant affinity to 19 other steroid hormone or other CNS receptors, ion channels, and transporters.

## 2.5.2.3. Safety pharmacology programme

The  impact  of  vamorolone  on  vital  functions  has  been  evaluated  in  the  core  battery  of  safety pharmacology investigations in adherence to prevailing ICH S7A and B guidelines (CPMP/ICH/539/00; CPMP/ICH/423/02). Vamorolone did not inhibit human ether-a-go-go-related gene (hERG) potassium currents up to the highest concentration of 20 µM in vitro .  Accordingly, oral vamorolone doses up to 50 mg/kg did not impair cardiovascular and respiratory function in telemetered dogs. Likewise, multiple oral administrations of the same  dose  in  the  chronic toxicity study in dogs  did not affect electrocardiogram (ECG) parameters but induced reversible mild heart rate increases at the 39-week post dose interval.

Vamorolone did not induce neurobehavioural changes in a functional observation battery in mice, which coincides with results of the 10 weeks juvenile toxicity study in this species that did not indicate any impact on motor activity, auditory startle habituation or the performance in the Morris water maze (see below).

## 2.5.2.4. Pharmacodynamic drug interactions

No PD drug-drug interaction (DDI) studies have been performed or are deemed necessary.

## 2.5.3. Pharmacokinetics

The pharmacokinetic (PK) characteristics of vamorolone were evaluated in vitro and after single oral or i.v.  administration  in  mice,  rats  and  dogs.  These  investigations  were  complemented  by toxicokinetic determinations in repeated dose toxicity studies in mice, dogs and monkeys, metabolic profiling and in vitro DDI studies.

Vamorolone was quantified in the range of 1.0 - 1,000 ng/ml in plasma of mice, dogs and monkeys by liquid chromatography coupled with tandem mass spectrometry, which was validated in compliance with GLP for use in pivotal toxicology studies.

Vamorolone  showed  moderate  to  high  permeability  in  Caco-2  monolayers  and  artificial  membranes in vitro . Its solubility was higher in artificial gastric fluids simulating fed compared to fasted state, which has been clinically substantiated (see below and section 4.2 of the Summary of Product Characteristics (SmPC)). For investigations of PK in vivo parameter, the poor water solubility of vamorolone necessitated its formulation in either the non-ionic water-dispersible surfactant Labrafil or in a mixture of ethanol, DMSO, PEG400 and hydroxypropylβ -cyclodextrin (HPβ -CD).

Single oral vamorolone doses of 50 mg/kg in mice and rats or 30 mg/kg in dogs, resulted in relatively fast  absorption  in  mice  (time  to  maximum  drug  concentration  (tmax)  of  2 h))  with  bioavailability  of 74.5 %, whereas absorption of the same dose was delayed and oral bioavailability lower in rats (tmax of 4 h; F of 47.8 %) and dogs (tmax of 6 h; F of 53.2 %). The oral elimination half-life was shortest in mice (~40 min) and prolonged in rats and dogs (~2.3 h). Similarly, mice showed higher clearance than rats and dogs after single i.v. injection of 10 mg/kg vamorolone.

<div style=\"page-break-after: always\"></div>

Following multiple oral vamorolone administrations for up to 26 weeks in mice, 39 weeks in dogs and 7 days in monkeys, the tmax was confirmed at 1-2 h mice, prolonged to 2-4 h in dogs and seemingly extended to 4-12 h in monkeys, although the low number of monkeys might have precluded reliable determinations. The peak plasma concentrations increased in a roughly dose-proportional manner in all three animal species. Whilst dose proportionality was also apparent for area under the drug concentration versus time curve from 0 to 24 hours (AUC0--24h) in dogs and monkeys, the increase was more than dose-proportional in mice. In all species, maximum drug concentration (Cmax) and AUC0--24h lacked any obvious sex difference. However, the Cmax and AUC0--24h based vamorolone exposure clearly dropped in the course of all multiple dose investigations in mice (1.5- to 5.7-- fold lower) and monkeys (1.2- to 2.9-fold lower), particularly at mid and high dose levels. In contrast, AUC0--24h tended to increase over the study duration in dogs (1.2- to 3.2--fold) pointing towards drug accumulation.

Vamorolone demonstrated comparable plasma protein binding in mice (86.7 %), dogs (77-81.1 %) and humans (88.1 %) in vitro . The blood/plasma ratio was similar between mice and humans (0.68 vs. 0.87), whereas the distribution of vamorolone into red blood cells was 2-fold lower in mice (0.33) than in humans (0.74).

Vamorolone rapidly and effectively transferred into the brain of mice with maximum plasma/brain ratio of approximately 0.6 at 0.5 h after single oral administration. A subsequent Quantitative Whole Body Autoradiography (QWBA) study revealed wide tissue distribution of  14 C-labelled vamorolone in pigmented rats with highest radioactivity levels in the gastrointestinal tract and liver. A slight distribution to melanincontaining pigmented layer of the retina was also detected. Thereafter, radioactivity was eliminated with prolonged half-lives of about 107 h in stomach, 47 h in caecum, 85 h in small and large intestine and 109 h in liver. Low levels of up to 3 % of the total AUC were determined in skeletal muscle, heart and kidney medulla, but were retained in these organs for an extended period as indicated by half-lives of 25.4 days, 16.9 days and 12.4 days, respectively.

Vamorolone  unveiled  similar in vitro metabolic  stability  when  incubated  for  1 h  with  pooled  liver microsomes  of  mice  (88.5 %),  dogs  (92.5 %),  monkeys  (100.3 %)  and  humans  (82.7 %),  which contrasts the poor stability in rats (35 %). Accordingly, minimal to moderate metabolism of vamorolone was found within 4 h in hepatocytes of mice, dogs, monkeys, and humans compared to the extensive metabolic degradation in rats.

In vitro metabolic reactions comprised primarily hydroxylation, hydrogenation, hydroxyl oxidation and glucuronidation.  Subsequent  high  resolution in vivo metabolic profiles identified ten circulating metabolites of vamorolone in plasma of mice, dogs, and adult healthy human volunteers. Except the oxidation  product  M5  and  the  dehydrogenation  metabolite  M6  in  mice  as  well  as  the  hydrogenated compound M10 in dogs, all other metabolites were glucuronide conjugates. Four of these glucuronides are  major  metabolites  representing  &gt;10 %  of  the  total  vamorolone-related  AUC  in  human  plasma. However, only the hydrogenated main glucuronide M7 was similarly quantified in dog plasma, whereas the direct O-glucuronide M3 of vamorolone and the hydrogenated major glucuronides M8 and M9 just amounted to &lt;1 % of total drug levels in mice and dogs.

The major human metabolites M3 and M7 were also confirmed in paediatric DMD patients aged 4 to 7 years and amounted to 34.42 % and 37.84 % of the total vamorolone-related exposure. As observed in adult human subjects, the amounts of M3 were higher in young DMD patients than in mice and dogs, while those of M7 were similar between dogs and paediatric patients. Albeit three less prominent human metabolites were additionally determined (&lt;3 % of the drug-related exposure), the hydrogenated major glucuronides M8 and M9 and other minor metabolites of adult human subjects were not found, which might be explained by the shorter sampling period of just 8 h in DMD patients compared to the 24 h time frame in adult subjects.

<div style=\"page-break-after: always\"></div>

The excretion of vamorolone was investigated following i.v. bolus injection in bile duct-cannulated albino rats and after oral administration in the mass-balance study in pigmented rats. In line with the extensive turnover of vamorolone in rat liver microsomes in vitro ,  the plasma levels of unchanged vamorolone were low and tiny amounts of the injected i.v. dose were detected in bile (0.04 %) and urine (0.6 %). Likewise, orally administered  14 C-labelled vamorolone was predominantly excreted via faeces (~80 %) compared to urine (~10 %) within 24 h.

In PK DDI studies, ≥5 µM vamorolone concentration-dependently induced CYP3A4 and to a lesser extent of CYP2B6, but did not induce CYP1A2, CYP2C8, CYP2C9 and CYP2C19. Vamorolone showed no relevant inhibition of CYP450 enzymes (CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6 and CYP3A4/5) and minor inhibition of UGT1A1 (uridine 5 diphospho glucuronosyltransferase) (24.4 %) and UGT2B7 (7.65 %) at the highest 50 µM concentration.

Vamorolone was no substrate for the drug transporters BCRP (breast cancer resistance protein), BSEP, (bile salt export pump) P-gp (P-glycoprotein), MATE1 (multidrug and toxin extrusion protein), MATE2-K, OAT1  (organic  anion  transporting  polypeptide),  OAT3,  OCT2  (organic  cation  transporter),  OATP1B1 (organic  anion  transporting  polypeptide)  and  OATP1B3.  In  addition,  vamorolone  did  not  reveal  any significant inhibition of BCRP, BSEP, MATE-1, P-gp, OAT1, OCT2, OATP1B1 and OATP1B3. Nevertheless, vamorolone inhibited the renal transporters MATE2-K with half maximal inhibitory concentration (IC50) of 12.9 µM and OAT3 with IC50 of 19.6 µM.

## 2.5.4. Toxicology

Vamorolone  was  evaluated  in  oral  repeated-dose  toxicity  studies  for  up  to  6 months  in  mice  and 9 months  in  dogs,  while  exploratory  dose-finding  over  7 days  was  also  conducted  in  Cynomolgus monkeys.  Mice  were  selected  as  pharmacologically  responsive  species  and  because  of  their  similar metabolic  profile  to  humans,  whereas  dogs  were  chosen  due  to  the  established  experience  with glucocorticoid effects in this species.

## 2.5.4.1. Single dose toxicity

Single dose toxicity studies have not been conducted with vamorolone, which coincides with prevailing ICH and European guidance (EMA/CPMP/ICH/286/1995; EMA/CHMP/SWP/81714/2010). Nevertheless, the dose escalations in initial dose-range findings studies indicated that the approximately lethal doses after oral vamorolone administration were &gt;500 mg/kg in mice and monkeys and &gt;750 mg/kg in dogs.

## 2.5.4.2. Repeat dose toxicity

Repeat-dose toxicity studies revealed a largely consistent profile of various toxicities that were induced in a dose- and time-dependent manner, albeit different species-specific sensitivities towards vamorolone were also eminent. No vamorolone related mortalities were evident. The target organs for vamorolone toxicities  comprised  the  lymphatic  system,  liver/gall  bladder,  pancreas,  adrenal  glands  and  kidneys, reproductive  organs  of  both  sexes,  thyroid,  salivary  glands,  skin  and  skeletal  muscle.  Long-term vamorolone administration also promoted food consumption and weight gain in mice and dogs. In chronic toxicity studies, no-observed-adverse-effect levels (NOAELs) of 45 mg/kg/day in mice and 2 mg/kg/day in  male  dogs  were  established,  whereas  a  NOAEL  could  not  be  defined  for  female  dogs  given  the prominent interference of vamorolone with ovarian cycling (see below).

<div style=\"page-break-after: always\"></div>

## Lymphatic system

In all toxicity studies in mice and dogs, lymphoid tissues including spleen, thymus and lymph nodes (mesenteric and mandibular lymph nodes as well as gut-associated lymphoid tissue) were generally smaller  at  vamorolone  doses  ≥10 mg/kg/day.  The  decreased  size  reflected  the  mild  to  moderate depletion of lymphocytes within lymphoid tissues and in the circulation at ≥5 mg/kg/day vamorolone in mice  and  ≥2 mg/kg/day  in  dogs.  After  cessation  of  vamorolone  administration,  compensatory lymphocyte hyperplasia was observed in thymus and spleen of mice, whereas the lymphoid depletion did not completely reverse in the recovery periods of the 28 days and 39 weeks toxicity studies in dogs.

## Liver, gall bladder

Vamorolone doses ≥10 mg/kg/day further increased the liver weight in all toxicity studies in mice and dogs.  The  liver  hypertrophy  correlated  histologically  with  mild  to  moderate  centrilobular  hepatocyte vacuolation  representing  glycogen  and  lipid  accumulations,  respectively.  Concomitantly,  triglycerides and cholesterol were reversibly elevated upon longterm dosing of ≥10 mg/kg/day vamorolone in mice and dogs. In the chronic toxicity study in dogs, hypertrophy and vacuolation was additionally observed in the gall bla dder mucosa at ≥2 mg/kg/day and in bile duct epithelia at ≥10 mg/kg/day. Moreover, single hepatocellular and focal/subcapsular inflammation/necrosis developed doseand timedependently in mice (100 mg/kg/day after 7 days, ≥10 -30 mg/kg/day after 28 days and ≥15 mg/kg/day after 26 weeks) but was only detected in the 50 mg/kg/day high dose group of the 39 weeks toxicity study  in  dogs.  The  focal  inflammation/necrosis  might  be  secondary  to  the  observed  hepatocellular hypertrophy and vacuolation. Given the short recovery periods of 14 to 28 days of subchronic and chronic toxicity  studies,  hepatocellular  vacuolation  and  liver  inflammation/necrosis  only  partially  reversed  in individual mice and only diminished in severity in dogs.

Hepatic changes were associated with dose- and time-related elevations of liver enzymes in mice and dogs. Long-term administration of 45 mg/kg/day vamorolone in mice induced alanine aminotransferase (ALT; up to +5.3-fold), aspartate aminotransferase (AST; +1.7-fold), alkaline phosphatase (ALP; up to +3-fold)  and  bilirubin  (+1.5-fold).  More  pronounced  increases  of  liver  enzymes  were  determined following chronic vamorolone doses of 50 mg/kg/day in dogs comprising AP (up to +11.1-fold), ALT (up to +7.7-fold), AST (up to +2.1-fold) and gamma glutamyl transferase (GGT; up to +18.8-fold). The increased liver enzymes partially normalised in the recovery periods in mice and dogs. The liver and gall bladder inflammations also possibly accounted for elevations of inflammatory parameters (neutrophils, monocytes, fibrinogen, albumin, globulin and platelets) after vamorolone doses of ≥10 mg/kg/day in mice and ≥50 mg/kg/day in dogs. Some of these markers were also affected in the dose range finding (DRF) study in monkeys.

## Pancreas

Minimal to mild increases of pancreatic islet hypertrophy were detected in several mice administered the 45 mg/kg/day vamorolone high dose in the chronic toxicity study and persisted with lower incidence and severity until the end of the recovery period. Comparable findings were neither identified after shorter vamorolone treatment durations at higher doses in mice, nor in dogs.

## Adrenal gland

Repeated  vamorolone  administration  ≥5 mg/kg/day  in  mice  promoted  mild  to  moderate  vacuolar degeneration in the X zone of the adrenal cortex and atrophy of the cortical zona fasciculata . Following chronic dosing, ceroid pigment deposits were additionally observed. In dogs, bilateral adrenal cortex atrophy in the zona fasciculata and zona reticularis was evident at ≥2 mg/kg/day, which was adverse at ≥10 mg/kg/day  and  accompanied  by  hypertrophy  in  the zona  glomerulosa .  The  adrenal  cortical vacuolation, atrophies and ceroid deposits did not completely reverse in the recovery period in mice and dogs,  particularly  in  those  groups  that  had  formerly  received  the  respective  vamorolone  high  dose.

<div style=\"page-break-after: always\"></div>

However, the minimal to mild hypertrophy in the zona fasciculata in mice and in the zona glomerulosa in dogs partially compensated for the adrenal cortex atrophy after long-term administrations.

## Kidney

Increased kidney weights (up to +51.8 %) with bilateral tubular vacuolation were detected after chronic administration of ≥10 mg/kg/day vamorolone in female and following the 50 mg/kg/day high dose in male dogs. These changes were especially in high dose animals reflected in higher urine volumes (up to +6-fold) with concomitantly decreased serum urea nitrogen (up to -44 %), creatinine (up to -56 %) and chloride  (-4 %)  and  higher  potassium  (+13 %)  and  phosphorus  (up  to  +51 %)  concentrations.  The increased diuresis resulted in the dehydration of high dose animals, resolved in dogs until end of the recovery period at the vamorolone mid dose level, but persisted both histologically and  in terms of electrolyte concentrations with lower magnitude in the high dose group. Different electrolyte imbalances were noted at higher vamorolone dosages ≥300 mg/kg/day in the 14 days DRF study in monkeys, but not observed in mice.

## Testis, ovary

Vamorolone  did  not  significantly  affect  sperm  motility,  caudal  epididymis  sperm  concentrations  and relative amounts of abnormal sperm in the chronic toxicity study in mice. Histological examinations of male dogs indicated degenerations of spermatocytes and spermatids within seminiferous testis tubules of the 50 mg/kg/day vamorolone high dose group leading to oligospermia and germ cell debris in the epididymides. The prostate gland of these males was smaller in size (approx. -60 %) and had minimally to moderately reduced secretory product. Upon vamorolone treatment cessation, the spermatocyte/spermatid degenerations partially recovered and remained identifiable in each one male dog of the mid and high dose groups, whereas the diminished prostate glands and exudates did not reverse in high dose animals.

In female animals, repeated vamorolone administrations for 28 days reduced ovarian weights at doses ≥30 mg/kg/day  in  mice  and  lowered  uterus/cervix  weight  in  dogs.  Long-term  vamorolone  doses ≥2 mg/kg/day in the 39 weeks repeat-dose toxicity study in dogs resulted in bilateral absence of corpora lutea in  the  ovaries  and  other  tissues  of  the  reproductive  tract  of  affected  females  confirmed  the anovulation. In addition, mild vacuolation was identified in mammary gland duct epithelia of female dogs of the 50 mg/kg/day high dose group. Upon completion of the recovery phase, corpora lutea were still absent in one high dose female suggesting partial reversibility. Hence, a NOAEL could not be established for female dogs in this chronic toxicity study.

## Thyroid

The thyroid/parathyroid gland weight was higher in the chronic toxicity study in male dogs at vamorolone doses  ≥10 mg/kg/day,  which  correlated  with  bilaterally  increased  colloid  within  thyroid  follicles.  In contrast, thyroid/parathyroid gland weights overlapped between vamorolone-treated female dogs and corresponding  controls,  which  hampered  to  identify  an  unambiguous  difference.  The  study  director hypothesised that surrounding mediastinal adipose tissue could have contributed to the variability in thyroid/parathyroid gland weights. However, mean weights at the end of the treatment phase rather pointed towards a dose-dependent effect, which was more prominent in male dogs (up to +97.5 %). Nevertheless, thyroid/parathyroid weights normalised until the end of the recovery period.

## Parotid salivary glands

The parotid salivary glands of male and female dogs administered ≥10 mg/kg/day vamorolone in the chronic  toxicity  study  revealed  minimal  to  moderate  increases  of  multifocal  to  diffuse  cytoplasmic epithelial basophilia. The severity of this finding was reduced at the end of the recovery period but did not completely reverse in affected males and was still visible in one female dog of the 10 mg/kg/day

<div style=\"page-break-after: always\"></div>

group. Comparable findings were also detected in juvenile mice, but not in the chronic toxicity study in adult mice.

## Skin

Vamorolone  doses  of  100 mg/kg/day  for  28 days  and  of  45 mg/kg/day  for  26 weeks  in  mice  and developed ≥10 mg/kg/day in the chronic toxicity study in dogs caused epidermal collagen thinning and diminished the number of anagen hair follicles resulting in alopecia/hypotrichosis. Decreased anagen follicles recovered incompletely until study termination in most mice that had previously received 15 or 45 mg/kg/day vamorolone doses, but largely resolved in dogs.

## Skeletal muscle

Mild skeletal muscle atrophy of the exemplarily investigated biceps femoris was evident in dogs treated chronically with 50 mg/kg/day vamorolone, which was characterised by decreased myofibre size due to diminished sarcoplasm. The reduced muscle fibre bundles were separated by adipose tissue. Muscle atrophy was incompletely reversible until the end of the recovery period and remained detectable in each one male and one female dog.

## Body weight

Repeated  vamorolone  doses  of  ≥10 mg/kg/day  for  28 days  in  mice  and  at  ≥60 mg/kg/day  in  the exploratory 28 days toxicity study in dogs reduced body weights and/or body weight gain. However, prolonged vamorolone administrations of 45 mg/kg/day for 26 weeks in mice and of ≥10 mg/kg/day for 39 weeks in dogs increased body weights and food consumption (+14 % and +23 % in male and female mice; +13 % to +46 % and +10 % to +21 % in male and female dogs). Upon completion of the recovery period, body weights remained slightly increased in male and female mice (+2 % and +25 % each), which correlated with the food consumption of the animals (-5.5 % in males and +9.3 % in females). The terminal body weights of dogs in the recovery phase were reduced in both sexes (up to -14 %) due to  clearly  lower  food  consumption  (-54 %  in  males  and  -61 %  in  females,  respectively).  Hence, alterations  in  body  weight  and  food  consumption  tended  to  reverse,  if  vamorolone  treatment  was stopped.

## 2.5.4.3. Genotoxicity

In vitro ,  vamorolone was negative for increased reverse mutations in Ames tests in bacteria and for chromosomal aberrations, polyploidy and endoreduplication in mouse  lymphoma  cells and a micronucleus assay in CHO-K1 cells, respectively. Vamorolone did also not increase the formation of micronuclei in polychromatic erythrocytes of mouse bone marrow in vivo .

## 2.5.4.4. Carcinogenicity

Carcinogenicity studies are planned to be conducted post approval as earlier agreed during scientific advice (EMA/CHMP/SAWP/545127/2019).

## 2.5.4.5. Reproductive and developmental toxicity

A  standard  battery  of  developmental  and  reproductive  toxicology  studies  was  not  conducted  since vamorolone is intended to treat DMD, which affects almost exclusively male patients.

<div style=\"page-break-after: always\"></div>

## Juvenile toxicity

Juvenile mice were evaluated for toxicity of vamorolone at dose levels up to 100 mg/kg/day for 8 weeks in an initial DRF study and for 10 weeks in the pivotal investigation. In both studies, vamorolone was orally  administered  from  PND 21  onwards.  This  corresponds  to  the  intended  paediatric  DMD  patient population of 2 years and older. The main target organs in juvenile mice overlap with those of adult mice, i.e., the liver, spleen, thymus, lymph nodes, and adrenal glands. The findings in the adrenal glands (cortical  atrophy),  liver  (hepatocellular  vacuolation,  hypertrophy,  necrosis  and  degeneration)  and lymphoid  organs  were  considered  consistent  with  the  pharmacological  activity  of  vamorolone  (i.e., synthetic glucocorticoid/corticosteroid). Vamorolone did not affect neurobehaviour, the histopathology of neuronal tissues as well as specific lymphocyte subtypes in juvenile mice. Toxicokinetic analysis of vamorolone in juvenile mice were also consistent with those obtained in adult mice showing no gender differences, dose-dependently increased Cmax and AUC-values followed by a 2- to 5-fold decline in AUCvalues after multiple dosing.

Different  from  adult  mice,  however,  minimal  to  mild  mandibulary  salivary  gland  hypertrophy accompanied by significantly decreased mandibular gland weight was detected in juvenile female mice at ≥15 mg/kg vamorolone, which was test-article related. No histopathological changes in mandibular salivary gland were noted upon completion of the recovery period, but decreased salivary gland weights were still present at a lower magnitude.

In males reduced mean tibia and body length were observed at 100 mg/kg and ≥15 mg/kg vamorolone, respectively.  In  females  no  effect  on  body  lengths  was  observed,  but  tibia  length  was  reduced  at ≥30 mg/kg. These findings correlated with lower body weights and were attributed to the slower growth of the animals. Bone mineral density and bone structure as well as biomarkers of bone metabolism have not been investigated in the juvenile mouse toxicity studies.

No effects of vamorolone were observed on sexual maturation, first day of oestrous, oestrous cyclicity, reproductive  and  fertility  indices,  sperm  evaluations,  macroscopic  observation,  or  organ  weights  in juvenile mice. However, uterine examinations showed marked increases in pre- and post-implantation losses and decreased numbers of viable embryos in the 100 mg/kg dose group compared to controls, albeit these lacked statistical significance. Nonetheless, no comparison with historical control data has been performed.

The NOAEL for the 10 weeks juvenile toxicity study for general toxicity in male and female juvenile mice is proposed to be &lt;15 mg/kg/day based on the findings of adrenal atrophy, mandibulary salivary gland hypertrophy and decreased body lengths. Considering the AUC-levels at this 15 mg/kg/day vamorolone dose, no safety margin with respect to human exposure at the maximum recommended human dose (MRHD) exists.

## 2.5.4.6. Toxicokinetic data

Safety margins based on the Cmax- and AUC0-last-related exposure at the respective NOAELs determined in repeat-dose toxicity studies were negligible in adult or juvenile mice or not existent in dogs when compared to corresponding levels in human DMD patients at the MRHD.

## 2.5.4.7. Local tolerance

Given its administration as oral suspension, the local tolerability of vamorolone has not been investigated in dedicated studies in accordance with the pertinent European guideline (EMA/CHMP/SWP/2145/2000 Rev. 1, Corr. 1*). However, vamorolone showed favourable local tolerance after repeated oral dosing in mice, dogs and monkeys.

<div style=\"page-break-after: always\"></div>

## 2.5.4.8. Other toxicity studies

As expected from the immunosuppressive activity of vamorolone and other glucocorticoids, 100 mg/kg/day vamorolone and prednisolone doses ≥10 mg/kg/day comparably inhibited the TDAR in female mice, while TDAR was completely abolished in male animals.

In accordance with ICH M7 requirements, the two vamorolone epoxides VBP-15-B-2 and VBP-15-B-3 did not  indicate  any  mutagenic  risk  in  a  Quantitative  structure-activity  relationships in silico analysis complemented by a bacterial reverse mutation assay.

Vamorolone did not absorb in the range of 290-400 nM and has a molar extinction coefficient (MEC) of approximately 14,800 l·mol -1 ·cm -1 .

## 2.5.5. Ecotoxicity/environmental risk assessment

The  environmental  risk  assessment  (ERA)  provided  for  the  steroid  active  substance  vamorolone  is considered incomplete. Vamorolone is considered as a potential endocrine active substance based on structure,  mode  of  action,  and  non-clinical  mammalian  data  on  development  and  reproduction.  The PECsurfacewater  value  did  not  exceed  the  action  limit  of  0.01 µg/l.  The  n-octanol/water  distribution coefficient (log Dow) of vamorolone was determined to be &lt;4.5. Thus, no PBT assessment is necessary.

A Phase II environmental risk assessment was not performed by the applicant for vamorolone.

However, the applicant confirmed to conduct the tiered ERA Phase II under a post approval commitment and committed to conduct the proposed studies based on whether vamorolone is readily biodegradable. A detailed letter of commitment has been submitted. According to an updated study schedule of the applicant the final ERA is scheduled to end Q3-2027.

The  ERA  could  not  be  completed  due  to  outstanding  issues  and  the  CHMP  agreed  that  it  could  be completed during the post-authorisation phase.

Table 1: Summary of main study results

| Substance (INN/Invented Name): vamorolone                | Substance (INN/Invented Name): vamorolone   | Substance (INN/Invented Name): vamorolone                      | Substance (INN/Invented Name): vamorolone   |
|----------------------------------------------------------|---------------------------------------------|----------------------------------------------------------------|---------------------------------------------|
| CAS-number (if available): 13209-41-1                    | CAS-number (if available): 13209-41-1       | CAS-number (if available): 13209-41-1                          | CAS-number (if available): 13209-41-1       |
| PBT screening                                            |                                             | Result                                                         | Conclusion                                  |
| Bioaccumulation potential- log K ow                      | OECD107 at 20°C by the shake flask method   | log Pow at pH 5: 2.4 log Pow at pH 7: 2.5 log Pow at pH 9: 2.4 | Potential PBT (N)                           |
| Phase I                                                  | Phase I                                     | Phase I                                                        | Phase I                                     |
| Calculation                                              | Value                                       | Unit                                                           | Conclusion                                  |
| PEC surfacewater , refined (prevalence, Fpen = 0.000028) | 0.0042                                      | µ g/L                                                          | >0.01 threshold (N)                         |
| Other concerns (e.g. chemical class)                     |                                             | Potentially endocrine active substance                         | (Y)                                         |

## 2.5.6. Discussion on non-clinical aspects

## Pharmacology

Vamorolone shares the effective anti-inflammatory transrepression activity of NFκ B target genes via agonistic  interaction  with  the  GR  with  other  members  of  the  pharmaceutical  class  of  corticosteroid agents. In contrast to other corticosteroids like prednisolone or dexamethasone, however, vamorolone revealed diminished transcriptional activation properties of genes, whose expression is driven by the glucocorticoid response element (GRE). Apart from this retained anti-inflammatory (transrepression) and reduced  transactivation  effects  of  vamorolone,  further  characterisation  of  potential  downstream

<div style=\"page-break-after: always\"></div>

signalling pathways including the possible role of membrane glucocorticoid receptors (mGRs) has not been investigated so far.

Vamorolone was also found to act as antagonist at the MR in vitro , which further contrasts the agonistic properties of other corticosteroids. The basis for the differential pharmacological activities seemingly relies on the molecular structure of vamorolone, which harbours a double bond between carbon atoms 9 and 11 of the steroid C-ring. Consequently, vamorolone lacks a hydroxyl or carbonyl group at carbon 11 of the steroid C-ring that is contained in all other known glucocorticoids.

X-ray  crystal  structures  of  the  ligand  binding  domain  of  the  GR  complexed  with  either  vamorolone, prednisolone  or  deacetylated  deflazacort  suggest  that  the  missing  hydroxyl  group  prevents  efficient hydrogen bond formation of vamorolone with Asn564 of the GR, which might account for its preserved transrepression  and  reduced  transactivation  properties  at  the  GR  (Liu et al .,  2020).  Likewise,  the hydroxyl group at carbon 11 of other glucocorticoids is essential for effective hydrogen bonding with Asn770 in the ligand-binding domain of the MR (Rafestin-Oblin et al ., 2002) and, hence, required for MR agonist activity (Heier et al ., 2019). As vamorolone lacks the hydroxyl group at carbon 11, it was found to act as MR antagonist in vitro .

Contrary to prednisolone, vamorolone concentration-dependently retained and possibly improved plasma membrane integrity of myotubes after experimental damage in vitro (Heier et al ., 2019; Sreetama et al ., 2018). The applicant hypothesises that the double bond between carbons 9 and 11 of vamorolone lowers its hydrophilicity, which might allow the more favourable orientation of vamorolone within membranes as earlier reported for the membrane-stabilizing properties of tirilazad (Audus et al ., 1991; Wang et al . 1996). It seems noteworthy that vamorolone does not contain the positively charged piperazine moiety of tirilazad, which has been implicated to interact with negative phosphate groups of membrane lipids (Kavanagh and Kam, 2001). In the absence of further data, it remains therefore to be shown whether a similar membrane interaction also applies to vamorolone.

Compared  to  the  vamorolone  parent  compound,  its  glucuronide  metabolites  revealed  minimal  GRmediated  transrepression  and  transactivation,  which  was  attributed  to  steric  interference  with  GR complex formation. However, the identity of the two investigated glucuronides could retrospectively not be  clarified.  Hence,  pharmacological  inactivity  cannot  be  reliably  concluded  for  the  disproportionate human glucuronides,  which  are  not  appreciably  formed  in  mice  and  dogs  (see  below).  This  further reduces  the  predictive  value  of  the  non-clinical  toxicology  programme,  which  did  not  establish  any relevant  safety  margins  in  terms  of  human  safety.  As  these  limitations  are  meanwhile  reflected  in section 5.3 of the proposed SmPC, the issue is not further pursued.

'Proof-of-concept' for  the  proposed  clinical  DMD  therapy  was  obtained  in  the  well-established  mdx mouse  model.  As  the  severity  of  the  dystrophic  phenotype  of  mdx  mice  depends  on  the  genetic background and the age of these animals, mdx mice were administered vamorolone or prednisolone either from PND 15 for 6 weeks or from adulthood for 4 months. Despite similar molecular weights, oral vamorolone doses between 5 to 30 mg/kg/day were compared with a low 5 mg/kg/day prednisolone dose in mdx mice and in another mouse model of acute lung inflammation, which hampers to reliably evaluate the benefits and side effects of the two corticosteroids. However, 5 mg/kg prednisolone appears to be the maximum feasible oral dose in long-term experiments in mdx mice and avoids the detrimental impact of higher doses (Sali et al ., 2012). With respect to the clinical translatability of the PD in vivo results, the apparent selection of female mdx mice had been questioned. Nevertheless, the efficacy of vamorolone  in  other  inflammatory  disease  models  in  male  animals  and  the  clinical  developmental programme in DMD patients do not suggest sex-specific differences in the PD effects.

Vamorolone and prednisolone similarly improved muscular function and diminished Cathepsin B protease activity, particularly in young mdx mice. Vamorolone also reduced diaphragm inflammations. Considering the lower propensity of vamorolone for GRE-mediated transactivation of muscle atrophy markers, the

<div style=\"page-break-after: always\"></div>

known in vivo risk for muscle atrophy during long-term therapy with glucocorticoids seems to be lower with vamorolone. Still, the 50 mg/kg/day vamorolone high dose evoked mild skeletal muscle atrophy in dogs of the chronic toxicity study, which incompletely recovered in the rather short treatment cessation period of 4 weeks (see below).

It should be noted that vamorolone did not evoke cardiac hypertrophy in both age groups of mdx mice and mild signs of cardiac fibrosis were restricted to young animals, while prednisolone induced both cardiac hypertrophy and cardiac fibrosis at the two age levels. This seems to be related to the different activity of vamorolone and prednisolone at the MR (antagonist vs. agonist).

In  line  with  the  different  induction  of  the  bone  resorption  marker  RANKL  between  vamorolone  and prednisolone (see above), the magnitude of the effect of vamorolone on bone development in PND 12 and  young  mdx  mice  (body  and  tibia  length,  trabecular  thickness)  was  lower  than  observed  with prednisolone. Nevertheless, vamorolone significantly reduced tibia and/or body lengths in juvenile mouse toxicity studies, suggesting that potential growth-retardations by vamorolone cannot be dismissed (see below). Moreover, the potential risk for direct effects on the growth plate and the developing skeleton leading to skeletal fragility cannot be defined yet, because bone mineral density and structure has so far not been analysed.

The missing hydroxyl group at carbon 11 further entails that vamorolone cannot serve as substrate for local  and  systemic  11 β -hydroxysteroid  dehydrogenases  (11β -HSD),  whose  activities  have  been implicated in the adverse side effects of other glucocorticoid drugs (muscle wasting, bone loss, insulin resistance,  hypertension,  and  weight  gain;  Morgan et al., 2014;  Fenton et al .,  2019).  However, experimental confirmation for the lack of vamorolone metabolism via 11β -HSD is lacking. In view of the vamorolone effects on muscle and bone in toxicology studies, it remains therefore to be shown, if the absence of 11β -HSD metabolism translates into a relevant benefit.

The core battery of safety pharmacology studies of vamorolone revealed no inhibition of hERG currents up to 20 µM vamorolone in vitro . The applicant claims that this 20 µM concentration translates into a 45fold safety margin compared to the free vamorolone plasma level of 0.44 µg/ml at the MRHD. However, the documentation of the hERG measurements is rather of exploratory nature and the applicant did not adequately justify the lack of GLP compliance, although the study was conducted in 2010, i.e., after implementation of the pertinent ICH S7A and B guidelines in 2001 and 2005. In addition, the assay was conducted outside the mutual acceptance of data area of the OECD. This limits the scientific reliability of the  hERG  assay  results.  Nevertheless,  oral  vamorolone  doses  up  to  50 mg/kg  did  not  impair cardiovascular and respiratory function in telemetered dogs. Likewise, multiple oral administrations of the same dose in the chronic toxicity study in dogs did not affect ECG parameters, but induced reversible mild heart rate increases at the 39-week post dose interval. The corresponding mean Cmax of about 1.21 µg/ml  vamorolone  is  slightly  below  human  peak  plasma  levels  at  the  MRHD  of  vamorolone (1.31 µg/ml).  A  minor  safety  margin  might  still  exist,  if  the  lower  plasma  protein  binding  in  dogs compared to humans is considered (free fraction of 21 % vs. 12 %). Although, vamorolone did not impact on the QT interval in a clinical single (SAD) and multiple (MAD) ascending dose trial in healthy adult  volunteers  (study  no.  VBP15-001),  three  DMD  patients  administered  vamorolone  in  clinical phase 2b presented with QTcF &gt;60 msec over baseline and another DMD patients with absolute QTcF &gt;500 msec (study no. VBP015-004). This issue was hence clinically pursued.

Vamorolone did not stimulate neurobehavioural abnormalities in a functional observation battery in mice and in juvenile toxicity studies in this species. However, adversely decreased activity and impaired limb function was noted upon chronic administration of the 50 mg/kg/day vamorolone high dose in dogs, which might be reflective of psychiatric symptoms known from clinical therapy of high glucocorticoid doses (Harris et al ., 2015).

<div style=\"page-break-after: always\"></div>

## Pharmacokinetics

Two  differently labelled vamorolone substances were used as internal standard during final methodological validations for quantification in mouse plasma and dog plasma and in the mass-balance investigation in rats. Both compounds contained the respective  13 CD3- and  14 C-radiolabels at the same carbon atom, which bares a negligible impact on the respective determinations.

Single oral doses vamorolone were rapidly absorbed (tmax of 2 h) with high bioavailability of 74.5 % in mice, while absorption was delayed to 4-6 h and bioavailability lower (~48-53 %) in rats and dogs. Multiple administrations dose-proportionally increased vamorolone exposure (Cmax and AUC0-24h) in all animal species, but clearly dropped during prolonged administrations in mice and monkeys (1.2- to 5.7fold lower). Conversely, the vamorolone exposure increased in dogs (1.2- to 3.2-fold) pointing towards accumulation. The reason for the vamorolone decline in mice and monkeys compared to the accumulation in dogs is unknown but was regarded clinically irrelevant as it had not been observed in humans.

Vamorolone showed extensive tissue distribution reaching highest levels in the gastrointestinal tract and liver compared to low (~3 %) but retained levels in skeletal muscle, heart and kidney medulla. The slight binding to melanin-containing retina layers is not of concern (see discussion on the phototoxic potential below). The placental and milk transfer of vamorolone has not been investigated, which is regarded dispensable in view of the envisaged patient population and had been earlier considered by the CHMP during protocol assistance concerning the possibility to waive reproduction toxicity studies.

Vamorolone was metabolically stable in liver microsomes or hepatocytes of mice, dogs, monkeys and humans  (88.5-100 %),  while  it  was  extensively  degraded  in  rats  (35 %).  However,  the  profiling experiments to determine the involvement of hepatic CYPs  and  UGTs  in the hydroxylation, hydrogenation, hydroxyl oxidation and glucuronidation reactions are of limited scientific value, because the submitted study reports do not even meet the standards for documentation of academic research and lack any comprehensible delineation of methodological particulars, results and discussion. Hence, the involvement of particular CYPs and UGTs cannot be reliably concluded from these investigations. This gap in the scientific knowledge has been adequately specified in section 5.2 of the SmPC.

The  metabolism  of  vamorolone  has  not  been  completely  elucidated in vivo .  Still,  the  comparison  of animal  data  with  human  profiles  of  paediatric  and  adult  subjects  indicates  that  at  least  all  major metabolites  were  identified.  Overall,  ten  circulating  metabolites  of  vamorolone  were  determined  in plasma  of  mice,  dogs  and  adult  healthy  human  volunteers  that  were  sequentially  numbered  and generated by oxidation, hydrogenation, dehydrogenation, glucuronidation or the combination thereof. Four major glucuronide metabolites were found that amount to &gt;10 % of the total vamorolone-related AUC in human plasma, but only the hydrogenated main glucuronide M7 was similarly quantified in dogs. In contrast, the direct O-glucuronide M3 of vamorolone and the hydrogenated major glucuronides M8 and M9 just amounted to &lt;1 % of total drug levels in mice and dogs. The applicant claims that the three disproportionate human glucuronide metabolites M3, M8 and M9 are pharmacologically inactive and, hence, toxicologically irrelevant. However, these glucuronides were not tested for potential GR activity, so the proposed impact of steric hindrance between the steroid and glucuronide structures, which could potentially further reduce the reactivity of the keto group in the respective metabolites remains unknown. Nevertheless,  the applicant clarified that glucuronidation  of  the  three  disproportionate  human metabolites M3, M8 and M9 occurs at the respective hydroxyl groups resulting in the formation of Oglucuronides, which are usually pharmacologically inactive. As the possible impact on the predictive value of the toxicology programme was considered for section 5.3 of the proposed SmPC, the issue is not further pursued.

In bile duct-cannulated rats and in the mass-balance study, unchanged vamorolone was only recovered in tiny amounts in plasma and was primarily excreted via faeces (~80 %) within 24 h. The high metabolic

<div style=\"page-break-after: always\"></div>

capacity and rapid excretion in rats likely prompted the selection of mice for the toxicology programme of vamorolone.

PK DDI studies only demonstrated significant CYP3A4 induction at ≥15 µM vamorolone. With respect to the unbound clinical Cmax of 0.44 µM at the MRHD of vamorolone, its potential for clinically relevant CYP3A4 induction seems to be low. No relevant inhibition of CYP enzymes by vamorolone was found. The minor inhibition of UGT1A1 and UGT2B7 by 50 µM vamorolone is regarded clinically irrelevant given its &gt;110-fold lower unbound Cmax at the MRHD (0.44 µM).

Vamorolone was no substrate  for  major  drug  transporters  and  only  inhibited  the  renal  transporters MATE2-K with IC50 of 12.9 µM and OAT3 with IC50 of 19.6 µM. The pertinent European guideline entails that relevant in vivo inhibition of renal transporters can only be excluded if the inhibition constant is higher or equal to 50-times the unbound peak plasma drug concentration (CPMP/EWP/560/95/Rev. 1 Corr. 2). The IC50 of MATE2-K is lower than 50x the unbound Cmax of 0.44 µM vamorolone (22 µM), while that  of  OAT3  is  almost  equivalent.  Thus,  the  potential  clinical  risk  for  interactions  with  these  renal transporters required further discussion, which was clinically pursued.

## Toxicology

The mild to moderate lymphocyte depletions in spleen, thymus and lymph nodes at vamorolone doses ≥5 mg/kg/day in mice and ≥2 mg/kg/day in dogs are related to the primary anti-inflammatory activity of  vamorolone  as  indicated  in  section 5.1  of  the  proposed  SmPC.  The  obvious  sex  difference  in  the inhibition  of  the  TDAR  between  male  and  female  mice  by  100 mg/kg/day  vamorolone  compared  to ≥10 mg/kg/day  prednisolone  might  be  attributable  to  the  distinct  interference  of  androgens  and oestrogens with T and B cell responses (Da Silva, 1999).

Vamorolone doses ≥10 mg/kg/day induced partially reversible liver hypertrophy in all toxicity studies in mice and dogs, which correlated with mild to moderate centrilobular hepatocyte vacuolation containing glycogen  and  lipid  accumulations,  likely  reflects  the  stimulation  of  gluconeogenesis  as  previously reported for prednisone (Fittschen and Bellamy, 1984; Harris et al ., 2015). Secondary to the observed hepatic  hypertrophy  and  vacuolation,  hepatocellular  and  focal/subcapsular  inflammation/necrosis developed  dose-  and  timedependently  at  ≥15 mg/kg/day  in  mice  and  at  50 mg/kg/day  in  dogs. Concomitantly, lipid metabolism was altered, inflammatory markers and liver enzymes (ALT, AST, AP and bilirubin) were elevated in mice and dogs. GGT was found to be additionally increased in dogs and had been selected, because it was described as better suited marker for hepatic injury in DMD patients given its preferential liver expression (Rosales et al . 2008), whereas the release of AST and AP from dystrophic muscle hampers the reliable interpretation of their blood elevations. Of note, mean levels of GGT and glutamate dehydrogenase, another liver specific enzyme with potential prognostic value in DMD (Schomaker et al .,  2020),  were  largely  within  normal  limits  in  the  course  of  various  clinical  trials  of vamorolone.  Nevertheless,  glucocorticoid  drugs  are  well-known  to  damage  the  liver.  Albeit  hepatic toxicity  is  already  listed  as  important  potential  risk  in  the  risk  management  plan  (RMP),  the  SmPC includes routine risk minimisation measures in sections 4.2, 4.3 and 4.4.

The applicant interpreted the pancreatic islet hypertrophy in mice of the 45 mg/kg/day high dose group of the chronic toxicity study as pharmacologically-mediated adaptive change. This is agreed given the apparent induction of hepatic gluconeogenesis by vamorolone (see above) and the known potential of glucocorticoids  to  induce  insulin  resistance  leading  to  compensatory  pancreatic β -cell  hyperplasia (Greaves, 2012; Harris et al ., 2015). The elevated fasting insulin following administration of the MRHD of vamorolone in human DMD patients similarly points towards higher pancreatic islet activity, but no increased incidences of diabetes conditions were noticed. This was followed from a clinical perspective.

The adrenal cortical atrophies in the zona fasciculata and reticularis observed upon repeated vamorolone dosing ≥5 mg/kg/day in mice and ≥2 mg/kg/day in dogs that relatively spare the zona glomerulosa

<div style=\"page-break-after: always\"></div>

coincide  with  existing  experience  gained  with  other  glucocorticoid  agents  (Greaves,  2012)  and  are, hence,  ascribable  to  the  suppression  of  the  hypothalamic-pituitary-adrenal  (HPA)  axis.  Excess glucocorticoid  administration  leads  to  negative  feedback  in  the  pituitary  gland  resulting  in  the suppression of ACTH secretion (Rosol et al ., 2001). This in turn inhibits CYP11A1 and leads to reduced cholesterol metabolism, accumulation of fat vacuoles in the cortical cells, and eventual adrenal cortex atrophy, because ACTH is important for maintaining cortical cell numbers. Impaired adrenal function is a well-established side effect of long-term glucocorticoid administration (Harris et al ., 2015). As adrenal insufficiency has been also noted in vamorolone-treated DMD patients, a warning has been proposed in section 4.4  of  the  SmPC,  whereas  adrenal  suppression  is  listed  as  undesirable  effect  in  section 4.8. Nevertheless, this issue requires clinical follow-up (see clinical AR).

In  contrast,  the  higher  kidney  weights  with  bilateral  tubular  vacuolation,  increased  diuresis  and dehydration after chronic vamorolone administration ≥10 mg/kg/day in dogs, which persisted with lower severity in dogs of the high dose group at the end of the recovery phase but were not seen in mice are of unlikely clinical significance, because kidney findings developed at lower exposure of dogs compared to DMD patients receiving the MRHD. In addition, kidney function was not impaired during short and long-term clinical vamorolone therapy.

Vamorolone  did  not  significantly  affect  sperm  morphology,  motility  and  viability  after  long-term treatment of adult and juvenile mice. However, spermatocytes and spermatids were found to degenerate in the testes of male dogs administered 50 mg/kg/day vamorolone in the chronic toxicity study resulting in oligospermia and germ cell debris in the epididymides. Moreover, the prostate gland of these males was  smaller  and  contained  less  exudate.  The  sperm  degenerations  were  incompletely  and  prostate effects not reversible. Nevertheless, the duration of a complete spermatogenic cycle in Beagle dogs of around  60 days  was  not  covered  by  the  rather  short  recovery  period,  so  reversibility  could  not  be adequately assessed (Soares JM et al .  2009). The impairments of male dog fertility were meanwhile highlighted in section 4.6 of the SmPC with more detailed description of the findings in section 5.3.

Vamorolone even more severely impacted on female fertility. Repeated vamorolone doses ≥30 mg/kg/day  for  28 days  diminished  ovarian  weights  in  mice  and  uterus/cervix  weight  in  dogs, whereas longterm administrations of ≥2 mg/kg/day for 39 weeks in dogs eliminated ovarian corpora lutea and  induced  mild  epithelial  vacuolation  in  mammary  ducts.  As  the  lack  of corpora  lutea was incompletely reversible, a NOAEL could not be established for female dogs in the chronic toxicity study. However, the impaired female fertility is insignificant for the intended clinical indication DMD, which as an X-linked disease almost exclusively affects boys.

The suppression of male and female fertility by vamorolone is mechanistically related to the known interference of exogenous  glucocorticoids with the hypothalamus-pituitary-gonadal axis, which 1) decreases the gonadotropin-releasing hormone secretion by the hypothalamus that leads to 2) the reduced  release  of  luteinizing  hormone  and  follicle-stimulating  hormone  from  the  pituitary  and subsequently  3) inhibits  gonadal  gametogenesis.  In  addition,  glucocorticoids  also  directly  suppress steroidogenesis in the testis and ovary (reviewed by Whirledge and Cidlowski, 2010). The androgen biosynthesis can be further impacted by adrenal insufficiency.

The  causality  for  the  increased  thyroid/parathyroid  gland  weight  by  chronic  vamorolone  doses ≥10 mg/kg/day in male dogs remains to be unravelled, because glucocorticoid agents generally interfere with  the  hypothalamic-pituitary-thyroid  axis  resulting  in  decreased  secretion  of  thyroid-stimulating hormone (TSH) by the pituitary (Wilber and Utiger, 1969). In fact, lower serum TSH levels were found in several dogs administered 180 mg/kg/day vamorolone in the exploratory 28 days repeat-dose toxicity study, although the poor assay sensitivity and low number of study animals (n=2/sex/group) hampered reliable  conclusions.  Of  note,  thyroid  function  was  not  evaluated  during  clinical  development  of

<div style=\"page-break-after: always\"></div>

vamorolone, but a warning is proposed in section 4.4 of the SmPC. This issue was therefore clinically discussed.

In the chronic toxicity study in dogs, vamorolone doses ≥10 mg/kg/day induced minimal to moderate increases of multifocal to diffuse cytoplasmic epithelial basophilia with the parotid salivary glands of both sexes. The severity of this finding was reduced at the end of the recovery period but did not completely recover in affected males and remained detectable in one female dog of the 10 mg/kg/day group. These parotid  gland  findings  were  associated  with  excess  salivation,  which  started  from  weeks 6  to  8  and continued throughout the study and were also noted in vehicle-controls. A causal relationship with the Labrasol/0.5 % carboxymethylcellulose vehicle appears therefore reasonable considering also that this vehicle was not used in other toxicology species.

Vamorolone  reduced  epidermal  collagen  of  the  skin  resulting  in  alopecia/hypotrichosis  at  doses  of 100 mg/kg/day for 28 days and 45 mg/kg/day for 26 weeks in mice as well as at ≥10 mg/kg/day for 39 weeks in individual dogs. Decreased anagen follicles were incompletely reversible in most mice that had previously received ≥15 mg/kg/day vamorolone, while they almost completely resolved in dogs. Compromised skin integrity is a common adverse effect of glucocorticoid drugs (Harris et al ., 2015), but the incidences of skin and hair alterations were generally low and similar across treatment groups in the clinical programme of vamorolone. Thus, the non-clinical findings do not warrant specific RMMs.

Of note, partially reversible mild skeletal muscle atrophy of the exemplarily investigated biceps femoris was found in both sexes of dogs treated with 50 mg/kg/day vamorolone in the chronic toxicity study. This  muscular  atrophy  in  dogs  contrasts  the  preservation  of  skeletal  muscle  function  as  well  as  the protection  from  muscular  inflammation  and  degeneration  by  30 mg/kg/day  vamorolone  in  mdx  and PND 12 mice. Thus, non-clinical data cannot unequivocally support the claimed therapeutic benefit of vamorolone in DMD patients.

Despite  lower  body  weights  after  vamorolone  doses  of  ≥10 mg/kg/day  for  28 days  in  mice  and  at ≥60 mg/kg/day in the exploratory 28 days toxicity study in dogs, prolonged vamorolone administrations of  45 mg/kg/day  for  26 weeks in mice and of ≥10 mg/kg/day  for  39 weeks  in  dogs  increased  food consumption and, hence, body weights. Upon cessation of vamorolone treatment, body weights tended to lower, but remained slightly elevated in accordance with the food consumption of mice, while they were diminished in dogs. Increased body weights and appetite are frequent adverse events during longterm glucocorticoid therapy (Harris et al .,  2015), have been observed in the clinical development of vamorolone and are listed in section 4.8 of the proposed SmPC.

Longterm vamorolone dosing ≥2 mg/kg/day in male and at 50 mg/kg/day in female dogs minimally to mildly increased numbers of adipocytes in the bone marrow of the sternum that displaced haematopoietic tissue.  No  comparable  effect  was  apparently  identified  during  inspection  of  femur  bone  marrow  and sternal findings normalised in the recovery period. The study director hypothesised a pharmacological relationship  of  vamorolone  with  the  adipocyte  increases,  which  seems  plausible,  because  long-term glucocorticoid treatment reduces bone mass by contributing to decreased osteogenic at the expense of increased adipogenic differentiation from mesenchymal stem cells (reviewed by Hachemi et al ., 2018). Although vamorolone did not affect bone length (femur, tibia) in the chronic toxicity studies in mice and dogs, bone development bone was impaired in PND 12, young mdx mice (Damsker et al ., 2013) and particularly in juvenile mice (see below).

In view of these toxicities, the vamorolone high dose of 45 mg/kg/day was established as NOAEL during chronic  treatment  of  mice,  which  might  be  questioned  given  the  incomplete  reversibility  of  hepatic inflammation/necrosis and adrenal atrophies. Following long-term vamorolone administration in dogs, the adversity of adrenal toxicities led to a NOAEL of 2 mg/kg/day in male dogs, whereas no NOAEL could be established for females due to the partially reversible lack of corpora lutea . At these NOAELs, both Cmax- and AUC-based safety margins with respect to the exposure in human DMD patients receiving the

<div style=\"page-break-after: always\"></div>

MRHD were negligible in mice or not definable in dogs. This limits the predictive value of the toxicology programme and has meanwhile been considered in section 5.3 of the SmPC.

Vamorolone did not exert a relevant genotoxic potential in vitro and in vivo . A sufficiently high safety margin can be assumed based on toxicokinetic data of repeat-dose toxicity studies in mice. This been sufficiently summarised in section 5.3 of the proposed SmPC. Accordingly, the applicant plans to defer carcinogenicity studies post-approval as previously agreed with the CHMP (EMA/CHMP/SAWP/545127/2019).  However,  vamorolone did not induce treatment-related preneoplastic lesions in chronic toxicity studies in mice and dogs. It should be also noted that long-term clinical  therapy  with  other  glucocorticoids  do  not  suggest  a  particular  carcinogenic  hazard  of  this pharmaceutical class. In view of the recently published ICH S1B(R1) guideline (EMA/774371/2022), it is therefore suggested to reconsider the need for 2-year carcinogenicity studies.

The absence of a standard battery of developmental and reproductive toxicology studies for the MAA is considered acceptable in accordance with the ICH S5 guideline and earlier CHMP protocol assistance (EMA/CHMP/SAWP/545127/2019).

Among toxicities in juvenile mice, which differed from adult counterparts, partially reversible minimal to mild mandibulary salivary gland hypertrophy developed at ≥15 mg/kg vamorolone without any safety margin regarding human exposure at the MRHD. These salivary gland changes have been adequately reflected in section 5.3 of the SmPC. Literature data also suggest a potential effect of vamorolone on salivary gland development in juvenile mice and that juvenile mice may be more vulnerable than adults due to the cellular differentiation of the salivary gland in the postnatal phase. As the human relevance is  currently unknown, the applicant agreed to include specific evaluations of salivary glands into the design of a future 10-week juvenile toxicity study in mice aged 5-7 days at study start, in case this study will be conducted to support clinical treatment of younger children.

The reduced mean tibia and body length in males each at 100 mg/kg and ≥15 mg/kg vamorolone and the shortened tibia length at ≥30 mg/kg in females were attributed to the slower growth of the animals, because findings correlated with lower body weights. Nevertheless, the observations rather suggest that vamorolone has the potential to induce growth retardation like other glucocorticoids. The effects on tibia and/or body lengths occurred at the lowest dose group for which no safety margin to human exposure exists. Therefore, these effects should be regarded as clinically relevant and adverse. The findings on tibia and body lengths are adequately reflected in section 5.3 of the SmPC.

Another well-known effect of chronic glucocorticoid administration is the induction of osteoporosis, which has  been  also  reported  in  children  (Ward,  2020).  Glucocorticoids  have  diverse  direct  effects  on  the growth plate and developing skeleton leading to skeletal fragility. Unfortunately, no investigations on bone mineral density and bone structure as well as biomarkers of bone metabolism have been performed in  the  juvenile  mouse  toxicity  studies.  According  to  the  latest  PDCO  opinion  for  vamorolone  (EMEA001794-PIP02-10-M05), June 2022, however, the applicant plans to conduct a 10-week juvenile toxicity study in CD-1 mice aged 5-7 days at study start and agreed to include measurements of bone mineral density and bone structure and investigations of biomarkers of bone metabolism into the design of this study.

Vamorolone apparently did not affect sexual maturation and fertility in male and female juvenile mice, but markedly increased pre- and post-implantation losses and decreased numbers of viable embryos were observed at 100 mg/kg vamorolone. Variabilities in the respective study designs precluded the comparison with historical  control  data  from  the  contract  laboratory.  However,  the  comparison  with historical controls from previous pre-/postnatal development studies indicated general concordance in the numbers of viable foetuses, which resolved further concerns.

The major findings from the juvenile toxicity studies in mice were included into section 5.3 of the SmPC.

<div style=\"page-break-after: always\"></div>

Vamorolone  did  not  absorb  in  the  range  of  290-400 nM  and  its  MEC  is  substantially  above  the 1000 l·mol -1 ·cm -1 threshold for photoreactive compounds of the ICH S10 guideline (EMA/CHMP/ICH/752211/2012). Although vamorolone could be traced at low levels in eye and skin of rats in the QWBA study, no ophthalmological abnormalities were detected in repeat-dose toxicity studies with vamorolone for up to 26 weeks in mice, 39 weeks in dogs and 7 days in monkeys. During clinical development,  vamorolone  did  not  induce  cataracts  and  intraocular  pressure  even  normalised  after switching  from  prednisone  to  vamorolone.  Moreover,  skin  changes  were  generally  similar  between human treatment groups. As Vamorolone shows close structural relationship with other glucocorticoids, which  are  topically  and  systemically  used  for  therapy  of  acute  dermal  photosensitivity  reactions (Khandpur et al ., 2017), a significant phototoxic potential of vamorolone is regarded unlikely and further investigations are not deemed necessary.

The  quantitative  structure-activity  relationship  (SAR) in silico analyses  of  the  two  drug  substance impurities VBP-15-B-2 and VBP-15-B-3 using expert rule- and statistical-based MultiCASE Ultra and the expert rule-based Derek Nexus software did not identify any genotoxic potential.

The impurity profile of vamorolone includes potentially 16 β -vamorolone, vamorolone acetate and ketovamorolone, which have been qualified at 1.8- to 6.2-fold multiples in the chronic toxicity study in mice.

As a result of the above considerations, the available data do not allow to conclude definitively on the potential risk of vamorolone to the environment.

The applicant commits to perform the following studies as follow-up measures:

The applicant confirms its commitment in conducting the tiered ERA Phase II in the context of a post approval commitment and commits to conducting the studies proposed by CHMP, based on whether vamorolone is readily biodegradable.

- The biodegradability studies for vamorolone shall take place in Q1-2024, and results will be submitted by end Q1-2025.
- Aerobic and Anaerobic Transformation in Aquatic Sediment System (OECD TG 308) study is planned to start in Q1-2025 and results will be submitted by end Q3-2025.
- Literature review daphnia reproduction is planned for Q1-2025 which includes a CHMP request to waive daphnia reproduction if daphnia are less sensitive than fish.
- The applicant starts to conduct a daphnia reproduction study (OECD TG 211) if daphnia are more sensitive than fish by Q1-2025 with final results to be submitted by end Q3-2025.
- Medaka Extended One Generation Reproduction Test (chronic fish full life-cycle study) (OECD TG 240) study is planned to start Q1-2025 and the results will be submitted by end Q3-2027.

## 2.5.7. Conclusion on the non-clinical aspects

All but one of the 'Other concerns' raised in the non-clinical assessment have been resolved. Comments on the product information have adequately been addressed. From a non-clinical point of view, marketing authorisation can be considered.

The CHMP considers the following measures necessary to address the non-clinical issues:

The applicant confirms its commitment in conducting the tiered ERA Phase II in the context of a post approval commitment and commits to conducting the studies proposed by CHMP, based on whether vamorolone is readily biodegradable.

<div style=\"page-break-after: always\"></div>

- The biodegradability studies for vamorolone shall take place in Q1-2024, and results will be submitted by end Q1-2025.
- Aerobic and Anaerobic Transformation in Aquatic Sediment System (OECD TG 308) study is planned to start in Q1-2025 and results will be submitted by end Q3-2025.
- Literature review daphnia reproduction is planned for Q1-2025 which includes a CHMP request to waive daphnia reproduction if daphnia are less sensitive than fish.
- The applicant starts to conduct a daphnia reproduction study (OECD TG 211) if daphnia are more sensitive than fish by Q1-2025 with final results to be submitted by end Q3-2025.
- Medaka Extended One Generation Reproduction Test (chronic fish full life-cycle study) (OECD TG 240) study is planned to start Q1-2025 and the results will be submitted by end Q3-2027.

## 2.6. Clinical aspects

## 2.6.1. Introduction

## GCP aspects

The Clinical trials were performed in accordance with GCP as claimed by the applicant.

The applicant has provided a statement to the effect that clinical trials conducted outside the Community were carried out in accordance with the ethical standards of Directive 2001/20/EC.

- Tabular overview of clinical studies

<div style=\"page-break-after: always\"></div>

Table 2: Overview of vamorolone clinical studies and other supportive studies for the treatment of DMD

| Trial No. NCT No. Eudract No.         | Study Design and Description                                                                                                                                                                                                                                                                                                                                                                                                                                                            | Number of Subjects and Population to be studied                                                       | Study Drug Regimen, Schedule, and Route                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | Study Objectives/ Primary Endpoint                                                                                                                                                                                                                             | Safety Assessments                                                                                                                                                              | No. of Centers Countries                                                                  |
|---------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------|
| Controlled Studies in DMD             | Controlled Studies in DMD                                                                                                                                                                                                                                                                                                                                                                                                                                                               | Controlled Studies in DMD                                                                             | Controlled Studies in DMD                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | Controlled Studies in DMD                                                                                                                                                                                                                                      | Controlled Studies in DMD                                                                                                                                                       | Controlled Studies in DMD                                                                 |
| VBP15-004 NCT03439670 2017-002704-27  | Phase 2b , randomised, double-blind, parallel group, placebo- and active- controlled; To evaluate the efficacy, safety, tolerability, PD, and PPK of vamorolone vs. placebo and prednisone and to evaluate persistence of effect over a 48- week treatment period. The study comprised the following periods: Treatment Period #1 24 weeks (Weeks 1- 24) Transition Period 4 weeks (Weeks 25-28) Treatment Period #2 20 weeks (Weeks 28-48) Dose tapering Period 4 weeks (Weeks 49- 52) | 121 ambulant boys with DMD between 4 to <7 years of age at study entry, who were corticosteroid naïve | Subjects were allocated to 1 of the 6 treatment groups in a 2:2:1:1:1:1 ratio as follows: 1. Vamorolone 2 mg/kg whole study 2. Vamorolone 6 mg/kg whole study 3. Prednisone 0.75 mg/kg in Treatment Period # 1 then Vamorolone 2 mg/kg in Treatment Period #2 4. Prednisone 0.75 mg/kg in Treatment Period # 1 then Vamorolone 6 mg/kg in Treatment Period #2 5. Placebo in Treatment Period # 1 then Vamorolone 2 mg/kg in Treatment Period #2 6. Placebo in Treatment Period # 1 then Vamorolone 2 mg/kg in Treatment Period #2 | PK, PD, efficacy, safety and tolerability Primary endpoint: change from baseline in TTSTAND velocity (rises/sec) for the vamorolone 6 mg/kg group compared to placebo at Week 24                                                                               | AEs, muscle function, BMI, physical examinations, vital signs, ECG, and clinical laboratory evaluation of hematological and biochemical parameters (blood sample, urine sample) | 33 centers: Australia Belgium Canada Czech Republic Greece Israel Netherlands Spain UK US |
| Uncontrolled Studies in DMD           | Uncontrolled Studies in DMD                                                                                                                                                                                                                                                                                                                                                                                                                                                             | Uncontrolled Studies in DMD                                                                           | Uncontrolled Studies in DMD                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | Uncontrolled Studies in DMD                                                                                                                                                                                                                                    | Uncontrolled Studies in DMD                                                                                                                                                     | Uncontrolled Studies in DMD                                                               |
| VBP15-002 NCT 02760264 2016-004262-26 | Phase 2a , open-label, MAD study to assess the safety, tolerability, PK, PD, and exploratory efficacy of vamorolone in boys with DMD over a 14-day treatment period, followed by a 14-day post- treatment follow-up period                                                                                                                                                                                                                                                              | 48 ambulant boys with DMD between 4 to <7 years of age at study entry, who were corticosteroid naïve  | VAM 0.25, 0.75, 2.0, and 6.0 mg/kg Orally QD for 14 days                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | Safety, tolerability, PK, PD and exploratory efficacy Primary objective: safety and tolerability Exploratory objectives: Efficacy: QMT, TTRW, TTSTAND, TTCLIMB, NSAA, 6MWT                                                                                     | See above                                                                                                                                                                       | 11 centers: Australia Canada Israel Sweden US                                             |
| VBP15-003 NCT02760277 2016-004263-38  | Phase 2 , multicenter, open-label, multiple dose, sequential assignment, 24 weeks extension study to assess the long-term safety and efficacy of vamorolone in boys with DMD                                                                                                                                                                                                                                                                                                            | 48 ambulant boys with DMD, who completed Study VBP15-002                                              | VAM 0.25, 0.75, 2, and 6 mg/kg/day orally QD for 24 weeks                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | Long-term safety, tolerability, efficacy and PD Primary objective: Long-term safety, tolerability, efficacy Primary efficacy endpoint: TTSTAND velocity: comparison to an untreated historical control group (CINRG DNHS) for change from baseline to Week 24. | See above                                                                                                                                                                       | 11 centers: Australia Canada Israel Sweden US                                             |
| VBP15-LTE NCT03038399 2017-003568-10  | Phase 2 open-label, parallel group, multicenter long term, 24 months extension study to assess the long term safety and efficacy of vamorolone in boys with DMD                                                                                                                                                                                                                                                                                                                         | 46 ambulant boys with DMD who completed Study VBP15-003; Maximum age at                               | VAM up to 6 mg/kg/day orally QD for 24 months. Dose adjustment was allowed between dose levels of 2, 4 and 6 mg/kg/day 1                                                                                                                                                                                                                                                                                                                                                                                                          | Long-term safety, tolerability, efficacy and PD Primary objective: Long-term safety, tolerability, efficacy                                                                                                                                                    | See above                                                                                                                                                                       | 11 centers: Australia Canada Israel Sweden US                                             |

<div style=\"page-break-after: always\"></div>

| Trial No. NCT No. Eudract No.                                | Study Design and Description                                                                                                    | Number of Subjects and Population to be studied                       | Study Drug Regimen, Schedule, and Route                                                                                     | Study Objectives/ Primary Endpoint                                                                                                                                                                                                                                                                                                                       | Safety Assessments                                                                                        | No. of Centers Countries              |
|--------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------|---------------------------------------|
|                                                              |                                                                                                                                 | completion was 9.6 years                                              |                                                                                                                             | Primary efficacy endpoint: TTSTAND velocity change from VBP15-002 baseline to VBP15-LTE Month 24.                                                                                                                                                                                                                                                        |                                                                                                           |                                       |
| External comparison FOR-DMD NCT01603407 EudraCT: 20100237443 | Phase III randomised, prospective, interventional, double-blind, 36-60 months study, comparing 3 corticosteroid regimens in DMD | 196 male subjects with DMD aged ≥ 4 years and< 8 years at study entry | Daily prednisone (0.75 mg/kg): Intermittent prednisone (0.75 mg/kg, 10 days on, 10 days off) Daily deflazacort (0.9 mg/kg). | Comparison of three commonly used corticosteroid regimens in regard to functional outcome and treatment satisfaction Primary endpoint: a three-dimensional (multivariate) outcome of 1) time to rise from floor, from supine to standing, 2) forced vital capacity, and 3) global satisfaction with Treatment Satisfaction Questionnaire for Medication. | AEs, clinical laboratory evaluations, physical examinations, vital signs, ECGs, DXA, and spinal fractures | 40 sites: Canada Germany Italy UK USA |

1 Subjects who received 0.25 or 0.75 mg/kg were allowed to escalate the vamorolone dose to the next higher dose level after receiving the current dose level for at least 1 month, with a maximum of 3 dose level escalations, to the maximum of 6.0 mg/kg/day; subjects were allowed to de -escalate vamorolone dose due to intolerability. Subjects whose dose level was decreased from 6.0 mg/kg/day to 2.0 kg/kg/day could have their dose level subsequently increa sed to 4.0 mg/kg/day per Amendment #1 if they had been on the 2.0 mg/kg/day dose level for at least 1 month and, in the opini on of the investigator,  balancing  efficacy  with  safety  concerns,  they  could  have  benefited  from  an  intermediate  higher  dose  level.  LTE=long-term  extension;  MAD=multiple  ascending  dose;  PBO=placebo; PRED=prednisone;  QD=once  daily;  UK=United  Kingdom;  US=United  States;  VAM=vamorolone;  AE  =  adverse  event;  BMI  =  body  mass  index;  DMD  =  Duchenne  muscular  dystrophy;  ECG  = electrocardiogram; PD = pharmacodynamics; PK = pharmacokinetics; PPK = population pharmacokinetics; daily; SAE = serious adverse event; QMT = Quantitative Muscle Testing; TTRW = Time to Run/Walk 10 Meters Test; TTSTAND = Time to Stand Test; TTCLIMB = Time to Climb Test; NSAA = North Star Ambulatory Assessment; 6MWT = Six-minute Walk Test

<div style=\"page-break-after: always\"></div>

## 2.6.2. Clinical pharmacology

## 2.6.2.1. Pharmacokinetics

## Summary of pharmacokinetic properties

Vamorolone is well absorbed and distributes quickly into tissues. The major route of elimination is by metabolism  with  subsequent  excretion  of  metabolites  into  urine  and  feces.  The  PK  are  linear  and vamorolone exposure increases proportionally with either single or multiple doses. Vamorolone does not accumulate with repeated administration.

## Analytical methods

In general validations of bioanalytical methods used for analysis of different clinical trials samples have been  performed  in  accordance  with  the  requirements  stated  in  the  relevant  European  guideline. Validations are satisfactory performed covering required parameters (selectivity, precision, accuracy, range, linearity, recovery, dilution integrity, stability).

## Modelling

The population PK (popPK) of vamorolone in paediatric DMD patients was adequately described by a one-compartment disposition model with sequential zero-order followed by first order absorption. The elimination  of  vamorolone  was  found  to  be  linear  and  allometric  scaling  was  employed  with  fixed exponents of 0.75 and 1 for oral clearance (CL/F) and oral volume of distribution (V/F), respectively, to include bodyweight into the model. Patient data was limited to the age from 4 to &lt;7 years, which means that statements regarding paediatric and adolescent patients in other age groups (2 to &lt;4 years and 7 to &lt;18 years) were based on extrapolation and simulation. As the shrinkage in absorption parameters in the paediatric popPK model was high (&gt;29%) individual predicted Cmax values could not be used for exposure response modelling, which limited the usefulness of the model. Predicting Cmax precisely in paediatric patients might be relevant for comparing between different formulations used.

The popPK model was updated with PK data from the ongoing study VBP15-006 using the to be Marketed Formulation (ROS2/) 6 mg/kg in patients aged 2 to &lt;4 years (n=2), 7 to &lt;12 years (n=3), and 12 to &lt;18 years (n=1). Although simulations suggest that the youngest age group (2 to &lt;4 years) might show similar exposure compared to patients aged 4 to &lt;7 years, this conclusion is associated with a large degree of uncertainty because of the very low number of cases (n=2).

The popPK model was further updated using data from patients n=16 aged 2 to &lt;4 years and aged 7 to &lt;18 years from ongoing study VBP-006. For the analysis of popPK, data from ongoing study VBP-006 were used for external validation of the model. After validation, VBP-006 data were added to the analysis dataset and the updated final model was used to simulate exposure of different age groups comparing the Clinical Formulation (ROS1) and to be Marketed Formulation (ROS2/). The main difficulty was that the new ROS2 formulation showed higher exposure and was only used in study VBP-006. For the age group 4 to &lt;7 years formulation ROS1 was used. An adjusted dose cap at a weight of 40 kg (at 240 mg for the 6 mg/kg dose and at 160 mg for 4 mg/kg) is supported. The applicant was asked to address the following concerns regarding modelling to ensure that the model is fit for purpose:

To  be  able  to  describe  the  formulation  effect  properly,  effect  of  food  and  effect  of  formulation  on bioavailability should not be combined as covariates in the popPK model. As the effect of ROS2 under fed and fasted conditions was similar (0.556 and 0.571 Intiquan 2023a), one single ROS2 formulation effect was estimated not differentiating between fasted and fed conditions. The redefined model was used to simulate the effect of the different  formulations  on  AUC  for  all  age  groups  in  boxplots  also

<div style=\"page-break-after: always\"></div>

depicting individual data points for AUC. Boxplots were used to compare the AUC for 6 mg/kg, 4 mg/kg, and 2 mg/kg for the ROS2 formulation in patients aged 2 to &lt;4 years to the AUC of 6 mg/kg for the ROS1 formulation in patients aged 4 to &lt;7 years of age (fed status). After refinement of the popPK model, AUC was compared between patients aged 4 to &lt;18 years using 4 mg/kg ROS2 formulation and patients aged 4 to &lt;7 years using 6 mg/kg ROS1 formulation in boxplots also depicting individual data points for AUC to ensure that the exposure is within the target range for dose reduction for different age and weight groups.

Furthermore, body weight was included on volume of distribution using conventional allometric scaling in an updated final model. The current refined model was compared to a model assuming an allometric exponent of body weight effect on volume fixed to 1 and to a modelling estimating the allometric exponent for bodyweight on volume. Forest plots and simulated concentration-time profiles showed an unusually small effect of bodyweight on central volume which might be explained through the flip-flop kinetics of vamorolone.

The popPK model was further used to inform exposure-response modelling for PD effects on morning cortisol and efficacy of vamorolone (North Star Ambulatory Assessment (NSAA), Six-minute Walk Test (6MWT), time to stand (TTSTAND)) which was not accepted (Pharmacodynamics section).

## Absorption

In the single dose study in healthy volunteers after oral administration, vamorolone was relatively rapidly absorbed with median tmax values ranging from 1.5 to 1.78 hours (range 1.00 to 3.00 hours) across dose groups. After peak plasma concentrations are reached, the decline of vamorolone is generally mono exponential with average half-life (t½) values of ≤1.8 hours for the lower doses up to 1 mg/kg and average t½ values between 2.50 and 4.26 hours at doses from 3 to 20 mg/kg.

Consistent with the short t½ relative to the 24-hour dosing frequency, there was no accumulation and concentration  versus  time  profiles  from  Day  1  and  Day  14  are  similar.  Median  tmax  values  were approximately 3 hours after the lowest dose (1.0 mg/kg/day) on Day 1 and Day 14 and seem to be shorter at the higher doses. Median tmax values at doses from 3.0 to 20.0 mg/kg/day ranged from 1 to 2 hours on Day 1 and from 1.25 to 2.5 hours on Day 14.

After oral administration with 8 ounces of whole milk (or its equivalent in fat), the median tmax in DMD boys was 2 hours at 2.0 and 6.0 mg/kg. Estimated vamorolone plasma exposures in subjects with DMD given 6.0 mg/kg/day are on average (mean [SD]) 970 ng/mL (270) and 3606 ng.hr/mL (897) for Cmax and area under the plasma concentration time curve from time 0 to infinity (AUC0-inf), respectively (Day 14).

## Bioavailability and food effect

The absolute bioavailability of vamorolone has not been studied as an intravenous formulation for use in humans is not available. Based on the urinary excretion of vamorolone metabolites it can be assumed that the oral bioavailability of vamorolone under fed conditions is at least 56.7% which is consistent with the bioavailability observed in animal species (range 47.8 to 74.5%).

The effect of food (high-fat meal) on the PK of vamorolone administered as the Clinical Formulation ROS1 was initially investigated in study VBP15-001. The geometric mean Cmax and AUC both increased approximately 2.5-fold when vamorolone Clinical Formulation (ROS1) was administered with a high-fat meal, compared to under fasted conditions. The effect of meal type (low-fat meal and high-fat meal) on the PK of vamorolone after administration of the Clinical Formulation (ROS1) was further evaluated in the  relative  bioavailability  and  food  effect  study  VBP15-PK-FORM-002.  The  results  show  that  a  lowfat/low calorie meal had a similar food effect on the Clinical Formulation (ROS1) compared to the highfat/high calorie meal. The mean vamorolone PK profiles following the two types of meal are essentially

<div style=\"page-break-after: always\"></div>

superimposable. The geometric mean Cmax and median tmax are the same after coadministration with low-fat  or  high-fat  meal.  AUC0-tlast  and  AUC0-inf  are  approximately  9%  higher  with  the  high-fat  meal compared to the low-fat meal, with 90% confidence interval (CI) within the reference range of (80, 125) applied for the evaluation of food effect studies.

The effect of food (low-fat meal and high-fat meal) on the PK of vamorolone after administration of the to be Marketed Formulation (ROS2/) was also evaluated in study VBP15-PK-FORM-002. The results show that the to be Marketed Formulation (ROS2) is much less sensitive to concomitant food intake compared to  the  Clinical  Formulation  (ROS1).  When  the  to  be  Marketed  Formulation  (ROS2/)  is  taken  fasted, vamorolone is absorbed quickly and reaches tmax on average (median) after 1 hour (range 0.5 to 4.0 hours). Concomitant food intake delays the absorption but has little influence on the overall exposure in terms of Cmax and AUC. For the To be Marketed Formulation (ROS2/), the median (range) tmax after a low-fat meal is 2 hours (0.5 to 5.0 hours) and Cmax is slightly reduced by 4% after a low-fat meal when compared to the fasting condition. After the high-fat meal the tmax is similar to the low-fat meal (median 2 hours, range 0.5 to 4 hours) and Cmax is on average 18% lower than after the fasted condition. The overall exposure in terms of AUC (AUC0-tlast and AUC0-inf) is increased by 14% for the low-fat meal and 13% for the high-fat meal when compared to the fasting administration.

Overall, the updated popPK model shows that the food effect for the ROS2/ 'to be marketed' formulation is far less pronounced and intake independent of food is acceptable.

The to be Marketed Formulation (ROS2/) was compared to the Clinical Formulation (ROS1) under fasting conditions in the relative bioavailability study VBP15-PK-FORM and it was shown that the to be Marketed Formulation (ROS2/) shows an improved bioavailability of vamorolone with approximately 2.8-fold higher Cmax and 1.9-fold higher AUC. When administered with a low-fat meal, the difference between the to be Marketed Formulation (ROS2/) and the Clinical Formulation (ROS1) is 14% for AUC and 35% for Cmax. When administered with a high-fat meal, the difference between the to be Marketed Formulation (ROS2/) and the Clinical Formulation (ROS1) is 3% to 4% for AUC and 14% for Cmax.

The differences in vamorolone peak concentrations (35% and 14% higher vamorolone Cmax with the to be Marketed Formulation compared to the clinical formulation when given with a low-fat or high-fat meal, respectively) is not considered clinically relevant as vamorolone does not cause any acute adverse events (AEs) that would potentially be driven by Cmax. The ER evaluation of safety revealed no strong association of safety signals with increased plasma levels. As the new to be Marketed formulation is not bioequivalent with the clinical formulation, the applicant provided an updated popPK model using preliminary PK data from ongoing study VBP15-006. For the new formulation, the 6 mg/kg dose significantly exceeds the predefined  target  exposure  range,  which  could  have  a  potential  impact  on  tolerability.  In  contrast, exposure levels of the 2 mg/kg appeared to be consistently below the predefined range. However, after further updates to the popPK model it is now expected that the ROS2 formulation has an about 20% increase in overall exposure across all age groups and dose levels.

## Distribution

The  protein  binding  of  vamorolone  in  human  plasma  is  approximately  88%.  In  the  blood  partition experiment, the blood to plasma ratio was 0.87 and the red blood cell (RBC) to plasma ratio was 0.74. In the human  mass  balance  study  using  [ 14 C]-vamorolone, radiolabelled vamorolone  and  its metabolite(s) did not appear to distribute into RBCs or other cellular components of whole blood cells.

## Elimination

## Metabolism

The in  vivo metabolism  of  vamorolone  was  investigated  in  plasma,  urine,  and  feces  after  single administration  in  samples  from  a  human  mass  balance  study  (VBP15-MB)  and  after  repeated

<div style=\"page-break-after: always\"></div>

administration (14 days once daily) in plasma samples from the multiple ascending dose study in healthy subjects (VBP15-001) and from the Phase 2a study in DMD patients (VBP15-002).

The major vamorolone metabolite in plasma over 24 hours is the direct glucuronide M5, representing 32.5% of the signal in the sample. The second most abundant metabolite in plasma is M10, which is formed from vamorolone by hydrogenation and glucuronidation and represents 23.3% of the signal in the sample. M10 is further hydrogenated to yield the glucuronides M6 (18.8% of signal) and M8 (20.6% of signal). Vamorolone itself represents 4.4% of signal in plasma over the 24-hour period.

The metabolic pattern in urine confirms the metabolic profile observed in plasma. The four major plasma metabolites M5, M6, M8, and M10 (all glucuronides) are also the major metabolites in urine representing together 36% of dose. Direct excretion of vamorolone into urine is minimal. The major compound related material in feces is vamorolone, representing 55.1% of the sample and 15.4% of dose. The metabolites observed in feces were not identified and seem to represent vamorolone adducts.

While human metabolites are generally well described, the involved enzymes have not been convincingly identified.  Therefore,  the  full  potential  for  DDI  has  not  been  sufficiently  investigated  and  requires additional clarification. It was agreed that the applicant can submit the relevant in vitro study results within 6 months post approval.

Vamorolone metabolic profiling in plasma from DMD patients showed results that were consistent with the evaluations from healthy adult subjects. The two major metabolites were the direct glucuronide M5 and the hydrogenated glucuronide M10 representing 34.42% and 37.84% of total drug related exposure. In plasma from DMD patients, the intermediate M12 was detected in small amounts, while the further hydrogenated glucuronides M6 and M8 were not observed. It is very likely that this difference compared to the metabolic pattern observed in healthy adults is driven by the difference in PK sampling periods. In patients with DMD only samples up to 8 hours were collected and therefore earlier metabolites (e.g., M12) have a higher relative abundance and can therefore be detected. The collection period in healthy adults was 24 hours and therefore downstream metabolites such as M6 and M8 become more relevant and were observed.

UGT1A3 and UGT2B7 and to a minor extent UGT2B17 were identified as the most likely metabolizing enzymes,  although  uncertainties  still  exist  due  to  inadequate  non-clinical  data.  The  UGT  enzymes involved in the drug metabolism and the potential for drug-drug-metabolism are further investigated in new in vitro studies. The applicant has committed to complete the studies within 6 months after approval. With the proposed additional warning provided in the SmPC, this is acceptable. It was further shown that CYP3A4, CYP3A5, CYP2C8, and CYP2C9 can metabolise vamorolone in vitro , but it appears that oxidation via CYPs is a minor pathway of vamorolone metabolism in vivo .

In addition, the applicant has provided four new in  vitro study reports. In addition to the requested investigation of inhibition of CYP enzymes by vamorolone metabolite and inhibition of UGT1A3 by parent drug, the inhibition potential on common drug transporters was investigated. Minor inhibition potential was only found at concentrations that are outside the clinically relevant range.

## Excretion

Following a single oral dose of [ 14 C]-vamorolone in healthy adult male subjects, approximately 30% of dose is excreted in feces (15.4% unchanged) and 57% of dose is excreted in urine as metabolites (&lt; 1% unchanged). The major metabolites in urine are glucuronides (M5, M6, M8 and M10).

## Dose proportionality and time dependencies

In Study VBP15-001 over the single dose range of 0.1 to 20 mg/kg in healthy male adults Cmax and AUC0inf increased proportional with dose. Similar results were obtained for the same dose range on Day 1 and Day 14 of them MAD part of that study. In the assessment of the linearity of the vamorolone PK in

<div style=\"page-break-after: always\"></div>

subjects with DMD on Day 1 and Day 14 of daily dosing the 95% CI of the slope for Cmax and AUC0-inf in plasma did include the value 1.00 indicative of linear relationships across this range of dose levels (0.25 to 6.0 mg/kg).

Vamorolone has an elimination t½ of approximately 2 hours. Consistent with the short t½ relative to the 24-hour dosing frequency, steady state is achieved with the first dose and no accumulation is observed with daily administrations. In healthy adult males, the PK parameters after a single dose of vamorolone under fasting conditions on Day 1 are similar to the PK parameters after 14 days of daily dosing on Day 14. In subjects with DMD, PK profiles on Day 14 compared to PK profiles on Day 1 show slightly higher Cmax and AUC values but the popPK evaluation did not suggest a change in PK over time.

## Special populations

## Impaired Hepatic Function

In Study VBP15 HI (N = 16) comparing subjects with moderate hepatic impairment (HI) (Child-Pugh Class B) with healthy matched controls, average Cmax (geometric mean) was approximately 1.7-fold higher (727 ng/mL in subjects with HI and 439 ng/mL in healthy subjects) and AUC0-inf was increased by approximately 2.6-fold (4760 hr.ng/mL in subjects with HI and 1800 hr.ng/mL in healthy subjects). CL/F and Vz/F were 41.1 L/h and 230 L, respectively, in subjects with moderate HI compared to 97 L/h and 315 L, respectively, in healthy subjects. The vamorolone t1/2 in subjects with moderate HI was on average 3.87 hours compared to 2.25 hours in healthy subjects. The tmax was similar in both populations ranging from 2.00 to 4.00 hours.

In  paediatric  patients  with  DMD,  HI  is  extremely  rare.  The  applicant  provided  justification  that  dose adjustment in moderate but not in mild HI is needed. In patients with moderate HI, the dose should be reduced to 2mg/kg/day for patients up to 40kg and to 80mg for patients with a body weight of 40kg and higher  (SmPC Section 4.2). There is no experience with vamorolone in patients with severe HI and administration is contraindicated (SmPC section 4.3).

## Influence of Weight

The final popK model was used to predict vamorolone PK at different body weight ranges by simulating 200 hypothetical individuals for each year of age from 2 to 18 years with body weights sampled from the NHANES database. AUCss and Cmax were calculated for a dose of 6.0 mg/kg/day with and without caping the dose at certain body weights. For patients weighing up to 40 kg, the 6 mg/kg/day dose provides a consistent exposure in terms of AUCss with &gt; 80% of patients within the target range defined by the vamorolone exposure observed in 4 to &lt; 7-year-old patients. Applying a dose cap of 240 mg for patients above 40 kg is predicted to provide consistent exposure for paediatric patients up to 70 kg but would potentially lead to underdosing in heavier patients weighing more than that. The proposed dosing algorithm of 6 mg/kg for paediatric patients up to 40 kg and a fixed dose of 240 mg for patients weighing 40 kg is predicted to achieve the most consistent vamorolone exposure within the target region across all paediatric age groups.

## Pharmacokinetic interaction studies

Vamorolone is eliminated by various routes involving numerous metabolic enzymes. Clinically significant DDIs  of  vamorolone  with  enzyme  inhibitors  or  inducers  are  therefore  unlikely.  Based  on in  vivo metabolism investigations, glucuronidation was identified as major metabolic pathway for vamorolone.

Further,  the  applicant  has  provided  four  new in  vitro study  reports.  In  addition  to  the  requested investigation of inhibition of CYP enzymes by vamorolone metabolite and inhibition of UGT1A3 by parent drug the inhibition potential on common drug transporters was investigated. Minor inhibition potential was only found at concentrations that are outside the clinically relevant range.

<div style=\"page-break-after: always\"></div>

Since  oxidation  via  CYP3A4  was  observed in  vitro ,  a  DDI  study  with  the  strong  CYP3A4  inhibitor itraconazole was conducted in vivo (VBP15-DDI). The study showed a weak effect of itraconazole on vamorolone PK (1.45-fold increase of vamorolone AUC and no significant effect on Cmax) and confirmed that metabolism via CYP3A4 is a minor pathway for vamorolone. No dose adjustment is recommended when vamorolone is co-administered with CYP3A4 modulators.

The threshold for a potentially clinically relevant interaction as specified in the EMA guidance for DDI investigations was reached for transporters OAT3 and MATK2-K. The signal is borderline. The applicant decided  to  not  perform  a  clinical  study  to  evaluate  the  potential  impact  of  vamorolone  on  these substrates. As in vivo inhibition of OAT3 and MATE2-K cannot be ruled out the issue was further discussed taking  into  account  whether  vamorolone  is  likely  to  be  co-administered  with  compounds  that  are substrates for these transporters. Overall, the risk for clinically relevant interaction seems low and no restrictions in the SmPC are required at present.

## 2.6.2.2. Pharmacodynamics

## Mechanism of action

Vamorolone is a novel dissociated steroid that contains a delta 9,11 double bond in its chemical structure and is  differentiated  from  other  glucocorticoid/corticosteroid  compounds  which,  in  their  active  form, contain a hydroxyl group  in  the  11 β -position.  As  a  consequence,  vamorolone  has  a  unique pharmacological activity profile and acts as selective agonist of the GR, and as antagonist of the MR.

Nonclinical studies have shown that vamorolone maintains transrepression activity (e.g., reduction in the expression of NFĸB mediated inflammatory activity) needed for its anti -inflammatory effect, while reducing the transactivation of  GRE mediated transcriptional responses associated with  some of the corticosteroid  side  effects.  Furthermore,  vamorolone  appears  to  effectively  protect  cell  plasma membranes from physical damage.

## Primary and Secondary pharmacology

## Primary pharmacology

The  SOMAscan  assay  was  utilised  to  analyze  the  response  to  vamorolone  of  the  following  proinflammatory biomarkers: CD23, MDC, IL22BP, LTa1/b2, IGFBP-2, ITGA1 ITGB1, and MMP-12. Of the seven  pre-specified  exploratory  efficacy  biomarkers,  all  but  ITGA1  ITGB1  showed  dose-dependently decreased levels with increasing doses of vamorolone from pre-dose to post two weeks of treatment, suggesting  an  anti-inflammatory  effect  of  vamorolone  similar  to  glucocorticoids.  Four  of  the  7  proinflammatory  efficacy  biomarkers  (CD23,  IL22BP,  MDC,  and  IGFBP-2)  demonstrated  a  statistically significant dose-dependent decrease.

## Secondary pharmacology

Well established PD biomarkers predictive of safety concerns of glucocorticoids were measured in various clinical studies with vamorolone. These biomarkers are related to insulin resistance (fasting glucose and insulin),  adrenal  suppression  (first  in  morning  cortisol  and  ACTH)  and  changes  in  bone  turnover (osteocalcin, procollagen 1 N-terminal propeptide (P1NP) for bone formation and Type 1 collagen Ctelopeptides (CTX) for bone resorption).

Results should be considered exploratory in nature and interpreted with caution. They might hint at a more favourable side effect profile compared to common glucocorticoids, however ultimately adequate long-term clinical safety data for the relevant age groups are required. Further details can be found as part of the clinical safety assessment on bone health.

<div style=\"page-break-after: always\"></div>

## Pharmacodynamic interactions and genetic differences in PD response

A general scientific  discussion  of  potential  PD  interactions  with  concomitant  medication  and  possible influences of genetic differences on the PD response was provided. The SmPC section 4.5 states that vamorolone to be used with caution in combination with renin-angiotensin-aldosterone system inhibitors and  monitoring  of  potassium  levels  1  month  after  starting  a  combination  between  vamorolone  and mineralocorticoid receptor antagonists is now suggested.

## Relationship between plasma concentration and effect

The exposure-response (ER) relationships for the six-dose responsive inflammatory biomarkers (CD23, MDC, IL22BP, LTa1/b2, IGFBP-2, and MMP-12) were investigated using the PK and SOMAscan data from the VBP15-002 Week 2 visit. AUC was the exposure variable, and a sigmoid Maximum effect (Emax) model was applied. Vamorolone showed the highest potency for changes in IGFBP-2, as indicated by the lowest AUC value of vamorolone achieving 50% maximal effect (E50) value.

The order of E50 from highest to lowest for the five remaining biomarkers was MDC &gt; IL22BP &gt; CD23 &gt; LT α1/β2 &gt; MMP12. More than 90% of the maximal effect on all biomarkers was observed at AUC ranges achieved  with  6 mg/kg  daily  dosing.  IGFBP-2  is  the  only  investigated  biomarker  showing  significant target engagement (&gt;80%) at the 2 mg/kg dose level.

Effects of vamorolone on ECG were investigated in the FIH study in healthy volunteers. Exposure at the highest investigated dose level over 14 days was about twice as high as that in the highest to be expected clinical exposure scenario. Based on these results a waiver for a dedicated QTc study can be granted.

## Pharmacodynamic Modelling

ER modelling was used for efficacy endpoints (TTSTAND velocity, 6MWT, Time to Run/Walk 10 Meters Test (TTRW), Time to Climb 4 Steps Test (TTCLIMB) and NSAA), longitudinal evaluation of body mass index (BMI) z-score, and for AEs (cushingoid features and gastrointestinal disorders). These analyses are regarded to be of limited value due to assumptions of the model and uncertainties in the estimated parameters.

ER modelling for different efficacy endpoints (NSAA, 6MWT, TTSTAND) was updated to describe efficacy of the 4 mg/kg dose of the ROS2 formulation in patients 4 to &lt;7 years of age compared to ROS1. It is considered not appropriate to draw conclusions to the age group of 2 to &lt;4 years as no observed data from this age group with the ROS2 formulation was used in model development. The result that no age dependency  was  observed  from  4  to  &lt;7  years  through  the  model  is  not  regarded  as  a  meaningful conclusion regarding the age group 2 to &lt;4 years because of the very narrow age range investigated. Furthermore, model development was hampered due to low sample sizes at the estimated EC50, leading to model instabilities which were addressed using a fixed parameter for curvature. Estimated Emax values were unexpectedly high. High shrinkage was observed in IIV (up to 99% for all three efficacy endpoints). The efficacy model is not considered appropriate to predict efficacy for the 4 mg/kg dose in DMD patients for the ROS2 formulation across all age groups. TThis is especially relevant for the 2-4 year old patients for whom a 4mg/kg treatment dose was initially proposed.

Furthermore,  ER  modelling  was  conducted  to  predict  changes  in  morning  cortisol  for  different formulations (ROS1 and ROS2) and different doses (2 mg/kg, 4 mg/kg, 6 mg/kg) compared to 0.75 mg/kg prednisone in different age groups. Observed differences between healthy adults and paediatric DMD patients that could not be directly assigned to either study, age, or disease status and only limited patient data was available outside the age range of 4 to &lt;7 years.

<div style=\"page-break-after: always\"></div>

## 2.6.3. Discussion on clinical pharmacology

The PK and PD of vamorolone have been evaluated in six studies in healthy volunteers and in four studies with patients with DMD. Overall, the clinical pharmacology has been well characterised. Initial points for clarification  concerned PK data of the To-be Marketed formulation in DMD patients and the updated popPK model, metabolism, and DDI. All issues are considered resolved. In the absence of clinical data for the 2 to 4 year old patients special emphasis was put on the reliability of the popPK model. As no reliable dose-efficacy model could be developed dose justification for this age range was based purely on extrapolation of overall drug exposure from patients aged 4 to 7 years. In the view of the results from the popPK model, the CHMP could not agree on the proposed posology for DMD patients aged 2-4 years. The applicant agreed to restrict the indication to DMD patients aged 4 years and above.

## 2.6.4. Conclusions on clinical pharmacology

The clinical pharmacology has been well characterised. With the restriction of the indication to patients aged 4 years and above, it is considered that all concerns on clinical pharmacology have been resolved. The clinical pharmacology in the approved indication has been adequately evaluated.

## 2.6.5. Clinical efficacy

Primary evidence for efficacy is derived from 1 pivotal phase 2b study, Study VBP15-004. Additional supportive data is provided by dose-finding studies, Study VBP15-002 and VBP15-003 as well as Study VBP15-LTE. Further, efficacy results from Study VBP15-004 at 48 weeks were compared with results of two matched DMD standard of care treatment groups, prednisone and deflazacort from the Finding the Optimum Regimen for DMD study (FOR-DMD).

For a tabulated overview on pivotal placebo-controlled and long-term clinical studies, please refer to section 2.6 of this document.

## 2.6.5.1. Dose response studies

The doses to be used were established based on pre-clinical data and on the results of the phase I studies (see  also  Clinical  Pharmacology  (PK/PD)  and  non-clinical  sections).  Based  on  the  provided  exposure response modelling, no clear exposure response relationship for the examined clinical endpoints was shown (Reference is made to pharmacodynamics section above).

## A Phase IIa Open-Label, Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Exploratory Efficacy of Vamorolone in Boys with Duchenne Muscular Dystrophy (DMD) (Study VBP15-002)

Study VBP15-002 was conducted from 28 June 2016 to 9 November 2017. It was a first-in patient, proof of concept, multi-center, open-label, multiple ascending dose study evaluating the safety, tolerability, PK,  PD,  and  exploratory  efficacy  following  oral  administration  of  vamorolone  0.25  mg/kg/day,  0.75 mg/kg/day, 2.0 mg/kg/day and 6.0 mg/kg/day over a 14-day treatment period followed by a 14-day post-treatment follow-up period in boys ages 4-&lt;7 years with DMD. A total of 48 subjects were enrolled in the study. Subjects who completed the 2-week Follow-up Period were eligible to receive vamorolone in an open-label extension study under a separate clinical protocol (VBP15-003) or to receive standard of care treatment (including glucocorticoids) for DMD.

<div style=\"page-break-after: always\"></div>

Male corticosteroid naïve subjects, ≥4 - &lt;7 years of age at study entry, diagnosed with DMD by confirmed dystrophin deficiency or identifiable mutation within the DMD gene, who were able to complete TTSTAND without assistance at the study Screening and Baseline Visits were included into the study.

Efficacy was defined as exploratory objective. Exploratory clinical efficacy was assessed by Quantitative Muscle Testing (QMT), TTRW, TTSTAND, TTCLIMB, NSAA, and 6MWT at pre-treatment (Screening and Baseline), Week 2 (Day 13), and the final Week 4 (Day 28) Follow-up Visit.

Efficacy evaluations were based on the safety population, i.e., all subjects who received at least one dose of study medication.

## Demographics and baseline characteristics

Overall, demographic and baseline characteristics for the safety population were comparable among the four dose level groups. The mean (±SD) age of subjects in the four dose level groups ranged from 4.7 ± 0.89 to 5.2 ± 1.03 years. Mean (±SD) weight and BMI were similar across the four dose level groups, ranging  from  18.53  ±  2.012  to  21.47  ±  3.165  kg  and  16.51  ±  1.002  to  17.39  ±  1.071  kg/m2, respectively. Mean (±SD) months since DMD diagnosis ranged from 21.4 ± 14.85 to 28.7 ± 17.26 across the four dose level groups.

## Disposition of subjects

Forty-eight (48) subjects were enrolled in the study and received at least one dose of study medication (0.25  mg/kg/day:  12  subjects;  0.75  mg/kg/day:  12  subjects;  2.0  mg/kg/day:  12  subjects;  6.0 mg/kg/day: 12 subjects); all 48 subjects completed the 4-week study.

## Exploratory Efficacy Results

Mean changes from baseline to the end of treatment (Week 2) and end of the 2-week off-treatment follow-up period (Week 4) in functional assessments were generally minimal and not dose-related.

## A  Phase  II  Open-label,  Multicenter  Extension  Study  to  Assess  the  Long-term  Safety  and Efficacy of Vamorolone in Boys with Duchenne Muscular Dystrophy (DMD) (VBP15-003)

Study VBP15-003 was conducted from 28 July 2016 to 26 April 2018. It was a multi-center, open-label, multiple dose study to evaluate the long-term safety, tolerability, clinical efficacy, and PD of vamorolone at dose levels of 0.25 mg/kg/day, 0.75 mg/kg/day, 2.0 mg/kg/day and 6.0 mg/kg/day administered over a Treatment Period of 24 weeks in boys aged 4-7 years with DMD. Subjects who had previously completed study VBP15-002 were eligible for enrolment. A total of 48 subjects were enrolled in the study.

Subjects received vamorolone throughout the 24-week Treatment Period in this study at the same dose level they received in study VBP15-002. Subjects who elected to discontinue vamorolone treatment at the conclusion of this study at the end of participation in the Treatment Period received vamorolone for an additional 1-4 weeks according to a dose-tapering protocol following the end of the Treatment Period.

## Efficacy was defined as secondary objective.

The  primary  clinical  efficacy  endpoint  was  TTSTAND  velocity  (rises/second):  comparison  with  an untreated historical control group (Cooperative International Neuromuscular Research Group [CINRG] Duchenne Natural History Study [DNHS]) for change from baseline to Week 24. Secondary efficacy endpoints were TTSTAND, TTCLIMB, TTRW, 6MWT, NSAA), and QMT, analysed as change from baseline to each of the on-treatment and post-treatment assessment time points. Efficacy assessments were performed at baseline, Week 12 (±1 w), Week 24 (±1w). Quality of life was assessed by completion of the Paediatric Outcomes Data Collection Instrument (PODCI).

<div style=\"page-break-after: always\"></div>

Efficacy evaluations were based on the Full Analysis Set (FAS): all subjects who received at least one dose of study medication in study VBP15-003 and had at least one post-baseline assessment.

Descriptive  summaries  of  variables  were  provided  where  appropriate.  In  general,  for  continuous variables,  the  number  of  non-missing  values  (n)  and  the  mean,  standard  deviation  (SD),  median, minimum, and maximum were tabulated. For categorical variables, the counts and proportions of each value were tabulated. Unless otherwise noted, baseline was defined as the last measurement taken prior to first exposure to study drug (Baseline Visit for VBP15-002).

The comparator group for efficacy consisted of 31 subjects from the CINRG-DNHS study who met all entry criteria of VBP15-003 and remained glucocorticoid-naïve through a 24-week period.

With regard to efficacy, a mixed model for repeated measures (MMRM) adjusted by baseline age was used to compare the vamorolone groups with the external comparator of steroid-naïve subjects from the CINRG-DNHS study. The baseline assessment from study VBP15-002 was used for change from baseline calculations. For within study analyses, change from baseline was analysed using a paired t test.

Demographic data were collected, and baseline characteristics were measured at the time of enrolment in the VBP15-002 core study. Reference is made to study VBP15-002.

## Disposition of subjects

48  subjects  were  enrolled  in  the  study  and  received  at  least  one  dose  of  study  medication  (0.25 mg/kg/day: 12 subjects; 0.75 mg/kg/day: 12 subjects; 2.0 mg/kg/day: 12 subjects; 6.0 mg/kg/day: 12 subjects) and were analysed for efficacy; 46 subjects completed the study and were enrolled in the subsequent VBP15-LTE long-term extension study. Two of these 46 subjects participated in the 2- to 5week Dose-tapering Period prior to enrolling in the VBP15-LTE study.

<div style=\"page-break-after: always\"></div>

## Efficacy results

Table 3: Efficacy results in Study VBP15-003 (full analysis set)

|                                     | ChangefromBaseline atWeek24   | ChangefromBaseline atWeek24   | ChangefromBaseline atWeek24   | ChangefromBaseline atWeek24   | ChangefromBaseline atWeek24   |
|-------------------------------------|-------------------------------|-------------------------------|-------------------------------|-------------------------------|-------------------------------|
| Endpoint                            | VAM 0.25 mg/kg                | VAM 0.75 mg/kg                | VAM 2 mg/kg                   | VAM 6 mg/kg                   | CINRG DNHS (steroid- naiive)  |
| TTSTAND velocity, rises/sec         |                               |                               |                               |                               |                               |
| N                                   | 10                            | 12                            | 12                            | 11                            | 29                            |
| Mean                                | -0.01                         | 0.00                          | 0.05                          | 0.04                          | 0.01                          |
| SD                                  | 0.066                         | 0.062                         | 0.061                         | 0.045                         | 0.068                         |
| p value vs DNHS                     | 0.4062                        | 0.9554                        | 0.0397                        | 0.1048                        |                               |
| p value vs 0.25 mg/kg               |                               | 0.5067                        | 0.0192                        | 0.0442                        |                               |
| TTRW 10 meters velocity, meters/sec |                               |                               |                               |                               |                               |
| N                                   | 12                            | 12                            | 12                            | 11                            | 30                            |
| Mean                                | -0.05                         | 0.06                          | 0.06                          | 0.27                          | -0.01                         |
| SD                                  | 0.311                         | 0.210                         | 0.210                         | 0.254                         | 0.256                         |
| p value vs DNHS                     | 0.7248                        | 0.3768                        | 0.3500                        | 0.0035                        |                               |
| p value vs 0.25 mg/kg               |                               | 0.082                         | 0.2895                        | 0.0059                        |                               |
| TTCLIMB velocity, task/sec          |                               |                               |                               |                               |                               |
| N                                   | 12                            | 12                            | 12                            | 11                            | 31                            |
| Mean                                | 0.00                          | 0.01                          | 0.04                          | 0.05                          | 0.01                          |
| SD                                  | 0.076                         | 0.066                         | 0.090                         | 0.061                         | 0.062                         |
| p value vs DNHS                     | 0.8532                        | 0.6581                        | 0.0811                        | 0.0507                        |                               |
| p value vs 0.25 mg/kg               |                               | 0.6107                        |                               |                               |                               |
| 6MWTdistance,meters                 |                               |                               |                               |                               |                               |
| N                                   | 10                            | 12                            | 10                            | 9                             |                               |
| Mean                                | -11.6                         | 18.9                          | 29.2                          | 43.9                          |                               |
| SD                                  | 29.45                         | 41.08                         | 35.91                         | 43.72                         |                               |
| p value vs 0.25 mg/kg               |                               | 0.0644                        | 0.0153                        | 0.0019                        |                               |
| NSAA total score                    |                               |                               |                               |                               |                               |
| N                                   | 12                            | 12                            | 12                            | 11                            |                               |
| Mean                                | 0.8                           | 1.1                           | 2.3                           | 2.5                           |                               |
| SD                                  | 2.83                          | 2.94                          | 1.78                          | 2.62                          |                               |
| p value vs 0.25 mg/kg               |                               | 0.7844                        | 0.3099                        | 0.2157                        |                               |

6MWT=6-Minute Walk Test; CINRG DNHS= Duchenne Natural History Study; NSAA=North Star Ambulatory Assessment;

TTCLIMB=Time to Climb; TTRW=Time to Run/Walk; TTSTAND=Time to Stand; VAM=vamorolone

QMT:  Mean  changes  from  baseline  across  the  four  dose  level  groups  generally  showed  only  small improvement compared to baseline scores in elbow extensors, knee flexors, and knee extensors, changes from baseline in QMT of elbow flexors were minimal and not dose related. QMT of knee extensors showed dose-related improvement for change from baseline to Week 24. Changes from baseline to weeks 12 and 24 were minimal (elbow extensors) or not dose-related (elbow extensors and knee flexors). Results for the PODCI showed high variability with no dose-dependent effect.

Efficacy results for TTSTAND, TTRW, and TTCLIMB velocity in the CINRG-DNHS control group were overall comparable to that seen for the lower vamorolone dosages, i.e., 0.25 and 0.75 mg/kg/day although the lowest  vamorolone  dose  of  0.25  mg/kg  appears  to  be  worse  than  the  natural  history  data.  Mean improvements from baseline to Week 24 in TTSTAND velocity, TTRW velocity, and TTCLIMB velocity and 6MWT distance were greater for the vamorolone 2 and 6 mg/kg treatment arms when compared with the lower doses of vamorolone and the external untreated CINRG control group, except for TTRW velocity (vamorolone 0.75 and 2 mg/kg provided similar changes). Based on the well accepted minimally clinically

<div style=\"page-break-after: always\"></div>

important differences (MCIDs), the effect sizes of the improvements for the vamorolone 2 and 6 mg/kg group  in  TTSTAND,  TTRW  and  TTCLIMB  velocity  and  6MWT  distance  can  be  considered  clinically meaningful  (-0.023  rises/sec,  -0.212  meters/sec,  and  0.035  tasks/sec,  for  TTSTAND,  TTRW,  and TTCLIMB velocity, respectively, and 30 meters for 6MWT distance) [Duong et al, 2021; McDonald et al, 2013]. Greater improvements for the vamorolone 6 mg/kg arm in comparison to the vamorolone 2 mg/kg dose were only seen for results on TTRW velocity and 6MWT distance.

## A 24-month Phase II Open-label, Multicenter Long-term Extension Study to Assess the Longterm Safety and Efficacy of Vamorolone in Boys with Duchenne Muscular Dystrophy (DMD) (Study VBP15-LTE)

Study VBP15-LTE was conducted from 01 February 2017 to 30 April 2020. It was a multicenter, openlabel,  multiple  dose  study  evaluating  the  long-term  safety,  tolerability,  clinical  efficacy,  and  PD  of vamorolone at dose levels of 0.25 mg/kg/day, 0.75 mg/kg/day, 2.0 mg/kg/day, 4.0 mg/kg/day, and 6.0 mg/kg/day administered over a treatment period of 24 months to young boys with DMD. A total of 46 subjects  were  enrolled.  Subjects  who  completed  the  Phase  II  extension  study  VBP15-003  Week  24 assessments were eligible for enrolment.

Included subjects were subjects who were diagnosed with DMD by confirmed dystrophin deficiency or identifiable mutation within the DMD gene prior to enrolment into the VBP15-002 core study at age 4&lt;7 years, who completed the VBP15-002 core and the VBP15-003 extension studies prior to enrolment into VBP15-LTE, and who were not treated at time of enrolment nor had been previously treated with oral glucocorticoids or other oral immunosuppressive agents for longer than 3 months cumulative with last previous use at least 3 months prior to first dose of study medication in VBP15-LTE.

Subjects initially received vamorolone at the same dose level they received in study VBP15-003 (0.25 mg/kg/day, 0.75 mg/kg/day, 2.0 mg/kg/day, or 6.0 mg/kg/day); subjects were allowed to escalate vamorolone dose to the next higher dose level after receiving their current dose for at least one month, to  the  maximum  of  6.0  mg/kg/day;  subjects  were  allowed  to  de-escalate  vamorolone  dose  due  to intolerability. Subjects whose dose was decreased from 6 mg/kg/day to 2 kg/kg/day could have their dose subsequently increased to 4 mg/kg/day if they had been taking the 2 mg/kg/day dose for at least one month and, in the opinion of the Investigator, balancing efficacy with safety concerns, they could have benefited from an intermediate higher dose. Subjects who transitioned off vamorolone treatment at the end of participation in the Treatment Period (24 months) received vamorolone for an additional 1-4 weeks according to a dose-tapering protocol following the end of the Treatment Period and prior to discharge from the study.

Subjects had been previously treated with vamorolone for 6 months in VBP15-002 (2 weeks treatment) and  VBP15-003  (24  weeks  'treatment)  and  so  the  combined  treatment  duration  during  VBP15-002, VBP15-003, and VBP15-LTE was 30 months.

Efficacy was defined as secondary objective, i.e., to investigate the effects of vamorolone, administered orally at daily doses up to 6 mg/kg over a 24-month Treatment Period, on muscle strength, mobility and functional exercise capacity vs. untreated DMD historical controls.

## Changes in the Planned Analyses

Comparisons  with  external  DMD  historical  control  populations  (the  untreated  DMD  historical  control population  CINRG-DNHS)  dataset  showed  insufficient  corticosteroid-naïve  subjects  (n  =  6)  with  30month data to match the VBP15-LTE 24-month assessment time point for efficacy assessments. The study objectives were therefore modified to remove comparisons to the external comparator populations that were not feasible.

<div style=\"page-break-after: always\"></div>

As subjects had previously received vamorolone for an additional six months in VBP15-002 (treatment duration: 2 weeks) and VBP15-003 (treatment duration: 24 weeks), the pre-specified analyses which measured  changes  from  baseline  used  VBP15-002  baseline  as  baseline.  Thus,  most  pre-specified analyses evaluated the effect of a total of 30 months of vamorolone treatment (VBP15-LTE Month 12 and Month 24 time points reflect 18 months and 30 months, respectively, of total vamorolone treatment).

## Efficacy endpoints

## Primary (revised)

- TTSTAND velocity (rises/second) change from VBP15-002 baseline to VBP15-LTE Month 24.

## Secondary

- TTSTAND  velocity  (rises/second)  change  from  baseline  to  Month  12;  and  TTCLIMB  velocity (tasks/sec), TTRW velocity (meters/second), 6MWT total distance travelled, NSAA total score, and QMT knee and elbow extension and flexion, each analysed as change from baseline to Month 12 and Month 24.

Efficacy  evaluations  were  based  on  the  FAS:  all  subjects  who  received  at  least  one  dose  of  study medication in VBP15-LTE and had at least one post-baseline assessment in the VBP15-LTE study. Unless otherwise noted, baseline was defined as the last measurement taken prior to first exposure to study drug (baseline Visit for VBP15-002).

## Demographics

The age range covered in this study was from 4 years at baseline to up to 9.6 years at the end of the study.

## Disposition of subjects

46 subjects were enrolled in the study (11 subjects [0.25 mg/kg/day], 12 subjects [0.75 mg/kg/day], 12 subjects [2.0 mg/kg/day], and 11 subjects [6.0 mg/kg/day]) and all 46 subjects were analysed for efficacy. A total of 41 out of the 46 DMD subjects (89.1%) completed the 24-month treatment period of VBP15-LTE (and therefore the 30-month treatment period of VBP15-002, VBP15-003 and VBP15-LTE combined) through to VBP15-LTE Month 24 (11 subjects [23.9%] at the 2 mg/kg/day dose level, three subjects [6.5%] at the 4mg/kg/day dose level, and 27 subjects [58.7%] at the 6 mg/kg/day dose level). Of the 11 subjects who completed VBP15-LTE at 2 mg/kg/day, five subjects had either started at 2 mg/kg/day or had been up titrated to 2 mg/kg/day and had remained at that dose, and six subjects had been down titrated from 6 mg/kg/day. All three subjects who completed the study at 4 mg/kg/day had been down titrated from 6 mg/kg/day. All 27 subjects who completed the study at 6 mg/kg/day had either started treatment at 6 mg/kg/day or had been up titrated to 6 mg/kg/day.

<div style=\"page-break-after: always\"></div>

## Efficacy Results:

Table 4: Efficacy in Study VBP15-003 at week 24 and Study VBP15-LTE at 18 months and 30 months (full analysis set and 30-month subset)

|                              | Study VBP15-003   | Study VBP15-003   | Study VBP15-LTE   | Study VBP15-LTE   |
|------------------------------|-------------------|-------------------|-------------------|-------------------|
| Change from Baseline         | Week 24           | Week 24           | Month 18          | Month 30          |
|                              | 2 mg/kg           | 6 mg/kg           | 2 + 6 mg/kg       | 2 +6 mg/kg        |
| TTSTAND velocity (rises/sec) |                   |                   |                   |                   |
| N                            | 12                | 11                | 22                | 21                |
| Mean (SD)                    | 0.05 (0.06)       | 0.04 (0.05)       | 0.04 (0.07)       | -0.01 (0.12)      |
| 6MWT distance (meters)       |                   |                   |                   |                   |
| N                            | 10                | 9                 | 17                | 15                |
| Mean (SD)                    | 29.2 (35.9)       | 43.9 (43.7)       | 62.2 (60.5)       | 32.0 (92.0)       |
| TTRW velocity (meters/sec)   |                   |                   |                   |                   |
| N                            | 12                | 12                | 23                | 18                |
| Mean (SD)                    | 0.06 (0.21)       | 0.27 (0.26)       | 0.36 (0,31)       | 0.06 (0.67)       |
| TTCLIMB velocity (tasks/sec) |                   |                   |                   |                   |
| N                            | 12                | 11                | 23                | 18                |
| Mean (SD)                    | 0.04 (0.09)       | 0.05 (0.06)       | 0.07 (0.08)       | 0.04 (0.17)       |

6MWT=6-minute walk test; SD=standard deviation; TTCLIMB=time to climb; TTSTAND=time to stand; TTRW=time to run/walk

Overall, the improvements in TTSTAND, TTRW and TTCLIMB velocity, and 6MWT distance seen with vamorolone 2 and 6 mg/kg at Week 24 in Study VBP15-003 were maintained up to Month 18 in Study VBP15-LTE followed by a gradual decline towards baseline after month 18.

## 2.6.5.2. Main study

Study VB15-004: A Phase 2b, randomized, double-blind, parallel group, placebo- and activecontrolled study with double-blind extension to assess the efficacy and safety of vamorolone in ambulant boys with Duchenne muscular dystrophy (DMD)

## Methods

The study consisted of a screening period (Day -33 to Day -2), a baseline period (Day -1), period 1 (Day 1 to week 24), a 4-week transition period (Week 25 to Week 28) for subjects who received either placebo or prednisone in period 1 (subjects who received vamorolone in period 1 were continued on the same dose of vamorolone during this period), period 2 (Week 28 +1 day to Week 48): all subjects received vamorolone 2.0 or 6.0 mg/kg for 20 weeks, a 4-week dose tapering period (Week 49 to Week 52): subjects  who  elected  not  to  continue  vamorolone  treatment  had  the  vamorolone  dose  progressively reduced and discontinued.

The study included two sequential 24-week periods.

In Period 1, subjects were randomised to 1 of 6 groups in a 2:2:1:1:1:1 ratio: vamorolone 2.0 mg/kg, vamorolone  6.0  mg/kg,  2  groups  of  placebo  and  2  groups  of  prednisone  0.75  mg/kg/day,  with randomisation stratified by age at study entry (&lt;6 years and ≥6 y ears).

To maintain the double-blind in this treatment period, all subjects received either a matching placebo for vamorolone (i.e., a placebo oral suspension), a matching placebo for prednisone (i.e. a placebo tablet) or both (i.e. placebo oral suspension and placebo tablet).

Following  completion  of  Period  1,  all  subjects  entered  a  4-week  Transition  Period,  during  which vamorolone or its matching placebo were administered at the same dose as in Period 1, but the dose of prednisone and its matching placebo tablet were tapered to zero. According to the applicant, this tapering

<div style=\"page-break-after: always\"></div>

period  was  designed  to  re-establish  adrenal  function,  since  suppression  may  have  occurred  with prednisone in Period 1.

Thereafter, subjects entered Period 2 during which all subjects who previously were treated with either prednisone or placebo were treated with vamorolone 2.0 or 6.0 mg/kg and subjects who had received vamorolone in Period 1 continued treatment on their vamorolone dose.

Table 5: Study VBP15-004 design

<!-- image -->

| Period#1 [Day1toWeek24(168days)]   | Period#1 [Day1toWeek24(168days)]   | Transition [Week25to 28]   | Period #2 [Weck29to48（140 days)]   | Period #2 [Weck29to48（140 days)]   | Dose- tapering Period [Week49t0 531   | Rando. groups   |
|------------------------------------|------------------------------------|----------------------------|------------------------------------|------------------------------------|---------------------------------------|-----------------|
| Treatment (24weeks)                | n                                  | Transition [Week25to 28]   | Treatment (20wecks)                | n                                  | Dose- tapering Period [Week49t0 531   | Rando. groups   |
| Yamorolone,2.0mg/kg/day            | 30                                 |                            | Vamorolone,2.0mg/kg/day            | 30                                 |                                       | 一               |
| Vamorolone,6.0mg/kg/day            | 30                                 |                            | Vamorolone,6.0mg/kg/day            | 30                                 |                                       | 2               |
| Prednisone,0.75mg/kg/day           | 30                                 |                            | Vamorolone,2.0mg/kg/day            | 15                                 |                                       | 3               |
| Prednisone,0.75mg/kg/day           | 30                                 |                            | Vamorolone,6.0mg/kg/day            | 15                                 |                                       | 4               |
| Placebo                            | 30                                 |                            | Vamorolone,2.0mg/kg/day            | 15                                 |                                       |                 |
| Placebo                            | 30                                 |                            | Vamorolone,6.0mg/kg/day            | 15                                 |                                       | 6               |

Specific modifications to study conduct were implemented during the COVID-19 pandemic (reference is made to Conduct of the study).

The following efficacy assessments were performed at screening/or baseline and afterwards as follows: TTSTAND assessments were conducted at week 6, 12, 24, 34, 40 and 48. TTCLIMB, TTRW, NSAA, Myometry, 6MWT and ROM assessments were performed at week 12, 24, 40 and 48. TSQM and PODCI were performed at week 24 and week 48, PARS III at week 12, 24 and 48, Ease of Study Medication Administration Assessment at week 2, 12, 24, 30, 40 and 48, Blindedness Assessment at week 24.

The applicant justified the use of the 0.75 mg/kg dose level of prednisone as internal comparator as this is  the  recommended  starting  dose  for  standard-of-care  treatment  for  DMD  in  the  DMD  Care Considerations Working Group (Birnkrant et al, 2018). Additionally, it is pointed out, that based on a review by [Matthews et al, 2016] meta-analyses showed that prednisone or prednisolone given at 0.75 mg/kg/day was an effective dose and that a higher dose tested (1.5 mg/kg/day) only showed little evidence of improvement in strength and function measures.

## · Study Participants

Main inclusion  criteria  relating  to  efficacy  were:  DMD  diagnosed  subjects  with  a  centrally  confirmed diagnosis  of  DMD  defined  as  any  one  of  the  following:  Dystrophin  immunofluorescence  and/or immunoblot showing complete dystrophin deficiency with a clinical picture consistent with typical DMD; Identifiable mutation within the DMD gene, where reading frame was predicted as 'out-of-frame' with a clinical picture consistent with typical DMD; Complete dystrophin gene sequencing showed an alteration that precluded production of the dystrophin protein, with a clinical picture consistent with typical DMD; s ubjects were ≥4 years and &lt;7 years of age at time of enrolment in the study ; had a body weight &gt;13.0 kg and ≤39.9 kg at screening, -,were able to walk independently without assistive devices and were able to complete the TTSTAND without assistance in &lt;10 seconds at Screening.

Main exclusion criteria were: being currently being treated or had received previous treatment with oral glucocorticoids or other immunosuppressive agents (past transient use of oral glucocorticoids or other oral immunosuppressive agents for no longer than 1 month cumulative, with last use at least 3 months prior to first dose of study medication, was considered for eligibility on a case by-case basis, unless discontinued for intolerance. Inhaled and/or topical glucocorticoids were permitted if last use was at least

<div style=\"page-break-after: always\"></div>

4 weeks prior to first dose of study medication or if administered at a stable dose beginning at least 4 weeks prior to first dose of study medication and anticipated to be used at this dose regimen for the duration of the study); had used mineralocorticoid receptor agents, such as spironolactone, eplerenone, canrenone, prorenone, or mexrenone within 4 weeks prior to the first dose of study medication; had major renal or hepatic impairment, diabetes mellitus, or immunosuppression or a history of any of these conditions including a history of primary hyperaldosteronism; had evidence of symptomatic cardiomyopathy  (an  asymptomatic  cardiac  abnormality  was  not  exclusionary)  or  a  chronic  systemic fungal or viral infection or a history of these infections; had used idebenone within 4 weeks prior to the first dose of study medication; was taking (or had taken within 3 months prior to the first dose of study medication) any medication indicated for DMD, including Exondys51 and Translarna.

## · Treatments

Vamorolone  2.0  mg/kg  was  administered  as  a  1.33%  wt/wt  oral,  orange-flavoured  suspension. Vamorolone 6.0 mg/kg was administered as a 4.0% wt/wt oral, orange-flavoured suspension. Prednisone was supplied as a 5-mg tablet in 15-tablet blister packs packaged in cartons wallets, administered orally.

This was a 'double dummy' design. In Treatment Period 1, each subject received oral doses of either vamorolone or its matching placebo and prednisone or its matching placebo for 24 weeks to maintain the double-blind.

Maintenance of the blind was aided by use of amber bottles and high acceptability for taste for both the vamorolone and placebo suspensions. Subjects in the prednisone and placebo groups received a placebo suspension. The same volume of either vamorolone 2 or 6 mg/kg or its matching placebo were orally administered using a volumetric syringe following a breakfast that included at least 8 g of fat; the dose administered was based on the subject's weight at the previous visit. Following administration of the study  drug  suspension,  the  volumetric  syringe  was  filled  once  with  water  and  the  water  was  orally administered. Additionally, either prednisone 0.75 mg/kg or its matching placebo were administered orally as tablet(s) based on weight bands once daily during Period 1 either immediately before or after vamorolone/placebo administration. The number of prednisone or matching placebo tablets that were administered was based on the subject's weight at the previous visit. Following tablet administration, the subject drank approximately 50 mL (ie, approximately 2 ounces) of water.

During the Transition Period, subjects were continued on the same dose of vamorolone or it´s matching placebo that was administered during Treatment Period 1. However, prednisone (5 mg tablet) or its matching placebo were dose tapered.

During Period 2, all subjects received either vamorolone 2.0 mg/kg or 6.0 mg/kg for 20 weeks as shown in Table 5. Neither the matching placebo for vamorolone nor prednisone nor its matching placebo were administered in Period 2.

No pre-defined  early  escape  clause,  e.g.,  due  to  AEs  or  disease  progression  and  no  defined  rescue medication has been included in the study design due to the lack of any concrete definition accepted in the scientific community for 'declining' phase to trigger the initiation of glucocorticoid therapy when the study  was  designed.  However,  parents  and  investigators  were  allowed  to  discontinue  the  subject's participation in the study at any time, should they consider, based on their individual decision, that glucocorticoid treatment should be started and that a delay until the completion of the 24-week period was not acceptable.

Although generally the use of systemic glucocorticoids was not allowed during the study due to their potential impact on study results, there was 1 subject in period 1 in the vamorolone 6 mg/kg treatment arm who received prednisone for 4 days to cover for missing doses of medication, and 2 subjects in the placebo arm and 4 subjects in the vamorolone 2 mg/kg arm who received hydrocortisone for short durations up to 4 days as glucocorticoid supplementation therapy in the context of stress situations to

<div style=\"page-break-after: always\"></div>

prevent adrenal crisis. In period 2 systemic corticoids were only used in the continuous vamorolone groups, with 2 subjects in the vamorolone 2 mg/kg treatment arm and 4 subjects in the 6 mg/kg arm with  the  longest  use  of  hydrocortisone  as  stress  dosing  for  6  days.  Overall,  the  treatment  with corticosteroids due to adverse events of a small number of patients for a rather short duration is not considered to impact the outcome of the efficacy results.

## · Objectives

## Primary objectives

· To compare the efficacy of vamorolone administered orally at a daily dose of 6.0 mg/kg over a 24week treatment period versus (vs) placebo in ambulant boys ages 4 to &lt;7 years with DMD

· To evaluate the safety and tolerability of vamorolone administered orally at daily doses of 2.0 mg/kg and 6.0 mg/kg in ambulant boys ages 4 to &lt;7 years with DMD

## Secondary objectives with regard to efficacy

· To compare the efficacy of vamorolone administered orally at a daily dose of 2.0 mg/kg over a 24week treatment period versus placebo in ambulant boys ages 4 to &lt;7 years with DMD

· To compare the efficacy of vamorolone administered orally at daily doses of 2.0 mg/kg and 6 mg/kg over a 24-week treatment period vs. daily prednisone 0.75 mg/kg in ambulant boys aged 4 to &lt;7 years with DMD

· To compare the efficacy of vamorolone administered orally at daily doses of 2.0 mg/kg and 6.0 mg/kg over a 48-week treatment period in ambulant boys aged 4 to &lt;7 years with DMD vs. untreated DMD historical controls (this objective could not be assessed because of a lack of data for the untreated DMD historical controls)

Although  not  pre-specified  as  an  objective  in  the  protocol,  efficacy  and  safety  were  also  evaluated following the switch from prednisone in Period 1 to vamorolone in Period 2.

## · Outcomes/endpoints

## Primary efficacy endpoint

- The change from baseline in TTSTAND velocity for the vamorolone 6.0 mg/kg group compared vs placebo at week 24.

Secondary efficacy endpoints (for week 24 tested in a pre-specified hierarchical order)

Change from baseline to week 24 for the following comparisons:

- TTSTAND velocity for the vamorolone 2.0 mg/kg/day vs placebo group
- 6MWT distance for vamorolone 6.0 mg/kg vs placebo
- 6MWT distance for vamorolone 2.0 mg/kg vs placebo
- TTRW velocity for vamorolone 6.0 mg/kg vs placebo
- TTRW velocity for vamorolone 2.0 mg/kg vs placebo
- 6MWT distance for vamorolone 6.0 mg/kg vs prednisone
- 6MWT distance for vamorolone 2.0 mg/kg vs prednisone

Additional  secondary  efficacy  endpoints  for  week  24  were  not  tested  for  multiple  comparisons  and included the following comparing each of the vamorolone doses versus placebo and each vamorolone

<div style=\"page-break-after: always\"></div>

dose versus prednisone: change from baseline in TTCLIMB velocity, change from baseline in NSAA score, change  from  baseline  in  knee  extension  muscle  strength,  Change  from  baseline  in  elbow  extension muscle strength.

All the secondary efficacy endpoints were also analysed for the vamorolone groups at week 48, but not in a pre-defined hierarchical order.

## · Sample size

In consideration of the primary efficacy analysis, comparison of vamorolone 6 mg/kg versus placebo, sample size calculations were performed using data from vamorolone-treated subjects from the VBP15002/VBP15-003 24-week treatment period. The analysis compared TTSTAND velocity from the combined 2.0  mg/kg and 6.0 mg/kg groups (treatment group) to the combined 0.25 and 0.75 mg/kg groups (pseudo  placebo  group).  The  sample  size  of  30  per  treatment  group  for  2.0  mg/kg,  6.0  mg/kg, prednisone, and placebo (ie, total enrolment of 120 subjects) provided approximately 91% power at alpha  level  0.05  to  detect  a  statistically  significant  difference  between  6.0  mg/kg  and  placebo  on TTSTAND velocity at Week 24. Subjects in prednisone and placebo groups were randomised into two groups each (n=15 per group). These groups were pooled for the Period 1 analyses.

## · Randomisation and Blinding (masking)

Subjects were randomly allocated to treatment to receive vamorolone 2.0 or 6.0 mg/kg, placebo, or prednisone 0.75 mg/kg/day, in a 2:2:1:1:1:1 ratio with subjects in the prednisone and placebo groups were randomised into two groups each. These groups were pooled by initial treatment (prednisone or placebo) for the treatment period 1 analyses. Randomisation was stratified by subject age at study entry (&lt;6 years versus ≥6 years).

## · Statistical methods

No interim analyses were planned for this study.

Analysis populations

## Intent-to-Treat (ITT) Population: All randomised subjects

Modified Intent-to-Treat (mITT)-1 Population: All randomised subjects who received at least one dose of  study  medication  during period  1  and had at least one post-baseline efficacy assessment 1  during Period 1. This was the primary analysis population for efficacy at Week 24 and for the overall study.

Modified Intent-to-Treat (mITT)-2 Population: All randomised subjects who received at least one dose of  study  medication  during period  2  and had at least one post-baseline efficacy assessment 1  during Period 2. This was the primary analysis population for efficacy during period 2.

Per  Protocol  (PP)  Population:  Subjects  in  the  mITT  Population  with  no  major  protocol  deviations. Exclusion of subjects from the PP Population will be made on a subject-by-subject basis prior to database soft lock at the end of the 24-week treatment period. The PPP will also exclude some subjects because of missed assessments due to the COVID-19 pandemic. Exclusion of subjects from the PPP will be made on a subject-by-subject basis prior to database hard lock. This was a secondary analysis population for efficacy at Week 24.

Safety-1 and Safety-2 Population: All subjects who received at least one dose of study medication during Period 1 (analysis population for safety at Week 24) and Period 2 (analysis population for safety at Week 48), respectively.

Primary analysis of the primary efficacy endpoint for FDA has been conducted with restricted maximum likelihood (REML) based MMRM using the observed cases (without multiple imputation) on the mITT-1 analysis set. The MMRM includes the TTSTAND velocity values (as changes from baseline) from Weeks

<div style=\"page-break-after: always\"></div>

6, 12 and 24 as dependent values. The model includes fixed effects for baseline age (as stratified in randomisation), treatment group (vamorolone 2.0 mg/kg/day, vamorolone 6.0 mg/kg/day, prednisone 0.75 mg/kg/day or placebo), week (Week 6, 12 or 24) and the treatment-by-week interaction. The baseline TTSTAND velocity will be included as a covariate.

Analysis of the primary efficacy endpoint for EMA used a missing data imputation approach assuming MNAR (missing not at random (Copy-Reference imputation). The estimand of the primary objective for the  EMA  analysis  used  a  treatment  policy  strategy  regarding  the  intercurrent  event  'premature discontinuation' (using a copy-reference approach for missing data imputation), a hypothetical strategy regarding the intercurrent event 'COVID-19 pandemic related event' and a composite strategy regarding the intercurrent event 'death'.

The missing data that have been recorded to be missing due to the COVID-19 pandemic were considered under the assumption of Missing at random (MAR). Missing data due to death or disease progression were imputed as '0'.

The following sensitivity analyses were provided by the applicant: (1) Analysis of the primary endpoint for FDA using a REML based MMRM and observed cases. (2) Analyses assessing the impact of COVID-19 (3) Analyses assessing the impact of missing data (4) Primary (EMA) analysis to be repeated in the ITT analysis set (5) Analyses assessing the impact of influential observations.

Analyses of secondary efficacy endpoints at Week 24:

## Va morolone vs. Placebo

To increase the strength of evidence, the secondary endpoints were tested in a hierarchical order, to maintain the studywise Type I error rate.

The  fixed  sequential  testing  process  start  with  the  primary  endpoint  TTSTAND  velocity,  comparing vamorolone 6.0 mg/kg versus placebo at Week 24. If positive, i.e., there is a statistically significant difference in favour of vamorolone 6 mg/kg, the following comparisons will be performed sequentially:

1. TTSTAND velocity, vamorolone 2.0 mg/kg vs placebo at Week 24
2. 6MWT distance, vamorolone 6.0 mg/kg vs. placebo at Week 24
3. 6MWT distance, vamorolone 2.0 mg/kg vs. placebo at Week 24
4. TTRW velocity, vamorolone 6.0 mg/kg vs. placebo at Week 24
5. TTRW velocity, vamorolone 2.0 mg/kg vs. placebo at Week 24.

Statistical testing of the primary/secondary efficacy endpoints will stop if a p-value &gt;0.05 occurs or if a pvalue ≤0.05 occurs in the wrong direction ( i.e., control better than vamorolone). In case the fixed sequential testing process stops, the results of the subsequent tests will be reported with nominal pvalues, but pvalues ≤0.05 in the right direction will not be considered proof of statistical testing success in these subsequent tests.

## Vamorolone vs. Prednisone

TTSTAND velocity, 6MWT distance, TTRW velocity, TTCLIMB velocity, NSAA score, and knee and elbow extension muscle strength were compared for each vamorolone dose vs. prednisone at Week 24 using an MMRM model, observed cases (i.e., without multiple imputation) and the mITT-1 analysis set. The MMRM included the response values (as changes from baseline) from Weeks 6, 12, and 24 as dependent values.  The  model  included  fixed  effects  for  baseline  age  (as  stratified  in  randomisation),  group (vamorolone 2.0 mg/kg, vamorolone 6.0 mg/kg, or prednisone 0.75 mg/kg), week (Week 6, 12, or 24) and treatment-by-week interaction. The baseline response value was included as a covariate. Within this

<div style=\"page-break-after: always\"></div>

model, pairwise comparisons (using LSM contrasts) were made to compare the treatment difference between vamorolone 6.0 mg/kg or 2.0 mg/kg with prednisone. An unstructured covariance structure was applied for MMRM. If this analysis fails to converge, Akaike's information criterion was used to select the best covariance structure from compound symmetry and autoregressive-1 (AR(1)). The denominator degrees of freedom was computed using the Kenward-Roger method.

Formal  statistical  testing  of  6MWT  distance  for  vamorolone  6.0  mg/kg  followed  by  2.0  mg/kg  vs prednisone was only conducted if the prespecified hierarchical testing order held (ie, p values ≤0.05).

For  TTSTAND  velocity,  6MWT  distance,  TTRW  velocity  and  NSAA  score,  the  comparison  of  efficacy endpoints between the vamorolone groups and prednisone group were focused on a global assessment of efficacy, aiming to show that the efficacy profile of the two vamorolone doses was comparable to prednisone.  There  was  no  pre-defined  order  of  the  endpoints  and  for  each  endpoint,  the  treatment differences and 95% CIs calculated with MMRM were summarised.

## Internal Comparisons of 48-Week Data

Efficacy endpoints at Week 48 were compared between the two dose levels of vamorolone (2.0 mg/kg vs. 6.0 mg/kg) in the set of subjects who were randomised to receive vamorolone in both Period 1 and Period 2. The differences between the doses were estimated with MMRM models similar to the ones used for the Week 24 analyses. Because there was no placebo group up to Week 48, no multiple imputation analyses were conducted, and all analyses were based on observed cases only.

The comparison focused on a global assessment of efficacy without formal statistical hypothesis testing. The following endpoints will be analysed: TTSTAND velocity, 6MWT distance, TTRW velocity, NSAA score.

## Results

## · Participant flow

## Table 6: Disposition of subjects by period 1 and period 2 treatment groups (ITT population)

|                                      | n (%)     | Vamorolone 2.0Vamorolone 6.0 n (%)   | + Vamorolone 2.0 n (%)   | Prednisone 0.75Prednisone 0.75 +Vamorolone 6.0 n (%)   | Placelbo + n (%)   | Placelbo + Vamorolone 2.0Vamorolone 6.0 n (%)   | Total n (%)   |
|--------------------------------------|-----------|--------------------------------------|--------------------------|--------------------------------------------------------|--------------------|-------------------------------------------------|---------------|
| Number Screened                      |           |                                      |                          |                                                        |                    |                                                 | 133           |
| Number of Screen Failures            |           |                                      |                          |                                                        |                    |                                                 | 12            |
| Withdrawal by ParentGuardian [2]     |           |                                      |                          |                                                        |                    |                                                 | 1(8.3)        |
| Screen failure[2]                    |           |                                      |                          |                                                        |                    |                                                 | 11 (91.7)     |
| Number Randomized                    | 30        | 30                                   | 15                       | 16                                                     | 15                 | 15                                              | 121           |
| Completed Study through Week 24[1]   | 28 (93.3) | 28 (93.3)                            | 15(100)                  | 15 (93.8)                                              | 14 (93.3)          | 14 (93.3)                                       | 114 (94.2)    |
| Completed Study [1]                  | 28 (93.3) | 26 (86.7)                            | 15(100)                  | 15 (93.8)                                              | 14 (93.3)          | 14 (93.3)                                       | 112 (92.6)    |
| DiscontinuedStudyPriortoWeek 24[1]   | 2 (6.7)   | 2(6.7)                               | 0                        | 1 (6.3)                                                | 1 (6.7)            | 1 (6.7)                                         | 7 (5.8)       |
| Withdrawal by Parent/Guardian [2]    | 2(100)    | 1 (50.0)                             | 0                        | 0                                                      | 0                  | 0                                               | 3(42.9)       |
| Withdrawal due to Adverse Event [2]  | 0         | 0                                    | 0                        | 1(100)                                                 | 0                  | 0                                               | 1 (14.3)      |
| Withdrawal byPhysicianDecision[2]    | 0         | 1 (50.0)                             | 0                        | 0                                                      | 0                  | 0                                               | 1(14.3)       |
| Other [2]                            | 0         | 0                                    | 0                        | 0                                                      | 1(100)             | 1(100)                                          | 2 (28.6)      |
| Discontinued Study Prematurely[1]    | 2(6.7)    | 4 (13.3)                             | 0                        | 1(6.3)                                                 | 1(6.7)             | 1(6.7)                                          | 9(7.4)        |
| Withdrawal by ParentGuardian [2]     | 2(100)    | 1 (25.0)                             | 0                        | 0                                                      | 0                  | 0                                               | 3(33.3)       |
| Withdrawal due to Adverse Event[2]   | 0         | 1 (25.0)                             | 0                        | 1(100)                                                 | 0                  | 0                                               | 2 (22.2)      |
| Withdrawal by Physician Decision [2] | 0         | 1(25.0)                              | 0                        | 0                                                      | 0                  | 0                                               | 1(11.1)       |
| Other [2]                            | 0         | 1 (25.0)                             | 0                        | 0                                                      | 1(100)             | 1(100)                                          | 3(33.3)       |

<div style=\"page-break-after: always\"></div>

A total of 133 subjects were screened for participation in study VBP15-004 and of these, 121 subjects were randomised: 30 subjects each in the vamorolone 6.0 mg/kg, vamorolone 2.0 mg/kg, and the combined placebo groups and 31 in the combined prednisone groups. 3 subjects (2 in the vamorolone 6.0 mg/kg arm and one randomised to placebo) were not treated and thus excluded from the safety and the mITT analysis populations (the mITT population excluded an additional subject in the placebo group who did not have any post-baseline efficacy assessments). In addition to these 4 subjects, 3 further subjects did not complete the study through week 24: 2 in the vamorolone 2mg/kg treatment arm and one under prednisone treatment.

114 (94.2%) and 112 (92.6%) of the randomised subjects completed period 1 (through week 24) and period 2 (through week 48), respectively. The proportion of subjects who completed the study under vamorolone 2.0 mg, vamorolone 6.0 mg, placebo and prednisone treatment was 93.3%, 86.7%, 93.3% and 96.8%, respectively. One subject in the prednisone group was prematurely discontinued before week  24  because  of  an  adverse  event.  After  week  24  two  additional  subjects  who  were  initially randomised to vamorolone 6 mg/kg and who received vamorolone throughout the study did not complete the final study: 1 subject was prematurely withdrawn because of an AE and 1 subject withdrew consent.

## · Recruitment

This study was conducted at 33 centers in 11 countries.

Date first subject enrolled: 29 June 2018 and Date last subject completed: 19 August 2021

## · Conduct of the study

Changes to the original protocol (dated 15 December 2017) included 4 global protocol amendments. Amendment No 4 (resulting in protocol version 5 with date 28 August 2020) included amongst others the revision of the primary efficacy objective and primary efficacy endpoint to compare vamorolone 6.0 mg/kg vs placebo at Week 24 instead of vamorolone 2 and 6 mg/kg vs placebo at Week 24; the removal of the secondary objective of comparing the efficacy of vamorolone 6.0 mg/kg vs 2.0 mg/kg and addition of a secondary objective of comparing the efficacy of vamorolone 2.0 mg/kg vs placebo at Week 24; to revise  the  secondary  efficacy  endpoints  for  Treatment  Period  #1;  to  revise  the  multiple  testing procedures  for  the  efficacy  endpoints;  to  revise  the  statistical  methodology  for  efficacy  and  safety analyses.

Additionally, protocol clarification letter #2.1 (27 March 2020) was issued to outline specific modifications that could be made to study conduct due to the COVID-19 pandemic. The key modifications to be made on a visit-, site-, or subject-specific basis were that in cases where on-site study visits are not possible for the completion of scheduled efficacy assessments, the TTSTAND will be conducted remotely by a trained  clinical  evaluator  by  videoconferencing  interface;  remote  assessment  of  TTSTAND  must  be completed  at  the  Baseline,  Week  24,  and  Week  48  assessment  time  points.  If  possible,  remote assessment of TTSTAND at Week 12 may also be performed. TTSTAND must be performed per protocol at the on-site Screening visit.

A total of 733 protocol deviations were reported during the study with 82 important protocol deviations that were recorded for 29 subjects in the Safety Population. A total of 271 COVID-19-related protocol deviations were recorded for 81 subjects overall in the Safety Population. A total of 8 important COVID19-related deviations were reported for 7 subjects overall for the Safety Population.

## · Baseline data

The majority of subjects in the mITT-1 population were White or Asian and the most common ethnicity was not Hispanic or Latino (82.9%, 10.3% and 95.7% of subjects, respectively). 66 (56.4%) subjects were enrolled in Europe and 51 (43.6%) in the USA. Across the treatment groups, the mean (SD) age

<div style=\"page-break-after: always\"></div>

was 5.42 (0.863) years (min 4.0, max 7.0). The mean (SD) height was 108.71 (7.851) cm, the mean (SD) body weight was 19.60 (3.181) kg, and the mean (SD) BMI was 16.49 (1.276) kg/m 2 .

Table 7: Disease characteristics at baseline (mITT-1 Population)

|                                                                          | Placebo                               | Prednisone 0.75 mg/kg                 | Vamorolone 2 mg/kg                    | Vamorolone 6 mg/kg                    | Total                                  |
|--------------------------------------------------------------------------|---------------------------------------|---------------------------------------|---------------------------------------|---------------------------------------|----------------------------------------|
| Months Since First DMD Symptoms Noticed n Mean (SD) Median Min., Max.    | 28 34.1 (16.70) 28.5 5,67             | 31 37.8 (17.25) 40.0 3,65             | 30 38.7 (18.88) 39.0 6,77             | 27 40.7 (17.89) 40.0 7,68             | 116 37.8 (17.63) 38.0 3,77             |
| TTSTAND (seconds) n Mean (SD) Median Min., Max.                          | 28 5.55 (1.93) 5.15 2,9; 10.7         | 31 4.92 (1.51) 4.40 2.8; 9.6          | 30 6.07(2.35) 5.45 3.7; 13.5          | 28 5.97 (1.99) 5.70 3.3; 10.8         | 117 5.61 (1.99) 5.00 2.8; 13.5         |
| TTSTAND velocity (rises/sec) n Mean (SD) Median Min., Max. 6MWT distance | 28 0.20 (0.06) 0.19 0.1; 0.3          | 31 0.22 (0.06) 0.23 0.1; 0.4          | 30 0.18 (0.06) 0.18 0.1; 0.3          | 28 0.19 (0.06) 0.18 0.1; 0.3          | 117 0.20 (0.06) 0.20 0.1; 0.4          |
| n Mean (SD) Median Min., Max. NSAA total score n Mean (SD) Median        | 24 354.50 (77.59) 346.50 247.0; 605.0 | 31 343.32 (55.84) 350.00 232.0; 465.0 | 27 316.07 (58.43) 326.00 179.0; 406.0 | 26 312.50 (56.19) 328.50 195.0; 425.0 | 108 331.57 (63.58) 338.50 179.0; 605.0 |
| Min., Max.                                                               | 28 18.89 (5.301) 17.50 9.0; 28.0      | 31 21.16 (5.45) 20.00 13.0; 32.0      | 30 17.20 (4.66) 16.50 9.0; 26.0       | 28 18.86 (4.07) 19.00 12.0; 28.0      | 117 19.05 (5.06) 18.00 9.0; 32.0       |

DMD = Duchenne Muscular Dystrohy; 6MWT=6-minute walk test; SD=standard deviation; TTSTAND=time to stand; NSAA=North Star Ambulatory Assessment.

## · Numbers analysed

## Table 8:  Number of subjects by analysis populations

|                         | Placebo(Per1) + VAM2mg/kg (Per2)   | Placebo(Perl) + VAM6mg/kg (Per2)   | Prednisone (Per1)+ VAM2mg/kg (Per2)   | Prednisone (Per1)+ VAM6mg/kg (Per2)   | VAM2mg/kg (PerlandPer2)   | VAM6mg/kg (Per1andPer2)   | Total      |
|-------------------------|------------------------------------|------------------------------------|---------------------------------------|---------------------------------------|---------------------------|---------------------------|------------|
| mITTPopulation-1[1,2]   | 14 (93.3)                          | 14 (93.3)                          | 15(100)                               | 16(100)                               | 30(100)                   | 28 (93.3)                 | 117 (96.7) |
| mlTTPopulation-2[1,3]   | 14 (93.3)                          | 14 (93.3)                          | 15(100)                               | 15 (93.8)                             | 28 (93.3)                 | 28 (93.3)                 | 114 (94.2) |
| PPPopulation[1,4]       | 14 (93.3)                          | 14 (93.3)                          | 15(100)                               | 15 (93.8)                             | 28 (93.3)                 | 27 (90.0)                 | 113 (93.4) |
| SafetyPopulation-1[1,5] | 15 (100)                           | 14 (93.3)                          | 15(100)                               | 16(100)                               | 30(100)                   | 28 (93.3)                 | 118 (97.5) |
| SafetyPopulation2[1,6]  | 14 (93.3)                          | 14 (93.3)                          | 15 (100)                              | 15 (93.8)                             | 28 (93.3)                 | 28 (93.3)                 | 114 (94.2) |

[1] Denominator is based on number of subjects randomised.

[2] All randomised subjects who had at least one dose of study medication and had at least one postbaseline efficacy assessment during Treatment Period 1.

[3] All randomised subjects who had at least one dose of study medication and had at least one postbaseline efficacy assessment during Treatment Period 2.

[4] All exclusions from the PP population were because a TTSTAND assessment at Week 24 was missing.

[5] All subjects who received at least one dose of study medication during Treatment Period 1.

[6] All subjects who completed Treatment Period 1 and received at least one dose of vamorolone during Treatment Period 2.

mITT=modified Intent-to-Treat; Per1=Period 1; Per2=Period 2; PP=per protocol

<div style=\"page-break-after: always\"></div>

## · Outcomes and estimation

## Week 24 Results

Primary efficacy endpoint: TTSTAND Velocity - Vamorolone 6 mg/kg versus Placebo

Primary analysis:

Table 9: TTSTAND velocity change from baseline to week 24: vamorolone 6 mg/kg versus placebo (and vamorolone 2 mg/kg versus placebo) (mITT-1 population)

| TTSTAND Velocity (rises/sec)    | Placebo (N =28)   | Vamorolone 6 mg/kg (N= 28)   | Vamorolone 2 mg/kg (N = 30)   |
|---------------------------------|-------------------|------------------------------|-------------------------------|
| Baseline 1                      |                   |                              |                               |
| N                               | 28                | 28                           | 30                            |
| Mean (SD)                       | 0.200 (0.0642)    | 0.186 (0.0588)               | 0.184 (0.0546)                |
| Median                          | 0.194             | 0.176                        | 0.184                         |
| Min; Max                        | 0.093:0.345       | 0.093;0.303                  | 0.074;0.270                   |
| Week 24 1                       |                   |                              |                               |
| N                               | 28                | 27                           | 29                            |
|                                 | 0.193 (0.0918)    | 0.242 (0.0785)               | Mean (SD) 0.225 (0.0921)      |
| Median                          | 0.192             | 0.238                        | 0.227                         |
| Min; Max                        | 0.000;0.357       | 0.108;0.476                  | 0.070;0.476                   |
| Change from Baseline at Week 24 | 1                 |                              |                               |
| N                               | 28                | 27                           | 29                            |
| Mean (SD)                       | -0.007 (0.0628)   | 0.054 (0.0666)               | 0.041 (0.0869)                |
|                                 | -0.011            | 0.041                        | Median 0.033                  |
| Min;Max                         | -0.120;0.161      | -0.082;0.198                 | -0.092;0.351                  |
| FDA Analysis 2                  |                   |                              |                               |
| LSM (SE) change from baseline   | -0.0120 (0.0135)  | 0.0483 (0.0136)              | 0.0328 (0.0131)               |
| LSM difference (SE)             |                   | 0.0603 (0.0188)              | 0.0449                        |
| 95% CI                          |                   | 0.0230,0.0976                | 0.0082:0.0816                 |
| p value                         |                   | 0.0018                       | 0.0171                        |
| EMA Analysis 3                  |                   |                              |                               |
| LSM (SE) change from baseline   | -0.0121 (0.0134)  | 0.0464 (0.0135)              | 0.0309 (0.0130)               |
| LSM difference (SE)             |                   | 0.0586 (0.0187)              | 0.0430                        |
| 95% CI                          |                   | 0.0218;0.0953                | 0.0069;0.0791                 |
| P value                         |                   | 0.0018                       | 0.0196                        |

TTSTAND velocity = 1 / TTSTAND and is expressed as rises/sec. Note that velocity was set to 0 for responses determined to be missing due to disease progression (inability to do the test). Moreover, at the first visit a subject could not perform the test due to disease progression, and at ALL subsequent visits, the raw score was left as missing and velocity was imputed as 0.

1 Descriptive statistics based on observed cases (without multiple imputation)

2 REML-based MMRM using observed cases (without multiple imputation)

3 REML-based MMRM using multiple imputation based the assumption of missing not at random

CI=confidence  interval;  LSM=least  squares  mean;  mITT=modified  Intent-to-Treat;  MMRM=mixed  model  for  repeated  measures; REML=restricted maximum likelihood; SD=standard deviation; SE=standard error; TTSTAND=time to stand.

In the primary analysis of change from baseline in TTSTAND velocity at week 24, a statistically significant difference  was  demonstrated  when  vamorolone  6  mg/kg/day  was  compared  against  placebo  (p  = 0.0018). TTSTAND velocity increased in the vamorolone 6 mg/kg group from 0.186 to 0.242 rises/sec and slightly decreased in the placebo group from 0.200 to 0.193 rises/sec at Week 24. The least squares mean (LSM) difference for vamorolone 6 mg/kg from placebo was 0.0586 rises/sec in the EMA analysis and  0.0603  rises/sec  in  the  primary  FDA  analysis.  The  improvement  in  TTSTAND  velocity  under

<div style=\"page-break-after: always\"></div>

vamorolone 6 mg/kg/day is considered clinically relevant as it is greater than the MCID for TTSTAND of 0.023 rises/sec.

Table 10:  Sensitivity analyses for TTSTAND velocity (mITT-1 population)

|                                                                                                 | LSM (SE) Vamorolone 6 mg/kg Vs Placebo         | LSM Difference (SE) 9596 CI                    | p value                                        |
|-------------------------------------------------------------------------------------------------|------------------------------------------------|------------------------------------------------|------------------------------------------------|
| Impactofthe COVID-19Pandemic                                                                    | Impactofthe COVID-19Pandemic                   | Impactofthe COVID-19Pandemic                   | Impactofthe COVID-19Pandemic                   |
| Primary analyeis (EMA)                                                                          | 0.0464 (0.0135) V8-0.0121 (0.0134)             | 0.0586 (0.0187) 0.0218,0.0953                  | 0.0018                                         |
| Missing or delayed due to COVID-191                                                             | （0100)17100-84（50100)9900                      | 0.0587 (0.0187) 0.0220,0.0954                  | 0.0017                                         |
| Altermntive nssessment method due to COVID-19?                                                  | 0.0459 (0.0137) v5, -0.0140 (0.0140)           | 0.0599 (0.0193) 0.0220, 0.0977                 | 0.0019                                         |
| Missing dhta semsitivity amalyses                                                               | Missing dhta semsitivity amalyses              | Missing dhta semsitivity amalyses              | Missing dhta semsitivity amalyses              |
| Primary analysis (mITT-1; FDA)                                                                  | 0.0483(0.0136)V8-0.0120(0.0135)                | 0.0603 (0.0188) 0.0230,0.0976                  | 0.0018                                         |
| Primary analysis (mITT-1: EMA)                                                                  | 0.0464(0.0135)V8.-0.0121(0.0134)               | 0.0586 ((0.0187)) 0.0218.0.0953                | 0.0018                                         |
| All randomized subjects?                                                                        | 0.0482(0.0138) V5.-0.0119 (0.0135)             | 0.0601 (0.0191) 0.0226,0.0975                  | 0.0017                                         |
| All rnndomizedsnbjects (EMA analysis)                                                           | 0.0407 (0.0136) v5. -0.0109 (0.0136)           | 0.0516(0.0188) 0.0148, 0.0885                  | 0.0060                                         |
| All randomized subjects with no missing data at baseline?                                       | 0.0484 (0.0137) v5. -0.0121 (0.0135)           | 0.0605 (0.0189) 0.0235, 0.0973                 | 0.0014                                         |
| All ramdomized subjeets with no missing data at baseline amd at least 1 postbaseline assessment | 0.0483 (0.0136) V8.-0.0121(0.0135)             | 0.0603 (0.0188) 0.0234,0.0972                  | 0.0014                                         |
| Randomizedsubjectswith no missing data                                                          | 0.0356(0.0144)V8.-0.0057(0.0135)               | 0.0413 (0.0195) 0.0027,0.0800                  | 0.0363                                         |
| Influentinl obser'vations sensitivity annlysis                                                  | Influentinl obser'vations sensitivity annlysis | Influentinl obser'vations sensitivity annlysis | Influentinl obser'vations sensitivity annlysis |
| Impact of influentinl observations5                                                             | 0.0454 (0.0124) v5. -0.0121 (0.0122)           | 0.0575 (0.0171) 0.0236, 0.0913                 | 0.0011                                         |

1  Assessments missing or delayed due to COVID-19 were set as missing and imputed similarly as for the EMA primary analysis.

2  Assessments that were conducted with alternative assessment methods due to COVID-19 were set as missing and imputed similarly as for the EMA primary analysis.

3  Missing data imputed based on assumption of missing at random regardless of the reason for missingness.

4  MMRM based on observed cases.

5  TTSTAND values &lt; 2.5 seconds imputed as 2.5 seconds; FDA analysis.

CI=Confidence interval; EMA=European Medicines Agency; FDA=Food and Drug Administration; LSM=Least squares mean; mITT= modified  intent-to-treat;  MAR=missing  at  random;  MMRM=mixed  model  for  repeated  measures;  MNAR=missing  not  at  random; REML=restricted maximum likelihood; SE=standard error; TTSTAND=time to stand.

Several sensitivity analyses have been performed to confirm the results of the primary analysis. Overall, sensitivity analyses demonstrate that the COVID-19 pandemic, missing data, and influential observations did not affect the results of the primary analysis at Week 24. The primary EMA analysis repeated in the ITT analysis set was also in accordance with the primary EMA analysis (mITT population). Per Protocol Analysis: The LSM change from baseline at week 24 in the vamorolone 6 mg/kg group was comparable to that in the mITT-1 population.

TTSTAND in seconds decreased in the vamorolone 6 mg/kg group and slightly increased in the placebo group at Week 24 with LSM (SE) changes from baseline of -1.0523 (0.3604) and 0.6187 (0.3664), respectively. The LSM difference for vamorolone 6 mg/kg from placebo was -1.67 seconds in favour of vamorolone (p=0.0009). The LSM difference for vamorolone 2 mg/kg against placebo was -0.9 seconds (p = 0.0607).

## Secondary Efficacy Endpoints - Pre-specified Hierarchical Testing Order:

## First  pre-specified  secondary  endpoint:  TTSTAND  Velocity  -  Vamorolone  2  mg/kg  versus Placebo

The first secondary efficacy endpoint was met: in the primary analysis (EMA analysis) of change from baseline in TTSTAND velocity at week 24, a statistically significant difference was demonstrated when vamorolone 2 mg/kg/day was compared against placebo (p = 0.0196). TTSTAND velocity increased in the vamorolone 2 mg/kg group from 0.184 to 0.225 rises/sec and slightly decreased in the placebo arm from 0.200 to 0.193 rises/sec at week 24. The LSM difference for vamorolone 2 mg/kg from placebo was 0.0430  rises/sec  (EMA  analysis)  and  comparable  to  the  primary  FDA  analysis.  The  improvement  in

<div style=\"page-break-after: always\"></div>

TTSTAND velocity mg/kg/day is considered clinically relevant also for 2 mg/kg as it is greater than the MCID for  TTSTAND  of  0.023  rises/sec.  Sensitivity  and  supportive  analyses  for  TTSTAND  velocity  in change from baseline under vamorolone 2 mg/kg compared to placebo confirmed the results of the primary analysis.

## Second and third pre-specified secondary endpoints: 6MWT Distance - Vamorolone 6 mg/kg and 2 mg/kg versus Placebo

The second and the third of the pre-specified secondary endpoints were met: in the primary analyses (EMA  analysis)  of  change  from  baseline  in  the  6MWT  distance  at  week  24,  statistically  significant differences were demonstrated for the vamorolone 6 mg/kg and the 2 mg/kg treatment arms when compared against placebo (p=0.0117 and p=0.0112, respectively). While in the vamorolone treatment groups the 6MWT distance increased it showed some decline under placebo. The LSM (SE) change from baseline for placebo, vamorolone 6 mg/kg and 2 mg/kg was -11.37 (10.6082), 24.57 (10.0582) and 24.98 (10.0352), respectively. The LSM difference for vamorolone 6 mg/kg and 2 mg/kg was 35.9 meters and 36.2 meters, respectively, which is compellingly clinically relevant. Provided sensitivity analyses supported the primary analyses, demonstrating that missing data and the analysis method had no impact on the results received.

## Fourths and fifths pre-specified secondary endpoint: TTRW Velocity - Vamorolone 6 mg/kg and 2 mg/kg versus Placebo

The fourth secondary efficacy endpoint of the pre-specified secondary endpoints was met: in the primary analysis (EMA analysis) of change from baseline in TTRW velocity at week 24, a statistically significant LSM difference of 0.237 meters/sec was demonstrated for vamorolone 6 mg/kg/day when compared against  placebo  (p  =  0.0020)  representing  clinically  relevance. TTRW velocity  was  increased  under vamorolone 6 mg/kg group (LSM change from baseline 0.2372 meters/sec) and was almost unchanged in the placebo group at Week 24 with a very minimal increase of 0.0171 meters /sec (LSM change from baseline).  With  respect  to  the  comparison  of  vamorolone  2  mg/kg  against  placebo,  TTRW  velocity increased only slightly from 1.563 meters/sec at baseline to 1.724 meters/sec at Week 24 for vamorolone and remained almost stable for placebo (LSM change from baseline 0.1387 and 0.0171, respectively). The LSM difference of 0.1216 meters/sec was not statistically significant (p = 0.1228). As the fifths secondary endpoint in the pre-specified hierarchical order was not met, thus, the hierarchical testing ended.

## Analyses Vamorolone vs Prednisone

## Sixth and sevenths pre-specified secondary endpoints: 6MWT Distance - Vamorolone 6 mg/kg and 2 mg/kg versus Prednisone

As the fifths secondary endpoint failed to show statistical significance, no formal statistical testing of 6MWT distance for vamorolone 6 mg/kg and 2 mg/kg vs prednisone was possible. While improvements from baseline at Week 24 in the mean 6MWT distance were almost comparable for both vamorolone treatment groups (6 mg/kg and 2 mg/kg), subjects under prednisone treatment improved numerically better (EMA analysis) with LSM (SE) changes from baseline for prednisone and vamorolone 6 mg/kg and 2 mg/kg of 44.12 (9.6444), 24.98 (10.0352) and 24.57 (10.0582), respectively. However, the LSM difference for change from baseline for vamorolone 6 mg/kg and for vamorolone 2 mg/kg each against prednisone was -19.55 (p = 0.14) and -19.14 (p = 0.17).

<div style=\"page-break-after: always\"></div>

Figure  2:  Comparisons  between  vamorolone  and  prednisone  in  timed  tests,  analysed  as percentual changes from baseline (mITT-1 population)

<!-- image -->

Test data are standardised by using the percentual change from baseline as the endpoint. The percentile changes are calculated as (value at visit - baseline value) / baseline value x 100%. All the percentual change values from the four tests are entered to a single statistical model (MMRM) A model comparable to the one presented in FDA-analysis is used, but in addition to the fixed factors included in the original MMRM, the parameter (TTSTAND, TTRW, TTCLIMB or 6MWT) and all 2- and 3-level interaction terms between treatment group,  visit  and  parameter  are  added.  The  model  uses  the  Kronecker  product  covariance  structure.  Accordingly,  the  covariance structure is set as type=un@un in the REPEATED statement of the MIXED procedure.

TTSTANDV= 1 / TTSTAND and is expressed as rises/sec; TTRWV =1 / TTRW and is expressed as meters/sec; TTCLIMBV=1 / TTCLIMB and is expressed as tasks/sec

TTSTANDV=time to stand velocity; 6MWT=6-minute walk test; TTRWV=Time to run/walk 10 Meters Test velocity; TTCLIMBV=Time to climb 4 steps test velocity; VAM2=vamorolone 2 mg/kg; VAM6=vamorolone 6mg/kg PDN=Prednisone.

To account for baseline imbalances and to allow to examine efficacy endpoints globally in spite of different units, the applicant provided percentual changes from baseline at Week 24 for the relevant outcome parameters.  The  improvements  seen  with  vamorolone  6  mg/kg  in  TTSTAND,  TTRW,  and  TTCLIMB velocity were almost comparable to those seen with prednisone at Week 24, while for the 6MWT and the NSAA score prednisone provided better results. The improvements seen with vamorolone 2 mg/kg were overall slightly smaller than those seen with prednisone, when evaluated globally.

## Additional secondary efficacy endpoints

TTCLIMB Velocity was increased in each of the vamorolone groups and slightly decreased in the placebo group from baseline at Week 24. The LSM difference was 0.07 tasks/sec for vamorolone 6 mg/kg from placebo (p= 0.0005 and p = 0.0008, respectively) and 0.06 tasks/sec for vamorolone 2 mg/kg from placebo in the EMA and the FDA analyses (p= 0.005 and p = 0.0056, respectively). The improvements in  TTCLIMB  velocity  with  vamorolone  2  and  6  mg/kg  were  both  greater  than  the  minimally  clinical important  difference. NSAA  Score increased  from  baseline  in  the  vamorolone  groups  and  slightly

<div style=\"page-break-after: always\"></div>

decreased in the placebo group at Week 24. The LSM difference was 3.6 points for vamorolone 6 mg/kg from placebo (p &lt;0.0001 each) and 3.2 points for vamorolone 2 mg/kg from placebo in the EMA and FDA analyses (p=0.0003 and p=0.0002, respectively. The increases in each of the vamorolone groups at Week 24 (approximately +3 points) can be considered clinically meaningful. Hand-held myometry: Change  from  baseline  to  week  24  in  hand-held  myometry  in  vamorolone  6  mg/kg  group  for  knee extensors was 0.0624 kg in the vamorolone group and 1.0147 kg in the prednisone group (p=0.0507) and for elbow flexors LSM change from baseline to week 24 was 0.4241 kg in the vamorolone group and 1.0218 kg in the prednisone group (p=0.0291). In the vamorolone 2 mg/kg group, change in hand-held myometry from baseline to week 24 for knee extensors was -0.03 kg in the vamorolone group (p=0.0388 when  compared  to  prednisone)  and  for  elbow  flexors  it  was  0.5555  kg  in  the  vamorolone  group (p=0.1105 when compared to prednisone). Increase in muscle strength for elbow flexors was slightly higher in vamorolone 2 mg/kg than in the 6 mg/kg group. Comparison was not alpha controlled.

## Week 48 Results

Vamorolone Treatment for 48 Weeks (continued Vamorolone Treatment)

Table 11: Change from baseline at week 24 and week 48 in motor function for vamorolone 2 mg/kg vs 6 mg/kg (mITT2 population)

| TISTAND velocity (rises/sec)                          | LSM (SE)                               | LSMI Difference (SE) 9596 CI       | p value   |
|-------------------------------------------------------|----------------------------------------|------------------------------------|-----------|
| Week 24 Change from Baseline                          |                                        |                                    |           |
| Vamorolone 6.0 mg/kg/day vs. Vamorolone 2.0 mg/kg/day | 0.0521 (0.0130) vs. 0.0265 (0.0127)    | 0.0256 (0.0174) -0.0094,0.0605     | 0.1478    |
| Week 48 Change from Baseline                          |                                        |                                    |           |
| Vamorolone 6.0 mg/kg/day vs. Vamorolone 2.0 mg/kg/day | 0.0446 (0.0138) vs.-0.0053 (0.0135)    | 0.0500 (0.0186) 0.0126,0.0874      | 0.0099    |
| 6MWT distance (meters)                                |                                        |                                    |           |
| Week 24 Change from Baseline                          |                                        |                                    |           |
| Vamorolone 6.0 mg/kg/day vs. Vamorolone 2.0 mg/kg/day | 38.5721 (10.3041) vs.29.2990 (10.5036) | 9.2731 (14.0844) -19.1046, 37.6507 | 0.5137    |
| Week 48 Change from Baseline                          |                                        |                                    |           |
| Vamorolone 6.0 mg/kg/day vs. Vamorolone 2.0 mg/kg/day | 49.6823 (12.5359) v5.14.9190 (12.3367) | 34.7634 (17.0194) 0.4506, 69.0761  | 0.0472    |
| TTRIW velocity (meters/sec)                           |                                        |                                    |           |
| Week 24 Change fiom Baseline                          |                                        |                                    |           |
| Vamorolone 6.0 mg/kg/day vs. Vamorolone 2.0 mg/kg/day | 0.3080 (0.0516) vs. 0.1740 (0.0524)    | 0.1340 (0.0705) -0.0076, 0.2755    | 0.0631    |
| Week 48 Change firom Baseline                         |                                        |                                    |           |
| Vamorolone 6.0 mg/kg/day vs. Vamorolone 2.0 mg/kg/day | 0.2519 (0.0747) vs. 0.1544 (0.0746)    | 0.0976 (0.1032) -0.1099,0.3051     | 0.3492    |
| NSAA Score                                            | LSM (SE)                               | LSM Difference (SE) 9596 CI        | p-value   |
| Week 24 Change fromBaseline                           |                                        |                                    |           |
| Vamorolone 6.0 mg/kg/dayvs Vamorolone 2.0 mg/kg/day   | 3.0943 (0.6610) vs.2.7050 (0.6697)     | 0.3893 (0.9033) -1.4266, 2.2052    | 0.6684    |
| Week 48 Chamge from Baseline                          |                                        |                                    |           |
| Vamorolone 6.0 mg/kg/day vs Vamorolone 2.0 mg/kg/day  | 3.0834 (0.8287) v8. 2.5933 (0.8259)    | 0.4901 (1.1404) -1.8041,2.7843     | 0.6694    |

The LSM estimates are derived from a REML-based MMRM model with enrollment stratification age group (4-5 years; 6&lt;7 years), treatment (vamorolone 2mg/kg/day and vamorolone 6mg/kg/day), week, baseline response, and the treatment-by-week interaction. Such week was included in the model as a categorical variable (weeks 6, 12,24,34, 40 and 48) along with the treatment-by-week interaction. An unstructured covariance structure is used, and the Kenward-Roger approximation was used to estimate denominator degrees of freedom.

CI=confidence interval; LSM=least square mean; REML=restricted maximum likelihood; SED=standard error.

Analyses  for  the  relevant  motor  function  endpoints  presented  above  are  based  on  the  mITT  -  2 population, defined as \"All randomised subjects who received at least one dose of study medication during period 2 and had at least one post-baseline efficacy assessment during Period 2'. Based on the LSM changes from baseline to Week 24 and Week 48, the clinically meaningful improvements in TTSTAND velocity, TTRW velocity and NSAA score seen with vamorolone 6 mg/kg at 24 weeks can be considered to be maintained for up to 48 weeks of treatment. An additional improvement in 6MWT distance was seen from Week 24 to Week 48 with vamorolone 6 mg/kg. With regard to vamorolone 2 mg/kg, there

<div style=\"page-break-after: always\"></div>

was observed a clinically significant decline in TTSTAND and 6MWT based on the LSM changes between week 24 and 48, where TTSTAND velocity after improvement at week 24 decreased at week 48 (LSM change from baseline was 0.0265 at week 24 and -0.0053 at week 48, the LSM difference of 0.05 between the two dosage groups at week 48 was clinically important); 6MWT distance after improvement at week 24 declined at week 48 (LSM change from baseline was 29.2990 at week 24 and 14.9190 at week 48, the LSM difference of  34.7934  between  the  two  dosage  groups  at  week  48  was  clinically significant). Also, a decline in TTRW was observed although LSM changes at week 24 and at week 48 are not considered clinically significant (LSM change from baseline was 0.1740 at week 24 and 0.1544 at week 48, but no difference between two dosage groups at week 48 was observed). A decline in NSAA score at week 48 was also observed, however, the result was still clinically meaningful in vamorolone 2 mg/kg group at week 24 and week 48 (2.7050 at week 24 and 2.5933 at week 48), and no difference between two dosage groups were found at week 48.

Due to the uncontrolled design from Week 24 to Week 48, these data are generally of limited value regarding efficacy. Nevertheless, the respective data could be considered indicative, that the effect of vamorolone is maintained after Week 24, for vamorolone 6 mg/kg as there was no decline across the relevant  outcome  parameters.  However,  the  observed  decline  for  the  vamorolone  2  mg/kg  dose  in TTSTAND velocity and 6MWT at week 48 cannot be dismissed. Given the lack of a pre-defined noninferiority margin, analyses do not allow to compellingly compare the two treatment arms in terms of statistical significance, i.e. lack of statistically significant difference does not allow for a conclusion of equivalent efficacy.

Also,  even  if  the  study  design  was  not  appropriate  to  assess  non-inferiority  with  prednisone,  from descriptive  data  an  important  difference  in  most  of  the  efficacy  endpoints  between  prednisone  and vamorolone 2 mg/kg was observed.

## Switch from Prednisone to Vamorolone

Overall, the treatment effects achieved under prednisone were maintained until week 48 when subjects were switched from prednisone treatment to vamorolone 6 mg/kg at Week 24. When subjects switched from prednisone to vamorolone 6 mg/kg, the mean TTSTAND velocity, TTRW velocity and NSAA score only slightly decreased and TTCLIMB velocity minimally increased. There was also small decline in the 6MWT distance while subjects, who continuously were treated with vamorolone 6m/kg still improved until Week 48. When subjects switched from prednisone to vamorolone 2 mg/kg, the mean TTSTAND and TTCLIMB velocity decreased more than the 6MWTD and TTRW velocity. No mean changes were seen for the NSAA score.

<div style=\"page-break-after: always\"></div>

## · Ancillary analyses

Subgroup analyses for TTSTAND velocity

Figure 3: Forest plot of TTSTAND velocity in subgroups (FDA analysis, mITT-1 population)

<!-- image -->

6MWT=six-minute walk test; mITT=modified intent-to-treat; TTSTAND=time to stand; USA=United States of America.

Subgroup  analyses  of  TTSTAND  velocity  were  comparable  across  the  different  subgroups  favouring vamorolone 6 mg/kg against placebo although they were only based on small number of patients.

Subgroup analyses based on 6MWT distance &lt;350 meters and ≥350 meters at baseline.

Since only 3 subjects in the vamorolone 6 mg/kg group had a baseline 6MWT distance ≥350 meters, subgroup analyses in this group were not applicable.

<div style=\"page-break-after: always\"></div>

Table 12: TTSTAND velocity MMRM, subgroup analysis - Patients with 6MWT distance &lt;350 m at baseline (FDA analysis, mITT-1)

6MWTdistancec350matbaseline

<!-- image -->

|               |                                                        |                                                           | Between-Group       | Between-Group        |         |
|---------------|--------------------------------------------------------|-----------------------------------------------------------|---------------------|----------------------|---------|
| Visit         | Comparison                                             | n LSM (SE)                                                | LSM Difference (SE) | LSMDifference 95% CI | p-Value |
| Week24Change  | Vamorolone6.0mg/kg/dayvs.Placebo                       | 23 vs.130.0511(0.0127)vs.-0.0184(0.0173)0.0695 (0.0207)   |                     | 0.0282, 0.1109       | 0.0013  |
| from Baseline | Vamorolone 6.0 mg/kg/day vs. Prednisone 0.75 mg/kg/day | 23 vs.13 0.0511(0.0127) vs.0.0655 (0.0166)                | -0.0144 (0.0203)    | -0.0550,0.0262       | 0.4815  |
|               | Vamorolone 2.0 mg/kg/day vs.Placebo                    | 17 vs.13 0.0182(0.0144)vs.-0.0184 (0.0173)0.0367 (0.0219) |                     | -0.0072,0.0806       | 0.0997  |
|               | Vamorolone 2.0 mg/kg/day vs. Prednisone 0.75 mg/kg/day | 17 vs.13 0.0182(0.0144)vs.0.0655 (0.0166)                 | -0.0472 (0.0215)    | -0.0903,-0.0042      | 0.0319  |
|               | Vamorolone 6.0 mg/kg/day vs. Vamorolone 2.0 mg/kg/day  | 23 vs.170.0511 (0.0127)vs.0.0182 (0.0144)                 | 0.0329(0.0189)      | -0.0048, 0.0706      | 0.0865  |

TTSTAND velocity=1/TTSTAND and is expressed as rises/second. MMRM=Mixed model for repeated measures; n=number of subjects with a valid response; LSM=least squares mean; SE=Standard error; CI=Confidence Interval.

The LSM estimates are derived from a restricted maximum likelihood (REML)-based MMRM model with enrollment stratification age group  (4-5  year;  6&lt;7  year),  treatment  (vamorolone  0.2mg/kg/day,  vamorolone  0.6mg/kg/day,  and  placebo),  week,  baseline response, and the treatment-by-week interaction. Study week in the model as categorical variable (weeks 6,12, and 24) along with the treatment-by-week interaction. An unstructured covariance structure is used and the Kenward-Roger approximation is used to estimate denominator degrees of freedom.

Overall, results for the motor function endpoints, i.e., TTSTAND velocity, 6MWT distance, TTRW velocity, TTCLIMB velocity and NSAA score were comparable to those in the primary analyses when vamorolone 6 mg/kg was compared against placebo for change from baseline to Week 24. Although results for the vamorolone 2 mg/kg group in comparison to placebo only showed nominally significance, they point in the same direction, representing an effect in comparison to placebo. When interpreting these results, it needs to be considered, that the study was not powered for these analyses that are based on small sample sizes.

## · Summary of main efficacy results

The following table summarises the efficacy results from the main study, study VBP15-004, supporting the present application. This summary should be read in conjunction with the discussion on clinical efficacy as well as the benefit risk assessment (see later sections).

Table 13: Summary of efficacy for trial VBP15-004

| Title: A Phase IIB, randomized, double-blind, parallel group placebo- and active-controlled study with double-blind extension to assess the efficacy and safety of vamorolone in ambulant boys with Duchenne muscular dystrophy (DMD)   | Title: A Phase IIB, randomized, double-blind, parallel group placebo- and active-controlled study with double-blind extension to assess the efficacy and safety of vamorolone in ambulant boys with Duchenne muscular dystrophy (DMD)                                                                                                                                                                                                                                                                                                                                                                                                    | Title: A Phase IIB, randomized, double-blind, parallel group placebo- and active-controlled study with double-blind extension to assess the efficacy and safety of vamorolone in ambulant boys with Duchenne muscular dystrophy (DMD)                                                                                                                                                                                                                                                                                                                                                                                                    |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Study identifier                                                                                                                                                                                                                        | VBP15-004, EUDRACT CT: 2017-002704-27, NCT03439670                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | VBP15-004, EUDRACT CT: 2017-002704-27, NCT03439670                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| Design                                                                                                                                                                                                                                  | Phase 2b, multicenter, randomised, double blind, parallel group, placebo and active controlled study to evaluate the efficacy, safety, pharmacodynamics (PD), and population pharmacokinetics (PPK) of vamorolone (VAM) versus placebo (PBO) and prednisone (PRED), and to evaluate persistence of effect over a treatment period of 48 weeks in ambulant boys aged 4 to < 7 years with DMD. The study comprised two parts: Part 1 was a 24-week randomised, double-blind, parallel group, placebo and active controlled period. In Part 2 all subjects were treated with VAM (both PBO- and PRED-treated subjects crossed over to VAM). | Phase 2b, multicenter, randomised, double blind, parallel group, placebo and active controlled study to evaluate the efficacy, safety, pharmacodynamics (PD), and population pharmacokinetics (PPK) of vamorolone (VAM) versus placebo (PBO) and prednisone (PRED), and to evaluate persistence of effect over a treatment period of 48 weeks in ambulant boys aged 4 to < 7 years with DMD. The study comprised two parts: Part 1 was a 24-week randomised, double-blind, parallel group, placebo and active controlled period. In Part 2 all subjects were treated with VAM (both PBO- and PRED-treated subjects crossed over to VAM). |
| Design                                                                                                                                                                                                                                  | Duration of main phase (Part 1):                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 24 weeks                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| Design                                                                                                                                                                                                                                  | Duration of run-in phase:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | Not applicable                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| Design                                                                                                                                                                                                                                  | Duration of transition phase:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 4 weeks (for subjects switching from PBO or PRED to VAM)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| Design                                                                                                                                                                                                                                  | Duration of extension phase (Part 2):                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 20-24 weeks                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| Design                                                                                                                                                                                                                                  | Duration of dose tapering:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 2-4 weeks (for subjects discontinuing VAM)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| Hypothesis                                                                                                                                                                                                                              | Superiority                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | Superiority                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| Treatment groups                                                                                                                                                                                                                        | PBO                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | Placebo, 24 weeks, n=28                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |

<div style=\"page-break-after: always\"></div>

| (Part 1) mITT population                                                                | PRED                                                                                                                                                                                         | PRED                                                                                                                                                                                         | PRED                                                                                                                                                                                         | Prednisone 0.75 mg/kg, 24 weeks, n=31                                                                                                                                                        | Prednisone 0.75 mg/kg, 24 weeks, n=31                                                                                                                                                        | Prednisone 0.75 mg/kg, 24 weeks, n=31                                                                                                                                                        |
|-----------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| (Part 1) mITT population                                                                | VAM 2                                                                                                                                                                                        | VAM 2                                                                                                                                                                                        | VAM 2                                                                                                                                                                                        | Vamorolone 2 mg/kg, 24 weeks, n=30                                                                                                                                                           | Vamorolone 2 mg/kg, 24 weeks, n=30                                                                                                                                                           | Vamorolone 2 mg/kg, 24 weeks, n=30                                                                                                                                                           |
| (Part 1) mITT population                                                                | VAM 6                                                                                                                                                                                        | VAM 6                                                                                                                                                                                        | VAM 6                                                                                                                                                                                        | Vamorolone 6 mg/kg, 24 weeks, n=28                                                                                                                                                           | Vamorolone 6 mg/kg, 24 weeks, n=28                                                                                                                                                           | Vamorolone 6 mg/kg, 24 weeks, n=28                                                                                                                                                           |
| Treatment groups (Part 2) mITT population 2                                             | VAM 2                                                                                                                                                                                        | VAM 2                                                                                                                                                                                        | VAM 2                                                                                                                                                                                        | Vamorolone 2 mg/kg, 24 weeks, n=28                                                                                                                                                           | Vamorolone 2 mg/kg, 24 weeks, n=28                                                                                                                                                           | Vamorolone 2 mg/kg, 24 weeks, n=28                                                                                                                                                           |
| Treatment groups (Part 2) mITT population 2                                             | VAM 6                                                                                                                                                                                        | VAM 6                                                                                                                                                                                        | VAM 6                                                                                                                                                                                        | Vamorolone 6 mg/kg, 24 weeks, n=28                                                                                                                                                           | Vamorolone 6 mg/kg, 24 weeks, n=28                                                                                                                                                           | Vamorolone 6 mg/kg, 24 weeks, n=28                                                                                                                                                           |
| Treatment groups (Part 2) mITT population 2                                             | PBO/VAM2                                                                                                                                                                                     | PBO/VAM2                                                                                                                                                                                     | PBO/VAM2                                                                                                                                                                                     | Vamorolone 2 mg/kg, 20 weeks, n=14                                                                                                                                                           | Vamorolone 2 mg/kg, 20 weeks, n=14                                                                                                                                                           | Vamorolone 2 mg/kg, 20 weeks, n=14                                                                                                                                                           |
| Treatment groups (Part 2) mITT population 2                                             | PBO/VAM6                                                                                                                                                                                     | PBO/VAM6                                                                                                                                                                                     | PBO/VAM6                                                                                                                                                                                     | Vamorolone 6 mg/kg, 20 weeks, n=14                                                                                                                                                           | Vamorolone 6 mg/kg, 20 weeks, n=14                                                                                                                                                           | Vamorolone 6 mg/kg, 20 weeks, n=14                                                                                                                                                           |
| Treatment groups (Part 2) mITT population 2                                             | PRED/VAM2                                                                                                                                                                                    | PRED/VAM2                                                                                                                                                                                    | PRED/VAM2                                                                                                                                                                                    | Vamorolone 2 mg/kg, 20 weeks, n=15                                                                                                                                                           | Vamorolone 2 mg/kg, 20 weeks, n=15                                                                                                                                                           | Vamorolone 2 mg/kg, 20 weeks, n=15                                                                                                                                                           |
| Treatment groups (Part 2) mITT population 2                                             | PRED/VAM6                                                                                                                                                                                    | PRED/VAM6                                                                                                                                                                                    | PRED/VAM6                                                                                                                                                                                    | Vamorolone 6 mg/kg, 20 weeks, n=15                                                                                                                                                           | Vamorolone 6 mg/kg, 20 weeks, n=15                                                                                                                                                           | Vamorolone 6 mg/kg, 20 weeks, n=15                                                                                                                                                           |
| Endpoints and definitions (incl. the most relevant secondary and exploratory endpoints) | Primary endpoint                                                                                                                                                                             | TTSTAND velocity                                                                                                                                                                             | TTSTAND velocity                                                                                                                                                                             | Change from baseline to week 24 in time to stand velocity (rises/sec)                                                                                                                        | Change from baseline to week 24 in time to stand velocity (rises/sec)                                                                                                                        | Change from baseline to week 24 in time to stand velocity (rises/sec)                                                                                                                        |
| Endpoints and definitions (incl. the most relevant secondary and exploratory endpoints) | Secondary endpoint                                                                                                                                                                           | 6MWT distance                                                                                                                                                                                | 6MWT distance                                                                                                                                                                                | Change from baseline to week 24 in six-minute walk test distance (metres)                                                                                                                    | Change from baseline to week 24 in six-minute walk test distance (metres)                                                                                                                    | Change from baseline to week 24 in six-minute walk test distance (metres)                                                                                                                    |
| Endpoints and definitions (incl. the most relevant secondary and exploratory endpoints) | Secondary Endpoint                                                                                                                                                                           | TTRW velocity                                                                                                                                                                                | TTRW velocity                                                                                                                                                                                | Change from baseline to week 24 in time to run/walk 10 metres (metres/sec)                                                                                                                   | Change from baseline to week 24 in time to run/walk 10 metres (metres/sec)                                                                                                                   | Change from baseline to week 24 in time to run/walk 10 metres (metres/sec)                                                                                                                   |
| Endpoints and definitions (incl. the most relevant secondary and exploratory endpoints) | Secondary endpoint                                                                                                                                                                           | NSAA score                                                                                                                                                                                   | NSAA score                                                                                                                                                                                   | Change from baseline to week 24 in North Star Ambulatory Assessment total score                                                                                                              | Change from baseline to week 24 in North Star Ambulatory Assessment total score                                                                                                              | Change from baseline to week 24 in North Star Ambulatory Assessment total score                                                                                                              |
| Database lock                                                                           | 17 Nov 2021                                                                                                                                                                                  | 17 Nov 2021                                                                                                                                                                                  | 17 Nov 2021                                                                                                                                                                                  | 17 Nov 2021                                                                                                                                                                                  | 17 Nov 2021                                                                                                                                                                                  | 17 Nov 2021                                                                                                                                                                                  |
| Results and Analysis Analysis description Primary (EMA) Analysis, primary endpoint      | Results and Analysis Analysis description Primary (EMA) Analysis, primary endpoint                                                                                                           | Results and Analysis Analysis description Primary (EMA) Analysis, primary endpoint                                                                                                           | Results and Analysis Analysis description Primary (EMA) Analysis, primary endpoint                                                                                                           | Results and Analysis Analysis description Primary (EMA) Analysis, primary endpoint                                                                                                           | Results and Analysis Analysis description Primary (EMA) Analysis, primary endpoint                                                                                                           | Results and Analysis Analysis description Primary (EMA) Analysis, primary endpoint                                                                                                           |
| Analysis population and time point description                                          | Modified intent to treat for Period 1 (mITT-1)(all randomised subjects who had at least one dose of study medication and had at least one post-baseline efficacy assessment during Period 1) | Modified intent to treat for Period 1 (mITT-1)(all randomised subjects who had at least one dose of study medication and had at least one post-baseline efficacy assessment during Period 1) | Modified intent to treat for Period 1 (mITT-1)(all randomised subjects who had at least one dose of study medication and had at least one post-baseline efficacy assessment during Period 1) | Modified intent to treat for Period 1 (mITT-1)(all randomised subjects who had at least one dose of study medication and had at least one post-baseline efficacy assessment during Period 1) | Modified intent to treat for Period 1 (mITT-1)(all randomised subjects who had at least one dose of study medication and had at least one post-baseline efficacy assessment during Period 1) | Modified intent to treat for Period 1 (mITT-1)(all randomised subjects who had at least one dose of study medication and had at least one post-baseline efficacy assessment during Period 1) |
| TTSTAND velocity (rises/sec)                                                            | Treatment groups                                                                                                                                                                             | Treatment groups                                                                                                                                                                             | VAM 6                                                                                                                                                                                        | VAM 6                                                                                                                                                                                        | PBO                                                                                                                                                                                          | PBO                                                                                                                                                                                          |
| Descriptive statistics and estimate variability for change from baseline to week 24     | Number of subjects                                                                                                                                                                           | Number of subjects                                                                                                                                                                           | 27                                                                                                                                                                                           | 27                                                                                                                                                                                           | 28                                                                                                                                                                                           | 28                                                                                                                                                                                           |
|                                                                                         | Mean (SD)                                                                                                                                                                                    | Mean (SD)                                                                                                                                                                                    | 0.054 (0.0666)                                                                                                                                                                               | 0.054 (0.0666)                                                                                                                                                                               | -0.007 (0.0628)                                                                                                                                                                              | -0.007 (0.0628)                                                                                                                                                                              |
| Effect estimate per comparison                                                          |                                                                                                                                                                                              |                                                                                                                                                                                              | Comparison groups                                                                                                                                                                            | Comparison groups                                                                                                                                                                            | VAM 6 (N=28)                                                                                                                                                                                 | PBO (N=28)                                                                                                                                                                                   |
| Effect estimate per comparison                                                          |                                                                                                                                                                                              |                                                                                                                                                                                              | LSM (SE)                                                                                                                                                                                     | LSM (SE)                                                                                                                                                                                     | 0.0464 (0.0135)                                                                                                                                                                              | -0.0121 (0.0134)                                                                                                                                                                             |
| Effect estimate per comparison                                                          |                                                                                                                                                                                              |                                                                                                                                                                                              | LSM difference (SE)                                                                                                                                                                          | LSM difference (SE)                                                                                                                                                                          | 0.0586 (0.0187)                                                                                                                                                                              | 0.0586 (0.0187)                                                                                                                                                                              |
| Effect estimate per comparison                                                          |                                                                                                                                                                                              |                                                                                                                                                                                              | 95% CI                                                                                                                                                                                       | 95% CI                                                                                                                                                                                       | 0.0218, 0.0953                                                                                                                                                                               | 0.0218, 0.0953                                                                                                                                                                               |
| Effect estimate per comparison                                                          |                                                                                                                                                                                              |                                                                                                                                                                                              | P-value                                                                                                                                                                                      | P-value                                                                                                                                                                                      | 0.0018                                                                                                                                                                                       | 0.0018                                                                                                                                                                                       |
| Analysis description                                                                    | Primary Analyses, secondary endpoints (in hierarchical order) and additional secondary endpoints                                                                                             | Primary Analyses, secondary endpoints (in hierarchical order) and additional secondary endpoints                                                                                             | Primary Analyses, secondary endpoints (in hierarchical order) and additional secondary endpoints                                                                                             | Primary Analyses, secondary endpoints (in hierarchical order) and additional secondary endpoints                                                                                             | Primary Analyses, secondary endpoints (in hierarchical order) and additional secondary endpoints                                                                                             | Primary Analyses, secondary endpoints (in hierarchical order) and additional secondary endpoints                                                                                             |
| Analysis population and time point description                                          | Modified intent to treat for Period 1 (mITT-1)                                                                                                                                               | Modified intent to treat for Period 1 (mITT-1)                                                                                                                                               | Modified intent to treat for Period 1 (mITT-1)                                                                                                                                               | Modified intent to treat for Period 1 (mITT-1)                                                                                                                                               | Modified intent to treat for Period 1 (mITT-1)                                                                                                                                               | Modified intent to treat for Period 1 (mITT-1)                                                                                                                                               |
| TTSTAND velocity (rises/sec)                                                            | Treatment groups                                                                                                                                                                             | Treatment groups                                                                                                                                                                             | VAM 2                                                                                                                                                                                        | VAM 2                                                                                                                                                                                        | PBO                                                                                                                                                                                          | PBO                                                                                                                                                                                          |
| Descriptive statistics and estimate variability for change from baseline                | Number of subjects                                                                                                                                                                           | Number of subjects                                                                                                                                                                           | 29                                                                                                                                                                                           | 29                                                                                                                                                                                           | 28                                                                                                                                                                                           | 28                                                                                                                                                                                           |
| to week 24                                                                              | Mean (SD)                                                                                                                                                                                    | Mean (SD)                                                                                                                                                                                    | 0.041 (0.0869)                                                                                                                                                                               | 0.041 (0.0869)                                                                                                                                                                               | -0.007 (0.0628)                                                                                                                                                                              | -0.007 (0.0628)                                                                                                                                                                              |
| Effect estimate per comparison                                                          | First secondary endpoint:                                                                                                                                                                    | First secondary endpoint:                                                                                                                                                                    | Comparison groups                                                                                                                                                                            | Comparison groups                                                                                                                                                                            | VAM 2 (N= 30)                                                                                                                                                                                | PBO (N= 28)                                                                                                                                                                                  |

<div style=\"page-break-after: always\"></div>

|                                                                                     | TTSTAND velocity (rises/sec) at Week 24; VAM 2 vs PBO                 | LSM (SE)            | 0.0309 (0.0130)                      | -0.0121 (0.0134)                     |
|-------------------------------------------------------------------------------------|-----------------------------------------------------------------------|---------------------|--------------------------------------|--------------------------------------|
|                                                                                     | TTSTAND velocity (rises/sec) at Week 24; VAM 2 vs PBO                 | LSM difference (SE) | 0.0430 (0.0184)                      | 0.0430 (0.0184)                      |
|                                                                                     | TTSTAND velocity (rises/sec) at Week 24; VAM 2 vs PBO                 | 95% CI              | 0.0069, 0.0791                       | 0.0069, 0.0791                       |
|                                                                                     | TTSTAND velocity (rises/sec) at Week 24; VAM 2 vs PBO                 | P-value             | 0.0196                               | 0.0196                               |
| 6MWT distance (m)                                                                   | Treatment group                                                       | VAM 6               | PBO                                  | PBO                                  |
| Descriptive statistics and estimate variability for change from baseline            | Number of subjects                                                    | 20                  | 19                                   | 19                                   |
| to week 24                                                                          | Mean (SD)                                                             | 28.8 (49.66)        | -23.9 (59.62)                        | -23.9 (59.62)                        |
| Effect estimate per comparison                                                      | Second secondary endpoint: 6MWT distance (m) at Week 24; VAM 6 vs PBO | Comparison groups   | VAM 6 (N= 28)                        | PBO (N= 28)                          |
| Effect estimate per comparison                                                      | Second secondary endpoint: 6MWT distance (m) at Week 24; VAM 6 vs PBO | LSM (SE)            | 24.5689 (10.0582)                    | -11.3670 (10.6082)                   |
| Effect estimate per comparison                                                      | Second secondary endpoint: 6MWT distance (m) at Week 24; VAM 6 vs PBO | LSM difference (SE) | 35.9359 (14.2577)                    | 35.9359 (14.2577)                    |
| Effect estimate per comparison                                                      | Second secondary endpoint: 6MWT distance (m) at Week 24; VAM 6 vs PBO | 95% CI              | 7.9867, 63.8851                      | 7.9867, 63.8851                      |
| Effect estimate per comparison                                                      | Second secondary endpoint: 6MWT distance (m) at Week 24; VAM 6 vs PBO | P-value             | 0.0117                               | 0.0117                               |
| 6MWT distance (m)                                                                   | Treatment group                                                       | VAM 2               | PBO                                  | PBO                                  |
| Descriptive statistics and estimate variability for change from baseline to week 24 | Number of subjects                                                    | 20                  | 19                                   | 19                                   |
| Descriptive statistics and estimate variability for change from baseline to week 24 | Mean (SD)                                                             | 31.0 (51.12)        | -23.9 (59.62)                        | -23.9 (59.62)                        |
| Effect estimate per comparison                                                      | Third secondary endpoint: 6MWT distance (m) at Week 24; VAM 2 vs PBO  | Comparison groups   | VAM 2 (N= 30)                        | PBO (N= 28)                          |
| Effect estimate per comparison                                                      | Third secondary endpoint: 6MWT distance (m) at Week 24; VAM 2 vs PBO  | LSM (SE)            | 24.9788 (10.0352) -11.3670 (10.6082) | 24.9788 (10.0352) -11.3670 (10.6082) |
| Effect estimate per comparison                                                      | Third secondary endpoint: 6MWT distance (m) at Week 24; VAM 2 vs PBO  | LSM difference (SE) | 36.3458 (14.3319)                    | 36.3458 (14.3319)                    |
| Effect estimate per comparison                                                      | Third secondary endpoint: 6MWT distance (m) at Week 24; VAM 2 vs PBO  | 95% CI              | 8.2538, 64.4379                      | 8.2538, 64.4379                      |
| Effect estimate per comparison                                                      | Third secondary endpoint: 6MWT distance (m) at Week 24; VAM 2 vs PBO  | P-value             | 0.0112                               | 0.0112                               |
| TTRW velocity (m/sec)                                                               | Treatment group                                                       | VAM 6               | PBO                                  | PBO                                  |
| Descriptive statistics and estimate variability for change from baseline            | Number of subjects                                                    | 25                  | 24                                   | 24                                   |
| to week 24                                                                          | Mean (SD)                                                             | 0.277 (0.2788)      | 0.017 (0.3321)                       | 0.017 (0.3321)                       |
| Effect estimate per comparison                                                      | Fourth secondary endpoint: TTRW velocity                              | Comparison groups   | VAM 6 (N= 28)                        | PBO (N=28)                           |
| Effect estimate per comparison                                                      | (m/sec) at Week 24: VAM 6 vs PBO                                      | LSM (SE)            | 0.2542 (0.0550)                      | 0.0171 (0.0565)                      |
| Effect estimate per comparison                                                      | (m/sec) at Week 24: VAM 6 vs PBO                                      | LSM difference (SE) | 0.2372 (0.0768)                      | 0.2372 (0.0768)                      |
| Effect estimate per comparison                                                      | (m/sec) at Week 24: VAM 6 vs PBO                                      | 95% CI              | 0.0867, 0.3876                       | 0.0867, 0.3876                       |
| Effect estimate per comparison                                                      | (m/sec) at Week 24: VAM 6 vs PBO                                      | P-value             | 0.0020                               | 0.0020                               |
| TTRW velocity (m/sec)                                                               | Treatment group                                                       | VAM 2               | PBO                                  | PBO                                  |
| Descriptive statistics and estimate variability for change from baseline            | Number of subjects                                                    | 24                  | 24                                   | 24                                   |
| to week 24                                                                          | Mean (SD)                                                             | 0.160 (0.2267)      | 0.017 (0.3321)                       | 0.017 (0.3321)                       |
| Effect estimate per comparison                                                      | Fifth secondary endpoint                                              | Comparison groups   | VAM 2                                | PBO                                  |
| Effect estimate per comparison                                                      | Fifth secondary endpoint                                              | LSM (SE)            | 0.1387 (0.0562)                      | 0.0171 (0.0565)                      |

<div style=\"page-break-after: always\"></div>

|                                                                                     | TTRW velocity (m/sec) at Week 24: VAM 2 vs PBO                        | LSM difference (SE)                      | 0.1216 (0.0788)                                       | 0.1216 (0.0788)                                       |
|-------------------------------------------------------------------------------------|-----------------------------------------------------------------------|------------------------------------------|-------------------------------------------------------|-------------------------------------------------------|
|                                                                                     | TTRW velocity (m/sec) at Week 24: VAM 2 vs PBO                        | 95% CI                                   | -0.0328, 0.2761                                       | -0.0328, 0.2761                                       |
|                                                                                     | TTRW velocity (m/sec) at Week 24: VAM 2 vs PBO                        | P-value                                  | 0.1228                                                | 0.1228                                                |
| 6MWT distance (m)                                                                   | Treatment group                                                       | VAM 6                                    | PRED                                                  | PRED                                                  |
| Descriptive statistics and estimate variability                                     | Number of subjects                                                    | 20                                       | 22                                                    | 22                                                    |
| for change from baseline to week 24                                                 | Mean (SD)                                                             | 28.8 (49.66)                             | 39.7 (30.62)                                          | 39.7 (30.62)                                          |
| Effect estimate per comparison                                                      | Sixth secondary endpoint: 6MWT distance (m) at Week 24: VAM 6 vs PRED | Comparison groups                        | VAM 6 (N= 28)                                         | PRED (N= 31)                                          |
| Effect estimate per comparison                                                      | Sixth secondary endpoint: 6MWT distance (m) at Week 24: VAM 6 vs PRED | LSM (SE)                                 | 24.5689 (10.0582)                                     | 44.1212 (9.6444)                                      |
| Effect estimate per comparison                                                      | Sixth secondary endpoint: 6MWT distance (m) at Week 24: VAM 6 vs PRED | LSM difference (SE)                      | -19.5523 (13.3737)                                    | -19.5523 (13.3737)                                    |
| Effect estimate per comparison                                                      | Sixth secondary endpoint: 6MWT distance (m) at Week 24: VAM 6 vs PRED | 95% CI                                   | -45.7672, 6.6626                                      | -45.7672, 6.6626                                      |
| Effect estimate per comparison                                                      | Sixth secondary endpoint: 6MWT distance (m) at Week 24: VAM 6 vs PRED | P-value (nominal)                        | 0.1438                                                | 0.1438                                                |
| 6MWT distance (m)                                                                   | Treatment group                                                       | VAM 2                                    | PRED                                                  | PRED                                                  |
| Descriptive statistics and estimate variability for change from baseline to week 24 | Number of subjects                                                    | 20                                       | 22                                                    | 22                                                    |
|                                                                                     | Mean (SD)                                                             | 31.0 (51.12)                             | 39.7 (30.62)                                          | 39.7 (30.62)                                          |
| Effect estimate per comparison                                                      | Seventh secondary endpoint: 6MWT distance (m) at Week 24: VAM 2 vs    | Comparison groups                        | VAM 2 (N= 30)                                         | PRED (N= 31)                                          |
| Effect estimate per comparison                                                      | PRED                                                                  | Least squares mean (standard error [SE]) | 24.9788 (10.0352) 44.1212 (9.6444) -19.1424 (13.8002) | 24.9788 (10.0352) 44.1212 (9.6444) -19.1424 (13.8002) |
| Effect estimate per comparison                                                      | Seventh secondary endpoint: 6MWT distance (m) at Week 24: VAM 2 vs    | 95% CI                                   | -46.1926, 7.9079                                      | -46.1926, 7.9079                                      |
| Effect estimate per comparison                                                      | Seventh secondary endpoint: 6MWT distance (m) at Week 24: VAM 2 vs    | P-value (nominal)                        | 0.1654                                                | 0.1654                                                |
| NSAA total score:                                                                   | Treatment group                                                       | VAM 6                                    | PBO                                                   | PBO                                                   |
| Descriptive statistics and estimate variability for change from baseline            | Number of subjects                                                    | 26                                       | 25                                                    | 25                                                    |
| to week 24                                                                          | Mean (SD)                                                             | 3.2 (3.18)                               | -0.2 (2.57)                                           | -0.2 (2.57)                                           |
| Effect estimate per comparison                                                      | NSAA total score at Week 24: VAM 6 vs PBO                             | Comparison groups                        | VAM 6 (N= 28)                                         | PBO (N= 28)                                           |
| Effect estimate per comparison                                                      | NSAA total score at Week 24: VAM 6 vs PBO                             | LSM (SE)                                 | 2.8660 (0.6134)                                       | -0.7345 (0.6287)                                      |
| Effect estimate per comparison                                                      | NSAA total score at Week 24: VAM 6 vs PBO                             | LSM difference (SE)                      | 3.6005 (0.8508)                                       | 3.6005 (0.8508)                                       |
| Effect estimate per comparison                                                      | NSAA total score at Week 24: VAM 6 vs PBO                             | 95% CI                                   | 1.9330, 5.2680                                        | 1.9330, 5.2680                                        |
| Effect estimate per comparison                                                      | NSAA total score at Week 24: VAM 6 vs PBO                             | P-value (nominal)                        | <0.0001                                               | <0.0001                                               |
| NSAA total score:                                                                   | Treatment group                                                       | VAM 2                                    | PBO                                                   | PBO                                                   |
| Descriptive statistics and estimate variability for change from baseline            | Number of subjects                                                    | 24                                       | 25                                                    | 25                                                    |
| to week 24                                                                          | Mean (SD)                                                             | 3.0 (3.11)                               | -0.2 (2.57)                                           | -0.2 (2.57)                                           |
| Effect estimate per comparison                                                      | NSAA total score at Week 24: VAM 2 vs PBO                             | Comparison groups                        | VAM 2 (N= 30)                                         | PBO (N= 28)                                           |
| Effect estimate per comparison                                                      | NSAA total score at Week 24: VAM 2 vs PBO                             | LSM (SE)                                 | 2.4907 (0.6378)                                       | -0.7345 (0.6287)                                      |
| Effect estimate per comparison                                                      | NSAA total score at Week 24: VAM 2 vs PBO                             | LSM difference (SE)                      | 3.2252 (0.8782)                                       | 3.2252 (0.8782)                                       |

<div style=\"page-break-after: always\"></div>

|                                                                                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 95% CI                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 1.5040, 4.9464                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 1.5040, 4.9464                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
|-------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                                                                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | P-value (nominal)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 0.0002                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 0.0002                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| TTSTAND velocity (rises/sec):                                                       | Treatment group                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | VAM 6                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | PRED                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | PRED                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| TTSTAND velocity (rises/sec):                                                       | Number of subjects                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 27                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 30                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 30                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| Descriptive statistics and estimate variability for change from baseline to week 24 | Mean (SD)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 0.054 (0.0666)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 0.068 (0.0658)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 0.068 (0.0658)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| Effect estimate per comparison                                                      | TTSTAND velocity (rises/sec) at Week 24; VAM 6 vs PRED                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | Comparison groups                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | VAM 6 (N= 28)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | PRED (N= 31)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
|                                                                                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | LSM (SE)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 0.0464 (0.0135)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 0.0661 (0.0129)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
|                                                                                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | LSM difference (SE)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | -0.0197 (0.0185)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | -0.0197 (0.0185)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
|                                                                                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 95% CI                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | -0.0559, 0.0165                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | -0.0559, 0.0165                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
|                                                                                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | P-value (nominal)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 0.2865                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 0.2865                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| TTSTAND velocity                                                                    | Treatment group                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | VAM 2                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | PRED                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | PRED                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| (rises/sec):                                                                        | Number of subjects                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 29                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 30                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 30                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| Descriptive statistics and estimate variability for change from baseline to week 24 | Mean (SD)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 0.041 (0.0869)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 0.068 (0.0658)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 0.068 (0.0658)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| Effect estimate per comparison                                                      | TTSTAND velocity (rises/sec) at Week 24; VAM 2 vs PRED                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | Comparison groups                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | VAM 2 (N= 30)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | PRED (N= 31)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| Effect estimate per comparison                                                      | TTSTAND velocity (rises/sec) at Week 24; VAM 2 vs PRED                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | LSM (SE)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 0.0309 (0.0130)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 0.0661 (0.0129)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| Effect estimate per comparison                                                      | TTSTAND velocity (rises/sec) at Week 24; VAM 2 vs PRED                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | LSM difference (SE)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | -0.0353 (0.0182)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | -0.0353 (0.0182)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| Effect estimate per comparison                                                      | TTSTAND velocity (rises/sec) at Week 24; VAM 2 vs PRED                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 95% CI                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | -0.0709, 0.0003                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | -0.0709, 0.0003                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| Effect estimate per comparison                                                      | TTSTAND velocity (rises/sec) at Week 24; VAM 2 vs PRED                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | P-value (nominal)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 0.0522                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 0.0522                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| Analysis description                                                                | Relevant subgroup analyses (post-hoc)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | Relevant subgroup analyses (post-hoc)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | Relevant subgroup analyses (post-hoc)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | Relevant subgroup analyses (post-hoc)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| Analysis population and time point description                                      | Modified intent to treat for Period 1 (mITT-1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | Modified intent to treat for Period 1 (mITT-1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | Modified intent to treat for Period 1 (mITT-1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | Modified intent to treat for Period 1 (mITT-1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| Effect estimate per comparison                                                      | Subgroup analysis: 6MWT distance (m) at Week 24: VAM 6 vs PRED for patients with baseline 6MWT <350 m                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | Comparison groups                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | VAM 6                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | PRED                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| Effect estimate per comparison                                                      | Subgroup analysis: 6MWT distance (m) at Week 24: VAM 6 vs PRED for patients with baseline 6MWT <350 m                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | LSM (SE)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 35.0101 (10.9607)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 29.0478 (15.0114)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| Effect estimate per comparison                                                      | Subgroup analysis: 6MWT distance (m) at Week 24: VAM 6 vs PRED for patients with baseline 6MWT <350 m                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | LSM difference (SE)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 5.9622 (17.4769)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 5.9622 (17.4769)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| Effect estimate per comparison                                                      | Subgroup analysis: 6MWT distance (m) at Week 24: VAM 6 vs PRED for patients with baseline 6MWT <350 m                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 95% CI                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | -28.2977, 40.2222                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | -28.2977, 40.2222                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| Effect estimate per comparison                                                      |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | P-value (nominal)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 0.7330                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 0.7330                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| Notes                                                                               | Descriptive statistics are based on observed cases (without multiple imputation). Primary, secondary and subgroup analyses used a restricted maximum likelihood (REML)- based mixed model for repeated measures (MMRM) using multiple imputation based the                                                                                                                                                                                                                                                                                                              | Descriptive statistics are based on observed cases (without multiple imputation). Primary, secondary and subgroup analyses used a restricted maximum likelihood (REML)- based mixed model for repeated measures (MMRM) using multiple imputation based the                                                                                                                                                                                                                                                                                                              | Descriptive statistics are based on observed cases (without multiple imputation). Primary, secondary and subgroup analyses used a restricted maximum likelihood (REML)- based mixed model for repeated measures (MMRM) using multiple imputation based the                                                                                                                                                                                                                                                                                                              | Descriptive statistics are based on observed cases (without multiple imputation). Primary, secondary and subgroup analyses used a restricted maximum likelihood (REML)- based mixed model for repeated measures (MMRM) using multiple imputation based the                                                                                                                                                                                                                                                                                                              |
|                                                                                     | assumption of missing not at random (MNAR). In this analysis, data that were missing due to COVID-19 were imputed based on assumption of missing at random (MAR) and all remaining missing data based on assumption of MNAR (using copy-reference imputation). Due to large baseline imbalance in 6MWT at baseline, especially between the vamorolone and prednisone groups, subgroup analyses are presented for 6MWT using a published threshold of baseline 6MWT distance of 350 m. All analyses, except the subgroup analysis that was conducted because of observed | assumption of missing not at random (MNAR). In this analysis, data that were missing due to COVID-19 were imputed based on assumption of missing at random (MAR) and all remaining missing data based on assumption of MNAR (using copy-reference imputation). Due to large baseline imbalance in 6MWT at baseline, especially between the vamorolone and prednisone groups, subgroup analyses are presented for 6MWT using a published threshold of baseline 6MWT distance of 350 m. All analyses, except the subgroup analysis that was conducted because of observed | assumption of missing not at random (MNAR). In this analysis, data that were missing due to COVID-19 were imputed based on assumption of missing at random (MAR) and all remaining missing data based on assumption of MNAR (using copy-reference imputation). Due to large baseline imbalance in 6MWT at baseline, especially between the vamorolone and prednisone groups, subgroup analyses are presented for 6MWT using a published threshold of baseline 6MWT distance of 350 m. All analyses, except the subgroup analysis that was conducted because of observed | assumption of missing not at random (MNAR). In this analysis, data that were missing due to COVID-19 were imputed based on assumption of missing at random (MAR) and all remaining missing data based on assumption of MNAR (using copy-reference imputation). Due to large baseline imbalance in 6MWT at baseline, especially between the vamorolone and prednisone groups, subgroup analyses are presented for 6MWT using a published threshold of baseline 6MWT distance of 350 m. All analyses, except the subgroup analysis that was conducted because of observed |
| Analysis description                                                                | baseline imbalances Exploratory analysis at Week 48                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | were prospectively planned.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | baseline imbalances Exploratory analysis at Week 48                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | baseline imbalances Exploratory analysis at Week 48                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |

<div style=\"page-break-after: always\"></div>

| Analysis population and time point description                                      | Modified intent to treat for Period 2 (mITT-2): all randomised subjects who had at least one dose of study medication and had at least one post-baseline efficacy assessment during Period 2   | Modified intent to treat for Period 2 (mITT-2): all randomised subjects who had at least one dose of study medication and had at least one post-baseline efficacy assessment during Period 2   | Modified intent to treat for Period 2 (mITT-2): all randomised subjects who had at least one dose of study medication and had at least one post-baseline efficacy assessment during Period 2   | Modified intent to treat for Period 2 (mITT-2): all randomised subjects who had at least one dose of study medication and had at least one post-baseline efficacy assessment during Period 2   |
|-------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| TTSTAND velocity (rises/sec):                                                       | Treatment group                                                                                                                                                                                | VAM 2                                                                                                                                                                                          | VAM 6                                                                                                                                                                                          | VAM 6                                                                                                                                                                                          |
| TTSTAND velocity (rises/sec):                                                       | Number of subjects                                                                                                                                                                             | 28                                                                                                                                                                                             | 27                                                                                                                                                                                             | 27                                                                                                                                                                                             |
| Descriptive statistics and estimate variability for change from baseline to week 48 | Mean (SD)                                                                                                                                                                                      | -0.002 (0.0666)                                                                                                                                                                                | 0.048 (0.0715)                                                                                                                                                                                 | 0.048 (0.0715)                                                                                                                                                                                 |
| Effect estimate per comparison                                                      | TTSTAND velocity (rises/sec) at Week 48: VAM 2 vs VAM 6                                                                                                                                        | Comparison groups                                                                                                                                                                              | VAM 6                                                                                                                                                                                          | VAM2                                                                                                                                                                                           |
| Effect estimate per comparison                                                      | TTSTAND velocity (rises/sec) at Week 48: VAM 2 vs VAM 6                                                                                                                                        | LSM (SE)                                                                                                                                                                                       | 0.0446 (0.0138)                                                                                                                                                                                | -0.0053 (0.0135)                                                                                                                                                                               |
| Effect estimate per comparison                                                      | TTSTAND velocity (rises/sec) at Week 48: VAM 2 vs VAM 6                                                                                                                                        | LSM difference (SE)                                                                                                                                                                            | 0.0500 (0.0186)                                                                                                                                                                                | 0.0500 (0.0186)                                                                                                                                                                                |
| Effect estimate per comparison                                                      | TTSTAND velocity (rises/sec) at Week 48: VAM 2 vs VAM 6                                                                                                                                        | 95% CI                                                                                                                                                                                         | 0.0126, 0.0874                                                                                                                                                                                 | 0.0126, 0.0874                                                                                                                                                                                 |
| Effect estimate per comparison                                                      | TTSTAND velocity (rises/sec) at Week 48: VAM 2 vs VAM 6                                                                                                                                        | P-value (nominal)                                                                                                                                                                              | 0.0099                                                                                                                                                                                         | 0.0099                                                                                                                                                                                         |
| 6MWT distance (m):                                                                  | Treatment group                                                                                                                                                                                | VAM 2                                                                                                                                                                                          | VAM 6                                                                                                                                                                                          | VAM 6                                                                                                                                                                                          |
| Descriptive statistics and estimate variability for change from baseline to week 48 | Number of subjects                                                                                                                                                                             | 21                                                                                                                                                                                             | 19                                                                                                                                                                                             | 19                                                                                                                                                                                             |
| Descriptive statistics and estimate variability for change from baseline to week 48 | Mean (SD)                                                                                                                                                                                      | 4.7 (66.74)                                                                                                                                                                                    | 56.7 (55.17)                                                                                                                                                                                   | 56.7 (55.17)                                                                                                                                                                                   |
| Effect estimate per comparison                                                      | 6MWT distance (m) at Week 48: VAM 2 vs VAM 6                                                                                                                                                   | Comparison groups                                                                                                                                                                              | VAM 6                                                                                                                                                                                          | VAM2                                                                                                                                                                                           |
| Effect estimate per comparison                                                      | 6MWT distance (m) at Week 48: VAM 2 vs VAM 6                                                                                                                                                   | LSM (SE)                                                                                                                                                                                       | 49.6823 (12.5359)                                                                                                                                                                              | 14.9190 (12.3367)                                                                                                                                                                              |
| Effect estimate per comparison                                                      | 6MWT distance (m) at Week 48: VAM 2 vs VAM 6                                                                                                                                                   | LSM difference (SE)                                                                                                                                                                            | 34.7634 (17.0194)                                                                                                                                                                              | 34.7634 (17.0194)                                                                                                                                                                              |
| Effect estimate per comparison                                                      | 6MWT distance (m) at Week 48: VAM 2 vs VAM 6                                                                                                                                                   | 95% CI                                                                                                                                                                                         | 0.4506, 69.0761                                                                                                                                                                                | 0.4506, 69.0761                                                                                                                                                                                |
| Effect estimate per comparison                                                      | 6MWT distance (m) at Week 48: VAM 2 vs VAM 6                                                                                                                                                   | P-value (nominal)                                                                                                                                                                              | 0.0472                                                                                                                                                                                         | 0.0472                                                                                                                                                                                         |
| TTRW velocity (m/sec)                                                               | Treatment group                                                                                                                                                                                | VAM 2                                                                                                                                                                                          | VAM 6                                                                                                                                                                                          | VAM 6                                                                                                                                                                                          |
| Descriptive statistics and estimate variability for change from baseline to week 48 | Number of subjects                                                                                                                                                                             | 24                                                                                                                                                                                             | 24                                                                                                                                                                                             | 24                                                                                                                                                                                             |
| Descriptive statistics and estimate variability for change from baseline to week 48 | Mean (SD)                                                                                                                                                                                      | 0.111 (0.3597)                                                                                                                                                                                 | 0.249 (0.3598)                                                                                                                                                                                 | 0.249 (0.3598)                                                                                                                                                                                 |
| Effect estimate per comparison                                                      | TTRW velocity (m/sec) at Week 48: VAM 2 vs VAM 6                                                                                                                                               | Comparison groups                                                                                                                                                                              | VAM 6                                                                                                                                                                                          | VAM2                                                                                                                                                                                           |
| Effect estimate per comparison                                                      | TTRW velocity (m/sec) at Week 48: VAM 2 vs VAM 6                                                                                                                                               | LSM (SE)                                                                                                                                                                                       | 0.2519 (0.0747)                                                                                                                                                                                | 0.1544 (0.0746)                                                                                                                                                                                |
| Effect estimate per comparison                                                      | TTRW velocity (m/sec) at Week 48: VAM 2 vs VAM 6                                                                                                                                               | LSM difference (SE)                                                                                                                                                                            | 0.0976 (0.1032)                                                                                                                                                                                | 0.0976 (0.1032)                                                                                                                                                                                |
| Effect estimate per comparison                                                      | TTRW velocity (m/sec) at Week 48: VAM 2 vs VAM 6                                                                                                                                               | 95% CI                                                                                                                                                                                         | -0.1099, 0.3051                                                                                                                                                                                | -0.1099, 0.3051                                                                                                                                                                                |
| Effect estimate per comparison                                                      | TTRW velocity (m/sec) at Week 48: VAM 2 vs VAM 6                                                                                                                                               | P-value (nominal)                                                                                                                                                                              | 0.3492                                                                                                                                                                                         | 0.3492                                                                                                                                                                                         |
| NSAA total score                                                                    | Treatment group                                                                                                                                                                                | VAM 2                                                                                                                                                                                          | VAM 6                                                                                                                                                                                          | VAM 6                                                                                                                                                                                          |
| Descriptive statistics and estimate variability for change from baseline to week 48 | Number of subjects                                                                                                                                                                             | 23                                                                                                                                                                                             | 24                                                                                                                                                                                             | 24                                                                                                                                                                                             |
| Descriptive statistics and estimate variability for change from baseline to week 48 | Mean (SD)                                                                                                                                                                                      | 2.3 (4.31)                                                                                                                                                                                     | 3.3 (3.70)                                                                                                                                                                                     | 3.3 (3.70)                                                                                                                                                                                     |
| Effect estimate per comparison                                                      | NSAA total score at Week 48: VAM 2 vs VAM 6                                                                                                                                                    | Comparison groups                                                                                                                                                                              | VAM 6                                                                                                                                                                                          | VAM2                                                                                                                                                                                           |
| Effect estimate per comparison                                                      | NSAA total score at Week 48: VAM 2 vs VAM 6                                                                                                                                                    | LSM (SE)                                                                                                                                                                                       | 3.0834 (0.8287)                                                                                                                                                                                | 2.5933 (0.8259)                                                                                                                                                                                |
| Effect estimate per comparison                                                      | NSAA total score at Week 48: VAM 2 vs VAM 6                                                                                                                                                    | LSM difference (SE)                                                                                                                                                                            | 0.4901 (1.1404)                                                                                                                                                                                | 0.4901 (1.1404)                                                                                                                                                                                |
| Effect estimate per comparison                                                      | NSAA total score at Week 48: VAM 2 vs VAM 6                                                                                                                                                    | 95% CI                                                                                                                                                                                         | -1.8041, 2.7843                                                                                                                                                                                | -1.8041, 2.7843                                                                                                                                                                                |
| Effect estimate per comparison                                                      | NSAA total score at Week 48: VAM 2 vs VAM 6                                                                                                                                                    | P-value (nominal)                                                                                                                                                                              | 0.6694                                                                                                                                                                                         | 0.6694                                                                                                                                                                                         |
| Notes                                                                               | Descriptive statistics are based on observed cases.                                                                                                                                            | Descriptive statistics are based on observed cases.                                                                                                                                            | Descriptive statistics are based on observed cases.                                                                                                                                            | Descriptive statistics are based on observed cases.                                                                                                                                            |

<div style=\"page-break-after: always\"></div>

patients included in mITT-2 who were randomised to receive VAM 2 or VAM 6 throughout the study (from baseline to Week 48) were included in the MMRM.

## 2.6.5.3. Analysis performed across trials (pooled analyses and meta-analysis)

## Comparison of efficacy results from study VBP15-004 with a matched population from Study FOR-DMD

To provide a comparison of efficacy and safety of vamorolone administered orally at daily doses of 2 and 6 mg/kg with corticosteroids over a 48-week treatment period, outcomes of vamorolone treated subjects in VBP15-004 were compared with the outcomes of prednisone- and deflazacort-treated boys from the FOR-DMD study. The FOR-DMD study was a multiple site, randomised, prospective, multicenter, doubleblind, study to compare three corticosteroid regimens (0.75 mg/kg/day prednisone; 0.75 mg/kg/day prednisone 10 days on/10 days off; 0.9 mg/kg/day deflazacort) over a treatment period of 36 to 60 months in 196 boys aged ≥ 4 years and &lt; 8 years with confirmed DMD. Included subjects who were corticosteroid  naïve  at  study  entry  were  able  to  rise  independently  from  the  floor  and  provided reproducible forced vital capacity (FVC) measurements. A composite primary outcome measure was used to assess the efficacy containing the time from supine to stand, percentage FVC and subject/parent global satisfaction with treatment. The study was conducted at 40 academic medical centers in the USA (14 sites), Canada (3 sites), UK (7 sites), Germany (4 sites) and Italy (4 sites).

While the studies were still ongoing, a comparison of study designs and conduct between the VBP15004 and FOR-DMD was performed, in order to prospectively assess the feasibility of the FOR-DMD as an external control group for study VBP15-004.

The comparison of efficacy endpoints between vamorolone and prednisone (or deflazacort) groups at Week 48 focused on a global assessment of efficacy without formal statistical hypothesis testing, aiming to  show  whether  the  efficacy  profile  of  the  two  vamorolone  doses  is  comparable  to  prednisone  (or deflazacort).  There  was  no  pre-defined  order  of  the  endpoints  and  the  results  were  planned  to  be presented  by  summarising  the  treatment  differences  and  95%  CIs  for  the  endpoints.  The  following efficacy endpoints were planned to be analysed: TTSTAND velocity, 6MWT distance, TTRW velocity and NSAA score.

## Subject Matching for Efficacy

All randomised subjects who had at least one dose of study medication during Treatment Period 2 of VBP15-004 (i.e., SAF-2) were considered for matching for efficacy.

A 2-stage matching approach was used to identify subjects from the FOR-DMD study to include in these analyses. In the first stage, subjects from the FOR-DMD study were matched based on the key inclusion criteria for this study, including confirmed DMD, between 4 and &lt; 7 years of age at baseline, able to walk independently, and able to complete TTSTAND without assistance.

In the second stage, propensity scores were calculated using a logistic regression model and the following factors that are known to predict DMD disease progression/severity: baseline age; Baseline TTSTAND velocity  (subjects  with  baseline  TTSTAND  &gt;  10  secs  were  excluded);  baseline  NSAA  score;  baseline weight as z-score; Baseline height as z-score.

## Efficacy Analyses

The pre-specified efficacy endpoints TTSTAND velocity, TTRW velocity, 6MWT distance, and NSAA score were compared for each vamorolone dose versus the matched external controls from the FOR-DMD study and analysed using the MMRM model, observed data (i.e., without imputation as there was no control group at 48 weeks), and mITT-2. The MMRM included the response values (as changes from baseline) from  Weeks 24 and 48 as dependent values. The model included fixed effects  for  baseline  age  (as

<div style=\"page-break-after: always\"></div>

stratified in randomisation), treatment group (vamorolone 2 mg/kg, vamorolone 6 mg/kg, prednisone 0.75 mg/kg), week (Week 24 or 48) and treatment-by-week interaction. The baseline value was included as a covariate. Within this model, pairwise comparisons (using LSM contrasts) were made to compare the treatment difference between vamorolone 6 mg/kg or 2 mg/kg with the FOR-DMD prednisone and deflazacort groups. An unstructured covariance structure was applied for MMRM. If this analysis failed to converge,  Akaike's  information  criterion  were  used  to  select  the  best  covariance  structure  from compound  symmetry  and  autoregressive-1  (AR[1]).  The  denominator  degrees  of  freedom  were computed using the Kenward-Roger method. The observations were weighted by the weights generated using propensity scores.

## Results

## Investigation of the validity of the external comparisons

The subjects randomised to prednisone who met the common inclusion criteria were compared across studies in VBP15-004 Period 1 and the first 6 months of FOR-DMD to test the validity of the external control  and  provide  additional  context  for  interpretation  of  the  FOR-DMD  data.  For  efficacy,  all  31 subjects  randomised  to  prednisone  in  Study  VBP15-004  were  matched  to  37  subjects  treated  with prednisone in FOR-DMD.

## External Comparison Evaluation

Table 14: Analysis sets for external comparisons of Study VBP15-004 and matched subjects in the FOR-DMD Study

|                                                                                         | VBP15-004(treatimentmg/kg)         | VBP15-004(treatimentmg/kg)         | FOR-DMD (treatment mg/kg)    | FOR-DMD (treatment mg/kg)    |
|-----------------------------------------------------------------------------------------|------------------------------------|------------------------------------|------------------------------|------------------------------|
|                                                                                         | Vamorolone 2.0                     | Vamorolone 6.0                     | Prednisone 0.75              | Deflazacort 0.90             |
| Randomized                                                                              | 30                                 | 30                                 | 65                           | 65                           |
| Not matched for Safety comparison                                                       | 2                                  | 2                                  | 15                           | 9                            |
| Not treated                                                                             | 0                                  | 2                                  | 2                            | 1                            |
| Not treated in VBP15-004Period2                                                         | 2                                  | 0                                  | Not applicable               | Not applicable               |
| Age <4 or >7 years                                                                      | 0                                  | 0                                  | 7                            | 7                            |
| Missing pretreatment TTSTANDwithout assistanceor6MWT                                    | 0                                  | 0                                  | 6                            | 0                            |
| DMDnotconfirmed                                                                         | 0                                  | 0                                  | 0                            | 1                            |
| Matched safety population for comparison                                                | 28                                 | 28                                 | 50                           | 56                           |
| Matched for efficacy analyses on propensity score                                       | 26                                 | 27                                 | 39                           | 47                           |
| Completed Month 6                                                                       | Required for inclusion in analysis | Required for inclusion in analysis | 48 (96.0%)                   | 54 (96.4%)                   |
| Completed Month 12                                                                      | 28 (100.0%)                        | 26 (92.9%)                         | 48 (96.0%)                   | 52 (92.9%)                   |
| Completed Month 30                                                                      | Not applicable                     | Not applicable                     | 43 (86.0%)                   | 48 (85.7%)                   |
| Reason for discontinuation a                                                            | Reason for discontinuation a       | Reason for discontinuation a       | Reason for discontinuation a | Reason for discontinuation a |
| Adverse event                                                                           | 0                                  | 1 (3.6%)                           | 1 (2.0%)                     | 2 (3.6%)                     |
| Withdrawal of consent/enrolled in another study/non- compliance/lost to follow-up/other | 0                                  | 1 (3.6%)                           | 6 (12.0%)                    | 5 (8.9%)                     |
| Withdrawal necessary                                                                    | 0                                  | 0                                  | 0                            | 1 (1.8%)                     |

6MWT=6-minute walk test; DMD=Duchenne muscular dystrophy; TTSTAND=time to stand test a  For VBP15-0404 up to month 12; Study FOR-DMD up to month 30.

<div style=\"page-break-after: always\"></div>

## Demographic and Other Baseline Characteristics

Although mean and median height were similar across the groups, the percentiles and z-scores for height indicate that subjects in the 2 mg/kg group in VBP15-004 were taller (mean percentile 32% and Z score -0.70 SDs) than those in the other treatment groups (mean percentile between 23 and 27% and z-score between -0.86 and -1.04). Weight and BMI including the percentiles and Z scores were generally similar across the groups. The matched prednisone groups were similar across the two studies. Imbalances were noted  between  the  vamorolone  groups  and  the  matched  prednisone  and  deflazacort  groups,  with subjects in the vamorolone groups having worse values at baseline; in particular, 6MWT distance was longer for the prednisone group in FOR-DMD compared with the deflazacort in FOR-DMD and vamorolone groups in VBP15-004. A similar finding was observed in the VBP15-004 case study report.

## Efficacy Results

## Validity of the external comparison for efficacy

The LSM changes in 6MWT distance were numerically higher for prednisone in FOR-DMD than in VBP15004 at Months 3 (LSM change 40 vs. 26 meters) and Month 6 (55 vs. 39 meters). However, there were no clinically meaningful differences between the studies for any of the efficacy endpoints. A subgroup analysis was performed on the subjects with baseline 6MWT distance &lt;350 meters and confirmed the results of the total population.

Table 15: MMRM analysis for change from baseline to month 6 and 12 in TTSTAND velocity: vamorolone compared with prednisone and deflazacort from the FOR-DMD Study (mITT-1 and mITT-2 populations)

| TTSTAND Velocity (rises/sec)      | I1                           | LSM (SE)                             | LSM Difference (SE) 95% CI       | p-value                      |
|-----------------------------------|------------------------------|--------------------------------------|----------------------------------|------------------------------|
| Month 6 Change froimBaseline      | Month 6 Change froimBaseline | Month 6 Change froimBaseline         | Month 6 Change froimBaseline     | Month 6 Change froimBaseline |
| Vamorolone 6mg/kgVs prednisone    | 27 vs 37                     | 0.0464 (0.0099)VS. 0.0441 (0.0137)   | 0.0023 (0.0162) -0.0297.0.0344   | 0.8855                       |
| Vamorolone 2 mg/kg vs prednisone  | 26 vs 37                     | 0.0176 (0.0099) vs. 0.0441 (0.0137)  | -0.0265 (0.0164) -0.0589,0.0059  | 0.1078                       |
| Vamorolone 6mg/kgvs deflazacoit   | 27 vs 45                     | 0.0464 (0.0099) VS. 0.0508 (0.0110)  | -0.0044 (0.0143) -0.0326,0.0238  | 0.7583                       |
| Vamorolone2mg/kgVs deflazacoit    | 26 vs 45                     | 0.0176 (0.0099) vs. 0.0508 (0.0110)  | -0.0332 (0.0144) -0.0617,-0.0048 | 0.0224                       |
| Month l2 Change fromBaseline      | Month l2 Change fromBaseline | Month l2 Change fromBaseline         | Month l2 Change fromBaseline     | Month l2 Change fromBaseline |
| Vamorolone 6 mg/kg Vs prednisone  | 26 vs 36                     | 0.0403(0.0107) VS. 0.0419 (0.0148)   | -0.0016 (0.0176) -0.0365,0.0333  | 0.9287                       |
| Vamorolone 2 mg/kg vs prednisone  | 26 vs 36                     | -0.0029 (0.0106) vs. 0.0419 (0.0148) | -0.0448 (0.0177) -0.0798.-0.0098 | 0.0126                       |
| Vamorolone 6 mg/kg vs deflazacort | 26 vs 42                     | 0.0403 (0.0107) vs. 0.0418 (0.0121)  | -0.0015 (0.0156) -0.0324, 0.0293 | 0.9225                       |
| Vamorolone 2 mg/kg Vs deflazacort | 26 vs 42                     | -0.0029(0.0106)VS 0.0418 (0.0121)    | -0.0447 (0.0157) -0.0757,-0.0137 | 0.0050                       |

a  The LSM change from baseline at Month 6 for the internal prednisone control was 0.07 rises/sec.

The observations are weighted by the weights generated using propensity scores.

The LSM estimates are derived from a REML-based MMRM model with enrolment stratification age group (4-5 years; 6-&lt;7 years), treatment (vamorolone 2.0 mg/kg/day, vamorolone 6.0 mg/kg/day, prednisone 0.75 mg/kg/day and deflazacort), week, baseline response, and the treatment-by-week interaction. Study week was included in the model as a categorical variable (Weeks 24 and 48 for VBP15-004 and Months 6 and 12 for FOR-DMD) along with the treatment-by-week interaction. An unstructured covariance structure was used, and the Kenward-Roger approximation was used to estimate denominator degrees of freedom.

CI  =  confidence  interval;  LSM  =  least  squares  mean;  MMRM  =  mixed  model  repeated  measures;  REML  =  restricted  maximum likelihood; SD = standard deviation; SE = standard error; TTSTAND = Time to Stand Test

TTSTAND velocity had increased in the vamorolone 6 mg/kg, prednisone, and deflazacort groups at Months 6 and 12. The increases were similar for the vamorolone 6 mg/kg group (LSM change 0.05 and 0.04  at  Months  6  and  12),  deflazacort  group  (LSM  changes  0.05  and  0.04  at  Months  6  and  12,

<div style=\"page-break-after: always\"></div>

respectively),  and  the  prednisone  group  (LSM  changes  were  0.04  and  0.04  at  Months  6  and  12, respectively); the vamorolone 2 mg/kg group showed minimal change (LSM changes 0.02 and -0.00).

The 6MWT distance was increased in all groups at Months 6 and 12. The largest increases were observed for the prednisone group at Months 6 and 12 (estimate 53 and 54 meters, respectively). At Month 6, the changes  were  larger  for  deflazacort  than  vamorolone  2  mg/kg  (mean  changes  39  and  31  meters, respectively),  and  smaller  for  vamorolone  6  mg/kg  (mean  change 26 meters) but at Month 12, the changes for vamorolone 6 mg/kg (45 meters) were larger than for deflazacort (39 meters) or vamorolone 2 mg/kg (11 meters). It is noted that the prednisone group in FOR-DMD also performed &gt;10 meters better than the prednisone group in VBP15-004. The LSM increases in 6MWT distance were smaller with vamorolone 2 mg/kg compared with the prednisone and deflazacort groups. The difference in 6MWT distance between vamorolone 2 mg/kg and prednisone at Month 12 was 43.5 meters all other differences were &lt;29 meters (i.e., below but close to the minimal clinically important difference).

## 2.6.5.4. Supportive study

The FOR- DMD study (Guglieri et al., 2022) was a phase 3 double blind study of 36-60 months duration comparing three corticoid regimens (daily deflazacort, daily prednisone and intermittent prednisone) with aim to find the optimal steroid regimen. It was used as external control for the long-term comparison versus vamorolone. A composite primary outcome measure was used to assess the efficacy containing the time from supine to stand, percentage FVC and subject/parent global satisfaction with treatment. With respect to this study, the submitted information only covers the study protocol, dated 24 June 2013, the report on external comparison of results of vamorolone study VBP15-004 with results of the FOR-DMD study (dated 23 September 2022), Appendix 4.2 of statistical analysis plan for study VBP15004: VBP15-004 vs FOR-DMD: comparison of study designs and conduct and a publication of the study (Guglieri  et  al,  2022).  According  to  the  author,  'among  patients  with  DMD  treatment  with  daily prednisone or daily deflazacort, compared with intermittent prednisone alternating 10 days on and 10 days off, resulted in significant improvement over 3 years in a composite outcome comprising measures of  motor  function,  pulmonary  function,  and  satisfaction  with  treatment;  there  was  no  significant difference between the 2 daily corticosteroid regimens.

## Study VBP15-006

Study  VBP15-006  is  an  ongoing  phase  2,  open-label,  multiple  dose  study  to  assess  the  safety, tolerability, PK, PD, exploratory efficacy, behaviour and neuropsychology, and physical functioning of vamorolone over a treatment period of 12 weeks in boys aged 2 to &lt;4 years and 7 to &lt;18 years with DMD. Vamorolone (ROS2 formulation) is administered at daily doses of 2 mg/kg or 6 mg/kg in steroidnaïve boys aged 2 to &lt;4 years, and in glucocorticoid-pretreated and previously untreated boys aged 7 to &lt;18 years with DMD. The primary objective of the study is to evaluate the safety and tolerability of vamorolone.  The  study  is  included  in  the  Paediatric  Investigation  Plan  for  vamorolone.  The  to-bemarketed formulation ROS2 is used in this study.

A total of 20 subjects are to be enrolled in the 2 to &lt;4 year-old age group (10 each at the 2 and 6 mg/kg dose level), 24 subjects are to be enrolled in the 7 to &gt;18 year-old age group (6 each in the 2 and 6 mg/kg dose groups, steroid-pretreated, 6 each in the 2 and 6 mg/kg dose groups, steroid-naive), plus 10  additional  subjects  aged  12  to  &lt;18 years  and  steroid-pretreated  are  to  be  enrolled  in  the  7  to &lt;18 years age group at a 6 mg/kg dose level (Protocol Amendment 2). With regard to the 2 to &lt;4-yearold group, the initial 10 eligible subjects were planned to be assigned to the 2 mg/kg treatment group, while the subsequent 10 eligible subjects were planned to be assigned to the 6 mg/kg treatment group. At  the  end  of  the  3-month  Treatment  Period  (Week  12),  subjects  are  given  the  option  to  receive

<div style=\"page-break-after: always\"></div>

vamorolone in an Extended Access Programme (EAP) (currently ongoing Canadian EAP - VBP15-EAPCAN), or to transition to standard of care treatment for DMD (may include glucocorticoids).

In subjects 2 to &lt;4 years of age, efficacy is to be assessed based on muscle function using the BayleyIII Gross Motor scale (GMSS). Physical functioning was assessed using the PODCI.

Patient disposition: As of data cut-off date of 21 July 2023, ten subjects aged 2 to &lt; 4 years have been treated with 2 mg/kg vamorolone and all have completed the 12-week study. Nine of these 10 subjects are continuing to receive vamorolone in the EAP and the other subject switched to standard of care glucocorticoid treatment. Median age at baseline was 3.3 years (range 2.8 to 4.0 years). Six subjects aged 2 to &lt; 4 years have been treated with 6 mg/kg vamorolone and have completed the study and are continuing to receive vamorolone in the EAP. Median age at baseline was 3.6 years (range 3.3 to 4.0 years).

The applicant presented preliminary study results during this procedure in order to provide information on  the  identified  knowledge  gaps  for  extrapolation  from  the  reference  population  4  to  &lt;7 years  to patients 2 to &lt;4 years of age.

Preliminary efficacy results on the GMSS in patients 2 to &lt;4 years of age: at baseline, median GMSS were lower than 7 indicating a delay in motor development compared to normal children of the same age. Subjects assigned to vamorolone 2 mg/kg had lower median value at baseline than those assigned to 6 mg/kg indicating a more pronounced motor delay. After 12 weeks, there was no relevant change from baseline in vamorolone 2 mg/kg suggesting no progression of developmental delay, while the mean score increased in the 6 mg/kg dose group with mean (SD) change from baseline to week 12 of 2.67 (1.211), suggesting an improvement in gross motor abilities.

For available clinical safety results, please see Clinical safety.

## 2.6.6. Discussion on clinical efficacy

## Design and conduct of clinical studies

Vamorolone was initially proposed to be indicated for the treatment of DMD in patients 2 years of age and older. During the procedure, the applicant confirmed to restrict the indication to paediatric patients 4 years and older.

The applicant submitted 1 pivotal study, study VBP15-004, a Phase 2a study of 2 weeks duration (VBP15002), a Phase 2 study of 24 weeks duration in subjects who completed study VBP15-002 (VBP15-003) and a Phase 2 study of additional 24 months duration in subjects who completed study VBP15-003 (VBP15-long-term),  all  studies  were  performed  with  the  ROS1  formulation  of  vamorolone.  Further, efficacy results from Study VBP15-004 at 48 weeks were compared with results of two matched DMD standard of care treatment groups from the FOR-DMD Phase 3 study. During the procedure, preliminary efficacy results were provided for the Phase 2 study VBP15-006.

Three open-label Phase 2 studies that contributed to the dose selection for the following study, study VBP15-004, have been conducted:

· Study VBP15-002 was a phase 2a, multicentre, open-label, first-in-patient, proof of concept, multipleascending dose study examining vamorolone doses of 0.25, 0.75, 2 and 6 mg/kg/day for 2 weeks, followed by a 2-week post-treatment follow-up period. 48 ambulatory corticosteroid naïve 4 to &lt; 7 years old boys with DMD were included, diagnosed with DMD by confirmed dystrophin deficiency or identifiable mutation within the DMD gene, who were able to complete the TTSTAND without assistance at the study screening and baseline Visits. All completed the 4 weeks of the study. The evaluation of safety and

<div style=\"page-break-after: always\"></div>

tolerability of multiple ascending oral doses of vamorolone was the primary objective, assessment of efficacy was defined as exploratory objective.

· Study VBP15-003, was a Phase 2, multi-center, open-label, multiple dose study to evaluate the longterm safety, tolerability, clinical efficacy, and PD of vamorolone at dose levels of 0.25 mg/kg/day, 0.75 mg/kg/day, 2 mg/kg/day and 6 mg/kg/day over a treatment period of 24 weeks in boys aged 4-7 years with  DMD.  Subjects  who  had  previously  completed  study  VBP15-002  were  eligible  for  enrollment. Subjects continued to receive vamorolone for 24 weeks at the same dose levels they already had received in study VBP15-002, that have been considered to be safe and well-tolerated in study VBP15-002. In principle, study 003 included a selected (enriched) patient population, as all included subjects already had been treated with vamorolone for 2 weeks.

Primary  study  objective  was  the  evaluation  of  long-term  safety  and  tolerability  of  vamorolone, administered orally at daily doses up to 6 mg/kg over a 24-week Treatment Period, the assessment of efficacy was defined as a secondary objective. Results on clinical efficacy endpoints were compared for each vamorolone treatment arm/dose against an age-matched untreated historical control group from the CINRG-DNHS.

Unless otherwise noted, baseline was defined as the last measurement taken prior to first exposure to study drug (Baseline Visit for VBP15-002). Primary clinical efficacy endpoint was the comparison of each dose level of vamorolone for change from study VBP15-002 baseline to VBP15-003 Week 24 in TTSTAND velocity to the age-matched natural historical control group from the CINRG-DNHS.

· Study VBP15-LTE was a Phase 2, multicentre, open-label study of additional 24 months in subjects who completed the 6-months VBP15-003 study (i.e, total treatment for 30 months or 2.5 years) to evaluate the long-term safety, tolerability, clinical efficacy, and PD of vamorolone at dose levels of 0.25 mg/kg/day,  0.75  mg/kg/day,  2  mg/kg/day,  4  mg/kg/day,  and  6  mg/kg/day.  Dose  adjustment  was allowed between dose levels of 2, 4, and 6 mg/kg. Subjects who completed the Phase II extension study VBP15-003 Week 24 assessments were eligible for enrolment. The age range covered in this study was from 4 years at baseline to up to 9.6 years at the end of the study.

Efficacy was planned to be based on comparison to natural historical controls (CINRG-DNHS), however this was not feasible given the small number of corticosteroid-naïve subjects (n = 6) with 30-month data to match the VBP15-LTE 24-month outcome parameters.

Subjects initially received vamorolone at the same dose level they received in study VBP15-003 (0.25 mg/kg/day,  0.75  mg/kg/day,  2  mg/kg/day,  or  6.0  mg/kg/day);  subjects  were  allowed  to  escalate vamorolone dose to the next higher dose level after receiving their current dose for at least one month, to  the  maximum  of  6  mg/kg/day;  subjects  were  allowed  to  de-escalate  vamorolone  dose  due  to intolerability. Subjects whose dose was decreased from 6 mg/kg/day to 2 kg/kg/day could have their dose subsequently increased to 4 mg/kg/day if they had been taking the 2 mg/kg/day dose for at least one month and, in the opinion of the Investigator, balancing efficacy with safety concerns, they could have benefited from an intermediate higher dose. Subjects who transitioned off vamorolone treatment at the end of participation in the treatment period (24 months) received vamorolone for an additional 14 weeks according to a dose-tapering protocol following the end of the Treatment Period and prior to discharge from the study.

Primary objectives were to evaluate the long-term safety and tolerability of vamorolone at daily doses up to 6 mg/kg over a 24-month Treatment Period, in boys who completed study VBP15-003; and to compare the efficacy, as measured by the TTSTAND, of vamorolone at daily doses up to 6 mg/kg over a 24-month Treatment Period vs. untreated DMD historical controls in young boys with DMD.

The pivotal study, Study VBP15-004 was a randomised, double-blind, parallel-group, 48-week study, to evaluate the efficacy, safety, PD, and population PK of vamorolone in ambulatory, corticosteroid naïve,

<div style=\"page-break-after: always\"></div>

4 to &lt;7 years of age-old boys with DMD. The study consisted of a treatment period 1 (day 1 to week 24) followed by a 4-week transition period (week 25 to week 28) for subjects who received either placebo or prednisone in period 1 (subjects who received vamorolone in period 1 were continued on the same dose of vamorolone during this period), period 2 (week 28 +1 day to week 48) where all subjects received vamorolone 2 or 6  mg/kg for 20 weeks and a 4-week dose tapering period (week 49 to week 52) where subjects  who  elected  not  to  continue  vamorolone  treatment  had  the  vamorolone  dose  progressively reduced and discontinued. During Scientific advice/Protocol assistance the CHMP clarified that the pivotal study has not been conducted in full compliance with the recommendations, mainly pertaining to the lack of concurrent comparative data at Week 48, which would have been preferred over external controls.

In Period 1, subjects were randomised to 1 of 6 groups in a 2:2:1:1:1:1 ratio: vamorolone 2 mg/kg, vamorolone  6  mg/kg,  2  groups  of  placebo  and  2  groups  of  prednisone  0.75  mg/kg/day,  with randomisation stratified by age at study entry (&lt;6 years and ≥6 years ).

To maintain the double-blind in this treatment period, all subjects received either a matching placebo for vamorolone (i.e. a placebo oral suspension), a matching placebo for prednisone (i.e. a placebo tablet) or both (i.e. placebo oral suspension and placebo tablet). 0.75 mg/kg prednisone was used as an internal comparator representing the starting dose of standard-of-care treatment for DMD. Prednisone is formally not  approved  in  the  EU  for  this  condition.  However,  several  studies  including  short-term  placebocontrolled studies (Griggs et al. Neurology 2016) as well as prospective long-term observational studies (CINRG-DHNS) have shown that glucocorticoid including prednisone have positive effects on the disease course.

Key inclusion criteria encompassed glucocorticoid naïve Duchenne patients diagnosed based on gene analysis and/or a muscle biopsy sample, tested for the presence of dystrophin protein. Included patients were defined to be ≥4 years and &lt;7 years of age at ti me of enrollment, able to walk independently and able to complete the TTSTAND without assistance in &lt;10 seconds.

Primary efficacy endpoint was the change from baseline in TTSTAND velocity for the vamorolone 6 mg/kg group compared vs placebo at week 24.

Change from baseline to week 24 was tested for the following secondary efficacy endpoints in a prespecified hierarchical order:

- TTSTAND velocity for the vamorolone 2.0 mg/kg/day vs placebo group
- 6MWT distance for vamorolone 6.0 mg/kg vs placebo
- 6MWT distance for vamorolone 2.0 mg/kg vs placebo
- TTRW velocity for vamorolone 6.0 mg/kg vs placebo
- TTRW velocity for vamorolone 2.0 mg/kg vs placebo
- 6MWT distance for vamorolone 6.0 mg/kg vs prednisone
- 6MWT distance for vamorolone 2.0 mg/kg vs prednisone

Additional  secondary  efficacy  endpoints  for  week  24  included  the  following  comparing  each  of  the vamorolone doses versus placebo and each vamorolone dose versus prednisone: change from baseline in TTCLIMB velocity, change from baseline in NSAA score, change from baseline in knee extension muscle strength and change from baseline in elbow extension muscle strength.

All the secondary efficacy endpoints were also analysed for the vamorolone groups at week 48, but not in a pre-defined hierarchical order.

<div style=\"page-break-after: always\"></div>

Overall, the choice of endpoints is acceptable and in line with the EMA guideline for the treatment of Duchenne muscular dystrophy (EMA/CHMP/236981/2011, Corr.1) as well as EMA advice recommendations. However, it is noted, that the outcome of the secondary variables in the hierarchy, all of them principally timed function assessments for lower limb function, are expected to be correlated with  results  of  the  primary  endpoint  as  they  are  covering  the  same  dimensions  of  motor  function. Strength in knees is most associated with ambulation function. Muscle strength might not be a sensitive measure for the included age group because it is not linearly correlated with function. Rapid decline starts after age of 7 and for this age group even small gains in muscle strength are associated with improvement in function (McDonald, 2013). Early start of corticosteroids has shown that increase in muscle strength is associated with prolongation of ambulation, therefore the impact on muscle strength is considered highly relevant for long-term outcomes.

Based on previous studies, the following MCIDs were chosen and are accepted: TTSTAND velocity 0.023 rise/sec, TTRW 0.212 m/sec and TTCLIMB 0.035 tasks/sec (Duong et al, 2021), 6MWTD of around 30 meters (McDonald et al, 2013) and NSAA total score 2.32 points (Haberkamp et al, 2019) while any estimates of MCIDs for muscle strength assessed with handheld myometry in patients with DMD are lacking.  Due  to  the  COVID-19  pandemic  it  was  allowed  for  scheduled  assessments  to  be  performed remotely, except for screening assessments, which must be performed at the study site. Sample size calculation appears to be acceptable. It is estimated that 30 patients per group are needed to ensure 91% power to detect a clinically significant difference between 6.0 mg/kg/day and placebo on TTSTAND velocity at Week 24.

Randomisation  is  acceptable.  Blinding  is  acceptable.  Success  of  blinding  was  assessed  at  Week  24. Interim analyses were not planned and conducted.

Overall, the statistical approach for pivotal study is adequately described and is acceptable. The primary analysis population for efficacy at week 24 was the mITT-1 Population (all randomised subjects who received at least one dose of study medication during period 1 and had at least one post-baseline efficacy assessment during Period 1). However, analyses based on the ITT population with relevant missing data imputation are generally considered of primary relevance; evaluations in the ITT population have at least been  defined  as  sensitivity  analysis  for  the  primary  endpoint  but  were  also  provided  for  all  other endpoints upon request.

The primary analysis of the primary efficacy endpoint for EMA consisted of a missing data imputation while for FDA only the observed measurements were used (without multiple imputation).

The proposed primary estimand is defined as the mean difference (vamorolone 6.0 mg/kg compared to placebo) according to the randomised groups, regardless of the treatment that was actually received in change from baseline to Week 24 in TTSTAND velocity in the target population, regardless of treatment discontinuation, regardless of treatment with co-medication, had there be no impact of the COVID-19 pandemic (hypothetical strategy), and assuming the worst outcome of the velocity (zero) in case of death (composite strategy). Overall, this approach is endorsed.

Intercurrent events are defined as premature discontinuation of study treatment, death and COVID-19 pandemic  related  events  (missed  or  delayed  assessments,  assessments  conducted  with  alternative methods).

For premature discontinuation of study treatment, the missing data were imputed under the assumption of MNAR. The missing data that have been recorded to be missing due to the COVID-19 pandemic were considered under the assumption of MAR. Only data for primary endpoint were imputed. Other missing data were not imputed. Missing data due to Covid-19 imputed under the MAR assumption can introduce bias in the analysis. The applicant clarified that the classification of missing data due to COVID-19 for the  analysis  of  the  primary  endpoint  was  performed  with  consistent  methods  across  the  study.

<div style=\"page-break-after: always\"></div>

Furthermore, the applicant clarified that measurement drop-outs that were not due to COVID-19 were imputed using Copy-Reference imputation and the measurement drop-outs that were due to COVID-19 were imputed using the assumption of MAR.

For data that are missing due to death, a composite strategy should have been used. In this scenario, the TTSTAND velocity value would be imputed as zero for the next visit that would have been scheduled following the death. Similar composite strategy would have been applied for the TTSTAND velocity values that are missing because the test could not be conducted due to disease progression. This approach is endorsed.

Multiplicity  across  primary  and  secondary  endpoints  was  handled  using  hierarchical  testing.  This preserved the study-wise type I error rate and is acceptable. The primary efficacy outcome, TTSTAND (velocity) was to be compared between the 6.0 mg/kg/day vamorolone group and the placebo group using a REML-based MMRM. The chosen model appears to be acceptable. Proposed sensitivity analyses also are acceptable.

Internal comparisons for the two vamorolone treatment groups were performed for change from baseline at Week 48 in the set of subjects who were randomised to receive vamorolone in both Period 1 and Period 2. Because there was no placebo group up to Week 48, no multiple imputation analyses were conducted, and all analyses were based on observed cases only. The comparison focused on a global assessment of efficacy without formal statistical hypothesis testing.

Subgroup analyses were performed for the primary endpoint TTSTAND velocity (pre-specified) and the 6MWT distance based on: age, baseline TTSTAND velocity, baseline 6MWT distance, race and country. To  take  baseline  imbalances  with  respect  to  disease  severity  into  account  and  to  define  more homogeneous treatment groups, the applicant performed additional subgroup analyses ( post hoc )  in subjects with baseline 6MWT distances of &lt;350 meters. The chosen threshold was justified based on a publication by McDonald 2013 that concluded that patients with a baseline 6MWT distance &lt;350 meters have a greater functional decline than those ≥ 350 meters. However, due to the very small number of patients reflecting the latter subgroup, i.e., only 3 subjects in the vamorolone 6 mg/kg group, analyses in patients with a baseline 6MWTD ≥ 350 meters were not applicable.

Several  sensitivity  and  supportive  analyses  were  pre-defined  in  the  SAP  to  show  robustness  of  the primary analysis. Amongst others, two sensitivity analyses were conducted to assess the potential impact of the COVID-19 pandemic on TTSTAND velocity, including missing or delayed testing and the use of a video instead of in-person testing.

The FOR-DMD study was a phase 3, multiple site, multicentre, randomised prospective double-blind study in ambulatory DMD patients to compare the efficacy and safety of the most three commonly used corticosteroid regimens (0.75 mg/kg/day prednisone; 0.75 mg/kg/day prednisone 10 days on/10 days off; 0.9 mg/kg/day deflazacort) over a treatment period of 36 to 60 months in 196 boys aged ≥ 4 years and  &lt;  8  years  with  confirmed  DMD  and  with  the  ability  to  rise  independently  from  the  floor  and reproducible FVC measurements. A composite outcome measure comprising time from supine to stand, percentage FVC and subject/parent global satisfaction with treatment was chosen as primary endpoint.

## Comparison of efficacy results from study VBP15-004 with a matched population from Study FOR-DMD

To provide a comparison of efficacy and safety of vamorolone administered orally at daily doses of 2 and 6  mg/kg  with  corticosteroids  over  a  48-week  treatment  period,  outcomes  of  those  subjects  having received vamorolone throughout 48 weeks in study VBP15-004 were subsequently compared against outcomes of prednisone- and deflazacort-treated boys from the FOR-DMD study.

A 2-stage matching approach was used to identify subjects from the FOR-DMD study to include in these analyses. In the first stage, subjects from the FOR-DMD study were matched based on the key inclusion

<div style=\"page-break-after: always\"></div>

criteria for this study, including confirmed DMD, between 4 and &lt; 7 years of age at Baseline, able to walk independently, and able to complete TTSTAND without assistance. In the second stage, propensity scores were calculated using a logistic regression model and the following factors assessed at baseline: age, TTSTAND velocity (subjects with baseline TTSTAND &gt; 10 secs were excluded), NSAA score, weight as  z-score  and  height  as  z-score.  The  dependent  variable  of  the  logistic  regression  model  was  the outcome that would be observed if the subject received the treatment (1 = treatment, 0 = control). The factors listed above were used as independent variables. The pre-specified efficacy (TTSTAND velocity, 6MWT  distance,  TTRW  velocity  and  NSAA  score)  and  safety  endpoints  were  compared  for  each vamorolone dose arm from study VBP15-004 with prednisone and deflazacort from the FOR-DMD study. Exploratory comparisons for the two prednisone groups served as validation for comparison across the two studies.

Study VBP15-006 (cut-off date of 21 July 2023) is an ongoing phase 2, open-label, multiple dose study to assess the safety, tolerability, PK, PD and exploratory efficacy of vamorolone over a treatment period of 12 weeks in boys aged 2 to &lt;4 years and 7 to &lt;18 years with DMD. Vamorolone is administered at daily  doses  of  2 mg/kg  or  6 mg/kg in steroid-naïve boys aged 2 to &lt;4 years, and in glucocorticoidpretreated and previously untreated boys aged 7 to &lt;18 years with DMD. In subjects 2 to &lt;4 years of age efficacy was to be assessed based on muscle function using the Bayley-III Gross Motor scale. Physical functioning was assessed using the PODCI. With regard to the 2 to &lt;4 year-old group, the initial 10 eligible subjects were planned to be assigned to the 2 mg/kg treatment group, while the subsequent 10 eligible subjects were planned to be assigned to the 6 mg/kg treatment group.

## Efficacy data and additional analyses

Study VBP15-002: 48 subjects were enrolled and all 48 completed the 4-week study. Mean changes from baseline to the end of the treatment for the functional outcome assessments, e.g., TTSTAND velocity, were generally minimal and not dose-related. However, given the short treatment period of only 2 weeks duration and a rather less affected patient population this is not unexpected.

## Study VBP15-003:

48 subjects were enrolled, 46 subjects completed the study. One subject in the 0.25 mg/kg/day dose level group was withdrawn by the parent/guardian to participate in another DMD clinical trial, and one subject in the 6 mg/kg/day dose level group was withdrawn by the parent/guardian for protocol burden.

The comparator group for efficacy consisted of 31 subjects from the CINRG-DNHS study who met all entry criteria of VBP15-003 and remained untreated through a 24-week period. With respect to safety, the comparator group consisted of 14 subjects who met the entry criteria of VBP15-003 and received daily prednisone therapy in the CINRG prednisone trial.

Efficacy results for TTSTAND-, TTRW- and TTCLIMB velocity in the CINRG control group were overall comparable to that seen for the lower vamorolone dosages, i.e., 0.25 and 0.75 mg/kg/day although the lowest  vamorolone  dose  of  0.25  mg/kg  appears  to  be  worse  than  the  natural  history  data.  Mean improvements from baseline to Week 24 in TTSTAND velocity, TTRW velocity, and TTCLIMB velocity and 6MWT distance were greater for the vamorolone 2 and 6 mg/kg treatment arms when compared against the lower vamorolone doses and against the external untreated CINRG-DNHS control group, except for TTRW velocity (vamorolone 0.75 and 2 mg/kg provided similar changes). Results for quantitative muscle testing and PODCI showed height variability with no dose-dependent effect. Based on the MCIDs, the improvements for the vamorolone 2 and 6 mg/kg group in TTSTAND, TTRW and TTCLIMB velocity and 6MWT  distance  were  considered  clinically  meaningful.  Greater  improvements  for  the  vamorolone  6 mg/kg arm in comparison to the vamorolone 2 mg/kg dose were only seen for results on TTRW velocity and 6MWT distance.

<div style=\"page-break-after: always\"></div>

Although the study provided several limitations with respect to the study design, results on efficacy indicate that the higher dosages provided better results than the lower dosages, i.e., 0.25 and 0.75 mg/kg. As the 6 mg/kg dose in comparison to the 2 mg/kg dose provided not clearly better results for all endpoints the most suitable/optimal dose with respect to efficacy could not sufficiently be defined at that time and therefore it is reasonable that both, the 2 mg/kg and the highest dose tested (6 mg/kg) have been carried forward to the phase II b study.

## Study VBP15-LTE:

46 subjects were enrolled in the study (11 subjects [0.25 mg/kg/day], 12 subjects [0.75 mg/kg/day], 12 subjects  [2  mg/kg/day],  and  11  subjects  [6  mg/kg/day])  and  all  46  subjects  were  analysed  for efficacy (FAS) and PD and safety (safety population); 41 subjects completed the study.

On the basis of the results received in the 24 months study VBP15-LTE, the evaluation of efficacy can be extended to a total treatment duration of up to 30 months.

Overall, the improvements in TTSTAND, TTRW and TTCLIMB velocity, and 6MWT distance seen with vamorolone 2 and 6 mg/kg at Week 24 in Study VBP15-003 were maintained up to Month 18 in Study VBP15-LTE followed by a gradual decline towards baseline after month 18. Eleven of 41 subjects were down titrated from 6 mg/kg/day to 2 or 4 mg/kg/day. Efficacy data for these 11 patients are rather limited. Although no consistency in results on motor function was seen, data are therefore difficult to interpret.

## Pivotal Study VBP15-004:

A total of 121 subjects were randomised with 30 subjects in each of the vamorolone treatment arms and the combined placebo groups and 31 in the combined prednisone groups. 3 subjects (2 in the vamorolone 6 mg/kg arm and one randomised to placebo) were not treated and thus excluded from the safety and the mITT analysis populations (the mITT population excluded an additional subject in the placebo group who did not have any post-baseline efficacy assessments). In addition to these 4 subjects, 3 further subjects  did  not  complete  the  study  through  week  24  with  2  subjects  in  the  vamorolone  2  mg/kg treatment arm and one under prednisone treatment.

Completion  rates  were  high  in  this  double-blind  study  with  114  (94.2%)  and  112  (92.6%)  of  the randomised  subjects  completed  period  1  (through  week  24)  and  period  2  (through  week  48), respectively.  The  proportion  of  subjects  who  completed  the  study  through  week  24  was  almost comparable across the treatment arms (each of 93.3 %) with only a slightly higher proportion of subjects who  completed  under  prednisone  treatment  (combined:  96.8%).  The  proportion  of  subjects  who completed the study under vamorolone 2 mg, vamorolone 6 mg, placebo and prednisone treatment was 93.3%, 86.7%, 93.3% and 96.8%, respectively. One subject in the prednisone group was prematurely discontinued before week 24 because of an adverse event. After week 24 two additional subjects who initially were randomised to vamorolone 6 mg/kg and who received vamorolone throughout the study did not complete the final study: 1 subject was prematurely withdrawn because of an AE and 1 subject withdrew consent.

Overall, the number of important and non-important deviations was similar across the treatment groups. The  most  frequent  deviation  due  to  Covid-19  was  modification  of  study  visit  but  only  few  (1-3  per treatment group) were outside permitted window. Placebo group had slightly higher number of important deviations but number of patients having deviations is similar across the groups. Number of patients randomised but not meeting eligibility criteria were low (0-3) and similar across treatment groups.

The included ambulatory patient population was a restricted patient population in the age range of 4 to 7 years with mean age around 5 years.

<div style=\"page-break-after: always\"></div>

According to the study protocol patients had to have a confirmed diagnosis of DMD, either by genetic testing  or  based  on  muscle  biopsy.  While  almost  all  patients  were  diagnosed  based  on  genetic confirmation by DNA and had no additional muscle biopsy, there were three subjects solely diagnosed based on muscle biopsy. Genetic mutations were similar across the study arms.

The study population consisted of male subjects with a mean (SD) number of 37.8 (17.63) months (range 3 to 77 months) between the first symptoms of DMD and study entry. However, in reference to the time since first DMD symptoms and taking into account baseline results of relevant function tests chosen for efficacy in this study, subjects in the vamorolone treatment groups seemed to have more advanced disease at baseline compared to the other groups, i.e., placebo and prednisone, respectively.

Treatment compliance was assessed by maintenance of drug dispensing and return records at the study site to the Week 2 Visit and Week 30 Visit. Overall, 90% of participants reached compliance above 80% in both study periods. Compliance was similar across study arms.

To  take  these  baseline  imbalances,  reflecting  disease  severity  into  account  and  to  define  more homogeneous treatment groups, the applicant performed additional post-hoc subgroup analyses for the efficacy endpoints in subjects with baseline 6MWT distances of &lt;350 meters. The chosen threshold was justified based on a publication by McDonald et al, 2013 that concluded that patients with a baseline 6MWT distance &lt;350 meters have a faster functional decline than those ≥ 350 meters.

Due to the very small number of patients reflecting the latter subgroup, i.e.,17 (54.8%) in the prednisone group  compared  with  9  (33.3%)  or  3  (11.5%)  in  the  vamorolone  2  mg/kg  and  6  mg/kg  group, respectively analyses in patients with a baseline 6MWTD ≥ 350 meters were not performed.

The study met its primary objective. In the primary analysis of change from baseline in TTSTAND velocity at week 24, a statistically significant difference was demonstrated when vamorolone 6 mg/kg/day was compared against placebo (p = 0.0018). TTSTAND velocity increased in the vamorolone 6 mg/kg group from 0.186 to 0.242 rises/sec and slightly decreased in the placebo group from 0.200 to 0.193 rises/sec at Week 24. The LSM difference for vamorolone 6 mg/kg from placebo was 0.0586 rises/sec in the EMA analysis and 0.0603 rises/sec in the primary FDA analysis. The improvement in TTSTAND velocity under vamorolone 6 mg/kg/day is considered clinically relevant as it is greater than the MCID for TTSTAND of 0.023 rises/sec.

A number of sensitivity and supportive analyses, including a Per Protocol Analysis, confirmed the results of  the  primary  analysis,  e.g.,  they  demonstrated  that  the  COVID-19  pandemic,  missing  data,  and influential observations did not affect the results received. The primary EMA analysis repeated in the ITT analysis set was also in accordance with the primary EMA analysis (mITT population). Using the ITT population at least for sensitivity analysis is appreciated as this is the preferred analysis population. In a  supportive  analysis  of  the  primary  efficacy  estimate,  a  higher  respondent  rate  was  observed  in TTSTAND velocity at week 24 (mITT-1 population) in vamorolone 6 mg group, compared to placebo (71.4%  vs  35.7  %) . However,  the  pre-defined  responder  analysis  was  based  on  any  versus  nonimprovement and magnitude of improvement was not considered.

As expected, results for the change from baseline to Week 24 for TTSTAND in seconds were in accordance with results of the primary analysis. TTSTAND in seconds decreased in the vamorolone 6 mg/kg group and slightly increased in the placebo group at Week 24 with LSM (SE) changes from baseline of -1.0523 (0.3604) and 0.6187 (0.3664), respectively. The LSM difference for vamorolone 6 mg/kg from placebo was -1.67 seconds in favour of vamorolone (p=0.0009).

In addition, the four secondary efficacy endpoints ranked highest in the hierarchical testing order showed statistically significant differences between vamorolone at doses of 2 and 6 mq/kg compared to placebo:

<div style=\"page-break-after: always\"></div>

In  the  primary  analysis  (EMA  analysis)  of  change  from  baseline  in  TTSTAND  velocity  at  week  24,  a statistically significant difference was demonstrated when vamorolone 2 mg/kg was compared against placebo (p = 0.0196). TTSTAND velocity increased in the vamorolone 2 mg/kg group from 0.184 to 0.225 rises/sec and slightly decreased in the placebo arm from 0.200 to 0.193 rises/sec at week 24. The LSM  difference  for  vamorolone  2  mg/kg  from  placebo  was  0.0430  rises/sec  (EMA  analysis)  and comparable to the primary FDA analysis. The improvement in TTSTAND velocity mg/kg/day is considered clinically relevant also for 2 mg/kg as it is greater than the MCID for TTSTAND of 0.023 rises/sec. The provided sensitivity and supportive analyses confirmed the results of the primary analysis.

In  the  primary  analyses  (EMA  analysis)  of  change  from  baseline  in  the  6MWT  distance  at  week  24, statistically  significant  differences  were  demonstrated for the vamorolone 6 mg/kg and the 2 mg/kg treatment arms when compared against placebo (p=0.0117 and p = 0.0112, respectively). While in the vamorolone treatment groups the 6MWT distance increased it showed some decline under placebo. The LSM (SE) change from baseline for placebo, vamorolone 6 mg/kg and 2 mg/kg was -11.37 (10.6082), 24.57 (10.0582) and 24.98 (10.0352), respectively. The LSM difference for vamorolone 6 mg/kg and 2 mg/kg was 35.9 meters and 36.2 meters, respectively, which is compellingly clinically relevant. Provided sensitivity analyses supported the primary analyses, demonstrating that missing data and the analysis method had no impact on the results received.

The fourth of the pre-specified secondary efficacy endpoints was met: the change from baseline to week 24 for TTRW velocity showed a statistically significant LSM difference of 0.237 meters/sec for vamorolone 6  mg/kg/day  when  compared  against  placebo  (p=0.0020)  representing  clinically  relevance. TTRW velocity was increased under vamorolone 6 mg/kg group (LSM change from baseline 0.2372 meters/sec) and was almost unchanged in the placebo group at Week 24 with a very minimal increase of 0.0171 meters /sec (LSM change from baseline).

With respect to the comparison of vamorolone 2 mg/kg against placebo, TTRW velocity increased only slightly  from  1.563  meters/sec  at  baseline  to  1.724  meters/sec  at  Week  24  under  vamorolone  and remained almost stable for placebo (LSM change from baseline 0.1387 and 0.0171, respectively). The LSM  difference  of  0.1216  meters/sec  was  not  statistically  significant  (p=0.1228).  In  the  sensitivity analyses to assess the impact of the analysis method (pooled motor function tests), the LSM differences from baseline in TTRW velocity at Week 24 for vamorolone 6 mg/kg and for vamorolone 2 mg/kg from placebo  were  nominally  statistically  significant,  even  though  the  difference  for  vamorolone  2  mg/kg against placebo was not significant in the primary analysis. Interpretation of the comparisons on the pooled motor function tests remains difficult, and the result may be driven by one component only.

As  the  fifths  secondary  endpoint  in  the  pre-specified  hierarchical  order  failed  to  show  statistical significance, no formal statistical testing of 6MWT distance for vamorolone 6 mg/kg and 2 mg/kg vs prednisone was possible. While improvements from baseline at Week 24 in the mean 6MWT distance were similar for both vamorolone treatment groups (6 mg/kg and 2 mg/kg), subjects under prednisone treatment  improved  numerically  more  (EMA  analysis)  with  LSM  (SE)  changes  from  baseline  for prednisone  and  vamorolone  6  mg/kg  and  2  mg/kg  of  44.12  (9.6444),  24.98  (10.0352)  and  24.57 (10.0582), respectively.

The LSM change from baseline in TTSTAND velocity at Week 24 in the vamorolone 6 mg/kg and in the prednisone group was 0.0464 rises/sec and 0.0661 rises/sec, respectively with a LSM difference of 0.0197 that is not considered clinically relevant. The LSM change from baseline to Week 24 in TTSTAND velocity was numerically lower in the vamorolone 2 mg/kg group when compared to prednisone (0.03 rises/sec vs 0.07 rises/sec, respectively).

Comparisons between vamorolone and prednisone: to account for baseline imbalances and to allow to examine efficacy endpoints globally in spite of different units, the applicant provided percent changes from baseline at Week 24 for relevant outcome parameters. The improvements seen with vamorolone 6

<div style=\"page-break-after: always\"></div>

mg/kg in TTSTAND, TTRW, and TTCLIMB velocity were very similar to those seen with prednisone at Week 24, while for the 6MWT and the NSAA score prednisone provided better results. The improvements seen with vamorolone 2 mg/kg were overall slightly smaller than those for prednisone, when evaluated globally. Change from baseline to week 24 in hand-held myometry (knee extensors) was 0.0624 kg in vamorolone  group  and  1.0147  kg  in  prednisone  group.  Comparison  with  prednisone  were  not  alfa controlled.

Differences (not alfa controlled) between vamorolone and prednisone was in hand-held myometry (elbow flexors), where LSM change from baseline to week 24 was 0.4241 kg in vamorolone group and 1.0218 kg in prednisone group, however, better result in elbow flexors was observed in vamorolone 2 mg/kg than 6 mg/kg (LSM change from baseline 0.5555 kg vs 0.4241 kg). At baseline better strength in elbow flexors were observed in vamorolone 6 mg/kg group, however, this difference at baseline could not solely explain increase in muscle strength in prednisone group. An increase in muscle strength in elbow flexors were not dose-dependent, where higher increase was seen in 2 mg/kg group compared to 6 mg/kg vamorolone group. It is not clear why increase in muscle strength was more pronounced in prednisone group, and whether increase in muscle strength would be observed in later disease stages.

## Additional secondary efficacy endpoints

TTCLIMB Velocity was increased in each of the vamorolone groups and slightly decreased in the placebo group from baseline at Week 24. The LSM difference was 0.07 tasks/sec for vamorolone 6 mg/kg from placebo (p= 0.0005 and p = 0.0008, respectively) and 0.06 tasks/sec for vamorolone 2 mg/kg from placebo in the EMA and the FDA analyses (p= 0.005 and p = 0.0056, respectively). The improvements in TTCLIMB velocity with vamorolone 2 and 6 mg/kg were both greater than the MCID.

NSAA Score increased from baseline in the vamorolone groups and slightly decreased in the placebo group at Week 24. The LSM difference was 3.6 points for vamorolone 6 mg/kg from placebo (p &lt;0.0001 each) and 3.2 points for vamorolone 2 mg/kg from placebo in the EMA and FDA analyses (p=0.0003 and p=0.0002, respectively. The increases in each of the vamorolone groups at Week 24 (approximately +3 points) can be considered clinically meaningful.

## Hand-held myometry (elbow flexors and knee extensors)

MMRM  analysis  for  change  from  baseline  to  week  24  in  knee  extension  indicated  improvement  in vamorolone 6 mg/kg vs placebo (LSM difference was 0.1634 kg) and also in vamorolone 2 mg/kg group (LSM difference was 0.0710 kg). Also, for elbow flexors both vamorolone doses resulted in a slight improvement, when compared with placebo (LSM difference 0.4132 kg in vamorolone 6 mg/kg and 0.5885 kg in vamorolone 2 mg/kg group). Muscle strength measurements were not alfa controlled.

The reason why muscle strength significantly improved in prednisone group, and in vamorolone groups knee extension muscle strength and elbow flexor muscle strength only slightly increased which could be translated as stability of results in patients 4 to &lt;7 years of age, is not clear. Measurements that reflect muscle strength are highly important, and total evidence of clinical efficacy and effect on motor function should be supported by an effect on muscle strength. The difference between prednisone and vamorolone in muscle strength cannot be solely explained by difference in baseline assessment between vamorolone and prednisone, where in vamorolone arms overall were weaker results. Intra- and inter- rater variability could  be  high  in  hand-held  myometry  tests;  however,  this  could  have  influenced  all  study  groups similarly.

Regarding  treatment  satisfaction,  which  was  exploratory  efficacy  endpoint,  no  differences  between vamorolone 2 and 6 mg/kg groups compared with either the placebo or prednisone groups in the scores for the effectiveness, convenience, and global satisfaction domains of the TSQM were observed.

<div style=\"page-break-after: always\"></div>

Subgroup  analyses  of  TTSTAND  velocity  yielded  comparable  results  across  the  different  subgroups favouring  vamorolone  6  mg/kg  against  placebo  although  they  were  only  based  on  small  number  of patients.

Results of the subgroup analyses based on 6MWD &lt;350 meters: Overall, results for the motor function endpoints were comparable to those in the primary analyses when vamorolone 6 mg/kg was compared against placebo for change from baseline to Week 24. Although results for the vamorolone 2 mg/kg group in comparison to placebo only showed nominally significance, they point in the same direction, representing  an  effect  in  comparison  to  placebo.  When  interpreting  these  results,  it  needs  to  be considered, that the study was not powered for these analyses that are based on small sample sizes.

## Vamorolone Treatment for 48 Weeks (continued Vamorolone Treatment)

Based  on  the  LSM  changes  from  baseline  to  Week  24  and  Week  48,  the  clinically  meaningful improvements in TTSTAND velocity, TTRW velocity and NSAA score seen with vamorolone 6 mg/kg at 24  weeks  can  be  considered  to  be  maintained  for  up  to  48  weeks  of  treatment.  An  additional improvement in 6MWT distance was seen from Week 24 to Week 48 with vamorolone 6 mg/kg.

Due  to  the  uncontrolled  design  from  Week  24  to  Week  48,  these  data  are  difficult  to  interpret. Nevertheless,  the  respective  data  indicate  that  the  effect  of  the  vamorolone  6  mg/kg  dosage  is maintained up to Week 48 as there was no decline across the relevant outcome parameters and the results were generally better than for the 2 mg/kg dosage. Based on the current scientific knowledge the  appropriate  treatment  duration  for  corticosteroids  in  DMD  is  still  unknown.  However,  it  is recommended to continue treatment after the loss of ambulation, based on the observation that longterm treatment with GC steroids results in the delay in time to loss of disease related milestones across the disease spectrum from delay in time to loss of ambulation, time to loss of upper limb function and time to crossing respiratory function thresholds.

The efficacy of 2 mg/kg dose appears not to be maintained up to Week 48. There was observed a clinically significant decline in TTSTAND and 6MWT at week 48 compared to results at week 24 and 6 mg/kg dose. To justify maintenance of efficacy for the 2 mg/kg dose, the applicant compared the efficacy results of 2 mg/kg from study VBP15-005 at week 48 with the results from the placebo treated group at week 52 of the POLARIS-DMD Trial (Finkel R. et al., 2021). The POLARIS-DMD study was a randomised, doubleblind, placebo-controlled, global phase 3 study of Edasalonexent in paediatric patients with DMD over a treatment period of 52 weeks in 131 boys aged ≥4 years and ≤8 years with confirmed DMD. Included subjects  who  were  corticosteroid  naïve  at  study  entry  were  able  to  perform  the  TTSTAND  without assistance in ≤ 10 seconds. The study included the assessment of change from baseline in the NSAA as primary endpoint and timed motor function tests (TTRW, TTCLIMB, TTSTAND). Although the difference of  means  after  48/52  weeks  between  the  vamorolone  2  mg/kg  treatment  arm  and  placebo-treated patients from POLARIS-DMD in TTSTAND velocity, TTCLIMB velocity and NSAA score were in favour of vamorolone 2 mg/kg and larger than the published MCIDs for the different endpoints, the comparisons of the vamorolone dose group against the placebo group from the POLARIS DMD study is of limited value. Due to the lack of concurrent controls, randomised and pre-specified comparisons confirmatory evidence of superior efficacy for vamorolone 2mg/kg against this external placebo group after 48/52 weeks of treatment cannot be assumed. Even if baseline characteristics are similar, a non-randomised between-study comparison is not accepted as confirmatory evidence since bias cannot be excluded.

In addition, the applicant provided a comparison of the results received in a subgroup of patients from the open-label long-term Study VBP15-LTE in comparison to patients from the For-DMD study. Subjects who received in Study VBP-LTE vamorolone in the dose range of 2-6 mg/kg throughout the study were compared against matched data from the FOR-DMD study over 2.5 years. Although it is admitted that the  provided  results  for  the  different  endpoints  were  comparable  between  the  pooled  vamorolone

<div style=\"page-break-after: always\"></div>

dosages and prednisone or deflazacort, this analysis does not provide further information for the separate vamorolone 2 mg/kg dose regarding maintenance of efficacy.

## Switch from Prednisone to Vamorolone

Overall, the treatment effects achieved under prednisone were maintained until week 48 after subjects had been switched to vamorolone 6 mg/kg (at Week 24).

When subjects switched from prednisone to vamorolone 6 mg/kg, the mean TTSTAND velocity, TTRW velocity and NSAA score only slightly decreased and TTCLIMB velocity minimally increased. There was a small decline in the 6MWT distance after the switch from prednisone to vamorolone, while subjects who continuously were treated with vamorolone 6m/kg continued to improve until Week 48, a finding that is difficult to interpret.

When subjects switched from prednisone to vamorolone 2 mg/kg, the mean TTSTAND and TTCLIMB velocity decreased more than the 6MWTD and TTRW velocity. No mean changes were seen for the NSAA score.

## Comparison of efficacy results from study VBP15-004 with a matched population from Study FOR-DMD

The comparisons of the vamorolone dose groups to both, prednisone and deflazacort from FOR-DMD are of limited value.

In order to assess comparable efficacy, the lower limit of the CI would have to be taken into account and compared to a reasonable non-inferiority margin. However, due to the lack of placebo-controlled studies of prednisone and deflazacort in the relevant population, a reasonable non-inferiority margin cannot be given. Furthermore, due to the lack of a pre-specified multiplicity procedure only unadjusted CIs are given.

## Investigation of the validity of the external comparisons

The subjects randomised to prednisone who met the common inclusion criteria were compared across studies in VBP15-004 Period 1 and the first 6 months of FOR-DMD to test the validity of the external control  and  provide  additional  context  for  interpretation  of  the  FOR-DMD  data.  For  efficacy,  all  31 subjects  randomised  to  prednisone  in  Study  VBP15-004  were  matched  to  37  subjects  treated  with prednisone in FOR-DMD.

The LSM changes in 6MWT distance were numerically higher for prednisone in FOR-DMD than in VBP15004 at Months 3 (LSM change 40 vs. 26 meters) and Month 6 (55 vs 39 meters). However, there were no clinically meaningful differences between the studies for any of the efficacy endpoints. A subgroup analysis was performed on the subjects with baseline 6MWT distance &lt;350 meters and confirmed the results of the total population.

TTSTAND velocity had increased in the vamorolone 6 mg/kg, prednisone, and deflazacort groups at Months 6 and 12. The increases were similar for the vamorolone 6 mg/kg group (LSM change 0.05 and 0.04  at  Months  6  and  12),  deflazacort  group  (LSM  changes  0.05  and  0.04  at  Months  6  and  12, respectively),  and  the  prednisone  group  (LSM  changes  were  0.04  and  0.04  at  Months  6  and  12, respectively); the vamorolone 2 mg/kg group showed minimal change (LSM changes 0.02 and -0.00).

The 6MWT distance was increased in all groups at Months 6 and 12. The largest increases were observed for the prednisone group at Months 6 and 12 (estimate 53 and 54 meters, respectively). At Month 6, the changes  were  larger  for  deflazacort  than  vamorolone  2  mg/kg  (mean  changes  39  and  31  meters, respectively),  and  smaller  for  vamorolone  6  mg/kg  (mean  change 26 meters) but at Month 12, the changes for vamorolone 6 mg/kg (45 meters) were larger than for deflazacort (39 meters) or vamorolone 2 mg/kg (11 meters). It is noted that the prednisone group in FOR-DMD also performed &gt;10 meters better than the prednisone group in VBP15-004. The LSM increases in 6MWT distance were smaller with

<div style=\"page-break-after: always\"></div>

vamorolone 2 mg/kg compared with the prednisone and deflazacort groups. The difference in 6MWT distance between vamorolone 2 mg/kg and prednisone at Month 12 was 43.5 meters all other differences were &lt;29 meters (i.e., below but close to the MCID).

Even in case unadjusted CIs are considered, the results indicate that vamorolone at the 2 mg/kg dosage has inferior efficacy compared to both comparators, i.e., prednisone and deflazacort. Although the results for the 6 mg/kg dosage appear more similar esp. to those of deflazacort, equivalent efficacy cannot be concluded for methodological reasons. Hence, no conclusion of comparable efficacy can be given for neither dose. On the contrary, the comparisons of the vamorolone 2 mg/kg dose seem to indicate a relevant  inferiority  with  nominally  significant  differences  and  lower  confidence  limits,  indicating  a potentially highly relevant difference to the disadvantage of vamorolone. It should be noted that these confidence limits are unadjusted limits. Using CIs adjusted for multiplicity would have resulted in even considerably lower confidence limits. In order to contextualise the comparisons between vamorolone and both  comparators , the  applicant  provided  an  overview  of  the  current  scientific  knowledge  regarding information on placebo-controlled studies for the treatment with corticosteroids in the different stages of  the  disease.  While  studies  in  the  ambulatory  population  have  several  shortcomings  based  on  the underlying study designs, no randomised controlled studies are available in the later, non-ambulatory patients. Relevant information cannot be provided, e.g., on estimated treatment effects and their CIs.

In  summary,  although  confirmatory  evidence  of  long-term  efficacy  comparable  to  that  of  either prednisone or deflazacort cannot be concluded from the analyses provided, this does not question the maintenance of efficacy for vamorolone, for the vamorolone 6 mg/kg dose that can be concluded from the Week 48 results of Study VB15-004.

Despite progressive muscular impairment, DMD boys are not significantly declining in motor function tests  from  4-  &lt;7  year  age  (McDonald  et  al,  2013).  Subjects  below  the  age  of  4  years,  as  well  as ambulatory  patients  in  the  decline  phase,  non-ambulatory  patients  and  patients  with  symptomatic cardiomyopathy  were  excluded  from  the  study.  However,  the  originally  proposed  target  population included all patients with DMD. During the procedure, the applicant presented an extrapolation report with discussion on disease similarity across age ranges, and pharmacology and comparable response to treatment.  In  general,  extrapolation  based  on  disease  similarity  with  regard  to  the  underlying pathomechanism is  supported.  This  is  also  the  case  for  the  claimed  pharmacological  similarity  with corticosteroids currently used for the treatment of DMD patients, where vamorolone has agonist activity towards  the  glucocorticoid  receptor,  thereby  maintaining  anti-inflammatory  activity,  and  antagonist activity towards the mineralocorticoid receptor.

Vamorolone  PK  properties  have  been  established  in  healthy  adult  volunteers  and  in  the  reference population aged 4 to &lt;7 years, while the target population originally applied for also included patients 2 to &lt;4-years and 7 - &lt;18 years. During the procedure, an updated PopPK model has been submitted with data from the ongoing study VBP15-006; PK data from subjects in the target age ranges have been added to the previously established PopPK model. Furthermore, study VBP15-006 was the first study to administer ROS2 (final formulation) to patients with DMD.

In general, the proposed extrapolation to the target population could have been supported from the PK point of view, as the pathophysiology of the disease is the same in children aged 2 to 4 years and 4 to 7 years and inflammatory processes have been shown to be present in DMD early-on, suggesting that for similar PK exposure, efficacy (anti-inflammatory effects) of vamorolone is likely to be similar between these two groups.

The previously established vamorolone PK model was further refined to describe exposure in paediatric patients with DMD following treatment with the ROS2 formulation. The original PopPK model was used to  predict  vamorolone  exposure  at  different  ages  and  weights  based  on  simulations.  A  predefined exposure range of the 6 mg/kg dose (5 th  to 95 th  AUC percentile of the age range 4-7 years) was assumed

<div style=\"page-break-after: always\"></div>

to correspond to the effective dose range, and similar exposure was to be achieved for all age groups. The  model  was  used  to  evaluate  various  cut-off  points  for  a  fixed  dose  regime.  According  to  the simulations, dosing of 6 mg/kg up to a body weight of 50 kg followed by a fixed dose of 300 mg for patients of 50 kg and above would lead to the highest percentage (≥86%) of patients within the age range from 2-18 years to fall consistently within the predefined exposure range.

A refined popPK model was developed to better simulate a potential effective dose for patients 2 to 4 years old that could as well be used to mitigate tolerability issues. According to simulations, AUC levels of ROS2 formulation are increased about 20% across all doses compared to ROS1. 4 mg/kg of ROS2 is expected to achieve 82% of the exposure of 6 mg/kg ROS1 and 246% of 2 mg/kg ROS1. Predicted drug exposure of 4 mg/kg ROS2 for all age groups is within the originally predefined exposure target range of the 5th to 95th exposure percentile of 6 mg/kg of the ROS1 formulation in the age range 4-7 years. Although the original target range appears somewhat arbitrarily defined it still provides some valuable insight into the potential efficacy of other doses, as the ROS1 6 mg/kg dose is the primary source of efficacy information.

Since even the 2 mg/kg dose with the lower exposure levels of the ROS1 formulation, which are well outside the predefined target exposure range provided evidence of some clinical benefit (despite not showing sufficient maintenance of efficacy in 4 to 7 years old patients), there is a strong rationale that the 4 mg/kg ROS2 dose should be well within the effective dose range based on exposure data.

Moreover, a majority of subjects in the EAP/ Compassionate Use programme (CUPs) with available dosing information are likewise being dosed at 4 mg/kg and this dose appears acceptable from a clinical safety perspective.

With regard to similarity in efficacy across the previously postulated age range, the applicant refers to a prospectively designed cohort study (CINRG-DNHS) (McDonald et al., 2018a) that included 440 DMD patients  between  2  and  28  years  of  age  who  were  followed  up  for  10  years.  The  study  showed prolongation  of  ambulation  and  reduced  risk  in  upper  limb  disease  progression  in  patients  using glucocorticoids  for  a  period  of  more  than  one  year.  However,  mean  age  at  the  baseline  visit  was 10.7 years (SD 5.7) and therefore the study does not provide sufficient evidence to postulate an effect for starting treatment in patients in the pre-symptomatic phase or in children &lt;4 years of age.

Up to now, there are only limited data assessing the effect of steroids in the youngest DMD patients. In this context, the applicant refers to a study published by Connolly et al. (2019) that included 25 infants with DMD in the age of 0.4 to 2.4 years who were treated with 5 mg/kg prednisone twice weekly. In comparison to an external untreated control group, treated subjects showed a significant effect in change in the Bayley III Scales of Infant Development (Bayley-III). Notwithstanding, interpretation of these data is hampered by the open-label design, the small number of patients included and the use of an external control.

With regard to the most appropriate time to initiate treatment in DMD boys, the applicant refers to the recent publication by Hiebeler et al., 2023, to confirm the existence of earlier diagnosis in DMD over the last decade. According to Hiebeler et al., 2023, the mean age of onset of symptoms is 2.9 years with some differences across different countries, e.g., first symptoms were observed in Austria and Germany around 3 years, compared with 2.6 years in Italy, 2.7 years in the UK and in the USA, and 2.85 years in Australia. To justify an early treatment initiation, the applicant again refers to recent treatment guidelines (Birnkrant et al 2018), which recommend discussing the use of steroids already at the stage of diagnosis. In the applicant´s view these 'considerations reflect the most current view of the scientific community on starting treatment as soon as patients are diagnosed in order to maximise the benefits in preserving physical  function'.  However,  Birnkrant  et  al,  2018  also  recommends  starting  corticosteroid  therapy before 'substantial physical decline' (Birnkrant et al 2018), that may be interpreted as a recommended start at the age of 4-6 years. Moreover, Duan et al. (2021) states 'the age of initiating steroids varies

<div style=\"page-break-after: always\"></div>

between patients but should not be before the patient reaches 2 years of age and is generally around 45 years of age' 1 .

In summary, although there is a shift in treatment recommendations to start treatment of Duchenne patients earlier in order to maximise treatment benefit, exact age specifications do not exist. This is supported by the review of Landfeldt et al. (2022), who states that 'there is currently no up-to-date scientific summary of the impact of early treatment in DMD' 2 .

The  pathogenesis  of  DMD  clearly  starts  very  early,  i.e.,  prenatally,  and  causes  cumulative  muscle destruction  (Connolly  et  al  2019).  Muscle  degeneration  is  already  recognised  in  early  symptomatic patients,  although  strength  and  functioning  continue  to  progress  in  early  disease  due  to  natural development and growth. Based on the pathogenesis of DMD with the same underlying pathomechanism at all stages of the disease and existing inflammation also already at the pre-symptomatic stages of the disease (Chen Y-W et al, 2005), early treatment initiation with vamorolone is considered reasonable 3 . In  this  context  it  should  also  be  considered  that  deflazacort  (Emflaza)  is  approved  by  the  FDA  in Duchenne patients from 2 years of age.

In summary, extrapolation of efficacy for vamorolone is generally considered possible.

During the procedure, the applicant also provided preliminary efficacy results for study VBP15-006. As of the data cut-off date, ten subjects aged 2 to &lt; 4 years have been treated with 2 mg/kg vamorolone and all have completed the study. Nine of these 10 subjects are continuing to receive vamorolone in the EAP and the other subject switched to standard of care glucocorticoid treatment.

At baseline, median GMSS were lower than 7 indicating a delay in motor development compared to normal children of the same age. Subjects assigned to vamorolone 2 mg/kg had lower median value at baseline than those assigned to 6 mg/kg indicating a more pronounced motor delay. After 12 weeks, there  was  no  relevant  change  from  baseline  in  vamorolone  2  mg/kg  suggesting  no  progression  of developmental delay, while the mean score increased in the 6 mg/kg dose group with mean (SD) change from baseline to week 12 of 2.67 (1.211), suggesting an improvement in gross motor abilities.

The applicant further discussed these results in comparison to the results of the study published by Connolly et al. (2019), that included 25 infants with DMD at the age of 0.4 to 2.4 years who were treated with 5 mg/kg prednisone twice weekly. In comparison to an external untreated control group, prednisone treated subjects showed a significant effect in change in the Bayley III Scales of Infant Development (Bayley-III). Treated boys gained an average of 0.5 points on the Bayley-III gross motor scale score while the historical control cohort on average declined by 1.3 points.

The provided preliminary efficacy results of study VBP15-006 are indicative of a dose-depending effect of vamorolone also in the youngest DMD patients. Also, the comparison to historical data supports the claimed  efficacy  of  vamorolone  in  the  youngest  patients.  However,  the  data  have  to  be  interpreted carefully, given the open-label study design, the small number of patients included and the use of an external control.

While the overall evidence supports vamorolone as being effective in the treatment of DMD patients between 2 and &lt; 4 years of age, an issue remained regarding the adequacy of the proposed dose of 4 mg/kg/day based on the refined popPK model. However, the originally claimed indication also including patients from 2 to &lt;4 years of age has finally not been further pursued by the applicant.

1  Duan, D., Goemans, N., Takeda, S. et al. Duchenne muscular dystrophy. Nat Rev Dis Primers 7, 13 (2021).

2 Landfeldt E, Ferizović N, Buesch K. Timing of Clinical Interventions in Patients With Duchenne Muscular Dystrophy: A Systematic Review and Grading of Evidence. J Neuromuscul Dis. 2022;9(3):353-364.

3  Chen YW, Nagaraju K, Bakay M, McIntyre O, Rawat R, Shi R, Hoffman EP. Early onset of inflammation and later involvement of TGFbeta in Duchenne muscular dystrophy. Neurology. 2005 Sep 27;65(6):826-34.

<div style=\"page-break-after: always\"></div>

With  regard  to  extrapolation  in  patient  population  &gt;7 years  of  age,  there  is  an  inevitable  clinical regression  in  patients  with  DMD  and  worsening  of  muscle  strength  also  occurs  in  patients  who  are clinically improving according to functional evaluation. As the pathogenic mechanism in DMD patients with different stages of the disease is the same, patients with DMD in the late ambulatory and early nonambulatory phase are expected to benefit from vamorolone treatment. Studies have shown that steroid use after loss of ambulation in DMD was associated with delayed progression of important pulmonary, cardiac and upper extremity functional deficits (McDonald et al, 2023, Functional and clinical outcomes associated with Steroid treatment among non-ambulatory patients with Duchenne muscular dystrophy, journal of neuromuscular disease); furthermore, steroids prolonged hand-to-mouth function and ability to turn in bed at night unaided. However, uncertainty remains about the glucocorticoid effect in late stage of disease e.g., during the late non-ambulatory phase. There are limited data in this population and, in general, the steroid effect decreases with the progression of the disease. Some studies have shown that the rate of decline in function or strength in non-ambulatory patients is not affected by steroid  use  (Connolly  et  al.,  2016)  but  this  could  partially  be  explained  by  lack  of  sensitivity  of  the proposed measures in the late stage of the disease. Despite these uncertainties, considering the disease similarity as well as the pharmacological mechanism of vamorolone, some benefit on pulmonary, cardiac and motor functions can be anticipated also in patients in the late non-ambulatory stage; however, the effect size remains unknown.

## 2.6.7. Conclusions on the clinical efficacy

No classical dose-finding study was performed but for both, vamorolone 6 mg/kg/day and 2 mg/kg/day in  the  primary  analysis  (EMA  analysis)  of  change  from  baseline  in  TTSTAND  velocity  at  week  24, statistically  significant  and  clinically  relevant  differences  were  demonstrated  when  vamorolone  was compared against placebo in ambulatory, corticosteroid naïve ≥ 4 to &lt;7 years old DMD patients in study VBP15-004. Effects of the primary analyses were corroborated by a number of sensitivity and supportive analyses of the primary endpoint as well as secondary endpoints evaluating motor function in Duchenne. The effect on TTSTAND velocity was generally consistent in pre-specified subgroups. Additional post hoc subgroup analyses for the efficacy endpoints in subjects with comparable 6MWT distances at baseline of &lt;350 meters also provided comparable results to those in the primary analyses.

Based on global assessments, the improvements in motor function with vamorolone 6 mg/kg were overall similar to those seen with prednisone at Week 24, except for the 6MWT and the NSAA score for which prednisone  provided  better  results.  The  improvements  seen  with  vamorolone  2  mg/kg  were  overall slightly smaller than those seen with prednisone.

Except for TTSTAND velocity, no clinically meaningful differences were seen in functional outcomes for vamorolone 2 mg/kg compared with vamorolone 6 mg/kg after 6 months of treatment. Due to the uncontrolled design from Week 24 to Week 48, these data are difficult to interpret. Nevertheless, the respective data indicate that the effect of the vamorolone 6 mg/kg dosage is maintained up to Week 48 as there was no decrease across the relevant outcome parameters but an additional increase in the 6MWT distance from Week 24 to Week 48 and the results were generally better than for the 2 mg/kg dosage. Results across the efficacy outcome measures for the vamorolone 2 mg/kg dose were rather inconsistent with observed clinically significant declines in relevant functional outcome parameters at Week 48, i.e., TTSTAND velocity and 6MWT but only minimal decrease in the NSAA score. Maintenance of efficacy for the vamorolone 2 mg/kg dose has not compellingly been shown, also based on the analyses provided during the procedure since pre-defined comparisons against placebo are lacking.

The applicant initially claimed that the recommended 6 mg/kg dose of vamorolone may be down titrated in a stepwise manner to 2 mg/kg as a minimum dose, based on individual tolerability. Generally, there should be an established effect on relevant outcome parameters even for the lower dose given the fact

<div style=\"page-break-after: always\"></div>

that vamorolone is intended for long-term use in a chronic disease. There is a high patient-to-patient variability  in  disease  onset  and  progression  observed  over  shorter  periods  of  time  with variations  in remaining muscle mass that drives the progression and clinical presentation. Although, the effect of the 2 mg/kg dose appears not to be sufficiently maintained up to Week 48, there should be an option to down-titrate the recommended dose 6 mg/kg to a lower dose in case of tolerability issues. This is in line with clinical practice where physicians may change the dosage for corticosteroids individually based on relevant case by case aspects.

Meanwhile, the applicant changed the proposed dose for down-titration to 4 mg/kg or to 2 mg/kg in case of tolerability issues by stating that patients should be maintained at the highest tolerated dose within the dose range. On the basis of the simulations from the new PopPK model, predicting a generally higher exposure  for  the  ROS2  formulations  compared  to  the  ROS1  formulation  across  all  dosages,  the intermediate  4  mg/kg  dose  (ROS2  formulation)  is  expected  to  sufficiently  maintain  efficacy.  Downtitration  to  the  4  mg/kg  dose  due  to  tolerability  issues  is  therefore  agreed  with  from  an  efficacy perspective  and  this  has  been  further  supported  by  the  updated  popPK  model  showing  that  AUC distributions predicted for the vamorolone 4 mg/kg dose (ROS2) overlap with the vamorolone 6 mg/kg dose (ROS1 fed) for the majority of patients in the claimed age range 4 years and older. Nevertheless, there might be situations when 4 mg/kg as a reduced dose can still not sufficiently mitigate tolerability issues, e.g., weight gain. Although, only partial efficacy can be attributed to the 2 mg/kg dose, which is similar to other GC treatment regimens that are, for example, administered intermittently or at lower than standard doses for the treatment of DMD in the absence of other treatment options, a small number of patients is effectively treated with this dose in the EAP.

The pre-planned matched comparison of the vamorolone 6 mg/kg group to the continuous prednisone and deflazacort groups from study FOR-DMD (comparing different GCs and dosing regimens) at 1 year suggest  similar efficacy esp. to deflazacort, but equivalent efficacy cannot  be  concluded  for methodological reasons. However, the pre-specified comparison of vamorolone at the 2 mg/kg dosage to these comparators showed inferior efficacy compared to both, i.e. prednisone and deflazacort.

No loss of efficacy was seen when subjects were switched from prednisone to vamorolone 6 mg/kg at Week 24, whereas small but also inconsistent declines were seen after the switch from prednisone to vamorolone 2 mg/kg.

With regard to the revised indication including patients from 4 years and above, extrapolation to DMD patients above 7 years of age can be supported.

The CHMP recommends that the applicant explore the possibility of further evaluating long-term efficacy, e.g. time to and age at loss of ambulation. Although, this data is not impacting B/R considerations, it could be valuable for patients, their families and their treating physicians.

## 2.6.8. Clinical safety

The body of the integrated vamorolone safety database includes four clinical phase 2a/b studies, one randomised controlled study (with an uncontrolled extension; VBP15-004), and three uncontrolled openlabel studies (VBP15-002, VBP15-003, and VBP15-LTE). Subjects who completed the clinical trials were offered access to continue treatment with vamorolone 2-6 mg/kg in an EAPs and CUPs. VBP15-006, a Phase 2 open-label, multiple dose study to assess safety, tolerability, PK, PD, and exploratory efficacy of vamorolone in boys 2 to &lt;4 years of age and 7 to &lt;18 years with DMD, was in the recruitment phase at the data cut-off for the MAA. For this study, preliminary safety data have become available during the procedure. Supportive safety information derives from external comparison with three glucocorticoid

<div style=\"page-break-after: always\"></div>

regimens prospectively assessed in a 3660 month, randomised, interventional, double-blind study (FORDMD study). To enable comparison to vamorolone, patients were matched.

Safety data were presented by pooling the four clinical studies: the primary focus on safety evaluation is  set  on Pool 1 ,  which  includes  the  Period 1  (24-weeks)  controlled  data  from  study  VBP15-004  for vamorolone  2 mg/kg,  6 mg/kg,  placebo  and  prednisone. Pool 2 provides  data  the  uncontrolled vamorolone-treated safety population (period 2 of study VBP15-004 and sequential open-label studies VBP15-002, VBP15-003, and VBP15-LTE). Pool 3 comprises data of all vamorolone-treated subjects in any multiple dose DMD study to account for longer-term safety data.

## 2.6.8.1. Patient exposure

164 male patients with DMD aged 4 to &lt;7 years at study entry were treated with vamorolone 0.256 mg/kg in clinical studies. The total age range across studies was 4 to 9.6 years.

Randomised controlled data are available from the 24-week Period 1 of Study VBP15-004: 29 subjects received placebo, 31 subjects received 0.75 mg/kg prednisone, 30 received vamorolone 2 mg/kg, and 28 received vamorolone 6 mg/kg. 92.9% to 96.8% of subjects completed Period 1. Median duration of exposure of 5.5 months for each treatment group. Over 90% of subjects in each group received study treatment for ≥ 6 months.

In studies VBP15-002/-003/ -LTE, 48 patients were randomised in the core study (-002) and were also treated in study -003. The safety population for study -LTE includes 46 subjects. Regarding the overall vamorolone exposure, it has been noted that there was a drug-free period in the range of 13 to 44 days between open-label studies -002 and -003, and -003 and -LTE.

In Pool 3, 153 of 163 subjects (93.3%) with vamorolone doses 2 - 6 mg/kg completed the studies. The reason for premature withdrawal in 8 out of 10 subjects was parent/ guardian decision. One patient each in the vamorolone 6 mg/kg group withdrew due to an AE (acute hepatitis) and consent withdrawn. The dominant dose was 2 mg/kg for 66 subjects (40.5%) and 6 mg/kg for 85 subjects (52.1%); 11 subjects (6.7%) were down titrated from 6 mg/kg, in 10 of them, this was because of a treatment-emergent adverse event (TEAE) of weight increased.

The median duration of exposure was 11.0 months for subjects who received vamorolone 2-6 mg/kg across all DMD studies, with 61.3% of subjects receiving vamorolone 2-6 mg/kg for ≥12 months and 12.3% for ≥30 months. Median duration of exposure was 10.9 months and 11.0 months in the 2 mg/kg and 6 mg/kg dominant dose group, respectively, and 30.5 months for the down-titrated dose group (of note, the down-titrated group included subjects only from the VBP15-LTE study, the other treatment groups mainly included subjects from VBP15-004). Based on the dominant dose definition, safety data ≥12 months (≥30 months) for 2 mg/kg and 6 mg/kg vamorolone are available for 35 and 54 patients (7 and 25 patients), respectively, in the total pool. Safety data of ≥12 months by age are available for 18 patients aged &lt;5 years and 17 patients ≥5 years for 2 mg/kg vamorolone and for 25 patients aged &lt;5 years and 29 patients ≥5 years for 6 mg/kg vamorolone.

As of 15 March 2023, 171 subjects from clinical vamorolone studies (age range 2 to 17 years) have received treatment with vamorolone 2-6 mg/kg in EAPs/CUPs of up to 11 months for subjects entering from study VBP15-006, to up to 4.6 years for subjects entering from study VBP15-004, to up to 6.7 years for subjects entering from studies VBP15-002/003/LTE.

The updated recommended dose for vamorolone in DMD patients 4 years and older is 6 mg/kg once daily in patients weighing less than 40 kg. In patients weighing 40 kg and above, the recommended dose is 240 mg once daily. Daily dose may be down titrated to 4 mg/kg/day or 2mg/kg/day, based on individual tolerability. 4 patients had an intermediate dose of 4 mg/kg at the end of study VBP15-LTE. A majority

<div style=\"page-break-after: always\"></div>

of subjects in the EAP/CUPs with available dosing information is also being dosed at 4 mg/kg up to the data cut-off.

Up to the DCO for study VBP15-006 (21 July 2023) focussing on the cohort of children 2 to &lt;4 years of age, median duration of exposure was 12.3 weeks in the 2 mg/kg dose group and 11.9 weeks in the 6 mg/kg dose group. 10 patients in this age cohort received 2 mg/kg and 6 patients were treated with the 6 mg/kg dose. So far, a total of 15 subjects continue treatment in the EAP. Age as per 21 July 2023 ranges from 3.9 to 5.4 years and the longest duration of exposure in the EAP for the 2 to &lt;4 years paediatric subjects in the EAP is 9 months.

## 2.6.8.2. Adverse events

The  overall  incidence  of  TEAEs  in  Pool 1  was  lowest  in  the  placebo  group,  followed  by  vamorolone 2 mg/kg, prednisone, and vamorolone 6 mg/kg (79.3%, 83.3%, 83.9%, and 89.3%). Half of the overall TEAEs  in  the  combined  vamorolone  2-6 mg/kg  group  were  drug-related  (33.3%  and  67.9%  for vamorolone 2 mg/kg and 6 mg/kg, respectively). No subject on vamorolone experienced severe TEAEs or TEAEs leading to permanent study treatment discontinuation. One serious adverse event (SAE) was recorded in the vamorolone 2 mg/kg group (viral gastroenteritis). TEAEs of special interest were similarly recorded in the vamorolone 6 mg/kg and prednisone group (78.6% and 77.4%).

TEAEs reported by &gt;2% of subjects in any vamorolone group and at a higher incidence compared to placebo are summarised in Table 16 . Within this table, the TEAEs reported for ≥10% of subjects in the vamorolone 2-6 mg/kg group in Pool 1 are shaded in grey.

<div style=\"page-break-after: always\"></div>

Table 16: TEAEs Reported by &gt; 2% of subjects in any vamorolone group and at a higher incidence than placebo - controlled safety population (Pool 1) and incidence of these TEAEs in POOL 3 (compiled by the Assessor)

|                                                      | Pool 1                                 | Pool 3                                                 | Pool 3                                            | Pool 3                                              | Pool 3                                                  | Pool 3                                      | Pool 3                       | Pool 3                                        | Pool 3                                                 | Pool 3     |
|------------------------------------------------------|----------------------------------------|--------------------------------------------------------|---------------------------------------------------|-----------------------------------------------------|---------------------------------------------------------|---------------------------------------------|------------------------------|-----------------------------------------------|--------------------------------------------------------|------------|
| System Organ Class Preferred Term                    | Placebo (N = 29) n (% ; EAIR) ; (Rate) | f Prednisone 0.75 mg/kg (N = 31) n (% ; EAIR) ; (Rate) | f Vamorolone mg/kg (N = 30) n (% ; EAIR) ; (Rate) | 2 f Vamorolone mg/kg (N = 28) n (% ; EAIR) ; (Rate) | 6 f Vamorolone 2 6 mg/kg (N = 58) n (% ; EAIR) ; (Rate) | - f Vamorolone mg/kg (N = 97) n (% ; (Rate) | EAIR) ; f n                  | 2 Vamorolone mg/kg (N = 99) (% ; EAIR) (Rate) | 6 ; f Vamorolone 6 mg/kg (N = 163) n (% ; EAIR) (Rate) | 2 - ; f    |
| Ear and labyrinth disorders                          | 0 ; 0                                  | 2 (6.5 ; 0.14) ; 2 (0.14)                              | 0 ; 0                                             | 1 (3.6 ; 0.08) ; (0.16)                             | 2 1 (1.7 ; 0.04) ; (0.08)                               | 2 6 (6.2 ; (0.08)                           | 0.09) ; 6 7 (7.1 (0.09)      | ; 0.08) ;                                     | 9 11 (6.7 ; 15 (0.09)                                  | 0.07) ;    |
| Ear pain                                             | 0 ; 0                                  | 2 (6.5 ; 0.14) ; 2 (0.14)                              | 0 ; 0                                             | 1 (3.6 ; 0.08) ; (0.16)                             | 2 1 (1.7 ; 0.04) ; (0.08)                               | 2 6 (6.2 ; (0.08)                           | 0.09) ; 6 7 (7.1 (0.09)      | ; 0.08) ;                                     | 9 11 (6.7 ; 15 (0.09)                                  | 0.07) ;    |
| Endocrine disorders                                  | 0 ; 0                                  | 7 (22.6 ; 0.53) ; 7 (0.50)                             | 2 (6.7 ; 0.15) ; 2 (0.15)                         | 8 (28.6 ; 0.70) ; (0.63)                            | 8 10 (17.2 ; 0.40) 10 (0.38)                            | ; 5 (5.2 ; (0.07)                           | 0.07) ; 5 14 14              | (14.1 ; 0.16) (0.15)                          | ; 19 (11.7 19 (0.11)                                   | ; 0.12) ;  |
| Cushingoid                                           | 0 ; 0                                  | 7 (22.6 ; 0.53) ; (0.50)                               | 7 2 (6.7 ; 0.15) ; (0.15)                         | 2 8 (28.6 ; 0.70) ; (0.63)                          | 8 10 (17.2 ; 0.40) 10 (0.38)                            | ; 5 (5.2 ; (0.07)                           | 0.07) ; 5 14 14              | (14.1 ; 0.16) (0.15)                          | ; 19 (11.7 ; 19 (0.11)                                 | 0.12) ;    |
| Gastrointestinal disorders                           | 7 (24.1 ; 0.64) 9 (0.69)               | ; 8 (25.8 ; 0.69) 12 (0.86)                            | ; 10 (33.3 ; 0.92) 16 (1.19)                      | ; 9 (32.1 ; 0.85) 13 (1.02)                         | ; 19 (32.8 ; 0.88) 29 (1.11)                            | ; 29 (29.9 61 (0.84)                        | ; 0.57) ; 41 91              | (41.4 ; 0.68) (0.95)                          | ; 64 (39.3 ; 154 (0.91)                                | 0.61) ;    |
| Abdominal pain                                       | 2 (6.9 ; 0.16) ; (0.15)                | 2 3 (9.7 ; 0.23) ; 3 (0.21)                            | 3 (10.0 ; 0.23) ; (0.22)                          | 3 2 (7.1 ; 0.16) ; (0.16)                           | 2 5 (8.6 ; 0.20) ; 5 (0.19)                             | 7 (7.2 ; (0.14)                             | 0.10) ; 10 10 10             | (10.1 ; 0.11) (0.10)                          | ; 16 (9.8 ; 20 (0.12)                                  | 0.10) ;    |
| Abdominal pain upper                                 | 1 (3.4 ; 0.08) ; (0.08)                | 1 3 (9.7 ; 0.23) ; 3 (0.21)                            | 0 ; 0                                             | 2 (7.1 ; 0.17) ; (0.23)                             | 3 2 (3.4 ; 0.08) ; 3 (0.11)                             | 4 (4.1 ; (0.10)                             | 0.06) ; 7 12 19              | (12.1 ; 0.14) (0.20)                          | ; 16 (9.8 ; 26 (0.15)                                  | 0.10) ;    |
| Constipation                                         | 2 (6.9 ; 0.16) ; (0.15)                | 2 1 (3.2 ; 0.07) ; 1 (0.07)                            | 3 (10.0 ; 0.24) ; (0.22)                          | 3 1 (3.6 ; 0.08) ; (0.08)                           | 1 4 (6.9 ; 0.16) ; (0.15)                               | 4 7 (7.2 ; (0.15)                           | 0.10) ; 11 12 17             | (12.1 ; 0.14) (0.18)                          | ; 19 (11.7 28 (0.16)                                   | ; 0.13) ;  |
| Diarrhoea                                            | 1 (3.4 ; 0.08) ; (0.08)                | 1 2 (6.5 ; 0.15) ; 3 (0.21)                            | 1 (3.3 ; 0.08) ; (0.07)                           | 1 2 (7.1 ; 0.16) ; (0.16)                           | 2 3 (5.2 ; 0.12) ; (0.11)                               | 3 7 (7.2 ; (0.11)                           | 0.10) ; 8 11 (11.1 13 (0.14) | ; 0.13)                                       | ; 18 (11.0 22 (0.13)                                   | ; 0.12) ;  |
| Nausea                                               | 0 ; 0                                  | 0 ; 0                                                  | 1 (3.3 ; 0.08) ; (0.07)                           | 1 0 ; 0                                             | 1 (1.7 ; 0.04) ; (0.04)                                 | 1 2 (2.1 ; (0.03)                           | 0.03) ; 2 2 (2.0 (0.08)      | ; 0.02) ;                                     | 8 4 (2.5 ; (0.06)                                      | 0.02) ; 10 |
| Toothache                                            | 0 ; 0                                  | 0 ; 0                                                  | 1 (3.3 ; 0.07) ; (0.07)                           | 1 1 (3.6 ; 0.08) ; (0.08)                           | 1 2 (3.4 ; 0.08) ; (0.08)                               | 2 2 (2.1 ; (0.03)                           | 0.03) ; 2 2 (2.0 (0.02)      | ; 0.02) ;                                     | 2 4 (2.5 ; (0.02)                                      | 0.02) ; 4  |
| Vomiting                                             | 2 (6.9 ; 0.16) ; 3 (0.23)              | 2 (6.5 ; 0.15) ; (0.14)                                | 2 5 (16.7 ; 0.40) ; (0.52)                        | 7 4 (14.3 ; 0.34) ; (0.31)                          | 4 9 (15.5 ; 0.38) ; 11 (0.42)                           | 13 (13.4 ; 0.21) 21 (0.29)                  | ; 15 (15.2 22 (0.23)         | ; 0.18)                                       | ; 27 (16.6 ; 44 (0.26)                                 | 0.19) ;    |
| General disorders and administration site conditions | 6 (20.7 ; 0.53) 8 (0.61)               | ; 2 (6.5 ; 0.15) ; (0.21)                              | 3 6 (20.0 ; 0.50) ; (0.52)                        | 7 1 (3.6 ; 0.08) ; (0.08)                           | 1 7 (12.1 ; 0.29) ; 8 (0.30)                            | 23 (23.7 ; 0.43) 48 (0.66)                  | ; 21 (21.2 34 (0.35)         | ; 0.26)                                       | ; 41 (25.2 ; 82 (0.48)                                 | 0.33) ;    |
| Influenza like illness                               | 0 ; 0                                  | 0 ; 0                                                  | 0 ; 0                                             | 1 (3.6 ; 0.08) ; (0.08)                             | 1 1 (1.7 ; 0.04) ; 1 (0.04)                             | 0 ; 0                                       | 4 (4.0 (0.04)                | ; 0.04) ;                                     | 4 4 (2.5 ; (0.02)                                      | 0.02) ; 4  |
| Pyrexia                                              | 6 (20.7 ; 0.53) 8 (0.61)               | ; 2 (6.5 ; 0.15) ; (0.21)                              | 3 6 (20.0 ; 0.50) ; (0.52)                        | 7 0 ; 0                                             | 6 (10.3 ; 0.24) ; 7 (0.27)                              | 20 (20.6 ; 43 (0.60)                        | 0.37) ; 14 23                | (14.1 ; 0.16) (0.24)                          | ; 33 (20.2 ; 66 (0.39)                                 | 0.25) ;    |
| Immune system disorders                              | 0 ; 0                                  | 0 ; 0                                                  | 1 (3.3 ; 0.08) ; 1 (0.07)                         | 0 ; 0                                               | 1 (1.7 ; 0.04) ; (0.04)                                 | 1 3 (3.1 ; (0.04)                           | 0.04) ; 3 2 (2.0 (0.02)      | ; 0.02) ;                                     | 2 5 (3.1 ; (0.03)                                      | 0.03) ; 5  |
| Seasonal allergy                                     | 0 ; 0                                  | 0 ; 0                                                  | 1 (3.3 ; 0.08) ; 1 (0.07)                         | 0 ; 0                                               | 1 (1.7 ; 0.04) ; 1 (0.04)                               | 3 (3.1 ; (0.04)                             | 0.04) ; 3 2 (0.02)           | (2.0 ; 0.02) ;                                | 2 5 (3.1 ; (0.03)                                      | 0.03) ; 5  |

<div style=\"page-break-after: always\"></div>

|                                                | Pool 1                    | Pool 3                                   | Pool 3                                               | Pool 3                                              | Pool 3                                                | Pool 3                                                  | Pool 3                                          | Pool 3                                            | Pool 3                                           | Pool 3                 |
|------------------------------------------------|---------------------------|------------------------------------------|------------------------------------------------------|-----------------------------------------------------|-------------------------------------------------------|---------------------------------------------------------|-------------------------------------------------|---------------------------------------------------|--------------------------------------------------|------------------------|
| System Organ Class                             | System Organ Class        | Placebo (N = 29) n (% ; EAIR) ; f (Rate) | Prednisone 0.75 mg/kg (N = 31) n (% ; EAIR) ; (Rate) | f Vamorolone 2 mg/kg (N = 30) n (% ; EAIR) ; (Rate) | f Vamorolone 6 mg/kg (N = 28) n (% ; EAIR) ; f (Rate) | Vamorolone 2 - 6 mg/kg (N = 58) n (% ; EAIR) ; f (Rate) | Vamorolone mg/kg (N = 97) n (% ; EAIR) ; (Rate) | 2 f Vamorolone mg/kg (N = 99) n (% ; EAIR) (Rate) | 6 ; f Vamorolone 6 mg/kg (N = 163) n (% ; (Rate) | 2 - EAIR) ; f          |
| Preferred Term Infections infestations         | and                       | 10 (34.5 ; 0.96) ; 20 (1.52) 9 (29.0     | ; 0.79) ; 11 (36.7 ; 17 (1.26)                       | 1.07) ; 8 (28.6 15 (1.17)                           | ; 0.77) ; 19 (32.8                                    | ; 0.92) ; 32 (1.22) 46 111                              | (47.4 ; 1.10) ; (1.54)                          | 43 (43.4 ; 0.71) 111 (1.15)                       | ; 74 223                                         | (45.4 ; 0.81) ; (1.31) |
| Conjunctivitis                                 | 1 (3.4 ; (0.08)           | 18 (1.29) 0.08) ; 1 0 ; 0                | 0 ; 0                                                | 1 (3.6 ; (0.08)                                     | 0.08) ; 1 1 (1.7 ; 0.04) (0.04)                       | ; 1 3 (3.1 (0.04)                                       | ; 0.04) ; 3                                     | 4 (4.0 ; 0.04) (0.05)                             | ; 5 6 (0.05)                                     | (3.7 ; 0.04) ; 8       |
| Ear infection                                  | 1 (3.4 ; (0.15)           | 0.08) ; 2 1 (3.2 ; 0.07) ; (0.07)        | 1 1 (3.3 ; 0.08) (0.07)                              | ; 1 1 (3.6 ; (0.08)                                 | 0.08) ; 1 2 (3.4 ; (0.08)                             | 0.08) ; 2 5 (5.2 (0.07)                                 | ; 0.07) ;                                       | 5 6 (6.1 ; 0.06) (0.07)                           | ; 7 10 12                                        | (6.1 ; 0.06) ; (0.07)  |
| Enterobiasis                                   | 0 ; 0                     | 0 ; 0                                    | 1 (3.3 ; 0.07) (0.07)                                | ; 1 1 (3.6 ; 0.08) (0.08)                           | ; 1 2 (3.4 ; 0.08) ; (0.08)                           | 2 2 (2.1 (0.03)                                         | ; 0.03) ; 2 3                                   | (3.0 ; 0.03) (0.04)                               | ; 4 4 (2.5 ; (0.04)                              | 0.02) ; 6              |
| Gastroenteritis viral                          | 0 ; 0                     | 0 ; 0                                    | 2 (6.7 ; 0.16) (0.15)                                | ; 2 0 ; 0                                           | 2 (3.4 ; 0.08) ; (0.08)                               | 2 5 (5.2 (0.07)                                         | ; 0.07) ; 5 2                                   | (2.0 ; 0.02) (0.02)                               | ; 2 8 (4.9 ; (0.05)                              | 0.05) ; 8              |
| Influenza                                      | 1 (3.4 ; 0.08) ; (0.08)   | 1 1 (3.2 ; 0.07) ; (0.07)                | 1 1 (3.3 ; 0.08) ; (0.07)                            | 1 0 ; 0                                             | 1 (1.7 ; 0.04) ; (0.04)                               | 1 5 (5.2 ; (0.07)                                       | 0.07) ; 5                                       | 9 (9.1 ; 0.10) (0.10)                             | ; 10 13 (8.0 ; 15 (0.09)                         | 0.08) ;                |
| Nasopharyngitis                                | 3 (10.3 ; 0.24) 6 (0.46)  | ; 3 (9.7 ; 0.23) ; 9 (0.64)              | 1 (3.3 ; 0.07) ; (0.07)                              | 1 2 (7.1 ; 0.17) (0.47)                             | ; 6 3 (5.2 ; 0.12) ; 7 (0.27)                         | 16 (16.5 ; 39 (0.54)                                    | 0.28) ;                                         | 18 (18.2 ; 0.22) 37 (0.38)                        | ; 30 (18.4 ; 76 (0.45)                           | 0.22) ;                |
| Pharyngitis streptococcal                      | 1 (3.4 ; (0.08)           | 0.08) ; 1 0 ; 0                          | 1 (3.3 ; 0.08) (0.15)                                | ; 2 0 ; 0                                           | 1 (1.7 ; 0.04) ; (0.08)                               | 2 5 (5.2 ; (0.17)                                       | 0.07) ; 12 3                                    | (3.0 ; 0.03) ; (0.03)                             | 3 7 (4.3 ; (0.09)                                | 0.04) ; 15             |
| Rhinitis                                       | 1 (3.4 ; 0.08) (0.15)     | ; 2 0 ; 0                                | 1 (3.3 ; (0.15)                                      | 0.08) ; 2 2 (7.1 ; 0.16) (0.16)                     | ; 2 3 (5.2 ; 0.12) ; 4 (0.15)                         | 3 (3.1 ; (0.06)                                         | 0.04) ; 4 5                                     | (5.1 ; 0.05) ; (0.06)                             | 6 8 (4.9 ; (0.06)                                | 0.05) ; 10             |
| Upper respiratory tract infection              | 4 (13.8 ; 0.33) 7 (0.53)  | ; 4 (12.9 ; 0.31) ; (0.43)               | 6 6 (20.0 ; 0.52) (0.52)                             | ; 7 2 (7.1 ; 0.16) (0.23)                           | ; 3 8 (13.8 ; 0.34) ; 10 (0.38)                       | 19 (19.6 ; 24 (0.33)                                    | 0.30) ; 12 24                                   | (12.1 ; 0.13) (0.25)                              | ; 28 (17.2 ; 48 (0.28)                           | 0.19) ;                |
| Viral infection                                | 0 ; 0                     | 0 ; 0                                    | 0 ; 0                                                | 1 (3.6 ; 0.08) (0.08)                               | ; 1 1 (1.7 ; 0.04) ; (0.04)                           | 1 2 (2.1 ; (0.04)                                       | 0.03) ; 3 3                                     | (3.0 ; 0.03) (0.03)                               | ; 3 4 (2.5 ; (0.04)                              | 0.02) ; 6              |
| Viral upper respiratory tract infection        | 0 ; 0                     | 1 (3.2 ; 0.07) ; 1 (0.07)                | 0 ; 0                                                | 0 ; 0                                               | 0 ; 0                                                 | 3 (3.1 ; (0.06)                                         | 0.04) ; 4 4                                     | (4.0 ; 0.05) ; (0.06)                             | 6 7 (4.3 ; (0.06)                                | 0.04) ; 10             |
| Injury, poisoning and procedural complications | 2 (6.9 ; 0.16) ; 4 (0.30) | 4 (12.9 ; 0.31) ; (0.57)                 | 8 6 (20.0 ; 0.50) ; (0.45)                           | 6 6 (21.4 ; 0.54) ; (0.55)                          | 7 12 (20.7 ; 0.52) ; 13 (0.50)                        | 15 (15.5 ; 23 (0.32)                                    | 0.24) ;                                         | 17 (17.2 ; 0.21) 30 (0.31)                        | ; 31 (19.0 53 (0.31)                             | ; 0.22) ;              |
| Arthropod bite                                 | 1 (3.4 ; 0.08) ; (0.23)   | 3 0 ; 0                                  | 1 (3.3 ; 0.08) ; (0.07)                              | 1 2 (7.1 ; 0.16) ; (0.16)                           | 2 3 (5.2 ; 0.12) ; (0.11)                             | 3 3 (3.1 ; (0.04)                                       | 0.04) ; 3 3                                     | (3.0 ; 0.03) ; (0.03)                             | 3 6 (3.7 (0.04)                                  | ; 0.04) ; 6            |
| Contusion                                      | 0 ; 0                     | 1 (3.2 ; 0.07) ; (0.07)                  | 1 3 (10.0 ; 0.24) (0.22)                             | ; 3 0 ; 0                                           | 3 (5.2 ; 0.12) ; (0.11)                               | 3 4 (4.1 (0.06)                                         | ; 0.06) ; 4 1 (0.01)                            | (1.0 ; 0.01) ;                                    | 1 5 (3.1 (0.03)                                  | ; 0.03) ; 5            |
| Fall                                           | 1 (3.4 ; 0.08) ; (0.08)   | 1 4 (12.9 ; 0.31) ; (0.50)               | 7 0 ; 0                                              | 3 (10.7 ; 0.26) ; (0.31)                            | 4 3 (5.2 ; 0.12) ; (0.15)                             | 4 6 (6.2 ; (0.11)                                       | 0.09) ; 8 11 19                                 | (11.1 ; 0.13) (0.20)                              | ; 16 (9.8 27 (0.16)                              | ; 0.10) ;              |
| Limb injury                                    | 0 ; 0                     | 0 ; 0                                    | 0 ; 0                                                | 1 (3.6 ; 0.08) ; (0.08)                             | 1 1 (1.7 ; 0.04) ; (0.04)                             | 1 3 (3.1 ; (0.06)                                       | 0.04) ; 4 1 (1.0 (0.01)                         | ; 0.01) ;                                         | 1 4 (2.5 ; (0.03)                                | 0.02) ; 5              |
| Muscle strain                                  | 0 ; 0                     | 0 ; 0                                    | 1 (3.3 ; 0.07) (0.07)                                | ; 1 0 ; 0                                           | 1 (1.7 ; 0.04) ; (0.04)                               | 1 2 (2.1 ; (0.03)                                       | 0.03) ; 2 2 (2.0 (0.02)                         | ; 0.02) ;                                         | 2 4 (2.5 ; (0.02)                                | 0.02) ; 4              |
| Skin laceration                                | 0 ; 0                     | 0 ; 0                                    | 1 (3.3 ; 0.07) ; (0.07)                              | 1 0 ; 0                                             | 1 (1.7 ; 0.04) ; 1 (0.04)                             | 2 (2.1 ; (0.03)                                         | 0.03) ; 2 3 (3.0 (0.04)                         | ; 0.03) ;                                         | 4 5 (3.1 ; (0.04)                                | 0.03) ; 6              |

<div style=\"page-break-after: always\"></div>

| Pool                                            | Pool                                            | 1                                      | Pool 3                                                 | Pool 3                                                     | Pool 3                                                     | Pool 3                                             | Pool 3                                             | Pool 3                                          | Pool 3                                              | Pool 3                                              | Pool 3                                              | Pool 3                                              | Pool 3                                                       | Pool 3                                                       | Pool 3                                                       |
|-------------------------------------------------|-------------------------------------------------|----------------------------------------|--------------------------------------------------------|------------------------------------------------------------|------------------------------------------------------------|----------------------------------------------------|----------------------------------------------------|-------------------------------------------------|-----------------------------------------------------|-----------------------------------------------------|-----------------------------------------------------|-----------------------------------------------------|--------------------------------------------------------------|--------------------------------------------------------------|--------------------------------------------------------------|
| System Organ                                    | Class                                           | Placebo (N = 29) n (% ; EAIR) ; (Rate) | f Prednisone 0.75 mg/kg (N = 31) n (% ; EAIR) ; (Rate) | f Vamorolone 2 mg/kg (N = 30) n (% ; EAIR) ; f (Rate) (N n | f Vamorolone 2 mg/kg (N = 30) n (% ; EAIR) ; f (Rate) (N n | Vamorolone 6 mg/kg = 28) (% ; EAIR) ; f (Rate) 6 n | Vamorolone 6 mg/kg = 28) (% ; EAIR) ; f (Rate) 6 n | Vamorolone 2 mg/kg (N = 58) (% ; EAIR) ; (Rate) | - f Vamorolone mg/kg (N = 97) n (% ; EAIR) ; (Rate) | - f Vamorolone mg/kg (N = 97) n (% ; EAIR) ; (Rate) | 2 f Vamorolone mg/kg (N = 99) n (% ; EAIR) ; (Rate) | 2 f Vamorolone mg/kg (N = 99) n (% ; EAIR) ; (Rate) | 6 f Vamorolone 2 - 6 mg/kg (N = 163) n (% ; EAIR) ; f (Rate) | 6 f Vamorolone 2 - 6 mg/kg (N = 163) n (% ; EAIR) ; f (Rate) | 6 f Vamorolone 2 - 6 mg/kg (N = 163) n (% ; EAIR) ; f (Rate) |
| Preferred Investigations                        | Term                                            | 1 (3.4 ; 0.08) ; (0.08)                | 1 2 (6.5 ; 0.15) ; 2 (0.14)                            | 0 ; 0                                                      | 0 ; 0                                                      | 3 (10.7 ; (0.23)                                   | 0.24) ; 3                                          | 3 (5.2 ; 0.12) ; (0.11)                         | 3 6 (6.2 ; (0.08)                                   | 0.08) ;                                             | 6 18 (18.2 ; 20 (0.21)                              | 0.21)                                               | ; 24 (14.7 26 (0.15)                                         | ; 0.16) ;                                                    |                                                              |
| Weight increased                                | Weight increased                                | 1 (3.4 ; 0.08) ; (0.08)                | 1 2 (6.5 ; 0.15) ; 2 (0.14)                            | 0 ; 0                                                      | 3                                                          | (10.7 ; (0.23)                                     | 0.24) ; 3 3                                        | (5.2 ; 0.12) ; (0.11)                           | 3 4 (4.1 ; (0.06)                                   | 0.06) ;                                             | 4 13 (13.1 ; 15 (0.16)                              | 0.15)                                               | ; 17 (10.4 19 (0.11)                                         | ; 0.11) ;                                                    |                                                              |
| Metabolism and nutrition disorders 0            | Metabolism and nutrition disorders 0            | ; 0                                    | 1 (3.2 ; 0.07) ; 1 (0.07)                              | 2 (6.7 ; (0.15)                                            | 0.15) ; 2 3                                                | (10.7 ; 0.25) (0.23)                               | ; 3 5 (8.6 ; (0.19)                                | 0.20) ;                                         | 5 2 (2.1 ; (0.03)                                   | 0.03) ;                                             | 2 9 (9.1 ; (0.11)                                   | 0.10) ;                                             | 11 11 (6.7 13 (0.08)                                         | ; 0.07) ;                                                    |                                                              |
| Vitamin D deficiency                            | Vitamin D deficiency                            | 0 ; 0                                  | 1 (3.2 ; 0.07) ; 1 (0.07)                              | 2 (6.7 ; (0.15)                                            | 0.15) ; 2 3 (0.23)                                         | (10.7 ; 0.25)                                      | ; 3 5 (8.6 (0.19)                                  | ; 0.20) ;                                       | 5 2 (2.1 ; (0.03)                                   | 0.03) ;                                             | 2 9 (9.1 ; (0.11)                                   | 0.10) ;                                             | 11 11 (6.7 13 (0.08)                                         | ; 0.07) ;                                                    |                                                              |
| Musculoskeletal connective disorders            | and tissue 3 3                                  | (10.3 ; 0.25) ; (0.23)                 | 4 (12.9 ; 0.31) ; 6 (0.43)                             | 0 ; 0 2                                                    | 0 ; 0 2                                                    | (7.1 ; 0.16) (0.16)                                | ; 2 2 (3.4 ; (0.08)                                | 0.08) ; 2                                       | 19 (19.6 28 (0.39)                                  | ; 0.30)                                             | ; 27 (27.3 ; 38 (0.40)                              | 0.36)                                               | ; 42 (25.8 66 (0.39)                                         | ; 0.31) ;                                                    |                                                              |
| Arthralgia                                      | Arthralgia                                      | 0 ; 0                                  | 1 (3.2 ; 0.07) ; 1 (0.07)                              | 0 ; 0                                                      | 0 ; 0                                                      | 1 (3.6 ; 0.08) (0.08)                              | ; 1 1 (1.7 ; (0.04)                                | 0.04) ;                                         | 1 2 (2.1 ; (0.03)                                   | 0.03) ;                                             | 2 2 (2.0 ; (0.02)                                   | 0.02) ;                                             | 2 4 (2.5 ; (0.02)                                            | 0.02) ; 4                                                    |                                                              |
| Back pain                                       | Back pain                                       | 1 (3.4 ; 0.08) ; 1 (0.08)              | 1 (3.2 ; 0.07) ; 1 (0.07)                              | 0 ; 0                                                      | 0                                                          | ; 0                                                | 0 ; 0                                              |                                                 | 4 (4.1 ; (0.06)                                     | 0.06) ;                                             | 4 3 (3.0 ; (0.04)                                   | 0.03) ;                                             | 4 7 (4.3 ; (0.05)                                            | 0.04) ; 8                                                    |                                                              |
| Myalgia                                         | Myalgia                                         | 1 (3.4 ; 0.08) ; 1 (0.08)              | 0 ; 0                                                  | 0 ; 0                                                      | 0 ; 0                                                      | 1 (3.6 ; 0.08) (0.08)                              | ; 1 1 (1.7 ; (0.04)                                | 0.04) ;                                         | 1 2 (2.1 ; (0.03)                                   | 0.03) ;                                             | 2 5 (5.1 ; (0.07)                                   | 0.05) ;                                             | 7 7 (4.3 ; (0.05)                                            | 0.04) ; 9                                                    |                                                              |
| Pain in extremity                               | Pain in extremity                               | 1 (3.4 ; 0.08) ; (0.08)                | 1 3 (9.7 ; 0.23) ; 4 (0.29)                            | 0 ; 0                                                      | 0                                                          | ; 0                                                | 0 ; 0                                              |                                                 | 11 (11.3 17 (0.24)                                  | ; 0.16)                                             | ; 12 (12.1 16 (0.17)                                | ; 0.14)                                             | ; 22 (13.5 33 (0.19)                                         | ; 0.15) ;                                                    |                                                              |
| Nervous system disorders                        | Nervous system disorders                        | 1 (3.4 ; 0.08) ; (0.08)                | 1 1 (3.2 ; 0.07) ; 1 (0.07)                            | 2 (6.7 ; 0.15) ; 2 (0.15)                                  | 2                                                          | (7.1 ; 0.17) (0.16)                                | ; 2 4 (6.9                                         | ; 0.16) ; (0.15)                                | 4 11 (11.3 16 (0.22)                                | ; 0.17)                                             | ; 12 (12.1 22 (0.23)                                | ; 0.13)                                             | ; 21 (12.9 38 (0.22)                                         | ; 0.14) ;                                                    |                                                              |
| Headache                                        | Headache                                        | 1 (3.4 ; 0.08) ; (0.08)                | 1 1 (3.2 ; 0.07) ; 1 (0.07)                            | 2 (6.7 ; 0.15) ; 2 (0.15)                                  | 2                                                          | (7.1 ; 0.17) (0.16)                                | ; 2 4 (6.9 (0.15)                                  | ; 0.16) ;                                       | 4 11 (11.3 16 (0.22)                                | ; 0.17)                                             | ; 12 (12.1 22 (0.23)                                | ; 0.13)                                             | ; 21 (12.9 38 (0.22)                                         | ; 0.14) ;                                                    |                                                              |
| Psychiatric disorders                           | Psychiatric disorders                           | 0 ; 0                                  | 3 (9.7 ; 0.24) ; (0.21)                                | 3 1 (3.3 ; 0.08) ; 1 (0.07)                                | 3                                                          | (10.7 ; (0.31)                                     | 0.25) ; 4                                          | 4 (6.9 ; 0.16) ; (0.19)                         | 5 6 (6.2 ; (0.08)                                   | 0.09) ;                                             | 6 11 (11.1 14 (0.15)                                | ; 0.13)                                             | ; 17 (10.4 20 (0.12)                                         | ; 0.11) ;                                                    |                                                              |
| Agitation                                       | Agitation                                       | 0 ; 0                                  | 0 ; 0                                                  | 0 ; 0                                                      | 0 ; 0                                                      | 1 (3.6 ; (0.08)                                    | 0.08) ; 1                                          | 1 (1.7 ; 0.04) ; (0.04)                         | 1 2 (2.1 ; (0.03)                                   | 0.03) ;                                             | 2 3 (3.0 (0.03)                                     | ; 0.03) ;                                           | 3 5 (3.1 ; (0.03)                                            | 0.03) ; 5                                                    |                                                              |
| Behaviour disorder                              | Behaviour disorder                              | 0 ; 0                                  | 1 (3.2 ; 0.07) ; 1 (0.07)                              | 1 (3.3 ; 0.08) ; 1 (0.07)                                  | 0                                                          | ; 0                                                | 1 (0.04)                                           | (1.7 ; 0.04) ; 1                                | 3 (3.1 ; (0.04)                                     | 0.04) ;                                             | 3 1 (1.0 (0.01)                                     | ; 0.01) ;                                           | 1 4 (2.5 ; (0.02)                                            | 0.02) ; 4                                                    |                                                              |
| Emotional disorder                              | Emotional disorder                              | 0 ; 0                                  | 1 (3.2 ; 0.07) ; 1 (0.07)                              | 0 ; 0                                                      | 0                                                          | ; 0                                                | 0 ; 0                                              |                                                 | 1 (1.0 ; (0.01)                                     | 0.01) ;                                             | 1 2 (2.0 (0.03)                                     | ; 0.02) ;                                           | 3 3 (1.8 ; (0.02)                                            | 0.02) ; 4                                                    |                                                              |
| Irritability                                    | Irritability                                    | 0 ; 0                                  | 1 (3.2 ; 0.07) ; 1 (0.07)                              | 0 ; 0                                                      | 3                                                          | (10.7 ; 0.25) (0.23)                               | ; 3 3                                              | (5.2 ; 0.12) ; (0.11)                           | 3 0 ; 0                                             |                                                     | 7 (7.1 (0.07)                                       | ; 0.08) ;                                           | 7 7 (4.3 ; (0.04)                                            | 0.04) ; 7                                                    |                                                              |
| Renal and urinary disorders                     | Renal and urinary disorders                     | 0 ; 0                                  | 0 ; 0                                                  | 1 (3.3 ; (0.07)                                            | 0.07) ; 1 1                                                | (3.6 ; 0.08) (0.08)                                | ; 1 2                                              | (3.4 ; 0.08) ; (0.08)                           | 2 2 (2.1 ; (0.03)                                   | 0.03) ;                                             | 2 2 (2.0 (0.02)                                     | ; 0.02)                                             | ; 2 4 (2.5 ; (0.02)                                          | 0.02) ; 4                                                    |                                                              |
| Chromaturia                                     | Chromaturia                                     | 0 ; 0                                  | 0 ; 0                                                  | 1 (3.3 ; (0.07)                                            | 0.07) ; 1 1                                                | (3.6 ; 0.08) (0.08)                                | ; 1 2 (3.4 (0.08)                                  | ; 0.08) ;                                       | 2 2 (2.1 ; (0.03)                                   | 0.03) ;                                             | 2 2 (2.0 (0.02)                                     | ; 0.02) ;                                           | 2 4 (2.5 ; (0.02)                                            | 0.02) ; 4                                                    |                                                              |
| Respiratory, thoracic and mediastinal disorders | Respiratory, thoracic and mediastinal disorders | 2 (6.9 ; 0.16) ; 3 (0.23)              | 3 (9.7 ; 0.23) ; (0.36)                                | 5 3 (10.0 ; (0.45)                                         | 0.24) ; 6 3                                                | (10.7 ; 0.25) (0.23)                               | ; 3 6 (10.3 (0.34)                                 | ; 0.24) ;                                       | 9 16 (16.5 23 (0.32)                                | ; 0.26)                                             | ; 25 (25.3 38 (0.40)                                | ; 0.32)                                             | ; 39 (23.9 61 (0.36)                                         | ; 0.29) ;                                                    |                                                              |

<div style=\"page-break-after: always\"></div>

|                                        | Pool 1                                 | Pool 3                                                 | Pool 3                                            | Pool 3                                              | Pool 3                                                    | Pool 3                                            | Pool 3                                            | Pool 3                                                         | Pool 3                                                         |
|----------------------------------------|----------------------------------------|--------------------------------------------------------|---------------------------------------------------|-----------------------------------------------------|-----------------------------------------------------------|---------------------------------------------------|---------------------------------------------------|----------------------------------------------------------------|----------------------------------------------------------------|
| System Organ Class Preferred Term      | Placebo (N = 29) n (% ; EAIR) ; (Rate) | f Prednisone 0.75 mg/kg (N = 31) n (% ; EAIR) ; (Rate) | f Vamorolone mg/kg (N = 30) n (% ; EAIR) ; (Rate) | 2 f Vamorolone mg/kg (N = 28) n (% ; EAIR) ; (Rate) | 6 f Vamorolone 2 - 6 mg/kg (N = 58) n (% ; EAIR) ; (Rate) | f Vamorolone mg/kg (N = 97) n (% ; EAIR) ; (Rate) | 2 f Vamorolone mg/kg (N = 99) n (% ; EAIR) (Rate) | 6 ; f Vamorolone 2 - 6 mg/kg (N = 163) n (% ; EAIR) ; f (Rate) | 6 ; f Vamorolone 2 - 6 mg/kg (N = 163) n (% ; EAIR) ; f (Rate) |
| Cough                                  | 1 (3.4 ; 0.08) ; 1 (0.08)              | 3 (9.7 ; 0.23) ; 3 (0.21)                              | 3 (10.0 ; 0.24) ; (0.45)                          | 6 2 (7.1 ; 0.16) ; (0.16)                           | 2 5 (8.6 ; 0.20) ; 8 (0.30)                               | 13 (13.4 ; 0.21) 19 (0.26)                        | ; 17 (17.2 ; 0.21) 24 (0.25)                      | ; 30 (18.4 ; 43 (0.25)                                         | 0.22) ;                                                        |
| Nasal congestion                       | 0 ; 0                                  | 2 (6.5 ; 0.15) ; 2 (0.14)                              | 0 ; 0                                             | 1 (3.6 ; 0.08) ; (0.08)                             | 1 1 (1.7 ; 0.04) ; 1 (0.04)                               | 0 ; 0                                             | 7 (7.1 ; 0.08) (0.08)                             | ; 8 7 (4.3 (0.05)                                              | ; 0.04) ; 8                                                    |
| Oropharyngeal pain                     | 1 (3.4 ; 0.08) ; 2 (0.15)              | 0 ; 0                                                  | 0 ; 0                                             | 0 ; 0                                               | 0 ; 0                                                     | 4 (4.1 ; 0.06) ; (0.06)                           | 4 4 (4.0 ; 0.04) (0.06)                           | ; 6 7 (4.3 (0.06)                                              | ; 0.04) ; 10                                                   |
| Skin and subcutaneous tissue disorders | 1 (3.4 ; 0.08) ; 1 (0.08)              | 1 (3.2 ; 0.07) ; 1 (0.07)                              | 1 (3.3 ; 0.07) ; (0.07)                           | 1 1 (3.6 ; 0.08) ; (0.08)                           | 1 2 (3.4 ; 0.08) ; 2 (0.08)                               | 1 (1.0 ; 0.01) ; (0.01)                           | 1 5 (5.1 ; 0.05) (0.05)                           | ; 5 6 (3.7 (0.04)                                              | ; 0.04) ; 6                                                    |
| Hypertrichosis                         | 1 (3.4 ; 0.08) ; 1 (0.08)              | 1 (3.2 ; 0.07) ; 1 (0.07)                              | 1 (3.3 ; 0.07) ; (0.07)                           | 1 1 (3.6 ; 0.08) ; (0.08)                           | 1 2 (3.4 ; 0.08) ; (0.08)                                 | 2 1 (1.0 ; 0.01) ; (0.01)                         | 1 5 (5.1 ; 0.05) (0.05)                           | ; 5 6 (3.7 (0.04)                                              | ; 0.04) ; 6                                                    |

Rate is calculated as Events per patient per year of exposure. EAIR is calculated as number of patients reporting the event at least once divided by total time spent at risk for the event to occur. The total time spent at risk is calculated as time to first occurrence of event or total treatment time for patients not experiencing the event in question. EAIR is annualised. Preferred Term is kept only if it is more common in Vamorolone than in Placebo group. EAIR = exposure adjusted incidence rate; f = event count; n = patient count; TEAE = Treatment-emergent adverse event. Source: EU Outputs

<div style=\"page-break-after: always\"></div>

Severity of events: the vast majority of TEAEs was mild in severity. There was a higher frequency of moderate TEAEs in the prednisone group compared with the other treatment groups (1.29, 0.69, 0.82, 0.47 moderate events per subject-year in the prednisone, placebo, vamorolone 2 and 6 mg/kg group, respectively). One subject in the prednisone group had a severe TEAE (aggression).

Drug-related  TEAEs  (possibly,  probably,  or  definitely  related)  were  reported  for  a  higher  number  of subjects in the vamorolone 6 mg/kg and prednisone group (67.9% and 45.2%) and a lower and similar number of subjects on placebo and vamorolone 2 mg/kg (27.6% and 33.3%). The event rate for drug related TEAEs was, however, higher for prednisone compared with the other treatment groups. The most frequently reported drug-related preferred term (PT) that was also highest for patients treated with vamorolone was Cushingoid.

Justification  of  ADRs  to  be  included  in  section  4.8  of  the  SmPC  was  provided  by  the  applicant  and comprised TEAEs by PT reported by more than 2 subjects in either vamorolone dose group and reported by at least 1 more subject in either of the vamorolone groups compared to placebo from the randomised Period 1 of Study VBP15-004. Causality assessment was based on a dose-response, the extent to which the AE was consistent with the pharmacology of drug, and whether the AE is known to be caused by related drugs.

For gastroenteritis, viral and upper respiratory infection , fall,  contusion , cough, constipation, rhinitis, arthropod bite, and Vitamin D deficiency, a causal relationship with vamorolone could not be identified based on the criteria mentioned above. Vitamin D deficiency has been reviewed by the applicant as potential adverse drug reaction (ADR) to be included upon request of CHMP; however, there seems to be no direct correlation between glucocorticoid dose and vitamin D concentrations in DMD patients, while DMD itself is strongly associated with high rates of vitamin D deficiency despite supplementation.

The following TEAEs were identified as potential ADRs: cushingoid ( dose-response, pharmacology, known effect for GCs ), abdominal pain/abdominal pain upper ( higher incidence vs. placebo; known effect for GCs ), diarrhoea ( dose-response, known effect of GCs ), vomiting ( dose-response in Pool 3; known effect for GCs ), weight increased ( dose-response, supported by measures of weight and BMI; known effect of GCs ), headache, and irritability ( dose-response, known effect of GCs ). The inclusion of these TEAEs as ADRs is supported by review of adverse events of special interest (AESIs) (i.e., grouping events based on the known effects of GCs), which confirmed a causal relationship. The review of laboratory and other safety parameters revealed additional ADRs, i.e. blood triglycerides increased (dose-dependent increase in the vamorolone groups early after treatment initiation with mean increase from baseline of 20% and 25% in  the  vamorolone  2  and  6 mg/kg  groups  and  no  change  in  the  placebo  group),  and cortisol decreased (dose-dependent mean and median decrease from baseline in morning cortisol at Week 12 and Week 24 in the vamorolone and prednisone groups). The frequency categories of ADRs are in line with  reported  frequencies  in  Pool 1  for  the  6 mg/kg  dose  that  serves  as  the  basis  for  inclusion  and frequency categorisation.

Long-term adverse effects of vamorolone can be retrieved from Pool 3 safety data. The incidences were higher in Pool 3 than in Pool 1 for severe TEAEs, non-mild TEAEs, clinically relevant TEAEs, TEAEs of special interest and serious TEAEs. TEAEs leading to dose reduction were only described for Pool 3 since dose reduction was not allowed during the controlled period of study VBP15-004.

Severity of TEAEs in Pool 3: Two severe TEAEs were recorded in the 2 mg/kg group (i.e., seizure and behaviour  disorder),  and  8  severe  events  occurred  in  the  6 mg/kg  group  (influenza-like  illness, appendicitis perforated, dehydration, agitation, myoglobinuria [2 events], testicular torsion, asthma, and hypoxia).

TEAEs considered related to study drug by the investigator with ≥ 5 events (PTs) in the vamorolone 26 mg/kg group were cushingoid (19 events), weight increased (19 events), abdominal pain (8 events),

<div style=\"page-break-after: always\"></div>

and abdominal pain upper (8 events), irritability (7 events), hypertrichosis (6 events), and increased appetite (5 events). Apart from Abdominal pain, the rates of these events were generally higher in the vamorolone 6 mg/kg group compared with the 2 mg/kg group.

For some systemic organ class (SOCs) and respective PTs, the incidences slightly increased during longer treatment duration, e.g. for gastrointestinal (GI) disorders, general disorders and administration site conditions, infections and infestations, investigations, musculoskeletal and connective tissue disorders, and respiratory, thoracic and mediastinal disorders, which can at least in parts be explained by the underlying disease (see Table 16 for TEAEs in Pool 1 that were also reported in Pool 3). With the limited data available for longer (uncontrolled) treatment duration in Pool 3, no additional safety concerns arise at present up to 30 months of exposure to vamorolone.

Moreover, the incidences of TEAEs after switching from prednisone or placebo to vamorolone 2 mg/kg and  6 mg/kg  have  been  evaluated.  Vitamin  D  deficiency  increased  after  switch  from  prednisone  to vamorolone 6 mg/kg (0% and 13.3%), which supports inclusion as an ADR in section 4.8 of the SmPC. Fatigue had a higher incidence after switch from prednisone (0%) to vamorolone 2 mg/kg and 6 mg/kg (13.3% each).

## Clinically relevant TEAEs

Clinically relevant TEAEs (defined as either at least moderate in severity or leading to withdrawal from study or being a serious event) were reported most frequently in the prednisone group (42%), followed by placebo (31%), vamorolone 2 mg/kg (26.7%), and vamorolone 6 mg/kg (14.3%). The only clinically relevant TEAEs reported by &gt; 1 subject were Vitamin D deficiency in the vamorolone 2-6 mg/kg group (1 subject each at 2 and 6 mg/kg) and aggression (2 subjects, 1 of which was severe) in the prednisone group. In Pool 3, clinically relevant TEAEs were reported in 34% and 40.4% of subjects in the vamorolone 2 mg/kg and 6 mg/kg group, respectively. Apart from weight increased, which was reported for 3.1% of subjects in the vamorolone 2 mg/kg group (Exposure adjusted incidence rate (EAIR) 0.04, rate 0.04) and 8.1% in the vamorolone 6 mg/kg group (EAIR 0.09, rate 0.08), no other clinically relevant TEAEs appeared to occur at a notably higher frequency in the 6 mg/kg compared with the 2 mg/kg group.

## Summary of TEAEs in study VBP15-006 in children 2 to &lt;4 years of age (DCO 21 July 2023) as compared to patients 4 to &lt;7 years of age in study VBP15-004 (in the first 12 weeks of treatment):

- There  was  no  serious  AE,  TEAE  leading  to  permanent  discontinuation,  or  TEAE  leading  to  dose interruption in children 2 to &lt;4 years of age for 2 and 6 mg/kg.
- At the 2 mg/kg dose level, TEAEs were generally similar for the subjects 2 to &lt;4 years and the 4 to &lt;7  year  (reference)  group  from  study  VBP15-004,  although  there  was  a  higher  frequency  of infections in the younger children.
- A higher frequency of TEAEs with the 6 mg/kg dose was observed in the 2 to &lt;4 years children in study VBP15-006 as compared to 4 to &lt;7 years-old (100% vs. 71.4%). The rate of events per year was more than double as high in the youngest age group treated with 6 mg/kg as compared to 4 to &lt;7 years - old (16.44 vs. 8.231).
- In the 6 mg/kg dose group, paediatric patients 2 to &lt;4 years differed from those 4 to &lt;7 years in GI disorders TEAEs (100% vs. 21.4%), adrenal suppression (50% vs. 0%), and psychiatric disorders (33.3% vs. 10.7%; event rate 2.86 vs. 0.621).

## Adverse events of special interest

AESI were defined by known side effects of glucocorticoids using a broad search strategy of Medical Dictionary for Regulatory Activities (MedDRA) customised medical queries (CMQ). AESI and their respective frequencies in Pool 1 and Pool 3 are depicted in Table 17. Overall incidence of AESI was higher during the first 90 days of treatment in either group in Pool 1 of study VBP15-004 as compared

<div style=\"page-break-after: always\"></div>

to AESI occurring after 90 days (and up to 6 months). Based on Pool 3 data, a majority of AESI had an onset in the first 6 months of treatment.

<div style=\"page-break-after: always\"></div>

Table 17: AESI: side effects of glucocorticoid drugs -safety population pool 1 and pool 3 (summarised by the Assessor)

|                            | Pool 1                                 | Pool 3                                                 | Pool 3                                            | Pool 3                                              | Pool 3                                                  | Pool 3                                            | Pool 3                                                | Pool 3                                                       |
|----------------------------|----------------------------------------|--------------------------------------------------------|---------------------------------------------------|-----------------------------------------------------|---------------------------------------------------------|---------------------------------------------------|-------------------------------------------------------|--------------------------------------------------------------|
| AESI                       | Placebo (N = 29) n (% ; EAIR) ; (Rate) | f Prednisone 0.75 mg/kg (N = 31) n (% ; EAIR) ; (Rate) | f Vamorolone mg/kg (N = 30) n (% ; EAIR) ; (Rate) | 2 f Vamorolone mg/kg (N = 28) n (% ; EAIR) ; (Rate) | 6 f Vamorolone 2 6 mg/kg (N = 58) n (% ; EAIR) ; (Rate) | - f Vamorolone mg/kg (N = 97) n (% ; EAIR) (Rate) | 2 ; f Vamorolone mg/kg (N = 99) n (% ; EAIR) ; (Rate) | 6 f Vamorolone 2 - 6 mg/kg (N = 163) n (% ; EAIR) ; f (Rate) |
| Total number of AESI TEAEs | 20 (69.0 ; 2.87) ; 45 (3.43)           | 24 (77.4 ; 3.93) ; 69 (4.93)                           | 20 (66.7 ; 2.70) 49 (3.64)                        | ; 22 (78.6 ; 3.41) ; 52 (4.07)                      | 42 (72.4 ; 3.03) 101 (3.85)                             | ; 69 (71.1 ; 2.48) 254 (3.51)                     | ; 80 (80.8 ; 2.66) 335 (3.48)                         | ; 126 (77.3 ; 2.67) ; 592 (3.49)                             |
| Behavior problems          | 4 (13.8 ; 0.34) ; 5 (0.38              | 10 (32.3 ; 0.99) ; 16 (1.14)                           | 5 (16.7 ; 0.43) ; 6 (0.45)                        | 6 (21.4 ; 0.53) ; 9 (0.70)                          | 11 (19.0 ; 0.48) ; 15 (0.57)                            | 20 (20.6 ; 0.34) 21 (0.29)                        | ; 24 (24.2 ; 0.31) 32 (0.33)                          | ; 42 (25.8 ; 0.33) ; 53 (0.31)                               |
| Bone fractures             |                                        |                                                        |                                                   |                                                     |                                                         | 2 (2.1 ; 0.03) ; (0.03)                           | 2 7 (7.1 ; 0.08) ; (0.08)                             | 8 8 (4.9 ; 0.05) ; 10 (0.06)                                 |
| Cushingoid features        | 0 ; 0                                  | 7 (22.6 ; 0.53) ; 7 (0.50)                             | 2 (6.7 ; 0.15) ; 2 (0.15)                         | 8 (28.6 ; 0.70) ; 8 (0.63)                          | 10 (17.2 ; 0.40) 10 (0.38)                              | ; 5 (5.2 ; 0.07) ; (0.07)                         | 5 14 (14.1 ; 0.16) 14 (0.15)                          | ; 19 (11.7 ; 0.12) ; 19 (0.11)                               |
| Diabetic conditions        | 1 (3.4 ; 0.08) ; 1 (0.08))             | 3 (9.7 ; 0.22) ; 3 (0.21)                              | 0 ; 0                                             | 1 (3.6 ; 0.08) ; (0.08)                             | 1 1 (1.7 ; 0.04) ; (0.04)                               | 1 1 (1.0 ; 0.01) ; (0.01)                         | 1 10 (10.1 ; 0.12) 11 (0.11)                          | ; 11 (6.7 ; 0.07) ; 12 (0.07)                                |
| Gastrointestinal symptoms  | 8 (27.6 ; 0.75) ; 10 (0.76)            | 8 (25.8 ; 0.69) ; 13 (0.93)                            | 9 (30.0 ; 0.82) ; 16 (1.19)                       | 8 (28.6 ; 0.74) ; 12 (0.94)                         | 17 (29.3 ; 0.78) 28 (1.07)                              | ; 29 (29.9 ; 0.57) 70 (0.97)                      | ; 40 (40.4 ; 0.66) 103 (1.07)                         | ; 61 (37.4 ; 0.58) ; 175 (1.03)                              |
| Hypertension               | 0; 0                                   | 1 (3.2 ; 0.07) ; 1 (0.07)                              | 1 (3.3 ; 0.07) ; 1 (0.07)                         | 0; 0                                                | 1 (1.7 ; 0.04) ; (0.04)                                 | 1 2 (2.1 ; 0.03) ; (0.03)                         | 2 1 (1.0 ; 0.01) ; (0.01)                             | 1 3 (1.8 ; 0.02) ; 3 (0.02)                                  |
| Immune suppression         | 13 (44.8 ; 1.38) ; 25 (1.90)           | 12 (38.7 ; 1.14) ; 22 (1.57)                           | 13 (43.3 ; 1.30) ; 20 (1.49)                      | 9 (32.1 ; 0.90) ; 16 (1.25)                         | 22 (37.9 ; 1.10) ; 36 (1.37)                            | 55 (56.7 ; 1.48) 142 (1.96)                       | ; 52 (52.5 ; 0.94) 137 (1.42)                         | ; 90 (55.2 ; 1.15) ; 280 (1.65)                              |
| Other adrenal disorders    |                                        |                                                        |                                                   |                                                     |                                                         | 1 (1.0 ; 0.01) ; (0.01)                           | 1 3 (3.0 ; 0.03) ; (0.03)                             | 3 4 (2.5 ; 0.02) ; 4 (0.02)                                  |
| Skin/ hair changes         | 2 (6.9 ; 0.16) ; 2 (0.15)              | 4 (12.9 ; 0.30) ; 4 (0.29)                             | 3 (10.0 ; 0.24) ; (0.22)                          | 3 1 (3.6 ; 0.08) ; 1 (0.08)                         | 4 (6.9 ; 0.16) ; (0.15)                                 | 4 5 (5.2 ; 0.07) (0.07)                           | ; 5 6 (6.1 ; 0.07) ; (0.06)                           | 6 11 (6.7 ; 0.07) ; 11 (0.06)                                |
| Weight gain                | 2 (6.9 ; 0.16) ; 2 (0.15)              | 3 (9.7 ; 0.23) ; 3 (0.21)                              | 1 (3.3 ; 0.08) ; (0.07)                           | 1 5 (17.9 ; 0.42) ; (0.39)                          | 5 6 (10.3 ; 0.24) ; (0.23)                              | 6 5 (5.2 ; 0.07) ; (0.07)                         | 5 18 (18.2 ; 0.21) 20 (0.21)                          | ; 23 (14.1 ; 0.16) ; 25 (0.15)                               |

Source: EU Outputs Table 14.2.3.15a.1 and Table 14.2.3.15c.1

<div style=\"page-break-after: always\"></div>

## Adrenal suppression

In  Pool 1,  vamorolone  and  prednisone  showed  a  greater  and  dose-dependent  decrease  in  morning cortisol compared with placebo. Mean (SD) baseline morning cortisol [µg/dL] was 7.21 (2.228), 7.69 .383), 8.63 (2.999), and 8.52 (2.412) for placebo, prednisone, vamorolone 2 mg/kg, and vamorolone 6 mg/kg. The mean change from baseline to Month 6 in the respective treatment groups was: 0.69 (2.769), -5.17 (2.89), -3.58 (3.044), and -7.06 (3.028). In Pool 3, a similar dose-dependent suppression of morning cortisol was seen after 6 and 12 months of exposure.

The proportion of subjects who presented with a low morning cortisol value (&lt;100 nmol/L) suggestive of adrenal suppression at Week 24 (Pool 1) was higher for vamorolone 6 mg/kg (92.6%) than prednisone (74.1%) followed by 26.1% for vamorolone 2 mg/kg and 4% on placebo.

During study VBP15-006, the same trend was observed for patients 2 to &lt;4 years of age; however, within 12 weeks of treatment, half of the children treated with the 2 mg/kg dose and all of those treated with the 6 mg/kg dose had a morning cortisol value &lt;100 nmol/L.

ACTH stimulation testing simulating stress situations was conducted in study VBP15-004. As a result, cortisol decreased in the order: vamorolone 6 mg/kg&gt; prednisone&gt; vamorolone 2 mg/kg&gt; placebo. The vast majority of subjects on vamorolone (6 mg/day group&gt; 2 mg/kg group) had a peak cortisol level below  the  response  threshold  level  (i.e.,  &lt;18 μ g/dL  [&lt;500 nmol/L]  after  30 min  and  60 min, respectively) following ACTH stimulation, which suggests adrenal suppression.

ACTH concentrations (time of collection not controlled) showed a dose-dependent reduction from VBP15002  baseline  values  by  approximately  30%  at  VBP15-LTE  Month 18  and  24  (months 24  and  30, respectively, of the total 30-month treatment period) in the 2.0 mg/kg dominant dose group and by approximately 60% in the 6.0 mg/kg dominant dose group.

Data on vamorolone withdrawal and dose tapering have not been systematically collected in the DMD programme. Adrenal suppression was found to be reversible 2 weeks after a 2-week daily exposure in study  VBP15-002.  In  the  2  weeks  after  treatment,  no  AEs  were  reported  indicative  of  adrenal insufficiency. The effects on long-term treatment cannot be deduced from the available clinical study data. Based on the level of adrenal suppression with vamorolone, there is no need for dose tapering when  switching  from  recommended  doses  of  daily  glucocorticoids  in  DMD;  it  is  recommended  to commence  vamorolone  at  6 mg/kg  daily  to  minimise  the  adrenal  insufficiency  risk  while  switching treatments.

Cushingoid features with vamorolone in Pool 1 were generally mild in severity, were more frequently reported in the 6 mg/kg group than with prednisone (28.6% and 22.6%) and were more frequently reported after 90 days of treatment in Pool 1. The incidence for vamorolone 2 mg/kg was lower (6.7%). Only one TEAE in the vamorolone 6 mg/kg group was moderate in severity. No subject interrupted or discontinued vamorolone at either dose due to cushingoid features. One subject reported Cushingoid features  after  switching  from  prednisone  to  vamorolone  6 mg/kg.  No  subject  reported  Cushingoid features in the 002/003/LTE study where this TEAE was not elicited at each visit. Reporting of cushingoid features did not increase with longer treatment duration in Pool 3.

Only a single TEAE (serious) of adrenal insufficiency has been reported so far in a patient in the EAP. Adrenal  insufficiency  is  a  consequence  of  long-term  glucocorticoid  treatment  and  it  can  lead  to  a potentially life-threatening adrenal crisis in times of stress. To avoid adrenal crisis, hydrocortisone (or prednisone) stress dosing was permitted during an illness, injury, or surgical procedure in clinical studies. No data are available on an adequate vamorolone stress dose on top of the regular treatment dosage.

<div style=\"page-break-after: always\"></div>

## Weight gain

The AESI weight gain (including PTs increased appetite and weight increased) was found dose-related with vamorolone and higher in the 6 mg/kg group as compared to prednisone in Pool 1. The incidences for  placebo,  prednisone,  vamorolone  2 mg/kg  and  6 mg/kg  were  6.9%,  9.7%,  3.3%,  and  17.9%, respectively. Moreover, weight gain was more frequently reported after 90 days of treatment with the 6 mg/kg dose in Pool 1.

In  Pool 3,  weight  gain  was  reported  for  5.2%  and  18.2%  of  subjects  on  vamorolone  2 mg/kg  and 6 mg/kg, respectively. For 6.7% of subjects in the total vamorolone 2-6 mg/kg group, weight gain was clinically relevant and led to down-titration from 6 mg/kg to lower doses. AESI of weight gain following switch  from  prednisone  or  placebo  to  vamorolone  in  study  VBP15-004  were  not  found  increased suggesting that most of the weight gain occurred in Period 1.

Weight increased has not been reported as TEAE in children 2 to &lt;4 years in the ongoing study VBP15006.

## Weight and Body-Mass Index - Pool 1

At Pool 1 baseline, median weight, weight percentiles and z-scores were lower in the vamorolone groups than in the placebo and prednisone group. Median change in weight at Month 6 was 0.70 kg, 2.1 kg, 1.4 kg,  and  2.3 kg,  for  subjects  in  the  placebo,  prednisone,  vamorolone  2 mg/kg,  and  vamorolone 6 mg/kg group, respectively. Median change in weight percentile (z-score) was -1.52 (-0.13 SD) for placebo, 5.50 (0.32 SD) for prednisone, and 4.30 (0.22 SD) and 10.73 (0.43 SD) for vamorolone 2 and 6 mg/kg, respectively. Clinically relevant increases in weight zscore (i.e. ≥1.0 SD) at Month 6 were more frequently seen in vamorolone 6 mg/kg (25.9%) than on prednisone (3.3%) while none was seen in vamorolone 2 mg/kg or placebo.

Comparison  of  changes  in BMI between  active  groups  are  more  appropriate  since  it  accounts  for prednisone's height stunting effect since weight changes are corrected for height changes. At baseline, median BMI was similar across groups (16.09 to 16.80 kg/m 2 ), while baseline median BMI percentiles and z-scores were higher in the prednisone group compared with the other groups (range 68.16 to 81.43 and  0.47  to  0.89  SD,  respectively).  Median  BMI  change  at  Month 6  was  -0.24 kg/m 2   for  placebo, 1.13 kg/m 2   for  prednisone,  and  0.60  and  0.56 kg/m 2   for  vamorolone  2  and  6 mg/kg,  respectively. Consistently, median changes for BMI percentiles and z-scores did not show a pattern of larger changes with vamorolone 6 mg/kg compared to prednisone. However, when mean instead of median changes are compared, these were higher for vamorolone 6 mg/kg than for prednisone.

A clinically relevant change in BMI zscore defined as a change of ≥1.0 SD was observed in 1 subject on prednisone and 3 subjects in each of the vamorolone groups, all of them completing the study. The 3 cases in vamorolone 6 mg/kg led to overweight (defined as &gt;1.0 SD) or obesity (defined as &gt;2.0 SD). All reported at least one TEAE of either cushingoid features or weight gain or increased appetite reflecting the clinical relevance of the changes. According to the applicant, these cases might be confounded by COVID restrictions with remote visits in early 2020.

## Weight and Body-Mass Index - Pool 3

Change in median body weight, percentiles and z-scores increased from baseline to Month 6 and up to Month 30 in the order vamorolone 2 mg/kg&lt; vamorolone 6 mg/kg&lt; vamorolone 6 mg/kg down-titrated. Median changes in BMI, percentiles, and z-scores from baseline at Month 6 for the 2 mg/kg dominant dose group were smaller than for the 6 mg/kg group and the 6 mg/kg down-titrated group. At Month 30, median changes BMI, percentiles and z-scores were 1.10 kg/m 2 , 2.28 and -0.08 SD, respectively for the 2 mg/kg group; 1.30 kg/m 2 , 2.02, and 0.09 SD, respectively, for the 6 mg/kg group; and 7.70 kg/m 2 , 9.60 and 1.00 SD, respectively, for the 6 mg/kg down-titrated group.

<div style=\"page-break-after: always\"></div>

At Month 30, clinically relevant BMI zscore changes (≥1.0 SD) were reported in 28.6% and 16% of patients in the vamorolone 2 mg/kg and 6 mg/kg group, respectively.

Switching  from  prednisone/  placebo  to  vamorolone  2 mg/kg  and  6 mg/kg  in  VBP15-004  resulted  in increase in weight z-score in the 6 mg/kg group after the switch but not for BMI z-score.

## Weight changes in the EAP

Based  on  the  provided  weight  percentiles  and  z-score  results  from  baseline  to  last  follow-up measurement prior to DCO in the EAP for all doses combined, weight percentiles clearly increased from median 65.4 to 88.0 (with a substantial median increase in z-score from 0.4 to 1.2).

An exploratory analysis has been conducted in patients with sufficient information on weight before and after down-titration. In patients with down-titration from vamorolone 6 mg/kg to 4 mg/kg, with weight gain being the most frequently reported reason, the annual rate of change in weight percentiles (and 95% CI) decreased from 19.0 (7.5, 30.5) with vamorolone 6 mg/kg to 4.6 (-0.8, 9.9) after down-titration to 4 mg/kg. A similar annual rate of change in weight percentiles has been observed before and after patients up-titrated from vamorolone 2 mg/kg to 4 mg/kg, i.e. 12.35 (95% CI 0.42, 24.29) to 10.60 (95% CI 3.81, 17.38).

Assessment of body composition by Dual-energy X-ray absorptiometry (DXA) measurements in Period 1 in study VBP15-004 was subject to robustness issues as indicated by the applicant. However, at Week 24, increases (measured as %-change from baseline) in total body fat mass were similar in the placebo and vamorolone  2 mg/kg  groups  (10.9%  and  11.5%,  respectively),  and  higher  in  the  prednisone  and vamorolone 6 mg/kg groups (17.6% and 27.6%, respectively). The mean percentage change in lean body mass at Week 24 was +6.0% in the placebo group, +10.5% and +12.7% in the vamorolone 2 and 6 mg/kg groups, respectively, and +13.5% in the prednisone group. During Period 2 of study VBP15004 (up to Week 48), further dose-related increases in mean total body fat mass and lean body mass were noted.

## Behaviour problems

In Pool 1, behaviour problems were reported for 13.8%, 32.3%, 16.7%, and 21.4% of subjects in the placebo,  prednisone,  and  in  the  vamorolone  2  and  6 mg/kg  groups.  The  most  relevant  finding  for vamorolone 6 mg/kg was irritability as TEAE (10.7%) that did not occur with vamorolone 2 mg/kg and placebo and for 3.2% of subjects on prednisone. Clinically relevant behaviour problems were highest for prednisone (22.6%), similar for placebo and vamorolone 2 mg/kg (3.4% and 3.3%), and not reported for vamorolone 6 mg/kg. The majority of behaviour problem TEAEs were reported in the first 6 months of treatment, with only few events reported beyond 6 months. Findings on clinically relevant worsening in psychosocial adjustment based on the PARS-III (Personal Adjustment and Role Skills) scores in the controlled period of Study VBP15-004 support the findings of a reduction in the incidence and severity of behaviour problems with vamorolone 6 mg/kg compared to prednisone. The incidence of clinically relevant worsening in any subscale with vamorolone 2 mg/kg was similar to placebo.

In Pool 3, behaviour problems were reported for 25.8% of subjects in the vamorolone 2-6 mg/kg group, similarly distributed across the treatment groups. Irritability was the TEAE with the largest difference between vamorolone 6 mg/kg and 2 mg/kg (7.1% vs. 0%).

Switching from prednisone to vamorolone in VBP015-004 was not related to an increase in behavioural problems; however, as expected, an increased incidence was noted after the switch from placebo to vamorolone 6 mg/kg.

In  the  2  to  &lt;4 years  cohort  in  the  ongoing  study  VBP15-006,  the  6 mg/kg  dose  led  to  behavioural problems in 2 of 6 treated patients (33.3%).

<div style=\"page-break-after: always\"></div>

## Gastrointestinal problems

Gastrointestinal symptoms have been reported in Pool 1 with similar incidence across groups (25.8% 30%).  Nevertheless,  vomiting  was  more  frequently  reported  in  both  vamorolone  groups  (2 mg/kg: 16.7%; 6 mg/kg: 14.3%), as compared to placebo and prednisone (6.9% and 6.5%). Slightly increased incidences were reported with longer treatment duration with vamorolone 6 mg/kg but not 2 mg/kg based on Pool 3 data. No altered GI tolerability was noted after switching from placebo/ prednisone to vamorolone in study VBP15-004 after 6 months. In children 2 to &lt;4 years in the ongoing study VBP15006, the 6 mg/kg dose led to GI disorders in all of the patients treated with this dose (and in only 1 patient on the 2 mg/kg dose).

GI disorder TEAEs, i.e. abdominal pain upper, vomiting, and diarrhoea have been included in the ADR table in section 4.8 of the SmPC.

## Bone fractures / bone health

No AESI of bone fractures were reported for vamorolone in Pool 1.

Across all DMD studies (Pool 3), 10 fractures were reported in 8 subjects (4.9%); the frequency of these events was lower with vamorolone 2 mg/kg (2.1%) than with 6 mg/kg (7.1%). Upper limb fracture and spinal compression fracture were reported for three and two subjects on vamorolone 6 mg/kg, all of them being clinically relevant. No such events were reported for vamorolone 2 mg/kg. Other fractures reported were foot fracture (2 patients), humerus fracture, spinal fracture, and thoracic vertebral fracture (one  patient  each).  No  bone  fracture  AESI  were  reported  after  switching  from  either  prednisone  or placebo to vamorolone in VBP15-004.

## Vertebral Fractures by Spine X-ray Surveys and Centralised Reading

Vertebral fractures by systematic lateral spine X-ray survey have been evaluated at baseline and at 24 weeks (but not at Week 48) in 117 patients in VBP15-004 and in 39 subjects at 30 months in VBP15LTE,  respectively.  Baseline  vertebral  fractures  were  present  for  one  patient  each  in  the  vamorolone 2 mg/kg and 6 mg/kg group. Two subjects (1.7%) had a total of five vertebral fractures identified by the  Genant  semi-quantitative  method:  1/29  (3.4%)  in  the  placebo  group  and  1/31  (3.2%)  in  the prednisone group. All fractures were grade 1 (mild) and occurred in the upper- and mid-thoracic regions. No treatment-emergent fractures have been noted at Week 24 in VBP15-004 in the vamorolone groups. Four  (10.3%)  patients  had  a  total  of  seven  vertebral  fractures  after  30 months  of  treatment  in  the VBP15-LTE  study  (fractures  were  grade  1  (mild)  and  occurred  in  the  mid-thoracic  region  and thoracolumbar junction) while no baseline readings were available, which hampers interpretability of the results. Comparison of matched patient data (for 36 months of treatment) from the VBP15-LTE (i.e. 12.8% after adjustment for duration of treatment) and the FOR-DMD study data revealed significantly higher  rates  of  vertebral  fractures  in  the  external  comparison  for  daily  deflazacort  (30.4%)  and prednisone  (26.9%),  while  intermittent  prednisone  in  FOR-DMD  was  the  most  benign  regimen  with regard to vertebral fracture prevalence (0%). Of note intermittent prednisone had a lower effect on muscle strength compared to daily deflazacort and prednisone. Again, the lack of baseline lateral spine X-rays for either study, i.e. VBP15-LTE and FOR-DMD, limits interpretation of the comparison since it remains unknown whether vertebral fractures were already present at baseline.

## Bone Age Results from Hand-Wrist X-rays of the phalanges (VBP15-LTE Fracture and Bone Age Report at 30 months)

In clinical practice, bone age is considered to be delayed when it is delayed more than a year relative to chronological age. Bone age has been determined in study VBP15-LTE after 30 months of vamorolone exposure in 39 patients and it was found to be delayed in these patients (mean difference between bone

<div style=\"page-break-after: always\"></div>

age and chronological age was -1.1 ± 1. 2 years; mean CI -1.5 to -0.7). In the absence of bone age determinations at baseline, these data are difficult to interpret.

The proportion of patients who had bone ages that were more than 2 SD above or below the mean were also calculated. More than 2 SD below the mean was reported in 19/39 boys (48.7%) consistent with maturational delay outside of the normal range. 25/39 boys (64%) in VBP15-LTE had a bone age that was more than a year delayed relative to chronological age.

## Bone biomarker s

Conventional GCs rapidly induce a decrease in bone formation (decrease in osteocalcin and P1NP blood concentration) and provoke an increase in bone resorption (elevation in serum CTX concentration). In Pool 1, mean values for osteocalcin, s-CTX1, and P1NP were similar across treatment groups at baseline. At Week 24, osteocalcin and P1PN decreased from baseline in a similar magnitude in the placebo and vamorolone 6 mg/kg group and more pronounced in the prednisone group and slightly increased from baseline  to  Week 24  in  the  vamorolone  2 mg/kg  group.  CTX  was  found  increased  from  baseline  in patients on vamorolone 2 mg/kg and 6 mg/kg versus placebo, while it was decreased in patients on prednisone, which is not in line with data on prednisone in healthy adults (Kauh et al., 2012). Similar results were also found in shift analysis with more subjects in the prednisone group having shifts from normal to low in CTX as compared to the other treatment groups. The applicant explained that the increase in CTX levels with vamorolone treatment compared with prednisone does not indicate bone loss per se, but rather a higher bone turnover resulting from improved linear growth, which is supported by literature data in healthy children (Rauchenzauner et al., 2007). This is different to the interpretation in adults for whom an increase in CTX reflects resorption of bone. After the switch from prednisone to vamorolone,  osteocalcin  and  P1PN  increased  and  remained  stable,  while  CTX  also  increased  after switching to vamorolone.

In Pool 3, biomarkers are more difficult to interpret but appear to change dose-dependently. Osteoblast activity  tends  to  be  higher  with  vamorolone  2 mg/kg  as  compared  to  vamorolone  6 mg/kg,  while osteoclast activity is affected vice versa. The interpretation is hampered by the lack of a comparator and the low number of patients with evaluable data at later timepoints.

Following the switch from prednisone to vamorolone, all bone biomarkers recovered to baseline values. Bone biomarkers did not decrease in subjects with continuous vamorolone treatment.

## Bone Mineral Content (BMC) and Bone Mineral Density (BMD)

Available  data  for  %-change  in  BMD  and  BMC  during  Period 1  in  study  VBP15-004  do  not  indicate significant differences across treatment groups. The median percent change from baseline to Week 24 for lumbar spine BMC was similar in the vamorolone 2 and 6 mg/kg and placebo group (5.9%, 6.0% and 6.5%, respectively), and lower in the prednisone group (2.7%). When normalised for lumbar vertebrae area, median percent change at Week 24 in lumbar spine BMD was slightly decreased in the prednisone group (-0.32%), mildly increased in the vamorolone groups (+0.68% and +0.83% for the vamorolone 2 and 6 mg/kg groups, respectively), and highest in the placebo group (+3.6%).

At least half of the patients in each treatment group in study VBP15-004 had serial measures of BMC and BMD for either two or three time points over 48 weeks. These data support that vamorolone did not worsen Lumbar spine bone mineral content (LS-BMC) and Lumbar spine bone mineral density (LS-BMD) in the vamorolone treated patients contrasting the negative effect elicited by prednisone. The clinical relevance of the differences seen between vamorolone and placebo in both LS-BMC and LS-BMC is not clear,  but  the  median  percent  change  (increase)  appeared  lower  with  vamorolone  as  compared  to placebo.

<div style=\"page-break-after: always\"></div>

Based on post hoc analysis of LS-BMD z-scores in study VBP15-004, lumbar spinal BMD z-score adjusted for height was negative at baseline and remained stable in all treatment groups over 48 weeks.

## Growth

In general, study patients in the vamorolone programme were shorter than the reference population as shown by the negative height z-score at baseline. In Study VBP15-004, there was a baseline imbalance in median height z-scores with lower values in the vamorolone 6 mg/kg group compared with the other treatment groups (-0.54 SD for placebo, -0.56 SD for prednisone, and -0.74 and -1.04 SD for vamorolone 2 and 6 mg/kg, respectively). Median height percentiles for these groups were 29.42, 28.85, 22.99, and 14.85 for placebo, prednisone, vamorolone 2 and 6 mg/kg, respectively.

After 24 weeks of treatment, median height percentile and z-scores decreased in the prednisone group, whereas the other treatment groups showed a median increase. Median change in height percentile (zscores) in the placebo, prednisone, and vamorolone 2 mg/kg and 6 mg/kg group was 0.49, -1.79, 1.73, and 1.64 (0.13 SD, -0.10 SD, 0.07 SD, and 0.11 SD).

Change from baseline in median height z-score increased from -0.03 SD to +0.11 SD in patients, who switched from prednisone to vamorolone 2 mg/kg and from -0.13 SD to +0.05 SD in patients, who switched from prednisone to vamorolone 6 mg/kg in Period 2.

A post hoc analysis was conducted using cut offs of +/- 0.2 SD to evaluate changes exceeding random annual changes observed in ambulant glucocorticoid-naïve children with DMD (0.03 SD) and in line with annual changes observed in ambulant glucocorticoid-treated children (-0.25 SD with daily deflazacort and -0.16 SD for daily prednisolone) (Stimpson et al., 2022). In Pool 1, height z-score data reveal a majority of patients in the prednisone group with decreases (&lt;0.2 SD or -0.2 -&lt;0 SD) at Month 6 and a majority of patients in both vamorolone groups with increases (0.0 &lt;0.2 SD and ≥0.2 SD) in height z -scores. Similar proportions of subjects in the placebo and vamorolone 6 mg/kg group had increases of ≥0.2 SD in height z -score (32.1% and 34.6%) compared with 16.7% and 18.5% in the prednisone and vamorolone 2 mg/kg groups, respectively.

Across all studies in DMD (Pool 3), the change of median height z-score after 3, 6, 12, and 30 months of treatment positively increased for both vamorolone groups but remained lower in the 6 mg/kg group. Post hoc categorical analysis of Pool 3 height z-score data reveals a stable percentage of patients with ≥0.2 SD in height z -scores in the vamorolone 6 mg/kg group up to Month 30, while increasing in the 2 mg/kg group.

According  to  the  external  comparison  on  growth  in  study  VBP15-004  with  the  FOR-DMD  results  at Month 12, height z-scores slightly increased with vamorolone 2 mg/kg and 6 mg/kg (median (SD) height z-score change from baseline 0.13 (0.277) and 0.29 (0.355)) while inhibition of growth resulted from treatment with deflazacort and prednisone (median (SD) height z-score change from baseline -0.47 (0.442) and -0.32 (0.310)). A comparison after 30 months of treatment in VBP15-LTE and FOR-DMD further supports the absence of negative effect on height velocity with height z-scores remaining stable in  boys  treated  with  vamorolone  (median  change  from  baseline  was  +0.13  SD),  whereas  boys  on deflazacort and prednisone in the FOR-DMD study lost -1.14 SD and -0.66 SD, respectively.

Patients aged 2 to &lt;4 years from study VBP15-006, who have been transitioned to the EAP, were found to have a median height percentile at baseline of 26.3 (interquartile range 12.7; 36.1), and 5 of the 9 subjects for whom measurements are available so far, had a decrease in height percentile over the EAP (between -1.4 and -52.2) and 4 subjects had an increase in height percentile (between 1.2 and 17.3). Median height percentile for the last postbaseline measurement before the DCO was 12.9 (interquartile range 5.5; 40.2).

<div style=\"page-break-after: always\"></div>

## Diabetic conditions

Evaluation of biomarkers of insulin resistance after 6 months of treatment in VBP15-004 revealed a dosedependent increase in fasting insulin that was of similar magnitude in the prednisone and vamorolone 6 mg/kg  group  (median  change  from  baseline  4.47  and  5.20,  respectively),  while  the  increase  for vamorolone 2 mg/kg was similar to placebo (median change 1.44 and 0.60). There were no relevant changes in fasting glucose in any group (median change from baseline -1.00 to 2.00). Hemoglobin A1c (HbA1c) slightly increased in the prednisone group (median change 0.10) but not in the placebo and vamorolone  2 mg/kg  and  6 mg/kg  group  (-0.10,  -0.10,  and  0.00).  Nearly  half  of  all  patients  on vamorolone 6 mg/kg had shifts from normal to high insulin versus 26.9% on prednisone, 18.2% on vamorolone 2 mg/kg, and 0% on placebo. Moreover, switching from prednisone to vamorolone 6 mg/kg but not to vamorolone 2 mg/kg led to an increase in fasting insulin from normal to high. Glucose and HbA1c remained nearly unaffected after switching. The pattern observed in Pool 1 could also be found in Pool 3: fasting insulin increased and mean changes were higher for vamorolone 6 mg/kg compared to 2 mg/kg after 12 months of treatment. No relevant changes were noted for fasting glucose and HbA1c over time.

There was no evidence for an increased incidence of diabetic condition AESIs in Pool 1 for vamorolone. TEAEs in the prednisone group were glycosylated haemoglobin increased, hypertriglyceridaemia, and thirst. Dehydration was reported in a patient on vamorolone. Thirst and dehydration were not associated with hyperglycaemia. There was no pattern to suggest an increased incidence after switching from either prednisone or placebo to vamorolone. In Pool 3, 10% vs. 1% of such conditions were reported in the vamorolone 6 mg/kg vs. 2 mg/kg group (mainly blood triglycerides increased, dehydration, hyperlipidaemia, polydipsia). Diabetes mellitus type 1 was reported as SAE in a 5-year-old patient in the CUP, who was treated with vamorolone for approx. one year prior to the event. Given that type 1 diabetes is an autoimmune disease, it is unlikely that vamorolone caused the diabetic condition in this patient.

## Skin and hair changes

In Pool 1, skin and hair change AESI were reported at a low frequency (in ≤10% of subjects in each of the  groups).  Hypertrichosis  was  the  most  frequently  reported  skin  and  hair  change  AE  with  similar incidence across groups (3.2% - 3.6%). No AE were reported in more than a single subject in each group (PTs in the vamorolone groups were hypertrichosis, erythema, and skin hyperpigmentation). There were no AESI of skin and hair changes following the switch from prednisone or placebo to vamorolone. Across all  DMD studies, skin and hair change AEs were reported for 6.7% of subjects in the vamorolone 26 mg/kg group, similarly in both treatment groups. Hypertrichosis was the only AESI more frequently reported in the vamorolone 6 mg/kg than in the 2 mg/kg group (5.1% vs. 1%). No clinically relevant skin and hair change AEs were reported in the vamorolone 2-6 mg/kg group.

## Infections (Immune Suppression CMQ)

Infection and immune-mediated TEAEs under the Immune Suppression CMQ were frequently reported in the DMD clinical programme. The incidence in Pool 1 was 44.8%, 37.7%, 43.3%, and 32.1% in the placebo, prednisone, vamorolone 2 mg/kg and 6 mg/kg group. Reporting of AESI correspond largely with infections in the Infections and infestations SOC since no immune-mediated TEAEs were reported. Clinically relevant infection AESI occurred with a higher incidence in the placebo and prednisone group (10.3% and 12.9%) as compared to vamorolone 2 mg/kg (6.7%) and 6 mg/kg (0%). Clinically relevant AESI with vamorolone 2 mg/kg (one patient each) were: ear infection, gastroenteritis viral, influenza, and respiratory syncytial virus infection. A single infection in Pool 1 was serious (gastroenteritis viral, vamorolone 2 mg/kg).

In Pool 3, AESI of infections were reported for 55.2% of subjects in the vamorolone 2-6 mg/kg and similar in both dose groups. The most frequently reported infection AESI were nasopharyngitis, upper

<div style=\"page-break-after: always\"></div>

respiratory tract infection, influenza, and ear infection. Clinically relevant AESIs reported by &gt; 1 subject in the vamorolone 2-6 mg/kg group were pharyngitis streptococcal, ear infection, influenza, pneumonia, upper respiratory tract infection, otitis media, conjunctivitis, gastroenteritis viral, respiratory syncytial virus infection, sinusitis and tooth infection.

Infections did not increase after switching from prednisone or placebo to vamorolone and were obviously not related to dose (neither in Pool 1 nor in Pool 3) and lacking a specific pattern.

Immunosuppression is an important potential risk for vamorolone in the RMP and long-term data are scarce  and  uncontrolled.  Section  4.4  of  the  SmPC  includes  a  warning  on  vaccination  regarding  the response to live or live attenuated vaccines. Live or live attenuated vaccines are not recommended in patients  with  immunosuppressive  doses  of  corticoids  and  should  strictly  be  avoided.  In  the  clinical vamorolone studies, patients were required to have had evidence of chicken pox immunity confirmed either  by  the  presence  of  IgG  varicella  antibodies  or  two  doses  of  varicella  vaccine.  A  warning  has therefore been included in section 4.4 of the SmPC regarding vaccination against varicella zoster virus and a contraindication for live or live-attenuated vaccines in line with conventional GCs in the 6 weeks prior to starting treatment.

## Hypertension

An effect of vamorolone on blood pressure could not be deduced from single-or repeated-dose studies in dogs during the preclinical programme. However, it is a dose-related effect with glucocorticoids.

Mean diastolic blood pressure (DBP) at baseline in Pool 1 was similar across treatment groups (ranging from  59.64  to  63.10 mmHg).  The  percentiles  and  height-adjusted  z-scores  for  DBP  in  the  placebo, prednisone, and vamorolone 2 mg/kg and 6 mg/kg group were: 77.03 and 0.98 SD; 69.35 and 0.70 SD; 77.20 and 0.94 SD; and 68.36 and 0.65 SD, indicating high baseline DBP values in children with DMD. Over 6 months of treatment, mean DBP/ percentile/ z-score change from baseline was higher in the vamorolone 6 mg/kg group as compared to the other treatment groups. No group showed an increase or decrease in mean DBP exceeding 5 mmHg.

Mean systolic blood pressure (SBP), percentiles and z-scores for SBP at baseline was 102.03 mmHg, 73.90 and 0.90 SD for placebo, 102.45 mmHg, 74.81 and 0.91 SD for prednisone, 99.90 mmHg, 68.57 and 0.70 SD for the vamorolone 2 mg/kg, and 97.86 mmHg, 69.04 and 0.62 SD for the vamorolone 6 mg/kg group. Over 6 months of treatment, mean SBP/ percentile/ z-score change from baseline was higher in both vamorolone groups as compared to the other treatment groups. The change from baseline in the vamorolone 2 and 6 mg/kg groups was an increase of not more than 5 mmHg at different time points up to 6 months of treatment. Three patients on vamorolone 6 mg/kg had a shift from baseline Stage 1 or lower hypertension to Stage 2 hypertension for DBP and a single subject on placebo. Shifts were,  however,  similar  in  active  groups  for  SBP.  There  was  no  pattern  to  suggest  an  effect  due  to switching to vamorolone from prednisone or placebo. In Pool 3, baseline mean DBP, percentile, and zscore was 61.88 mmHg, 74.35, and 0.85 SD in the 2 mg/kg group; and 60.61 mmHg, 70.92, and 0.73 SD, respectively in the 6 mg/kg group. Baseline mean SBP, percentile, and z-score was 100.27 mmHg, 70.55,  and  0.74  SD,  respectively,  in  the  2 mg/kg  group;  and  99.52 mmHg,  69.79,  and  0.69  SD, respectively, in the 6 mg/kg group. Data up to 30 months of treatment indicate small increases in mean change from baseline over time in DBP and SBP. When adjusted for height and age (percentiles and zscores) to correct for the expected increase in blood pressure in growing children, values over time for both DBP and SBP slightly increased from baseline over 12 to 30 months in the vamorolone 2 mg/kg group but remained roughly stable for the vamorolone 6 mg/kg group. Shifts from baseline Stage 1 or lower hypertension to Stage 2 hypertension for DBP and SBP were dose dependent.

<div style=\"page-break-after: always\"></div>

## 2.6.8.3. Serious adverse event/deaths/other significant events

No deaths were reported across all DMD studies.

## Serious adverse events

The incidence of SAEs in the DMD clinical studies was low and none was considered drug-related by the investigator. In total, 8 SAEs have been reported in clinical trials in patients receiving vamorolone and none in the prednisone and placebo group in the controlled period of study VBP15-004 (Table 18).

Table 18: SAEs in vamorolone DMD studies

| Study            |   Subject | Treatment   | Preferred Term              | Location Narratives      | of   |
|------------------|-----------|-------------|-----------------------------|--------------------------|------|
| VBP15-004 Part 1 |    283901 | 2 mg/kg     | Viral gastroenteritis       | VBP15-004 Section 14.3.4 | CSR  |
| VBP15-004 Part 2 |    282702 | 6 mg/kg     | Appendicitis perforated     | VBP15-004 Section 14.3.4 | CSR  |
| VBP15-004 Part 2 |    283402 | 6 mg/kg     | Asthma                      | VBP15-004 Section 14.3.4 | CSR  |
| VBP15-003        |    231901 | 0.75 mg/kg  | Pneumonia                   | ISS Appendix 3           |      |
| VBP15-003        |    233104 | 6 mg/kg     | Dehydration                 | ISS Appendix 3           |      |
| VBP15-003        |    233105 | 6 mg/kg     | Testicular torsion; Hypoxia | ISS Appendix 3           |      |
| VBP15-LTE        |    230801 | 0.75 mg/kg  | Pneumonia                   | ISS Appendix 3           |      |
| VBP15-LTE        |    232307 | 6 mg/kg     | Myoglobinuria (2 events)    | ISS Appendix 3           |      |

One subject had an SAE in the controlled period of study VBP15-004 (SAE: viral gastroenteritis; moderate in  severity):  a  6-year-old  in  the  vamorolone  2 mg/kg  group,  who  was  hospitalised  2  months  after initiation of vamorolone with suspected dehydration secondary to diarrhoea and vomiting. Study drug was interrupted for 2 days due to vomiting and hydrocortisone stress dosing was administered. The subject was released from hospital after 3 days, study drug was resumed, and the subject continued in the study.

5  of  8  SAEs  were  reported  in  the  6 mg/kg  vamorolone  group  and  included Appendicitis  perforated, Asthma, Dehydration, Testicular torsion/ hypoxia , and myoglobinuria (2 events). For the SAE of asthma, an underlying medical history in this patient was reported and the patient also had viral bronchiolitis. The SAE of dehydration was reported in the context of influenza infection. The two SAEs of myoglobinuria occurred after excessive activity and resolved with ongoing study treatment and corrective measures (IV hydration). Two SAEs of pneumonia in subjects treated with vamorolone 0.75 mg/kg were reported in the  context  of  a  virus  infection  and  resolved  with  corrective  treatment  despite  continuous  study treatment. Overall, an infectious aetiology in 5 of 8 SAEs is to be assumed.

No SAEs were reported after switching from either prednisone or placebo to vamorolone.

As per the data cut-off 15 March 2023 in the ongoing study VBP15-006, one subject in the 4 to &lt;7 years steroid naïve group on vamorolone 2 mg/kg, experienced a serious AE of gastroenteritis viral (rated as unrelated  to  vamorolone).  One  subject  in  the  7  to  &lt;12 years  steroid-treated  group  on  vamorolone 6 mg/kg, experienced a serious AE of rhabdomyolysis (possibly related to vamorolone; treatment was interrupted for 4 days and restarted without reoccurrence).

Up to 15 March 2023, 18 SAEs have been reported among 171 patients who entered the CUP/ EAP, i.e.

- -talipes correction, vomiting/ viral infection, viral wheeze, tibial fracture, epileptic seizures (2 SAEs in one patient), rectal bleeding, and diabetes mellitus in CUP.
- -appendicitis  perforated,  food  poisoning,  metapneumovirus  infection,  viral  infection,  respiratory distress, adrenal insufficiency/ COVID-19, atrial flutter, femur fracture, and gastroenteritis viral in VBP15-EAP.

<div style=\"page-break-after: always\"></div>

SAEs either occurred in the 6 mg/kg group or 4 mg/kg group. The SAEs of vomiting/ dehydration, viral wheeze, tibia fracture, diabetes mellitus, metapneumovirus infection, rhabdomyolysis/ viral syndrome, and  adrenal  insufficiency/  COVID  infection  are  not  unexpected  given  the  pre-specified  AESIs  for vamorolone. One patient in the EAP (subject 31-313103) had 3 SAEs reported at different time points (food poisoning, metapneumovirus infection, rhabdomyolysis/ viral syndrome). The SAE of atrial flutter was  probably  caused  by  post-COVID  arrhythmia.  The  overall  clinical  and  biochemical  presentation around reporting of two epileptic seizures in a single patient on vamorolone 4 mg/kg is likely in line with  untreated  DM  type 1  at  that  time.  After  initiation  of  insulin  treatment,  no  additional  seizures occurred despite ongoing vamorolone treatment (without interruption).

## 2.6.8.4. Laboratory findings

## Haematology

In Study VBP15-004, a dose-dependent increase in lymphocyte counts was observed in both vamorolone groups (mean increase ~23% and ~50% from baseline with vamorolone 2 and 6 mg/kg, respectively) as early as Week 2 that was roughly stable thereafter. Increases in lymphocyte counts with prednisone were of similar magnitude and with a similar time course as with vamorolone 6 mg/kg. No relevant changes were observed in the placebo group. Lymphocyte counts were similar before and after switching from prednisone to vamorolone 6 mg/kg.

Changes in monocyte counts followed a pattern similar to lymphocyte counts. The pattern of leukocyte counts was similar to that for lymphocytes, although, mean changes from baseline were slightly smaller: at Week 2, these were ~11% and 23% for vamorolone 2 mg/kg and 6 mg/kg, respectively, compared with prednisone (~50%) in line with the absence of an increase in neutrophil counts in the vamorolone groups.

No relevant changes in mean neutrophil counts were observed in either vamorolone group, with counts similar to placebo at each post-baseline visit. A significant increase in mean neutrophil counts (i.e., up to 100% from baseline) was observed in the prednisone group. Neutrophil counts returned to baseline after  switching  from  prednisone  to  vamorolone.  Consistent  results  were  observed  for immature granulocytes , with no relevant changes in vamorolone groups compared to placebo at Week 24, but up to a 100% increase in the prednisone group. However, after the first 2 weeks of treatment, an increase from baseline in immature granulocytes was also observed in the vamorolone 6 mg/kg group. This early increase  was  smaller  compared  to  prednisone,  i.e.,  50%  vs.  64%  mean  increase  from  baseline  to Week 2. There was no difference between vamorolone 2 mg/kg and placebo. The initial increase seen with vamorolone 6 mg/kg progressively disappeared with continuous treatment. At Week 18 and 24, there was no difference between vamorolone 2 mg/kg or 6 mg/kg and placebo, while the increase with prednisone persisted.

In line with the mean changes in WBC, shifts from normal to high values were seen in higher proportions of  subjects  in  the  prednisone  and  vamorolone  groups  (dose-dependent)  compared  with  placebo  for leukocytes,  lymphocytes,  monocytes  and  immature  granulocytes.  Shifts  in  lymphocyte  counts  were higher in the vamorolone 6 mg/kg group compared to prednisone. A lower proportion of subjects on vamorolone  6 mg/kg  vs.  prednisone  had  shifts  from  normal  to  high  for  leukocytes,  monocytes  and immature granulocytes.

Eosinophil counts were similar in the vamorolone and placebo groups. A decrease in eosinophil counts was observed with prednisone.

In  Pool 3,  changes  from  baseline  remained  roughly  stable  with  dose-dependent  differences  in lymphocytes, leukocytes, monocytes, and neutrophils.

<div style=\"page-break-after: always\"></div>

For red blood cells, haemoglobin and haematocrit, mean changes from baseline increased with dose in the vamorolone groups, with similar increases in the 6 mg/kg vamorolone and prednisone group in Pool 1 after  6 weeks  of  treatment  up  to  the  first  24 weeks  of  treatment.  Mean  values  for  erythrocytes, haemoglobin, and haematocrit were at the respective upper reference ranges. No relevant changes in mean  values  were  observed  for  placebo.  Haematocrit  stabilised  between  Week 24  and  48  in  the vamorolone 2 and 6 mg/kg groups, while haemoglobin continued to increase in Period 2 of Study VBP15004. In those subjects switching from prednisone to vamorolone, red blood cell counts, haemoglobin, and  haematocrit  values  decreased  to  a  level  similar  to  subjects  with  continuous  vamorolone  2  and 6 mg/kg treatment. No progressive increases were noted with longer treatment duration in Pool 3.

## Chemistry

## Lipid profile

In Pool 1, there was a dose-dependent small increase in high density lipoprotein (HDL) cholesterol in the vamorolone 2 mg/kg and 6 mg/kg group and with prednisone early after starting treatment (approx. 7%, 10%, and 13% mean increase from baseline). There was no change in the placebo group. Shifts in HDL-cholesterol  from  normal  to  low  occurred  most  frequently  with  placebo  (31%),  followed  by vamorolone (~14%) and prednisone (6.5%).

Triglycerides  dose-dependently  increased  in  the  vamorolone  2 mg/kg  and  6 mg/kg  group  and  with prednisone early after starting treatment. The mean increase from baseline was approx. 20%, 25%, and 50%, respectively. No relevant change was noted in the placebo group. A similar proportion of subjects had shifts in triglycerides from normal to high for vamorolone and prednisone.

Total cholesterol increased in the vamorolone groups in line with HDL and triglyceride changes and more pronounced in the prednisone group. More subjects in the vamorolone groups (3.4% and 17.9%) had shifts from normal to high cholesterol compared with the other treatment groups. Shifts from normal to high  low  density  lipoprotein  (LDL)  solely  occurred  in  the  vamorolone  groups  (3.4%  and  10.7%, respectively).

After  the  prednisone  tapering  period  at  the  start  of  Period 2  in  Study  VBP15-004,  total  and  HDL cholesterol returned to baseline values, but rose again when vamorolone was introduced during Period 2. LDL  cholesterol  remained  unchanged.  Triglycerides  returned  to  baseline  levels  after  the  prednisone tapering period and slightly increased after starting on vamorolone.

In Pool 3, there was a small dose-dependent increase in HDL cholesterol in the vamorolone groups. For LDL, total cholesterol and triglycerides, no specific pattern could be identified.

## Liver function

Nonclinical experience with vamorolone has shown liver toxicity in mice and dogs consistent with the class of glucocorticoids for which the liver is a target organ.

In the Phase 1 MAD study VBP15-001, three liver-related TEAEs (two of which were possibly related to study drug) were reported, occurring in 1 subject on placebo, and 1 subject in the 20 mg/kg vamorolone group  presenting  each  with hepatic  enzyme  increased/ ALT  increased .  The  latter  event  prompted discontinuation from the study. One subject on vamorolone 8 mg/kg was reported with blood bilirubin increased. In Pool 1, there were two subjects with TEAEs of hepatobiliary disorders, i.e. hepatitis acute with  vamorolone  6 mg/kg  and  hyperbilirubinaemia  with  vamorolone  2 mg/kg.  Hepatitis  acute  led  to discontinuation of vamorolone. In Pool 3, one additional patient presented with hepatomegaly in the vamorolone 2 mg/kg group, and one patient was reported with a TEAE of ALT increased (vamorolone 6 mg/kg).

<div style=\"page-break-after: always\"></div>

## Mean liver parameters and shifts over time

As expected for patients with DMD, ALT and AST were abnormally high (&gt;3 x upper limit of normal (ULN)) at baseline for all subjects. Mean changes in ALT and AST were highly variable in line with muscle disease and did not per se represent changes in liver function. AP declined in the prednisone group, but no  changes  were  recorded  up  to  Week 24  for  vamorolone  groups  and  placebo.  In  Pool 1,  ALP progressively  decreased  in  the  vamorolone  6 mg/kg  group  from  Month 12  on  and  fluctuated  in  the 2 mg/kg group. There were some changes in mean GGT and glutamate dehydrogenase (GLDH) values in Pool 1 but lacking clinically relevance: mean GGT was within normal ranges at baseline and slightly increased  in  the  prednisone  and  vamorolone  6 mg/kg  group  in  Pool 1,  but  not  with  placebo  and vamorolone  2 mg/kg.  A  similar  slight  increase  in  both  vamorolone  groups  was  found  during  longer treatment in Pool 3. Mean GLDH was normal at baseline and slightly increased up to Week 24 in all treatment groups in Pool 1. No further changes were noted in Pool 3. No relevant change occurred for bilirubin. Shifts from normal at baseline to high post-baseline in Pool 1 were absent for GGT and similar across treatment groups for GLDH and there was no increase in Pool 3. During this procedure, upon inspection request, a review of liver function data and interpretation of GLDH changes in study VBP15004 has been provided, which did not change previous conclusions regarding liver function in patients treated with vamorolone.

## Significant liver parameters

In Pool 1, there were no post-baseline abnormalities for GGT. High values of GLDH were already present at baseline in individual subjects. GLDH &gt; ULN post-baseline was similar for placebo and vamorolone 2 mg/kg (34.5% and 33.3%), and higher for vamorolone 6 mg/kg and prednisone (42.9% and 54.8%). A single patient had a post-baseline increase of GLDH &gt;3x ULN (6 mg/kg vamorolone; patient with acute hepatitis), which was accompanied by GGT &gt; ULN. Bilirubin &gt; ULN post-baseline was found highest in patients on placebo (27.6%) and lower in the active treatment groups (3.6% - 16.7%). Bilirubin &gt;2 x ULN or &gt; 3 x ULN was reported in a similar low number of patients in all treatment groups.

In Pool 3, the proportion of subjects with GLDH &gt; ULN was 48.5% for vamorolone 2-6 mg/kg and 4 patients had abnormal GLDH &gt; 2 x ULN. One of them is suspect to have had liver damage (' acute hepatitis ' leading to drug interruption) since a sudden rise of ALT and AST at Week 18 was associated with an increase of GGT, GLDH and no increase in bilirubin or ALP. A second episode of liver enzyme increases was noted several weeks after restart of vamorolone leading to permanent discontinuation. Acute  hepatitis  was  not  serious,  moderate  in  intensity  and  rated  probably  related  to  vamorolone. Significant changes of &gt;ULN for total bilirubin were reported in both vamorolone groups (22.7% and 18.8%). 6.1% and 3.5% of patients had total bilirubin &gt;2x ULN.

Overall, 8 subjects met Hy's law criteria (ALT or AST &gt; 3x ULN and total BILI &gt; 2× ULN) in Pool 1. Common for subjects with DMD, AST and ALT were always &gt;3x ULN, so the bilirubin level determined whether the subject met the definition of Hy's law. Except for Subject 284503 (' acute hepatitis '), all other cases had high bilirubin level already at baseline and were not associated with a concomitant increase in GLDH, GGT, ALP or ALT/AST. The event 'acute hepatitis' (vamorolone 6 mg/kg) presented with post-baseline increase of GLDH &gt;3x ULN, which was accompanied by GGT &gt; ULN and positive but delayed de-challenge and re-challenge, and thus indicative of liver damage. It remains uncertain whether vamorolone was directly or indirectly involved in the deterioration of the patient's liver function. From the timely course and in the absence of alternative causes so far, drug-induced liver injury seems likely in this patient. Four additional cases were reported in Pool 3; all except for a single event also occurred in study VBP15-004. These patients also had high baseline bilirubin values and absence of other liver enzyme abnormalities despite ALT/ AST increases.

Hepatotoxicity is referred to as important potential risk for vamorolone in the RMP based on the wellknown  potential  of  glucocorticoids  to  exert  hepatotoxic  effects  due  to  their  stimulation  of  the

<div style=\"page-break-after: always\"></div>

glucocorticoid  receptors  in  the  liver.  Based  on  the  lack  of  a  clear  clinical  signal  for  significant  liver parameters in Pool 1, a warning on hepatic effects has not been proposed in the product information for vamorolone.

Renal  function was  assessed  in  the  vamorolone  clinical  programme  but  seems  to  be  unaffected  by vamorolone during short- and longer-term treatment and therefore, no risk minimisation measures are in place.

## Other chemistry parameters

No  relevant  changes  were  observed  in  albumin,  total  protein,  electrolytes,  ALP  and  amylase  in  the vamorolone groups. Vitamin D (25-OH-Vitamin D) was low at baseline in all groups in Pool 1 in line with observations in the DMD population. Small increases from baseline in vitamin D levels were observed in the placebo group and lower mean increases in the vamorolone 2 and 6 mg/kg groups. A small decrease from baseline was observed in the prednisone group. There was no pattern of shifts for Vitamin D in Pool 1 and Pool 3 for vamorolone. Laboratory Vitamin D data contrast the reporting of TEAEs of Vitamin D deficiency in Pool 1, which increased after switch from prednisone to vamorolone 6 mg/kg in study VBP15-004 (0% and 13.3%). However, it could be clarified that reporting of vitamin D deficiency TEAEs in study VBP15-004 was probably influenced by the late inclusion of (adult) reference ranges from the central lab into the system. Moreover, the interpretation of TEAEs is further hampered by the lack of validated reference ranges for paediatric patients in the study, and thus, TEAE reporting was related to the adult 25-OH Vitamin D reference ranges.

## Vital signs, physical findings, and other observations related to safety

In Pool 1, mean heart rate and respiratory rate were similar at baseline and did not significantly change up  to  Month 6  in  neither  treatment  group.  Moreover,  no  specific  pattern  was  noted  in  Pool 3  for vamorolone treatment groups up to Month 30.

Vamorolone did not inhibit hERG potassium currents up to the highest concentration of 20 µM in vitro (study Bio-VBP-002-hERG). Moreover, vamorolone did not impact on the cardiovascular system in mice and dogs in the preclinical programme (reference is made to the nonclinical section).

Cardio-dynamic evaluation for vamorolone was performed as part of VBP015-001 in healthy male adults. In the SAD/ MAD portions of the trial, single/ multiple doses of vamorolone of up to 20 mg/kg or placebo were administered (for 14 days in the MAD portion). Based on the pooled SAD and MAD analysis, an effect  on  ∆∆QTcF  exceeding  10 ms  could  be  excluded  within  the  full  observed  range  of  plasma concentrations of vamorolone. Vamorolone at the tested doses produced a small heart rate increase but had no effect on cardiac repolarisation (QTcF) or other ECG parameters.

Descriptive statistics of the QTcF interval in Pool 1 demonstrated small mean decreases up to Month 6 in the placebo and prednisone group (~ -5 msec) and small mean increases in both vamorolone groups (~ +4 msec in the 2-6 mg/kg vamorolone group). In Pool 3, small mean increases from baseline in QTcF were dose-related. Mean changes from baseline in ECG parameters in Pool 1 were small and not clinically meaningful. The majority of subjects (96.2% on vamorolone 2 mg/kg and 100% for other treatment groups) had a maximum QTcF value below the range of potential clinical concern (≤450 msec), and 84.6%  to  100%  of  patients  across  treatment  groups  had  a  maximum  on-treatment  increase  from baseline for QTcF of &lt;30 msec. Suspicious ECG results of 11 subjects from Pool 3, including those with perceived QTcF &gt;60 msec and &gt;500 msec were reviewed by an external cardiologist. None of these subjects was confirmed to have had an abnormal ECG in clinical studies with vamorolone.

In  Pool 3,  a  maximum  QTcF  increase  from  baseline  of  &gt;30  -  &lt;60 msec  was  twice  as  high  in  the vamorolone 6 mg/kg group as compared to 2 mg/kg, while the incidence of maximum QTcF increase from baseline of &gt;60 msec was low and similar between groups (3.9% in the combined group). A single

<div style=\"page-break-after: always\"></div>

subject  on  vamorolone  6 mg/kg  also  had  an  absolute  QTcF  of  &gt;500 msec.  No  related  TEAEs  were reported in these patients and drug was not discontinued based on these outliers.

## 2.6.8.5. In vitro biomarker test for patient selection for safety

N/A

## 2.6.8.6. Safety in special populations

## Intrinsic factors

Age: Baseline age &lt;5 years and ≥5 years: higher incidences/ rates of severe TEAEs (7.8% vs. 3%), AESIs (82.8% vs. 73.7%), and SAEs (6.3% vs. 2%) were reported in the younger versus the older age group. The proportion of subjects with behaviour problems and GI symptoms was &gt;10 pp higher in the younger than the older subgroup. Additionally, the event rate for infection TEAEs grouped under the Immune Suppression CMQ was higher in the younger than the older subgroup (&gt;0.1 difference between event rates). Instead, bone fractures, cushingoid, and weight gain occurred more frequently in the older subgroup.

Race: The majority of DMD patients were Caucasian (~86%). The numbers of Asians, Hispanics, Blacks, and patients of other races were too low to draw meaningful conclusions.

Weight: Safety  according  to  baseline  weight  z-scores  either  below  or  above  median  revealed  the incidence of drug-related TEAEs (&gt; 10 pp difference across the subgroups) as well as the event rate to be higher in the heavier subgroup whereas total number of TEAEs was more frequent in the lower weight subgroup. As to be expected, subgroups by weight z-scores differed in that AESIs in line with metabolic conditions, i.e., cushingoid features, diabetic conditions, and weight gain, were more frequently reported in patients with weight z-scores above the median.

Height: Safety according to baseline height z-scores either below or above median revealed that the incidence of drug-related TEAEs, non-mild TEAEs, clinically relevant TEAEs, and TEAEs leading to dose reduction  were  more  frequent  in  the  taller  subgroup.  Incidences  of  AEs,  AESI,  and  AEs  leading  to temporary dose interruption were more frequent in the shorter subgroup.

BMI: Safety according to baseline BMI z-scores either below or above median revealed the incidence of non-mild TEAEs and clinically relevant TEAEs were more frequent in the lower BMI subgroup (&lt; 10 and ≥ 5 pp difference across the subgroups for each type of event). The incidences of diabetic conditions and weight gain were higher in the higher BMI subgroup (&gt;10 pp higher for weight gain).

Renal impairment: There is no clinical experience in patients with renal impairment. Vamorolone is not excreted unchanged via the kidney and increases in exposure due to renal impairment are considered unlikely.

Hepatic impairment: The effect of moderate hepatic impairment on vamorolone was studied in humans (Study VBP15-HI). Vamorolone Cmax and AUC0-inf values were approx. 1.7 and 2.6-fold higher in subjects with moderate hepatic impairment (Child-Pugh B) compared to age-, weight-, and sex-matched healthy adults. A post hoc analysis of the VBP-HI study data was performed and based on these data, exposure parameters of subjects with mild HI might be even less affected and should represent an increase in vamorolone concentration of between 10 and 15% compared to those of individuals with normal liver function. Therefore, the applicant recommends to only reduce the dose of vamorolone by one-third in patients with moderate hepatic impairment (Child-Pugh B), i.e., the 6 mg/kg dose should be reduced to 2 mg/kg  for  patients  up  to  40 kg  and  to  80 mg  for  patients  &gt;40 kg.    Moreover,  and  based  on  the

<div style=\"page-break-after: always\"></div>

exposure increase to vamorolone in patients with moderate HI, a contraindication for patients with Child Pugh C has been implemented in the SmPC.

## Extrinsic factors

Geographical region (USA [including Canada and Australia] and Europe [including Israel])

The incidence of non-mild AEs, clinically relevant TEAEs, and TEAEs leading to dose reduction (&gt; 10 pp difference  across  the  subgroups)  and  severe  TEAEs,  SAEs  and  TEAEs  leading  to  temporary  dose interruption (~&lt; 10 and ≥ 5 pp difference across the subgroups) were more frequent in the USA region. Behaviour problems, Infections grouped as Immune suppression CMQ and Weight gain were reported &gt; 10 pp more frequently in the USA region, whereas Cushingoid features were more &lt; 10 and ≥ 5 pp more frequent in the Europe region.

## 2.6.8.7. Immunological events

N/A

## 2.6.8.8. Safety related to drug-drug interactions and other interactions

Since oxidation via CYP3A4 was observed in vitro , an in vivo DDI study was conducted to assess the effect  of  a  strong  CYP3A4  inhibitor  (itraconazole)  on  the  PK  of  vamorolone  (VBP15-DDI).  The  study showed a weak effect of itraconazole on vamorolone PK (1.45-fold increase of vamorolone AUC and no significant effect on Cmax) and confirmed that metabolism via CYP3A4 is a minor pathway for vamorolone. No dose adjustment is recommended when vamorolone is co-administered with CYP3A4 modulators.

Vamorolone induces CYP3A4 in vitro and DDI with sensitive CYP3A4 substrates cannot be excluded. Coadministration of vamorolone with such compounds may lead to decrease the plasma concentrations of the substrates and appropriate dose adjustments may be necessary for these drugs.

Vitamin D is frequently administered in patients with DMD to prevent demineralisation of bone. Whether or not vamorolone causes a decrease in the synthesis of active vitamin D and impairing its biological action at the tissue level similar to glucocorticoids remains unknown.

## 2.6.8.9. Discontinuation due to adverse events

The  incidence  of  discontinuations  from  study  drug  due  to  AEs  was  low  across  all  studies.  Two  of 164 subjects treated with vamorolone (Pool 3) had a TEAE that led to study drug discontinuation:

- Subject 232102 (vamorolone 2 mg/kg) reported a TEAE of Muscular weakness (with repeated falls), which was moderate in severity and rated unrelated to vamorolone, while leading to study drug discontinuation upon request of the parent/guardian: AE onset was on VBP15-LTE Study Day 545 (Day 741 from the start of VBP15-002), approximately 6 weeks after down titrating vamorolone from 6 to 2 mg/kg due to weight gain. Muscular weakness is  most likely  to  be explained by progression of the underlying disease in this patient and probably ineffectiveness of the lower vamorolone dose.
- Subject 284503 (vamorolone 6 mg/kg) was discontinued from Period 2 of Study VBP15-004 due to a moderate TEAE of Hepatitis acute, which was the second episode of liver enzyme increases over half a year with vamorolone treatment and after drug interruption for the first episode.

In addition, 2 subjects discontinued a clinical pharmacology study due to a TEAE, 1 receiving placebo and 1 receiving vamorolone 20 mg/kg: Subject 2027 (vamorolone 20 mg/kg) was discontinued from

<div style=\"page-break-after: always\"></div>

Study VBP15-001 due to a TEAE of ALT increased, with onset on Day 7 and dosing discontinued on Day 10. The increase in ALT peaked at Day 12-14 and then returned to within normal limits. The TEAE was considered related to vamorolone.

## 2.6.8.10. Post marketing experience

N/A

## 2.6.9. Discussion on clinical safety

From the safety database, all the adverse reactions reported in clinical trials have been included in the Summary of Product Characteristics.

The main body of evidence with regard to clinical safety for vamorolone in the treatment of DMD for the to-be approved dose 6 mg/kg includes 163 patients aged 4 to &lt;7 years at study entry (the maximum age was 9.6 years at the end of VBP15-LTE) and dosed in four clinical studies that have been pooled for safety  analysis.  The  most  relevant  safety  data  derives  from  Pool 1  providing  comparison  between vamorolone fixed doses 2 mg/kg and 6 mg/kg, placebo and prednisone 0.75 mg/kg for 24 weeks of treatment based on the phase 2b study VBP15-004, Period 1. For Period 2, patients were switched from either  placebo  or  prednisone  to  vamorolone  2 mg/kg  or  6 mg/kg  or  remained  on  the  initial  dose  of vamorolone  and  continued  treatment  for  an  additional  20 weeks.  Switch  data  enable  detection  of changes in adverse events after the switch.

Long-term safety of vamorolone currently relies on data from patients continuously treated in study VBP15-004 up to 48 weeks, and open-label treatment in study VBP15-LTE (combined VBP15-002, 003, and  LTE)  forming  Pool 3,  which  allows  for  evaluation  of  clinical  safety  for  approx.  30 months  of vamorolone exposure. Between open-label studies -002 and -003, and -003 and -LTE there was a mean drug-free period of 18.27 days for 48 subjects. Moreover, long-term data for 171 patients, who have completed one of the vamorolone clinical studies (also including patients from study VBP15-006), are currently collected in EAPs (USA, Canada, and Israel) and CUPs. Therefore, the overall age range of patients in these programmes up to 15 March 2023 spans from 2 to 17 years. As per the updated data cut-off 21 July 2023, the applicant clarified that 83 of 99 subjects are being treated in one of three EAPs. A majority of 16 patients, who withdrew from the EAP did so because of subject or parent/ guardian decision, while only a single patient withdrew because of a TEAE (weight gain).

Updated safety data have been provided from the ongoing 12-week open-label study VBP15-006 for the age group 2 to &lt;4 years (data cut-off 21 July 2023) in support of the originally claimed indication, i.e. patients 2 years and older. No new data became available for age groups 7 to &lt;12 years (steroid-naïve and steroid-treated) and 12 to &lt;18 years (steroid-naïve and steroid-treated). The safety profile appears not different for the older age groups 7 to &lt;12 years and 12 to &lt;18 years compared to the reference population (4 to &lt;7 years), with the limitation that pubertal development has not been evaluated for vamorolone so far.

The safety of vamorolone in the youngest patients (i.e. 2 to &lt;4 years) is based on few available data (10 patients on vamorolone 2 mg/kg, and 6 patients on 6 mg/kg) suggesting that the 6 mg/kg dose is more likely to cause AEs of interest in these patients, i.e., behavioural events and adrenal suppression. Thus, titration from a lower dose (2 mg/kg) to an intermediate dose (4 mg/kg) was initially proposed until patients turn 4 years of age when treatment with 6 mg/kg is recommended. Longer-term safety data for 15 patients 2 to &lt;4 years have been made available for those having been transferred from VBP1-006 to an EAP. These subjects have a median of 9 months duration of treatment with vamorolone with a maximum of 15 months, mainly for the 4 mg/kg intermediate dose. Although, reporting of TEAEs

<div style=\"page-break-after: always\"></div>

was high in the 6 mg/kg dose group during the first 12 weeks of treatment, all these patients entered the EAP and remained on the 6 mg/kg dose. No unexpected or serious AEs have been reported with most of the TEAEs being infections. No psychiatric or endocrine events have been reported in the EAP at neither dose, while any effects on height and weight are difficult to interpret for the 2 to &lt;4 years group based on the limited data. Nevertheless, in the view of the CHMP objection to the proposed posology, the applicant agreed to restrict the indication to DMD patients aged 4 years and above.

In  VBP15-LTE,  vamorolone  doses  could  be  up-  or  down-titrated  after  the  first  month  of  treatment. Consequently, almost all patients with initial doses of 0.25/ 0.75/ 2 mg/kg had up-titration. 10 out of 11 subjects who escalated to 6 mg/kg had to reduce it again to a lower dose due to an increase in weight. 4 patients had an intermediate dose of 4 mg/kg at study end. Moreover, a majority of subjects in the EAP/ CUPs (of all ages) are currently dosed with 4 mg/kg. Efficacy and safety for the 4 mg/kg vamorolone dose has not been systematically evaluated. However, available data from patients currently treated in the EAP indicate that safety for this dose for some of the safety issues is probably closer to the 6 mg/kg, e.g. for effects on the HPA axis (based on updated PKPD modelling of morning cortisol), and for weight increased. TEAEs of weight increased remain the most common reason for dose reductions from 6 to 4 mg/kg  in  the  EAP.  Meanwhile,  the  recommendation  is  to  lower  the  dose  to  4 mg/kg  in  case  of tolerability issues or further down to 2 mg/kg, when tolerability issues are not sufficiently mitigated. Based on the experience in the EAPs, down titration from either 6 mg/kg or 4 mg/kg to 2 mg/kg was reported for 8 patients mainly due to weight gain. Given that the maintenance of effect for the 2 mg/kg dose (based on the ROS1 formulation) has been questioned, the posology section further advises to maintain patients at the highest tolerated dose within the dose range. Drug interruptions have more frequently been reported with the 4 mg/kg dose as compared to 6 mg/kg in the EAPs; however, this was explained by a higher rate of infection in this dose group, which required hydrocortisone stress dosing and thus, temporary interruption of vamorolone has been considered by the treating physicians. External data  from  study  FOR-DMD  comparing  three  different  glucocorticoid  regimens  (i.e.,  daily  prednisone 0.75 mg/kg, intermittent 10 days on-off prednisone, and deflazacort 0.9 mg/kg) are deemed generally acceptable by CHMP to overcome limitations with regard to the short -term prednisone control in study VBP15-004. However, this external comparison still underlies different methods or sensitivity in safety data collection and has to be cautiously interpreted.

Overall, 58 patients with DMD had exposure to vamorolone 2 mg/kg and 6 mg/kg in the controlled Part 1 of study VBP15-004, while 4 patients discontinued prior to Week 24 due to parent or physician decision. 28 and 27 patients had at least 6 months of exposure to vamorolone 2 mg/kg and 6 mg/kg. The safety population for the uncontrolled study VBP15-LTE includes 46 subjects.

The median duration of exposure was 11 months for subjects, who received vamorolone 2-6 mg/kg across  all  DMD  studies  with  a  cumulative  exposure  of  ≥12 months  for  100 patients  (61.3%)  and ≥30 months for 20 patients (12.3%). Based on the dominant dose definition, safety data of ≥12 months for 2 mg/kg and 6 mg/kg vamorolone are available for 35 and 54 patients, respectively. The exposure in patients &lt;5 years and ≥5 years to both vamorolone doses was balanced. Patients 2 to &lt;4 years from VBP15-006, who continue in an EAP, have at present a median duration of treatment with vamorolone of 9 months, and it is highest for the 4 mg/kg group.

In Pool 1, a majority of subjects (&gt;83%) across active treatment groups reported at least one TEAE (versus 79.3% in the placebo group). No subject on vamorolone experienced a severe TEAE or TEAE leading  to  permanent  study  treatment  discontinuation.  Half  of  the  overall  TEAEs  in  the  combined vamorolone 2-6 mg/kg group were rated related to treatment. Clinically relevant TEAEs (i.e. those being at least moderately severe or leading to study withdrawal or being SAEs) with vamorolone 2-6 mg/kg compared favourably to both, placebo and prednisone (20.7%, 31%, and 42%). AESI based on the known side effects of glucocorticoid drugs were reported in up to 78.6%. Onset of AESI in Pool 1 was reported to be within the first 6 months of treatment based on Kaplan-Meier curves.  Specifically, the

<div style=\"page-break-after: always\"></div>

overall incidence of AESI was higher during the first 90 days of treatment in either group in Pool 1 of study  VBP15-004  as  compared  to  AESI  occurring  after  90 days  (and  up  to  6 months),  with  some differences between AESI groups. Cushingoid features with vamorolone were more frequently reported after 90 days and weight gain was more frequently reported for the 6 mg/kg dose (but not for 2 mg/kg) after 90 days of treatment as compared to the first 90 days (10.7% vs. 7.1%).

No additional concern derives from longer treatment duration with vamorolone in Pool 3 based on limited and  uncontrolled  data  with  regard  to  the  overall  incidence  of  TEAEs  and  drug-related  TEAEs.  The incidences slightly increased during longer treatment duration for some SOCs/ PTs, which can at least in parts  be  explained  by  the  underlying  disease.  Likewise,  no  additional  safety  concern  derived  from ongoing treatment with vamorolone in patients 2 to 4 years from the preliminary safety data in the EAPs.

No death occurred in the clinical DMD studies and from the EAPs up to the data cut-off. Eight SAEs were reported in patients on vamorolone and none in the prednisone and placebo group. None was rated related to vamorolone, but all led to hospitalisation. One SAE was recorded in the vamorolone 2 mg/kg group (viral gastroenteritis) in Pool 1, while 7 SAEs were reported in the uncontrolled studies. 5 of 8 SAEs were reported in the 6 mg/kg vamorolone group and included Appendicitis perforated, Asthma, Dehydration, Testicular torsion/ hypoxia, and myoglobinuria (2 events). An infectious aetiology in 5 of 8 SAEs  has  to  be  assumed.  In  a  majority  of  SAEs,  hydrocortisone  stress  dosing  was  reported,  and corrective treatment was applied. Vamorolone either remained unchanged or was interrupted for a short period. None of the SAEs led to discontinuation of study drug. 18 SAEs have been reported so far among 171 patients in CUPs/ EAPs as per the March 2023 DCO and roughly complied with the defined AESIs. One SAE of atrial flutter was probably caused by post-COVID arrhythmia. Two SAEs of epileptic seizures likely occurred after untreated diabetes mellitus type 1 and are thus not causally related to vamorolone. Moreover, two SAEs have meanwhile been reported from the ongoing study VBP15-006, one in a subject aged 2 to &lt;4 years (viral gastroenteritis) and one in a subject 7 to &lt;12 years from the corticosteroidtreated group receiving 6 mg/kg vamorolone (rhabdomyolysis; possibly related).

Four subjects discontinued treatment due to TEAEs, one on prednisone and three on vamorolone: one subject  in  VBP15-LTE  with muscular  weakness on  2 mg/kg  vamorolone  after  down-titration  from 6 mg/kg (rated unrelated by the investigator but could be indicative of a lack of efficacy); one subject in Period 2 of VBP15-004 on 6 mg/kg vamorolone due to a moderate TEAE of hepatitis acute (probably related); one subject in VBP15-001 on 20 mg/kg vamorolone due to ALT increased (related).

When focussing on the recommended dose of 6 mg/kg, the most commonly reported TEAEs reported in ≥10% of patients were Cushingoid (28.6%), vomiting (14.3%), fall (10.7%), weight increased (10.7%), Vitamin D deficiency (10.7%), and irritability (10.7%). Of these, Cushingoid, Vitamin D deficiency, and headache dose-dependently increased.

No noteworthy concerns arise from the incidences of TEAEs after switching from prednisone or placebo to vamorolone 2 mg/kg and 6 mg/kg, except for an increase in Vitamin D deficiency and fatigue after switching from prednisone to vamorolone.

ADRs with vamorolone were based on adverse events for the recommended 6 mg/kg dose from Pool 1 taking  into  account  dose-response  and  pharmacological  plausibility.  Evaluation  of  laboratory  data additionally identified blood triglycerides increased and cortisol decreased as potential ADRs, but these have not been included in the ADR table in section 4.8 of the SmPC. Upon request, it could be clarified that the increase in blood triglycerides was not rated as clinically significant. Moreover, a decrease in morning cortisol is a pharmacodynamic effect rather than an adverse drug reaction, which is described in other parts of the SmPC (section 5.1 and 4.4). The presentation of ADRs and frequency categorisation in section 4.8 has been revised upon request and adequately reflects Pool 1 data.

The relevant safety concerns for vamorolone pertain to the following AESI:

<div style=\"page-break-after: always\"></div>

Vamorolone causes a dose-dependent adrenal suppression in line with low morning cortisol levels in Pool 1 that was even more pronounced as with prednisone. Mean change from baseline at Week 24 was highest in the vamorolone 6 mg/kg group, followed by prednisone and vamorolone 2 mg/kg. In support of  this  finding  is  the  number  of  patients  with  a  morning  cortisol  &lt;100 nmol/L  (indicative  of  adrenal insufficiency) that was almost 100% for vamorolone 6 mg/kg and 74% in the prednisone group. ACTH stimulation testing further confirmed inability to generate an adequate cortisol level in response to severe stress  in  the  order  vamorolone  6 mg/kg&gt;  prednisone&gt;  vamorolone  2 mg/kg&gt;  placebo.  Adrenal suppression  remained  roughly  stable  at  later  time  points  based  on  Pool 3  data.  Switching  from prednisone to vamorolone did not result in an increase in adrenal suppression, which supports direct switch from prednisone 0.75 mg/kg to vamorolone 6 mg/kg in clinical practise. In the 2 to &lt;4 year-old patients in study VBP15-006, a TEAE of adrenal suppression was reported in half of those treated with 6 mg/kg, while all patients treated with 6 mg/kg had a morning cortisol below 100 nmol/L at Week 12. In line with adrenal suppression, Cushingoid features with vamorolone in Pool 1 were more frequently reported in the 6 mg/kg group compared to prednisone (28.6% vs. 22.6%) and less in the 2 mg/kg group (6.7%). Events were predominantly mild, did not lead to treatment discontinuation, and did not increase with longer treatment duration in Pool 3. TEAEs of adrenal insufficiency have not been reported with vamorolone in the clinical DMD programme, except for a single SAE in the EAP in a patient, who did not  receive  hydrocortisone  supplementation  in  the  context  of  a  stress  situation.  Hydrocortisone  (or prednisone) stress dosing was permitted in clinical studies during an illness, injury, or surgical procedure to  avoid  an  adrenal  crisis.  In  line  with  the  study  protocol  of  VBP15-004  reflecting  clinical  practice recommendations  for  management  of  the  risk  for  adrenal  insufficiency  after  long-term  systemic glucocorticoid treatment (Bowden at al. 2019), information has been included in section 4.4 of the SmPC. This includes the need for dose tapering and the risk of aprupt withdrawal of vamorolone, as well as symptoms  of  adrenal  crisis  adequately  reflected  in  the  SmPC.  Dose  tapering  and  withdrawal  of vamorolone have not been evaluated systematically in the clinical programme. It is expected that adrenal suppression persists depending on the dose and duration of treatment. Adequate information has been included in SmPC section 4.2. In order to further raise the awareness and early recognition and treatment of  adrenal  crisis,  section  4.4  includes  an  advice  to  a  patient  alert  card  for  patients  treated  with vamorolone as an additional risk minimisation measure.

Treatment with vamorolone is associated with a dose-dependent increase in weight and BMI percentiles/ z-scores, which was not readily expected given the differential profile of vamorolone on glucocorticoidlike effects. Weight gain as AESI (combined increased appetite and weight increased) was reported more frequently in the vamorolone 6 mg/kg group as compared to prednisone or vamorolone 2 mg/kg. During VBP15-LTE,  11  of  41  subjects  (i.e.  6.7%  of  the  overall  study  population)  were  down-titrated  from 6.0 mg/kg due to a clinically relevant TEAE of weight increased in 10 subjects ('6 mg/kg down-titrated group' in Pool 3). BMI percentiles and z-scores reported in order to account for the stunting effect of prednisone on height indicated greater mean increases from baseline to Month 6 for both vamorolone 2 mg/kg and 6 mg/kg compared to prednisone. Clinically relevant changes in BMI z-scores at Month 6 of ≥1.0 were observed more frequently with vamorolone 2 mg/kg and 6 mg/kg compared to prednisone (11.1%, 11.5%, and 3.3%). In a majority of these subjects, cushingoid features were present. Switch from prednisone led to a decrease in median BMI z-score from baseline with vamorolone 2 mg/kg and further  increase  with  vamorolone  6 mg/kg.  As  expected  with  longer  treatment  of  up  to  30 months, median BMI percentile and z-score changes fluctuated up to Month 30.

Evaluation from the EAPs as per the DCO 21 July 2023 revealed that weight percentiles clearly increased from a baseline median 65.4 (start of EAP) to last follow-up measurement median 88.0. The median zscore increased from 0.4 to 1.2.

An analysis of the effect of down- and up-titration of vamorolone on weight changes was conducted by categorising patients to the High Dose Analysis set (6 mg/kg, reduced to 4 mg/kg) and to the Low Dose

<div style=\"page-break-after: always\"></div>

Analysis set (2 mg/kg, increased to 4 mg/kg). From the available plots for the HDS it appears that in a number of these patients dose reduction from 6 to 4 mg/kg led to a plateau in weight percentile (no additional  increase  in  weight  percentile  after  dose  reduction).  This  is  additionally  supported  by  the calculation of the annual rate of change in weight percentiles that is found to be lower after the switch from 6 to 4 mg/kg in the HDS. From the available plots for the LDS it appears that the dose increase from 2 to 4 mg/kg does not prevent from further increase in weight percentiles. This is supported by the fact  that  the  annual  rate  of  change  in  weight  percentiles  remains  similar  after  the  switch  from  2  to 4 mg/kg in the LDS. While this analysis is informative regarding weight changes in a very small sample size with only 17 and 16 subjects included, it cannot reliably reassure that the proposed dose reduction from 6 mg/kg to 4 mg/kg is sufficient to mitigate further weight increases with vamorolone given that the 4 mg/kg dose (ROS2 formulation) is assumed to provide ~79% of the exposure of the 6 mg/kg dose with the ROS1 formulation in the 4 to &lt;7-years-old.

Results of body composition with DXA at Week 24 showed an increase in total body fat that was highest in the vamorolone 6 mg/kg group. Of interest is a concomitant increase in lean body mass, which was in a similar range across active treatment groups (10.5% - 13.5%). Based on the DXA body composition measures alone, it cannot be differentiated whether the increase in lean body mass derives from an increase in muscle mass or indicates a certain degree of fluid retention.

Patients receiving vamorolone should be informed and monitored for the possibility of important weight gain  and  provided  with  age-appropriate  dietary  advice;  adequate  information  has  been  included  in section 4.4 of the SmPC.

The increase in weight and BMI needs to be set into context of an obvious lack of vamorolone to inhibit growth, which is a well-known adverse outcome of classical GCs like prednisone. While after 24 weeks of treatment patients on prednisone lost -0.1 SD in height z-score, vamorolone led to positive median changes from baseline (0.07 SD for 2 mg/kg and 0.11 SD for 6 mg/kg), which was similar to placebo (0.13 SD). Switching from prednisone after 24 weeks to vamorolone led to an increase in median height z-score up to Week 48. In Pool 3, the changes of median height z-scores remained positive after 3, 6, 12, and 30 months of treatment with vamorolone 2 mg/kg, with slightly lower z-scores in the 6 mg/kg group.  Furthermore,  external  comparison  of  median  height  z-scores  in  VBP15-004  to  the  FOR-DMD groups at Month 12 underlines the growth stunting effect of deflazacort and prednisone as compared to vamorolone. Comparison over 2.5 years (VBP15-LTE vs. FOR-DMD), revealed stable median height zscores with vamorolone (+0.13 SD), and growth stunting with deflazacort and prednisone-treatment (1.14 SD and -0.66 SD).

Height changes for children 2 to &lt;4 years from study VBP15-006 over 12 weeks were inconclusive.

Children 2 to &lt;4 years, who entered one of the EAPs, and for whom two measurements from EAP baseline to the first dose increase to 4 mg/kg are available as per the DCO (i.e. for 9 patients), height percentiles (height z-scores have not been reported) revealed increases but also decreases. While the decreases generally reflect natural variability, a single patient had an unexpected high decrease in height percentile (-52.2), which does not concur with the height percentile changes that have been presented for all age groups in the EAPs, i.e. the median height percentile that could be retrieved for the majority of subjects in  the  EAPs  as  per  the  DCO  (n=99)  was  22.7  at  first  measurement  in  the  EAP  and  30.5  at  last measurement before data cut-off, suggesting that there is no negative effect of vamorolone on growth. The  outlier  in  a  single  patient  might  be  attributed  to  the  known  limitations  regarding  height measurements in young paediatric patients, and especially those with DMD (non-standardised height measurements, scoliosis, etc.).

Bone health has been extensively evaluated in the clinical programme: no TEAEs/ AESI of bone fracture were reported for vamorolone over six months of treatment in Pool 1. In Pool 3, bone fracture AESI were reported  more  frequently  in  the  vamorolone  6 mg/kg  than  in  the  2 mg/kg  group  (7 patients  vs.

<div style=\"page-break-after: always\"></div>

2 patients).  Clinically  relevant  bone  fractures  (including  upper  limb  fracture,  foot  fracture,  spinal compression  fracture  and  humerus  fracture)  were  reported  in  1%  and  6.1%  of  subjects  in  the vamorolone 2 mg/kg and 6 mg/kg group. Four patients had spinal/ spinal compression fractures and thoracic vertebral fractures. Vertebral fractures are common in DMD and often remain asymptomatic and thus undetected. Spine X-ray survey was performed at baseline and at 24 weeks (VBP15-004) and 30 months (VBP15-LTE), respectively. While no vertebral fractures were noted in patients on vamorolone at Week 24 in VBP15-004, 10.3% of patients on vamorolone after 30 months of treatment in VBP15-LTE had vertebral fractures. Since no baseline readings were available, it remains unknown whether vertebral fractures in these patients were already present at baseline.

Comparison of spinal fractures reported by central review in Study VBP15-LTE (n=39) with a matched corticosteroid-treated  historical  control  cohort  from  FOR-DMD  (n=70)  revealed  a  lower  frequency  of vertebral fractures for vamorolone compared with daily prednisone and deflazacort based on a 30 months adjusted treatment duration. Again, the lack of baseline lateral spine X-rays for either study, i.e. for VBP15-LTE and FOR-DMD, severely limits interpretation of the comparison.

Comparison of bone age by hand X-rays in VBP15-LTE and chronological age after 30 months (2.5 years) of treatment with vamorolone revealed a delay of -1.1 ± 1.2 years, which does not favourably compare to literature data with a delay of -1.6 ± 2.2 years after 5.2 years of GC treatment in patients with DMD. Moreover, the bone age delay noted with vamorolone in study LTE after 30 months of treatment seems to be also more pronounced than noted for GC naïve patients with DMD (Annexstad et al. 2019).

Biomarkers of bone remodelling have been analysed but interpretation is difficult. In Pool 1, osteoblastrelated  bone  biomarkers  were  found  significantly  depressed  by  prednisone  while  the  decrease  from baseline in the placebo and vamorolone 6 mg/kg group was less pronounced, and even slightly increased with vamorolone 2 mg/kg at Week 24. Interpretation of bone resorption parameter CTX is even more challenging since it was found decreased with prednisone and increased for placebo and vamorolone in Pool 1. Bone metabolism in children is complex, and greatly differs from that of adults as it reflects both skeletal growth and modelling; thus, increase in CTX is not necessarily associated with bone resorption in  paediatric  patients  but  rather  indicates  bone  turnover  resulting  from  improved  linear  growth (Rauchenzauner et al., 2007). This has been supported by shift analysis at Week 24 resulting in few shifts  from  normal  to  low  in  the  vamorolone  groups  for  P1NP,  osteocalcin  and  CTX  compared  to prednisone (shifts from normal to low were significant for prednisone after 24 weeks).

After  switching  from  prednisone  to  vamorolone,  osteoblast  markers  improved  on  vamorolone,  while osteoclast biomarker likewise increased probably indicative of bone turnover. Over up to 30 months of treatment  with  vamorolone,  osteoblast  activity  tended  to  be  higher  with  vamorolone  2 mg/kg  as compared to vamorolone 6 mg/kg, while osteoclast activity was affected vice versa.

The median percent change from baseline to Week 24 for lumbar spine BMC was similar in the vamorolone 2 and 6 mg/kg and placebo group (5.9%, 6.0% and 6.5%, respectively), and lower in the prednisone group (2.7%). When normalised for lumbar vertebrae area, median percent change at Week 24 in lumbar spine BMD was slightly decreased in the prednisone group (-0.32%), mildly increased in the vamorolone groups (+0.68% and +0.83% for the vamorolone 2 and 6 mg/kg groups, respectively), and highest in the placebo group (+3.6%).

During Period 2 (up to Week 48), for BMC and BMD, there was a median % increase during (uncontrolled) Period 2  with  vamorolone  2 mg/kg  and  6 mg/kg.  While  prespecified  BMD  z-score  analysis  was  not conducted as planned, the applicant provided post-hoc BMD z-scores adjusted for height z-scores for baseline, Week 24, and Week 48. As a result, LS-BMD z-scores remained stable in all treatment groups over the 48 weeks of study lacking clinically significant changes, which are generally defined by a ≥0.5 decline in spine BMD z-score on serial BMD measurements over a 12-month period (Ward et al. 2018). Moreover, longitudinal DXA measures of lumbar spine DXA and total body DXA (i.e.

<div style=\"page-break-after: always\"></div>

screening+W 24+W 48,  screening+W 24,  screening+W 48,  or  W 24+W 48)  are  available  for  ~50  67.5% of patients from study VBP15-004, while a number of subjects missed one or more post-baseline DXA measurements due to COVID-19 pandemic restrictions and other reasons. Regarding the robustness of DXA measures, it should be noted that the scanners were not cross-calibrated but instrument quality controls demonstrated acceptable quality according to the provided data. In summary, patients, who received vamorolone in Period 1 of study VBP15-004 and continued on vamorolone in Period 2 retained LS-BMC and LS-BMD or even slightly improved at Week 48. In contrast, there is a clear negative effect for these parameters elicited by prednisone in the first 24 weeks of treatment in study VBP15-004, that is caught up in Period 2 after switching to vamorolone. Based on these data, vamorolone is less likely to contribute to an increased risk for factures in paediatric DMD patients as compared to prednisone, while it remains unclear whether long-term treatment would elicit differential effects compared to an untreated (placebo) population. DXA measurement in order to predict the risk for fractures in patients with DMD is not readily supported in the scientific community since fractures can likewise occur in patients with BMD z-scores higher than those used to define osteoporosis and given that DMD patients present with distinct features (e.g. stature and increased weight). However, LS- BMC/BMD measurements are still assumed to  contribute  to  the  overall  trajectory  of  bone  health.  This  is  also  in  line  with  the  recommendations provided by Birkrant et al. 2018 (i.e. spine x-ray to be prioritised over BMD).  Taken together the totality of the bone health results, vamorolone seems to have differential effects on bone health as compared to prednisone; however, the prediction of future fractures in DMD patients treated with vamorolone is not possible based on the provided data. In the RMP, bone fracture has been specified within safety on longterm use as missing information.

Treatment with vamorolone 6 mg/kg was associated with an increased risk of presenting with AESIs of behaviour problems compared to placebo but lower as compared to prednisone, supported by results from the PARS III scale measuring psychosocial adjustment. There was a clear difference in clinically significant events that were highest for prednisone (22.6%) and not reported for vamorolone 6 mg/kg. While  in  the  prednisone  group  psychomotor  activity  and  aggression  predominated,  more  subjects reported irritability in the vamorolone 6 mg/kg group as compared to prednisone (10.7% vs. 3.2%). Moreover, after up titration to 6 mg/kg from lower doses in VBP15-LTE, 4 subjects reported TEAEs from the  psychiatric  disorders  SOC.  The  vast  majority  of  events  were  mild,  and  none  led  to  treatment interruption,  down-titration,  or  discontinuation.  Behaviour  problems  slightly  differed  between  age subgroups &lt;5 and ≥5 years (in Pool 1, behaviour problems with vamorolone were found increased over placebo and prednisone in the younger subgroup). This finding is corroborated by newly emerging data from 2 to &lt;4 years-old in study VBP15-006, who reported behavioural disorder TEAEs with the 6 mg/kg dose but not with the 2 mg/kg dose during the first 12 weeks of treatment. Similarly, no such events have been reported after increasing the dose after 12 weeks in the EAP. Switching from prednisone to vamorolone in VBP15-004 was not related to an increase in behavioural problems. No increased risk for long-term treatment could be deduced from Pool 3. Given that behavioural problems were not severe or serious, were not considered clinically relevant or required active management or led to discontinuation, it is agreed that a warning statement might not be of clear value. Moreover, additional information in section 4.8 regarding behavioural ADRs (description of selected AEs section and update of an increased frequency of behavioural events in younger patients has been included.

The incidence of gastrointestinal symptoms was similar across treatment groups up to Week 24 in Pool 1, with vomiting being more frequently reported in patients from both vamorolone groups as compared to placebo and prednisone. All patients in the 2 to &lt;4 years cohort treated with 6 mg/kg in study VBP15006 reported GI disorders TEAEs during the first 12 weeks of treatment. None of the events was clinically significant. No increased risk was noted upon switching from placebo/ prednisone to vamorolone.

Vamorolone did not induce diabetic  conditions  in  paediatric  patients  with  DMD  in  study  VBP15-004. Fasting glucose and HbA1c remained nearly unchanged in all groups. However, vamorolone led to a

<div style=\"page-break-after: always\"></div>

dose-dependent increase in fasting insulin, which was found higher in the vamorolone 6 mg/kg group as compared to prednisone. Likewise, nearly half of all patients on vamorolone 6 mg/kg had shifts from normal to high insulin with fewer patients in the prednisone, vamorolone 2 mg/kg, and placebo group (26.9%, 18.2%, and 0%). Moreover, switching from prednisone to vamorolone 6 mg/kg (but not to vamorolone 2 mg/kg) in the EAP led to an increase in fasting insulin from normal to high. Glucose and HbA1c remained nearly unaffected after switching. In Pool 3,  fasting  insulin  further  increased  doserelated up to Month 12. The data are indicative of adaptive ß-cell processes to maintain normoglycaemia that are more pronounced with the high dose (6 mg/kg) vamorolone than with the prednisone dose used in the clinical trial. In line with study VBP15-004, there were no relevant changes for fasting glucose or HbA1c  for  subjects  across  the  age  groups  in  study  VBP15-006  receiving  vamorolone  2 mg/kg  and 6 mg/kg; however, no data on fasting insulin have been presented due to a shipment error. Any longterm implications on glucose homeostasis remain unknown and will be more relevant for patients with pre-existing risk factors. There was no evidence for an increased incidence of diabetic condition AESI in Pool 1 for vamorolone, while AESI in Pool 3 occurred more frequently in the 6 mg/kg group as compared to 2 mg/kg (10% vs. 1%). One subject in the EAP reported a SAE of new onset 'diabetes mellitus type 1' rated not related to vamorolone, which is agreed to given that it is of autoimmune origin. The product information includes adequate warning with regard to diabetic conditions.

There  were  few  AESIs  of  skin  and  hair  changes  in  Pool 1  (i.e.  hypertrichosis,  erythema,  skin hyperpigmentation)  in  patients  on  vamorolone.  Over  the  long  term,  the  frequency  of  these  events remained low and similar in both vamorolone groups.

There were no reports of cataracts or glaucoma in any subject treated for up to 30 months.

No evidence for an increased risk for infections with vamorolone was observed, and specific viral and opportunistic infections typically observed with immune suppression were not reported. During the first 6 months of controlled treatment, the incidence of infection AESI was slightly lower for the vamorolone groups than for placebo but similar to prednisone. Although, infections and infestations being the most frequently reported SOC throughout the DMD studies, the pattern of infections was in line with seasonal infections and those seen in immunocompetent paediatric patients. One event of gastroenteritis viral (vamorolone  2 mg/kg)  was  rated  serious  but  did  not  lead  to  discontinuation.  No  additional  concern derives from Pool 3 with regard to the infection AESI. Vaccination should be considered to safeguard immuno-compromised  patients  from  serious  infections.  A  warning  in  section  4.4.  recommending vaccination against varicella zoster virus for patients without history of chicken pox or vaccination and a contraindication for the use of live or live-attenuated vaccines in the 6 weeks prior to starting treatment and during the treatment in section 4.3 has been included. Infections due to immunosuppression is an important potential risk for vamorolone in the RMP. A class warning regarding a potential increased risk for infections with vamorolone due to immunosuppression has been included in section 4.4 of the SmPC. The absence of a relevant safety issue of vamorolone with regard to infections is probably related to its differential effects on blood cells. A dose-dependent increase in lymphocyte counts (~23% and 50% from baseline for vamorolone 2 mg/kg and 6 mg/kg, respectively) was observed in the first weeks of treatment similar to prednisone, while monocyte and leukocyte counts behaved similarly for vamorolone 2 mg/kg and 6 mg/kg but remained lower as compared to prednisone. While treatment with prednisone was  associated  with  up  to  100%  increase  in  neutrophil  counts,  these  (and  immature  granulocytes) remained nearly unchanged in vamorolone- and placebo-treated subjects. In Pool 3, all white blood cell lines slightly increased in a dose-dependent manner from baseline up to Month 30.

An effect of vamorolone on blood pressure could not be deduced from a cardiovascular and respiratory safety pharmacology study in telemetered Beagle dogs during the preclinical programme, and likewise, no effects were noted in single and repeated dose studies in dogs. Baseline DBP and SBP in Pool 1 show a tendency for increased blood pressure in in all treatment groups. Mean DBP change from baseline up to Month 6 was higher with vamorolone 6 mg/kg as compared to the other treatment groups, with the

<div style=\"page-break-after: always\"></div>

highest mean change from baseline at Week 18 (5 mm/Hg). For SBP, higher mean change increases were  reported  for  both  vamorolone  groups  compared  to  placebo  and  prednisone  of  5 mmHg  (at Week 24). Data on blood pressure collected in the clinical trials was not sufficiently standardised to robustly assess an effect of the drug on blood pressure. In addition, assessments of blood pressure in clinical trials with young children are known to be highly challenging. Studies VBP15-002/003/LTE and VBP15-004 only collected single  blood  pressure  measurements,  which  could  explain  high  variability, which in turn hampers an accurate assessment of small changes in blood pressure over time. More subjects presented with shifts from Stage 1 or lower to Stage 2 hypertension in SBP than in DBP but most of the shifts occurred at a single visit without confirmation at the next consecutive visit. In Pool 3, values over time for both diastolic and systolic blood pressure slightly increased from baseline over 12 to 30 months in the vamorolone 2 mg/kg group but remained roughly stable for the 6 mg/kg group after adjusting for height and age (percentiles and z-scores) to correct for the expected increase in blood pressure in growing children. Shifts from baseline Stage 1 or lower to Stage 2 hypertension for DBP and SBP were dose-dependent in Pool 3. No additional concern arose from study VBP15-006 with regard to blood pressure changes. No additional TEAEs have been reported as per the DCO 21 July 2023 in subjects participating  in  an  EAP.  Given  the  above-mentioned  observations,  a  warning  statement  as  well  as monitoring of blood pressure in the SmPC has been discussed. In summary, the blood pressure increases with vamorolone are not in line with animal findings, and a plausible mechanism that could explain increase is absent. Moreover, clinical data are of limited quality to establish an effect of vamorolone on blood pressure and show high variability of measurements. Last not least, the observed weight increases with vamorolone may have contributed to the changes in blood pressure. At present, the overall data do not support a warning while long-term outcome needs to be addressed post-marketing. Hypertension is included as missing information regarding safety on long-term use in the RMP.

ALT and AST were not considered specific parameters to assess hepatic function due the underlying disease (muscle loss) because these were already found increased at baseline and fluctuated during the studies. No relevant changes in liver specific mean GGT, GLDH, ALP or bilirubin values occurred in any group in Pool 1, and there was no consistent pattern to support treatment related changes over time. Clinically significant changes of specific parameters GLDH and GGT were either similar across treatment groups (GLDH) or even absent (GGT). Upon clarification by the applicant, there were three cases of treatment-emergent Hy's law in Pool 1 not meeting criteria for Hy's law at screening/ at baseline, one patient on prednisone and two patients on vamorolone 6 mg/kg. While Gilbert's syndrome was suspected in one of the vamorolone 6 mg/kg patients (direct bilirubin was normal), a single patient had GLDH &gt; 3x ULN and increases in other liver parameters in the context of hepatitis acute , and this case remains suspect of Hy's law (drug-induced liver injury) while no firm conclusion can be drawn based on limited information available. The patient was reported with splenomegaly at various time points. Two additional cases of treatment-emergent Hy's law criteria were reported in Pool 3, one on vamorolone 2 mg/kg and one on 6 mg/kg. While no concomitant increases of ALT, AST, GGT or GLDH or signs of liver damage were noted for these patients, direct bilirubin values are not available. Seven TEAEs in line with potential hepatic impairment have been reported across all studies. 3 out of 7 occurred in VBP15-001 (hepatic enzyme increased on placebo, ALT increased on vamorolone 20 mg/kg, and blood bilirubin increased on vamorolone 8 mg/kg). Hyperbilirubinaemia (2 mg/kg dose) and hepatitis acute (6 mg/kg) occurred in study VBP15-004. Two TEAEs were reported in Pool 3, hepatomegaly in the 2 mg/kg group and ALT increased in the 6 mg/kg group. Overall, three TEAEs related to liver function (acute hepatitis, increased hepatic  enzyme,  and  increased  alanine  aminotransferase)  led  to  the  discontinuation  of  vamorolone treatment during the DMD programme. Hepatic toxicity is referred to as important potential risk in the RMP  and  the  applicant  agrees  to  further  characterise  and  quantify  hepatotoxicity  (amongst  other potential safety issues) as part of the long-term safety in an observational PASS. Further, section 4.4 of the SmPC states that vamorolone has not been studied in patients with severe pre-existing hepatic injury (Child-Pugh class C) and must not be used in these patients (see section 4.3).

<div style=\"page-break-after: always\"></div>

Haematology parameters of red blood cells, haemoglobin and haematocrit showed dose-dependent mean increases mainly around the first 6 to 12 weeks of treatment that were similar for 6 mg/kg vamorolone and prednisone; no progressive increases were noted with longer treatment duration.

No changes in lipid profile were noted in the placebo group, while HDL cholesterol and triglycerides dosedependently  increased  for  vamorolone  from  baseline  in  Pool 1.  Increases  were  lower  compared  to prednisone for triglycerides and similar for HDL. LDL was found to be decreased from baseline up to Month 6  in  Pool 1  in  all  treatment  groups  and  no  pattern  could  be  identified  with  longer  treatment duration (Pool 3).

The following noteworthy observations have been made for chemistry parameters : alkaline phosphatase decreased  with  prednisone  but  not  with  vamorolone  or  placebo  in  Pool 1;  however,  in  Pool 3,  ALP progressively  decreased  from  Month 12,  especially  in  the  vamorolone  6 mg/kg  group,  questioning preservation of a 'bone-saving' effect with longer treatment duration.

Mean changes from baseline in 25-OH-Vitamin D were low and not related to dose, and did not support a progressive decrease over longer duration of treatment contrasting a dose-related reporting of Vitamin D deficiency TEAEs in the clinical studies. Upon review of TEAEs in line with vitamin D deficiency, several methodological issues were noted, i.e., more frequent reporting after implementation of reference ranges in  Period 2 of study VBP15-004 (but not during Period 1), and use of the adult reference ranges for Vitamin D instead of lower paediatric reference ranges. Shift analyses for 25-OH vitamin D in Pool 1 and Pool 3  do  not  indicate  an  increased  incidence  of  shifts  from  normal  to  low  during  treatment  with vamorolone, thus, inclusion as an ADR in section 4.8 of the SmPC is not considered necessary.

Thyroid  function  has  not  been  assessed  in  the  vamorolone  clinical  programme.  However,  it  seems reasonable and in line with glucocorticoid effects to conclude that - depending on the thyroid function of the patient - clearance might be reduced or increased. Respective warning has been included in section 4.4 of the SmPC. Few and random assessments of thyroid function in patients during VBP15-004 do not indicate reduction of TSH with vamorolone.

The DMD population is known to be susceptible to ECG changes (Thrush et al. 2009). Vamorolone was not found to affect ECG parameters in a chronic toxicity study in dogs in the preclinical programme. Some significant ECG changes have been noted for vamorolone in Pool 1 and Pool 3, which may in part be contributed to the underlying disease (abnormal Q waves, right bundle branch block). Suspicious ECG results of 11 subjects from Pool 3, including those with perceived QTcF &gt;60 msec and &gt;500 msec, have been transferred to an external cardiologist. Upon review, none of these subjects was confirmed to have had an abnormal ECG. The expert identified transcription errors of ECG values in the SCS, reporting of QTcB instead of QTcF, and ECG machine failures (false positives). Thus, vamorolone does not bear an effect on cardiac conduction in paediatric subjects with DMD. There were 3 subjects on vamorolone with increases from baseline in QTcF of &gt;60 msec in Pool 1.

Special populations have been studied, including (amongst others) age groups ( &lt;5 and ≥5 years), and subjects  with  hepatic  impairment.  AESIs  of  behaviour  problems,  GI  symptoms,  as  well  as  rates  of infections were more frequently reported in the younger patients. In contrast, higher reporting for bone fractures, Cushingoid features and weight gain was noted in the older subgroup. In study VBP15-HI, a single  dose  of  2 mg/kg  vamorolone  caused  an  increase  in  exposure  in  patients  with  moderate  HI compared to age, weight and sex matched healthy adults. Consequently, the dose administered in DMD patients with HI should not exceed 2 mg/kg. A contraindication for patients with Child-Pugh C (severe HI) has been included in section 4.3 given the observed increase in exposure in healthy volunteers with moderate HI and known liver effects of GCs.

The potential for clinically significant drug-drug interactions with vamorolone as victim or perpetrator drug  seems  not  to  be  of  clinical  concern  given  that  elimination  occurs  by  various  routes  involving

<div style=\"page-break-after: always\"></div>

numerous metabolic enzymes. This is supported by results of an in-vivo DDI study and an in-vitro study. Wording with regard to the (uneventful) outcome of these studies is depicted in section 4.5 of the SmPC.

## 2.6.10. Conclusions on the clinical safety

The safety database for vamorolone includes 163 patients in the age group 4 to &lt;7 years treated with doses  of  2 mg/kg  and  6 mg/kg  in  the  clinical  programme,  which  is  considered  acceptable  when considering that DMD is an orphan condition affecting 1 in 3600 - 9300 live male births. In order to extrapolate clinical safety from the reference population to the broader target population, the applicant provided  preliminary  data  from  the  ongoing  phase 2  open-label  study  VBP15-006  that  contribute  to clinical safety of vamorolone in steroid-naïve patients 2 to &lt;4 years of age and patients 7 to &lt;18 years with  and  without  previous  steroid  treatment.  The  target  population  has  been  revised  during  the procedure from 2 years of age and older to 4 years of age and older, thus, it does not include paediatric patients 2 to &lt;4 years of age.

The main limitations of the clinical programme are the restricted study population and the lack of active prednisone control beyond 6 months. While the overall length of follow-up in the clinical programme is rather short for concluding on the long-term safety of vamorolone as compared to prednisone, additional safety data from the EAPs are meanwhile available for 99 patients with a median exposure to vamorolone of 2.1 years in addition to the duration of exposure in the parent clinical studies (the longest duration was 4.4 years in the EAP as per the DCO).

The  overall safety profile of vamorolone  suggests  broad  qualitative similarities with classical glucocorticoids  with  distinct  quantitative  differences  in  a  number  of  (dose-dependent)  safety  issues, which might be explained by GR-mediated transrepressive activity while transactivation is reduced.

Based on the controlled safety data up to 6 months it appears that vamorolone - compared to prednisone at  the  administered dose - does not induce growth inhibition or bone loss, while effects on glucose metabolism, blood pressure and infections (as a consequence of immunosuppression) are uncertain. Despite the lack of an extended active prednisone control in study VBP15-004, the preliminary safety data from the EAPs suggest that the potential advantages of vamorolone over prednisone can probably be maintained with longer treatment while supportive external comparison with different GC treatment regimens from the FOR-DMD study needs to be interpreted with caution based on known limitations.

On the other hand, some AESI were found to occur with a frequency for the recommended vamorolone 6 mg/kg dose at least in the same magnitude or even slightly higher as compared to prednisone in the controlled study period, e.g., adrenal suppression and Cushingoid features. The long-term consequences of adrenal insufficiency following discontinuation of vamorolone cannot be determined with the available data.  Moreover,  the  increase  in  weight  and  BMI  was  higher  in  the  vamorolone  6 mg/kg  group  as compared  to  prednisone  and  led  to  down  titration  in  10 patients  in  the  uncontrolled  setting.  Down titration  to  lower  doses,  i.e.  4 mg/kg  (proposed  as  a  consequence  of  the  updated  popPK  model)  or 2 mg/kg  is  considered  to  mitigate  tolerability  issues  (e.g.  weight  gain)  with  vamorolone,  while maintaining the patient on the highest tolerable dose should be aimed at.

The provided short-term safety data from patients studied in the ongoing study VBP15-006 and longterm  safety  through  expanded  access  programmes  allow  extrapolation  of  clinical  safety  from  the reference population (patients 4 to &lt;7 years of age) to patients &gt;7 years of age with and without steroid experience.

In summary, the identified safety issues for vamorolone across the applied age range appear manageable with the proposed risk minimisation measures, i.e. adequate labelling in the product information and

<div style=\"page-break-after: always\"></div>

routine  pharmacovigilance  activities.  Moreover,  an  observational  PASS  study  has  been  proposed  to further characterise and quantify the long-term safety profile of vamorolone.

## 2.7. Risk Management Plan

## 2.7.1. Safety concerns

## Table 19: Summary of safety concerns

| Summary of safety concerns   | Summary of safety concerns                                                                                                                                                  |
|------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Important identified risks   | None                                                                                                                                                                        |
| Important potential risks    | Infections due to immunosuppression Hepatotoxicity Acute adrenal insufficiency (adrenal crisis)                                                                             |
| Missing information          | Use in patients above 12 years of age Safety on long-term use (in particular regarding bone fractures, weight gain, growth, hyperglycaemia, dyslipidaemia and hypertension) |

## 2.7.2. Pharmacovigilance plan

## Table 20: Ongoing and planned additional pharmacovigilance activities

| Study Status                                                                                                                                                                                                               | Summary of objectives                                                                                                                                                                                                      | Safety concerns addressed                                                                                                                                                                                                                                                                                                                           | Milestones                                                                                                                                                                                                                 | Due dates                                                                                                                                                                                                                  |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Category 1 - Imposed mandatory additional pharmacovigilance activities which are conditions of the marketing authorisation                                                                                                 | Category 1 - Imposed mandatory additional pharmacovigilance activities which are conditions of the marketing authorisation                                                                                                 | Category 1 - Imposed mandatory additional pharmacovigilance activities which are conditions of the marketing authorisation                                                                                                                                                                                                                          | Category 1 - Imposed mandatory additional pharmacovigilance activities which are conditions of the marketing authorisation                                                                                                 | Category 1 - Imposed mandatory additional pharmacovigilance activities which are conditions of the marketing authorisation                                                                                                 |
| None                                                                                                                                                                                                                       | None                                                                                                                                                                                                                       | None                                                                                                                                                                                                                                                                                                                                                | None                                                                                                                                                                                                                       | None                                                                                                                                                                                                                       |
| Category 2 - Imposed mandatory additional pharmacovigilance activities which are Specific Obligations in the context of a conditional marketing authorisation or a marketing authorisation under exceptional circumstances | Category 2 - Imposed mandatory additional pharmacovigilance activities which are Specific Obligations in the context of a conditional marketing authorisation or a marketing authorisation under exceptional circumstances | Category 2 - Imposed mandatory additional pharmacovigilance activities which are Specific Obligations in the context of a conditional marketing authorisation or a marketing authorisation under exceptional circumstances                                                                                                                          | Category 2 - Imposed mandatory additional pharmacovigilance activities which are Specific Obligations in the context of a conditional marketing authorisation or a marketing authorisation under exceptional circumstances | Category 2 - Imposed mandatory additional pharmacovigilance activities which are Specific Obligations in the context of a conditional marketing authorisation or a marketing authorisation under exceptional circumstances |
| None                                                                                                                                                                                                                       | None                                                                                                                                                                                                                       | None                                                                                                                                                                                                                                                                                                                                                | None                                                                                                                                                                                                                       | None                                                                                                                                                                                                                       |
| Category 3 - Required additional pharmacovigilance activities                                                                                                                                                              | Category 3 - Required additional pharmacovigilance activities                                                                                                                                                              | Category 3 - Required additional pharmacovigilance activities                                                                                                                                                                                                                                                                                       | Category 3 - Required additional pharmacovigilance activities                                                                                                                                                              | Category 3 - Required additional pharmacovigilance activities                                                                                                                                                              |
| PASS Planned                                                                                                                                                                                                               | Long term safety                                                                                                                                                                                                           | Important potential risks: Infections due to immunosuppression Hepatotoxicity, acute adrenal insufficiency (adrenal crisis) Missing information 'Safety on long-term use (in particular regarding bone fractures, weight gain, growth, hyperglycaemia, dyslipidaemia and hypertension)' Missing information 'use in patients above 12 years of age' | Final protocol                                                                                                                                                                                                             | Q3 2024                                                                                                                                                                                                                    |

<div style=\"page-break-after: always\"></div>

| Study Status                                                                                                                                                                                                                                                     | Summary of objectives                                                                              | Safety concerns addressed                                   | Milestones                                          | Due dates          |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------|-------------------------------------------------------------|-----------------------------------------------------|--------------------|
| VBP15-006 a Phase II Open-Label, Multiple Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Exploratory Efficacy of Vamorolone in Boys Ages 2 to <4 Years and 7 to <18 Years with Duchenne Muscular Dystrophy (DMD) Ongoing | To evaluate safety, tolerability, pharmacokinetics, pharmacodynamics and exploratory efficacy data | Missing information 'use in patients above 12 years of age' | Last Patient Last Visit Final Clinical Study Report | 30/06/2024 Q4 2024 |

## 2.7.3. Risk minimisation measures

## Table 21: Summary table of pharmacovigilance activities and risk minimisation activities by safety concern

| Safety concern                                                           | Risk minimisation measures                                                                                                                                                                                 | Pharmacovigilance activities                                                                                                                                                                                                                 |
|--------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Important potential risk 1: Infections due to immunosuppression          | Routine risk minimisation measures: SmPC sections 4.4, 4.8 PL sections 2 and 4 Additional risk minimisation measures: None                                                                                 | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: None Additional pharmacovigilance activities: • An observational PASS to further characterise and quantify long-term safety profile of Agamree |
| Important potential risk 2: Hepatotoxicity                               | Routine risk minimisation measures: SmPC sections 4.2, 4.3 and 4.4 PL sections 2 and 4 Additional risk minimisation measures: None                                                                         | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: None Additional pharmacovigilance activities: • An observational PASS to further characterise and quantify long-term safety profile of Agamree |
| Important potential risk 3: Acute Adrenal insufficiency (adrenal crisis) | Routine risk minimisation measures: SmPC sections 4.2 and 4.4 PL sections 2 and 4 Additional risk minimisation measures: A patient alert card to support early recognition and treatment of adrenal crisis | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: None Additional pharmacovigilance activities: An observational PASS to further characterise and quantify long-term safety profile of Agamree   |

<div style=\"page-break-after: always\"></div>

| Safety concern                                                                                                                                                | Risk minimisation measures                                                                                                    | Pharmacovigilance activities                                                                                                                                                                                                                                                                   |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Missing information 1: Use in patients above 12 years of age                                                                                                  | Routine risk minimisation measures: None Additional risk minimisation measures: None                                          | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: None Additional pharmacovigilance activities: • VBP15-006, Final study report due date: Q4 2024 • An observational PASS to further characterise and quantify long-term safety profile of Agamree |
| Missing information 2: Safety on long-term use (in particular regarding bone fractures, weight gain, growth, hyperglycaemia, dyslipidaemia and hypertension). | Routine risk minimisation measures: SmPC sections 4.4 and 4.8 PL sections 2 and 4 Additional risk minimisation measures: None | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: None Additional pharmacovigilance activities: • An observational PASS to further characterise and quantify long-term safety profile of Agamree                                                   |

## 2.7.4. Conclusion

The CHMP considers that the risk management plan version 1.0 is acceptable.

## 2.8. Pharmacovigilance

## 2.8.1. Pharmacovigilance system

The CHMP considered that the pharmacovigilance system summary submitted by the applicant fulfils the requirements of Article 8(3) of Directive 2001/83/EC.

## 2.8.2. Periodic Safety Update Reports submission requirements

The requirements for submission of periodic safety update reports for this medicinal product are set out in the Annex II, Section C of the CHMP Opinion. The applicant did request alignment of the PSUR cycle with the international birth date (IBD). The IBD is 26. October 2023.

## 2.9. Product information

## 2.9.1. User consultation

The results of the user consultation with target patient groups on the package leaflet submitted by the applicant show that the package leaflet meets the criteria for readability as set out in the Guideline on the readability of the label and package leaflet of medicinal products for human use .

<div style=\"page-break-after: always\"></div>

## 2.9.2. Additional monitoring

Pursuant to Article 23(1) of Regulation No (EU) 726/2004, Agamree (vamorolone) is included in the additional monitoring list as it is a new active substance which on 1 January 2011 was not in a medicinal product authorised in the EU.

## 3. Benefit-Risk Balance

## 3.1. Therapeutic Context

## 3.1.1. Disease or condition

DMD is a rare, disabling, progressive and ultimately fatal X-linked recessive neuromuscular disorder caused by mutations in the gene for dystrophin (Emery, 2002). Functional dystrophin is critical for the structural stability of myofibers in skeletal, diaphragm and cardiac muscle and is also of importance for smooth muscles. The disease primarily affects males with a birth incidence of 1 in 3,600 - 9,300 males (Mah et al .,  2014).  DMD  is  characterised  by  a  progressive  degeneration  of  skeletal  muscles,  with symptoms that  manifest  early,  at  around  3 years ,  causing  loss  of  ambulation  before  the  age  of  12, followed  by  cardiac  complications  (e.g.  dilated  cardiomyopathy  and  arrhythmia)  and  respiratory disorders, including chronic respiratory failure (Birnkrant et al., 2018). The median life expectancy at birth is around 30 years (Landfelt et al. 2020).

The current application of vamorolone is for the treatment of DMD in patients aged 4 years and older, which reflects the majority of the DMD patient population.

Vamorolone  is  an  anti-inflammatory  steroid  analogue  basically  aiming  at  slowing  down  progressive muscle weakness and delaying associated loss of ambulation.

## 3.1.2. Available therapies and unmet medical need

There are no approved treatments to cure or stop the ultimately fatal progression of DMD. Even with the introduction in the 1990s of assisted ventilation in the later stages of the disease, the mean age of survival (for those ventilated patients who do not develop early and severe cardiomyopathy) is still only 24  years.  Supportive  care  (e.g.,  physiotherapy)  and  glucocorticoids  remain  the  mainstays  of  DMD treatment and should continue after loss of ambulation (Birnkrant et al ., 2018). Although, glucocorticoid treatment  recommended  by  pertinent  treatment  guidelines  is  well-established,  i.e.  prednisone  and deflazacort, these treatments are not licensed for the treatment of DMD in Europe. Moreover, uncertainty exists regarding the most adequate corticosteroid dosing regimen and duration of treatment for DMD.

Translarna (ataluren) has received conditional marketing authorisation in the EU but its use is limited to ambulatory DMD patients aged 2 years and older with nonsense mutations. Therefore, an unmet medical need remains for the broader DMD patient population.

## 3.1.3. Main clinical studies

The main evidence of efficacy submitted is a single phase 2b, multicentre, randomised, double-blind, parallel group, placebo (n= 30) - and active-controlled (prednisone, n = 31) study of 24 weeks duration

<div style=\"page-break-after: always\"></div>

with double-blind extension till week 48 to assess the efficacy and safety of 2 dosages of vamorolone, i.e. 6 mg/kg/day (n= 30) and 2 mg/kg/day (n= 30) in ambulant boys with DMD.

The study included boys aged ≥4 years and &lt;7 years with a centrally confirmed diagnosis of DMD based on gene analysis and/or a muscle biopsy sample, tested for the presence of dystrophin protein. Included subjects had to be able to walk independently without assistive device and be able to complete the

TTSTAND without assistance in &lt;10 seconds. With regard to statistical aspects, the primary Analysis of the primary efficacy endpoint for EMA consisted of a missing data imputation while for FDA only the observed measurements were used (without multiple imputation).

A  pre-planned  matched  comparison  of  both  vamorolone  doses  over  the  48-treatment  period  to  the continuous prednisone and deflazacort groups from the external FOR-DMD study was also provided. The FOR-DMD  study  was  a  multiple  site,  randomised,  prospective,  multicenter,  double-blind  study  to compare three corticosteroid regimens (0.75 mg/kg/day prednisone; 0.75 mg/kg/day prednisone 10 days on/10 days off; 0.9 mg/kg/day deflazacort) over a treatment period of 36 to 60 months in 196 boys aged ≥ 4 years and &lt; 8 ye ars with confirmed DMD.

## 3.2. Favourable effects

The primary endpoint was the change from baseline in TTSTAND velocity for the vamorolone 6 mg/kg treatment arm compared vs placebo at week 24. TTSTAND velocity increased for vamorolone from mean (SD) 0.186 (0.0588) to mean (SD) 0.242 (0.0785) rises/sec and slightly decreased in the placebo group from mean (SD) 0.200 (0.0642) to mean (SD) 0.193 (0.0918) rises/sec at Week 24. The LSM difference for vamorolone 6 mg/kg from placebo was 0.0586 rises/sec in the primary EMA analysis (p = 0.0018) and 0.0603 rises/sec in the primary FDA analysis (p= 0.0018).

Several sensitivity analyses and supportive analyses have been performed that were in line with the results of the primary analysis. Overall, sensitivity analyses demonstrate that the COVID-19 pandemic, missing data, and influential observations did not affect the results of the primary analysis at Week 24. The primary EMA analysis repeated in the ITT analysis set was also in accordance with the primary EMA analysis (mITT population).

With  respect  to  the  first  pre-specified  secondary  endpoint,  change  in  TTSTAND  velocity  for  the vamorolone 2 mg/kg treatment arm compared to placebo at week 24, a statistically significant difference was demonstrated when vamorolone was compared against placebo (p = 0.0196). TTSTAND velocity increased in the vamorolone 2 mg/kg group from 0.184 to 0.225 rises/sec and slightly decreased in the placebo arm from 0.200 to 0.193 rises/sec at week 24. The LSM difference for vamorolone 2 mg/kg from placebo was 0.0430 rises/sec (EMA analysis) and comparable to the primary FDA analysis.

Regarding the second and third pre-specified secondary endpoint, change from baseline to week 24 in the 6MWT distance for vamorolone 6 mg/kg and 2 mg/kg vs placebo, statistically significant differences were demonstrated for the vamorolone treatment arms when compared against placebo (p=0.0117 and p = 0.0112, respectively). While in the vamorolone treatment groups the 6MWT distance increased it showed some decline under placebo. The LSM (SE) change from baseline for placebo, vamorolone 6 mg/kg and 2 mg/kg was -11.37 (10.6082), 24.57 (10.0582) and 24.98 (10.0352), respectively. The LSM difference for vamorolone 6 mg/kg and 2 mg/kg against placebo was 35.9 meters and 36.2 meters, respectively.

With respect to change from baseline to week 24 in the 6MWT distance for vamorolone 6 mg/kg and 2 mg/kg  vs  prednisone,  improvements  from  baseline  at  Week  24    were  similar  for  both  vamorolone treatment  groups  (6  mg/kg  and  2  mg/kg)  while  subjects  under  prednisone  treatment  improved numerically more (EMA analysis) with LSM (SE) changes from baseline for prednisone and vamorolone

<div style=\"page-break-after: always\"></div>

6 mg/kg and 2 mg/kg of 44.12 (9.6444), 24.98 (10.0352) and 24.57 (10.0582), respectively. The LSM difference for change from baseline for vamorolone 6 mg/kg and 2 mg/kg each against prednisone was -19.55 (p = 0.14) and -19.14 (p = 0.17), respectively.

In the comparison of efficacy endpoints between the vamorolone groups and prednisone for changes from baseline at week 24 that focused on global assessments, to account for baseline imbalances and to allow  to  examine  efficacy  endpoints  globally  in  spite  of  different  units,  the  improvements  seen  with vamorolone 6 mg/kg in TTSTAND, TTRW, and TTCLIMB velocity were very similar to those seen with prednisone at Week 24, while for the 6MWT and the NSAA score prednisone provided numerically better results. Overall, the improvements seen with vamorolone 2 mg/kg were slightly smaller than those seen with prednisone.

The improvements in TTSTAND velocity, TTRW velocity and NSAA score seen with vamorolone 6 mg/kg at 24 weeks were maintained for up to 48 weeks of treatment. There was no decrease across the relevant outcome parameters but an additional increase in the 6MWT distance from Week 24 to Week 48. Results with the 6 mg/kg dosage were generally better than those for the vamorolone 2 mg/kg dosage.

When subjects  switched  from  prednisone  to  vamorolone  6  mg/kg  at  week  24,  the  mean  TTSTAND velocity,  TTRW  velocity  and  NSAA  score  only  slightly  decreased  and  TTCLIMB  velocity  minimally increased.  There  was  a  small  decline  in  the  6MWT  distance  after  the  switch  from  prednisone  to vamorolone,  while  subjects  who  were  continuously  treated  with  vamorolone  6  mg/kg  continued  to improve until Week 48. When subjects switched from prednisone to vamorolone 2 mg/kg, the mean TTSTAND and TTCLIMB velocity decreased more than the 6MWTD and TTRW velocity. No mean changes were seen for the NSAA score.

Subgroup  analyses  of  TTSTAND  velocity  yielded  comparable  results  across  the  different  subgroups favouring  vamorolone  6  mg/kg  against  placebo  although  they  were  only  based  on  small  number  of patients.

Results on motor function endpoints in an additional post-hoc subgroup of patients with a 6MWT distance &lt;350 meters were comparable to those in the primary analysis population when vamorolone 6 mg/kg was compared against placebo for change from baseline to Week 24. Although effects observed for the vamorolone 2 mg/kg group in comparison to placebo were smaller, they point in the same direction and were nominally significant.

## 3.3. Uncertainties and limitations about favourable effects

The updated but preliminary PK modelling results based on data from study VBP15-006 indicate that the exposure  to  vamorolone  from  the  ROS2  formulation  (final  formulation)  for  the  6 mg/kg  dose  is significantly  higher  than  from  the  ROS1  formulation  that  has  been  used  in  the  pivotal  study,  often significantly exceeding the upper threshold of the target exposure range. In contrast, the 2 mg/kg dose in humans is consistently below the lower pre-defined threshold. The popPK model was further refined to  better  simulate  a  potential  effective  dose  for  patients  2  to  4  years  old,  who  have  originally  been envisaged for being part of the indication. Moreover, this dose should also be used to mitigate tolerability issues. According to simulations, AUC levels of ROS2 formulation are increased about 20% across all doses compared to ROS1. 4 mg/kg of ROS2 is expected to achieve 82% of the exposure of 6 mg/kg ROS1 and 246% of 2 mg/kg ROS1. Predicted drug exposure of 4 mg/kg ROS2 for all age groups is within the originally predefined exposure target range of the 5th to 95th exposure percentile of 6 mg/kg of the ROS1 formulation in the age range 4-7 years. Although, the original target range appears somewhat arbitrarily defined it still provides some valuable insight into the potential efficacy of other doses, as the ROS1 6 mg/kg dose is the primary source of efficacy information.

<div style=\"page-break-after: always\"></div>

Since even the 2 mg/kg dose with the lower exposure levels of the ROS1 formulation, which are well outside the predefined target exposure range provided evidence of some clinical benefit (despite not showing sufficient maintenance of efficacy in the reference population 4 to 7 years-old), there is a strong rational that the 4 mg/kg ROS2 dose should be well within the effective dose range based on exposure data. Moreover, a majority of subjects in the EAP/ CUPs with available dosing information are likewise being dosed at 4 mg/kg and this dose appears acceptable from a clinical safety perspective.

Regarding maintenance of efficacy, results across the efficacy outcome measures for the vamorolone 2 mg/kg dose were rather inconsistent with observed clinically significant declines in relevant functional outcome parameters at Week 48, i.e. TTSTAND velocity and 6MWT but only minimal decrease in the NSAA score. While evidence of short-term efficacy for the 2 mg/kg vamorolone dose based on the results of  study  VBP15-004  is  not  questionable,  maintenance  of  efficacy  could  still  not  convincingly  be demonstrated.

Therefore, an intermediate dose of 4 mg/kg also used in the EAPs was considered to be suitable as a reduced dose in case of tolerability issues. Based on the updated popPK model it could be shown that the AUC distributions predicted for the 4 mg/kg dose (ROS2) overlap with the 6 mg/kg dose (ROS1 fed) for the majority of patients in the age range 4 years and older, which supports that the exposure of the 4 mg/kg dose is within the target range. Based on clinical safety, this dose might, however, still not sufficiently  mitigate  all  tolerability  issues,  mainly  weight  gain.  Thus,  the  2 mg/kg  dose  -  despite uncertainties on the maintenance of effect - remains an alternative for down titration provided that patients should be maintained on the highest tolerable dose. This is in line with clinical practice with other GC regimens in the treatment of DMD.

The comparisons of the vamorolone dose groups to both, prednisone and deflazacort from a matched external  control  group  from  the  study  FOR-DMD  are  of  limited  value.  However,  even  if  only  the unadjusted confidence intervals are considered, the results indicate that vamorolone at the 2 mg/kg dosage has inferior efficacy compared to both comparators, i.e. prednisone and deflazacort. Although the results for the 6 mg/kg dosage appear more similar esp. to those for deflazacort, equivalent efficacy cannot be concluded for methodological reasons. Hence, equivalent efficacy cannot be established based on this comparison with an external control group.

## 3.4. Unfavourable effects

Vamorolone shares the effective transcriptional repression at the GR (i.e. inhibition of NF κ B-mediated inflammations) with established corticosteroids. Due to its structural difference, however, vamorolone shows limited  transactivation  of  genes,  whose  expression  is  driven  by  the  GRE.  This  may  lower  its potential for typical GC side effects. The structural peculiarity of vamorolone further entails that it acts as an MR antagonist, which contrasts the agonistic MR activity of other GCs. In addition, vamorolone is not a substrate for 11β HSD enzymes, thereby potentially reducing the risk for typical GC side effects (muscle atrophy, bone loss, insulin resistance, hypertension and weight gain).

The target organs for vamorolone toxicities identified from non-clinical studies comprised the lymphatic system, liver/gall bladder, pancreas, adrenal glands and kidneys, reproductive organs of both sexes, thyroid, salivary glands, skin and skeletal muscle.

The safety of vamorolone 2- 6 mg/kg has been evaluated in 163 paediatric male subjects in four clinical studies in the age range 4 years to &lt;7 years at study entry with 20 patient being treated for ≥30 months. Preliminary safety data for patients aged 2 to &lt;4 years (10 patients on vamorolone 2 mg/kg, and 6 of 10 patients planned on 6 mg/kg) and 7 to &lt;18 years (9 patients on vamorolone 2 mg/kg, and 4 patients on 6 mg/kg, either being steroid-naïve or steroid-treated) derive from the ongoing PIP study VBP15-006

<div style=\"page-break-after: always\"></div>

with a data cut-off of 15 March 2023. As of 15 March 2023, 171 patients continued vamorolone use through various EAP (including CUPs), with safety data available from patients aged 2-17 years.

No patient died in the DMD programme. Two patients discontinued vamorolone across the four clinical studies (due to muscular weakness and hepatitis acute). A total of 8 SAEs were reported for vamorolone across these studies (none for placebo or prednisone). In addition, 18 SAEs were reported in EUPs and CUPs up to March 2023. None of these SAEs was rated related to vamorolone.

Like glucocorticoids, vamorolone exhibited some characteristic properties, such as adrenal suppression, Cushingoid features, weight gain, and behavioural changes. These had similar or higher incidences in the vamorolone 6 mg/kg group when compared with prednisone in the controlled period in study VBP15004.

Vamorolone induced adverse adrenal cortical atrophies in repeat-dose toxicity studies in mice and dogs, which did not completely reverse following vamorolone cessation. Similarly, vamorolone caused a dosedependent adrenal suppression in human subjects. At Month 6, the level of adrenal suppression was highest for vamorolone 6 mg/kg, followed by prednisone and vamorolone 2 mg/kg based on mean (SD) morning  cortisol  values,  and  did  not  substantially  change  with  longer  treatment  duration  up  to 30 months. Adrenal suppression was further confirmed by ACTH stimulation testing in study VBP15-004. Switching from prednisone to vamorolone 6 mg/kg (not to vamorolone 2 mg/kg) led to further small decreases in morning cortisol.

Cushingoid features included weight gain and typical signs of hypercortisolism, and were most frequently reported during the first 6 months of treatment, dose-dependently with vamorolone (2 mg/kg: 6.7%; 6 mg/kg: 28.6%), mainly mild in severity. The incidence in the prednisone group was lower than in the proposed standard vamorolone dose of 6 mg/kg (22.6%). None of the TEAEs led to discontinuation of vamorolone. Cushingoid features did not increase with longer treatment up to 30 months. The exposure response (ER) analysis showed a linear relationship with vamorolone AUC τ, ss  and the risk developing Cushingoid features.  The  estimated  risk  of  exhibiting  Cushingoid  features  was  ≈0.07  at  the  median AUC τ, ss  for  patients  receiving  a  dose  of  2.0 mg/kg/day  and  ≈0.2  for  patients  receiving  a  dose  of 6.0 mg/kg/day. Cushingoid is a defined ADR in section 4.8 of the SmPC.

Long-term vamorolone administration in repeat-toxicity studies was found to increase food consumption leading to weight gain in mice and dogs, which tended to recover after vamorolone administration was terminated. Treatment with vamorolone in DMD patients was associated with a dose-dependent increase in  body  weight  and  BMI  mainly  during  the  first  6 months  of  treatment,  which  was  supported  by  an increase in total body fat mass that was higher for vamorolone 6 mg/kg as compared to prednisone. The change in median weight z-score at Month 6 was higher for vamorolone 6 mg/kg than for prednisone and vamorolone 2 mg/kg. In contrast, median BMI changes from baseline were higher for prednisone compared to both vamorolone groups, as were BMI z-score changes. However, clinically relevant changes in BMI zscore (i.e., ≥1.0 SD) after 6 months of treatment were more frequently seen in the vamorolone groups compared to prednisone (6 subjects versus 1 subject). Median changes in BMI dose-dependently increased with longer treatment of up to 30 months, while median z-score changes fluctuated. AESIs of weight  gain  in  Pool 1  (24-week  data)  were  more  frequently  reported  with  vamorolone  6 mg/kg  as compared with 2 mg/kg (17.9% vs. 3.3%) and more frequently than with prednisone (9.7%) and placebo (6.9%), but did not further increase with longer treatment duration. Weight increased and increased appetite are defined ADRs for vamorolone in section 4.8 of the SmPC.

In juvenile toxicity studies, vamorolone doses ≥15 mg/kg reduced tibia and body length pointing towards growth retardation known from other glucocorticoids. However, clinical vamorolone therapy was not found to inhibit growth based on controlled 6 months data. Median height z-scores slightly increased in the vamorolone 2 and 6 mg/kg (0.07 SD, and 0.11 SD), similar to placebo (0.13 SD), and decreased in the prednisone group at 24 weeks (-0.10 SD). Switching from prednisone after 24 weeks in Period 1 to

<div style=\"page-break-after: always\"></div>

vamorolone in Period 2 led to an increase in median height z-score up to Week 48. Across all DMD studies, there was a positive change of median height z-score after 3, 6, 12, and 30 months of treatment in both vamorolone groups that remained lower in the 6 mg/kg group. External comparison of median height z-scores in VBP15-004 to the FOR-DMD groups at Month 12 showed positive median changes in height  z-scores  for  both  vamorolone  groups  and  negative  median  changes  for  the  deflazacort  and prednisone  groups.  Comparison  over  30 months  of  treatment  in  VBP15-LTE  and  FOR-DMD  revealed stable positive height z-score changes with vamorolone, and gradual decreases with deflazacort and prednisone.

Bone fractures were not reported as AESI during the controlled 6 months period of study VBP15-004. Across all studies, 2.1% of subjects on vamorolone 2 mg/kg and 7.1% on 6 mg/kg had bone fractures. The latter group mainly had upper limb fractures and vertebral fractures. A lower limb fracture in a DMD patient may lead to immobilisation, which from transitory may become permanent and thus leading to a  non-ambulatory  state.  There  were  no  treatment-emergent  vertebral  fractures  in  either  of  the vamorolone  groups  as  evidenced  by  systematic  lateral  spine  X-ray  survey  up  to  6 months,  while 4 subjects (10.3%) were found to have had a total of seven vertebral fractures during uncontrolled study VBP15-LTE. Comparison of these data with a matched corticosteroid-treated historical control cohort from the FOR-DMD study showed a lower frequency of vertebral fractures after 30 months of vamorolone compared with both daily prednisone and daily deflazacort (&gt;27%).

Bone age was evaluated in study VBP15-LTE and found to be delayed after 30 months of vamorolone exposure (mean difference between bone age and chronological age was -1.1 ± 1.02 years). Mean changes in bone biomarkers osteocalcin, s-CTX1, and P1NP from Baseline to Month 6 were more similar in the placebo and vamorolone 2 and 6 mg/kg groups, whereas these bone markers decreased in the prednisone group. Heterogeneous results were found for bone biomarkers when analysed over a 2.5year period.

Vamorolone did not induce neurobehavioural changes in adult and juvenile mice, but adversely decreased activity and impaired limb function at 50 mg/kg/day doses in the chronic toxicity study in dogs, which might be reflective of psychiatric symptoms known from clinical therapy of high glucocorticoid doses (Harris et al ., 2015). Behavioural problems were more frequently reported in the active treatment groups of DMD patients (prednisone &gt; vamorolone 6 mg/kg &gt; vamorolone 2 mg/kg) as compared to placebo and  mainly  during  the  first  6 months  with  no  further  increase  during  longer  treatment.  AESI  of behavioural problems occurred dose-related for vamorolone and were considered clinically relevant in a single subject on vamorolone 2 mg/kg only (contrasting 22.6% of patients on prednisone). The most frequently reported behavioural problem with vamorolone 6 mg/kg was mild irritability (10.7%), which was also more frequently reported than for prednisone (3.2%). Irritability is defined as ADR in section 4.8 of the SmPC.

Gastrointestinal symptoms, including vomiting, abdominal pain, abdominal pain upper, diarrhoea, and constipation  were  among  the  most  frequently  reported  AESI  during  the  controlled  and  uncontrolled vamorolone clinical studies and occurred with similar incidences across all treatment groups (25.8% 30%) in Pool 1. Vomiting was more frequently reported in both vamorolone groups (2 mg/kg: 16.7%; 6 mg/kg:  14.3%)  as  compared  to  placebo  and  prednisone  (6.9%  and  6.5%).  GI  symptoms  with vamorolone  were  mild  in  severity,  did  not  lead  to  discontinuation  and  showed  evidence  for  dosedependency over the long-term treatment. GI disorders are defined ADRs in section 4.8 of the SmPC.

Pancreatic islet hypertrophy was noted in the chronic toxicity study in mice at vamorolone doses of 45 mg/kg/day,  which  was  interpreted as adaptive change  due  to the stimulation of hepatic gluconeogenesis  by  vamorolone.  Biomarkers  of  insulin  resistance  were  found  differentially  affected during clinical vamorolone treatment with fasting glucose and HbA1c nearly unchanged during 6 months of treatment in any group. Fasting insulin was found increased in the prednisone and even more in the

<div style=\"page-break-after: always\"></div>

6 mg/kg vamorolone group relative to placebo and vamorolone 2 mg/kg indicating compensatory insulin secretion to maintain euglycaemia. Shifts from normal to high insulin were reported for 50% of patients on  vamorolone  6 mg/kg  versus  26.9%  on  prednisone,  18.2%  on  vamorolone  2 mg/kg,  and  0%  on placebo. Fasting insulin levels did not increase during longer treatment duration beyond those reported in the controlled study period and mean glucose and HbA1c levels did not change. There were no subjects with hyperglycaemia. One subject in the EAP reported a SAE of new onset 'diabetes mellitus type 1', which is of autoimmune origin and thus not considered related.

Vamorolone  exerts  a  differential  effect  on  leukocyte  subpopulations:  lymphocyte  counts,  monocyte counts, and leukocyte counts dose-dependently increased. Neutrophil counts and immature granulocytes were found less affected by vamorolone up to 6 months as compared to prednisone and mean values were at placebo level. The incidence of infections grouped under the Immune suppression CMQ in Pool 1 was similar across treatment groups (32.1%-44.8%), but highest in the placebo group and a dose effect could not be observed. The reported events were mild or moderate in severity and in line with seasonal infections and those seen in immunocompetent paediatric patients. A single TEAE in Pool 1 was serious (gastroenteritis viral on vamorolone 2 mg/kg). Infections suggestive of immunosuppression were not reported  up  to  30 months  of  treatment.  Immunosuppression  is  an  important  potential  risk  for vamorolone.

Hypertension  is  a  known  adverse  effect  of  glucocorticoids,  but  blood  pressure  was  not  affected  by vamorolone in single- and repeated dose studies in dogs. In patients, mean clinical DBP and SPB changes from baseline at Month 6 were higher for vamorolone 6 mg/kg as compared to the other treatment groups. The mean change in DBP and SBP at different time points up to 6 months did not exceed 5 mmHg in the vamorolone 6 mg/kg group. 10.7% of subjects on vamorolone 6 mg/kg had a shift from baseline Stage 1 or lower hypertension to Stage 2 hypertension for DBP vs. only one subject on placebo. Shifts were, however, similar in active groups for SBP. Mean changes in DBP and SBP percentiles (adjusted for change in height and age over time) up to 30 months of uncontrolled treatment remained roughly stable with vamorolone 6 mg/kg.

Vamorolone was found to reversibly elevate triglycerides and cholesterol in long-term toxicity studies in mice  and  dogs.  Effects  of  vamorolone  on  clinical  lipid  parameters  in  Pool 1  include  dose-dependent increases  in  HDL  cholesterol  and  triglycerides  from  baseline,  which  were  lower  (for  triglycerides)  or similar (for HDL) as for prednisone. No relevant mean changes were seen in LDL cholesterol while shifts from  normal  to  high  LDL  in  Pool 1  solely  occurred  in  the  vamorolone  groups  (3.4%  and  10.7%, respectively).

Liver function: In all toxicity studies in mice and dogs, ≥10 mg/kg/day vamorolone induced partially reversible  liver  changes  (hypertrophy,  vacuolation,  inflammation/  necrosis)  associated  with  elevated hepatic enzymes. In patients, ALT and AST were already increased at baseline in line with the underlying muscle damage, while sporadic GLDH and bilirubin values above ULN were additionally noted. Small increases in mean GGT and GLDH have been noted mainly during the first 6 months. Two TEAEs of hepatobiliary disorders were reported with vamorolone in the controlled part of VBP15-004 (hepatitis acute and hyperbilirubinaemia). Across all studies, two additional TEAEs were reported (hepatomegaly and ALT increased). 2 patients treated with vamorolone (and one patient on prednisone) met the criteria for treatment-emergent Hy's law in Pool 1 (with an additional 2 patients in Pool 3). One of these subjects was diagnosed with 'acute hepatitis'. The event of 'Acute hepatitis' and a TEAE of ALT increased in a pharmacology study (VAM 20 mg/kg) led to treatment discontinuation. Hepatotoxicity is referred to as important  potential  risk  in  the  RMP  based  on  the  well-known  potential  of  glucocorticoids  to  exert hepatotoxic effects.

<div style=\"page-break-after: always\"></div>

TEAEs of Vitamin D deficiency were reported for vamorolone in a dose-dependent manner (6.7% and 10.7% for vamorolone 2 mg/kg and 6 mg/kg) and in 3.2% of patients on prednisone (not on placebo) and increased after switch from prednisone to vamorolone 6 mg/kg (0% and 13.3%).

Skin  and  hair  changes  in  Pool 1  in  the  combined  2  -  6 mg/kg  vamorolone  group  and  placebo  were reported  for  6.9%  of  subjects,  and  in  12.9%  of  prednisone-treated  patients.  The  most  frequently reported TEAE was hypertrichosis. No increased incidence was noted for Pool 3.

There were no reports of cataracts or glaucoma in any subject treated for up to 2.5 years.

## 3.5. Uncertainties and limitations about unfavourable effects

Overall, the safety profile of patients aged 4 to &lt;7 years is based on a limited controlled dataset of 58 patients exposed to vamorolone 2 - 6 mg/kg in study VBP15-004, with comparison to placebo and active prednisone for 6 months only. Uncontrolled data are available from Period 2 of VBP15-004 (for up to 48 weeks) after the switch of patients from placebo and prednisone to vamorolone and from studies VBP15-002, -003, and -LTE (up to 30 months). Long-term safety data for vamorolone from clinical trials are thus limited even though, additional data have become available from patients for a total exposure up to 6.7 years from the start of a clinical study (including the ongoing study VBP15-006) with treatment in EAP and CUP programmes. For patients 2 to &lt;4 years treated with 6 mg/kg, new safety data became available as per the DCO 21 July 2023 indicating that the 6 mg/kg dose in this population led to a higher reporting  of  some  of  the  dose-related  TEAEs,  i.e.  psychiatric  disorders  and  adrenal  suppression  as compared to the reference population (50% vs. 0% and 33.3% vs. 10.7%).

This is supported by findings from a post hoc analysis separating patients by age group &lt;5 years and ≥5 years  based  on  Pool 3  data  for  the  reference  population  with  quantitative  differences  in  AESI, especially higher incidences of behaviour problems, GI symptoms, but also higher rates of infections in the younger compared to the older subgroup.

Identified AESI for vamorolone with an impact on long-term safety (i.e. bone health/ fractures, adrenal suppression, weight gain) are difficult to be judged for their implications in very young patients since these few young patients so far have a rather short median exposure to vamorolone of 9 months.

Although, the safety profile in patients 7 to &lt;12 years and 12 to &lt;18 years is based on a limited number of  patients  at  present,  data  are  continuously  collected  in  EAPs  for  patients  treated  with  vamorolone during VBP15-002, -003, VBP15-LTE, VBP15-004, and VBP15-006.

Importantly, a delay in puberty is a well-known side effect with prolonged glucocorticoid treatment. Vamorolone has not been clinically studied for affecting pubertal development and any effect is unknown at present. Although, vamorolone did not affect male sexual maturation and fertility in juvenile mice, incompletely reversible adverse sperm degenerations and reduced prostate exudate were observed after 50 mg/kg/day vamorolone in male in dogs of the chronic toxicity study, which seems mechanistically related to the known interference of exogenous glucocorticoids with the hypothalamus-pituitary-gonadal axis  and  the  direct  suppression  of  testicular  steroidogenesis  (reviewed  by  Whirledge  and  Cidlowski, 2010).  The  androgen  biosynthesis  can  be  further  impacted  by  adrenal  insufficiency.  Additional information on pubertal development, i.e., on the hypothalamic-pituitary-gonadal axis, with vamorolone 6 mg/kg will be collected in an additional cohort of 10 patients aged 12 to &lt;18 years in study VBP15006. The extent of previous steroid treatment might, however, compromise the interpretation. The use in patients above 12 years of age is missing information in the RMP.

Safety on long-term use is specified as missing information in the RMP and includes safety issues which are crucial with long-term treatment, in particular regarding bone fractures, weight gain, growth, adrenal insufficiency, hyperglycaemia, dyslipidaemia and hypertension.

<div style=\"page-break-after: always\"></div>

Uncertainty has been raised regarding the time to recovery of the HPA axis following discontinuation of vamorolone treatment and the potential long-term consequences of secondary adrenal insufficiency after glucocorticoid/ vamorolone use. This has been dealt with inclusion of cautious wording in the product information. So far, only a single SAE of adrenal insufficiency has been reported in a patient in the EAP but acute events in line with adrenal insufficiency cannot be excluded in a paediatric patient population that is prone to infections, which could be a trigger for adrenal crisis. A warning regarding use of a steroid emergency card has been included in the SmPC. However, revision is needed according to PRAC Rapp comments (patient alert card; SmPC).

Uncertainty has been raised regarding appropriate management of weight increases: During VBP15-LTE, 10 of 11 patients on vamorolone 6 mg/kg were down-titrated to 2 or 4 mg/kg because of weight gain TEAEs.  For  these  10 subjects,  baseline  weight/  BMI  percentiles  and  z-scores  were  higher  as  in  the 2 mg/kg and 6 mg/kg dominant dose groups, which probably predestined them for significant weight gain. Dose reduction led to stabilisation of weight in these patients. As per the DCO 21 July 2023 in the EAP, an exploratory analysis of the effect of down- and up-titration of vamorolone on weight changes was conducted (6 mg/kg, reduced to 4 mg/kg and 2 mg/kg, increased to 4 mg/kg). Uptitration from 2 to 4 mg/kg appears not to prevent from further increase in weight percentiles but probably at a similar annual rate of change as with 2 mg/kg. Dose reduction from 6 to 4 mg/kg led to a plateau in weight percentiles (i.e., no additional increase in weight percentile after dose reduction). While this analysis is informative regarding weight changes in a small sample size, dose reduction from 6 mg/kg to 4 mg/kg might not be sufficient in clinical practise to mitigate weight increases with vamorolone in all patients necessitating further reduction to 2 mg/kg in a subset of patients. Information and provision with ageappropriate dietary advice has been included in the product information.

Growth retardation is a well-known effect of glucocorticoid treatment of children and was also observed in  juvenile  mice  administered  vamorolone.  However,  no  effect  on  growth  could  be  retrieved  for vamorolone based on controlled data up to 6 months and an effect also seems to be absent based on uncontrolled data up to 30 months compared to external FOR-DMD study data with conventional GCs.

Uncertainties have been raised regarding long-term effects on bone health, for which 'bone fractures' has been included as missing information in the RMP. Vertebral fractures have not been evaluated at baseline in study VBP15-002, therefore hampering interpretation of such fractures in 10.3% of patients after 30 months of treatment in VBP15-LTE. Biomarker data can only be supportive. There seems to be no  difference  between  biomarkers  of  osteoblast  activity  between  placebo  and  vamorolone  based  on Month 6 data (with clear decreases in the prednisone group). Moreover, osteoclast activity by CTX1 was found decreased for prednisone but increased for vamorolone, which is supported by an increase in CTX1 after  the  switch  from  prednisone  to  vamorolone  in  VBP15-004.  While  it  is  acknowledged  that  the interpretation  of  bone  formation  and  resorption  markers  differs  for  different  populations,  i.e.,  bone metabolism in children is more complex, and greatly differs from that of adults as it reflects both skeletal growth and modeling (Rauchenzauner et al., 2007; Bowden et al., 2016), a clear correlation of increases/ decreases in the controlled part of study VBP15-004 is lacking. DXA measurements have also been conducted and longitudinal DXA  measures of lumbar spine DXA  and total body DXA  (i.e. screening+W 24+W 48,  screening+W 24,  screening+W 48,  or  W 24+W 48)  are  available  for  ~50  67.5% of patients from study VBP15-004: Based on these data, a drug-related adverse effect on bone mineralisation cannot be deduced for vamorolone but for prednisone; thus, vamorolone is less likely to contribute to an increased risk for factures in paediatric DMD patients as compared to prednisone, while it remains unclear whether long-term treatment would elicit differential effects compared to an untreated (placebo) population.

The observed bone age delay of -1.1 ± 1.2 years compared to chronological age in study VBP15-LTE after 2.5 years of vamorolone exposure in 39 patients seems to be in line with literature data of a mean bone age delay of -1.6 ± 2.2 years (p&lt; 0.01) after 5.2 years of classic glucocorticoid therapy in DMD

<div style=\"page-break-after: always\"></div>

patients (Annexstad et al . 2019). However, in the absence of bone age determinations at baseline, these data are difficult to interpret. It should also be mentioned that bone age and the timing of onset of puberty are related. These are however minor issues in the context of the severity of the underlying disease.

Uncertainty remains with regard to long-term effects of vamorolone on glucose metabolism and insulin resistance . Vamorolone caused an increase in pancreatic islet activity in animal studies corroborated by a  dose-dependent  increase  in  fasting  insulin  in  line  with  prednisone  in  Pool 1  (remaining  constantly increased during longer treatment duration). The observed increase in fasting insulin can be interpreted as  compensatory  ß-cell  adaption  process  to  maintain  normoglycaemia  indicating  decreased  insulin sensitivity. No relevant changes were noted for fasting glucose and HbA1c, neither for short-term nor long-term treatment up to 30 months. However, it is generally thought that glucocorticoids result mainly in  an  increase  in  postprandial  blood  glucose  levels  (Clore  et  al.  2009).  These  data  have  not  been evaluated for vamorolone in the clinical studies. The diabetogenic potential of vamorolone (hyperglycaemia) will be further evaluated post-marketing by means of a PASS.

Uncertainty has been raised whether the differential effects of vamorolone on leukocyte subpopulations as  compared  to  conventional  glucocorticoids,  mainly  pertaining  to  the  absence  of  neutrophil  count increases,  prevents  from  acquiring  infections  typical  for  immunosuppression  (e.g.,  opportunistic infections) during longer treatment duration. Section 4.4 of the SmPC includes a warning regarding the possibility for an increased risk for infections with vamorolone. Information on the use and consequences of live or live-attenuated vaccines is included in section 4.4 of the SmPC, while the use of live or liveattenuated vaccines is contraindicated 6 weeks prior to treatment initiation and during treatment (section 4.3).

At present, a risk for drug-induced liver injury with vamorolone cannot readily be inferred from clinical trial data. While liver function parameters bilirubin, GLDH, and GGT in Pool 1 and Pool 3 were not clearly affected by vamorolone, a number of cases suspect of Hy's law have been reported in Pool 1 and Pool 3; however, with some of them formally fulfilling criteria already at baseline, thus, not being suspect of treatment-emergent  Hy's  law.  A  single  patient  presenting  with  acute  hepatitis  and  a  post-baseline increase of GLDH &gt;3x ULN, which was accompanied by GGT &gt; ULN, remains suspect of DILI due to the timely course the absence of alternative causes. Moreover, an increase in vamorolone exposure was found in a dedicated hepatic impairment study in healthy volunteers with moderate HI entailing dose reduction in the product information (sections 4.2, 4.4, and 5.2). Therefore, and since patients with severe hepatic impairment were excluded from clinical studies with vamorolone, a contraindication has been included in section 4.3, and a reduced dose is to be applied in patients with moderate hepatic impairment.

While effects on blood pressure were not observed in preclinical studies in dogs, the absence of an effect in humans cannot be ruled out from comparative data during the first 6 months of treatment despite the fact that vamorolone does not share the mechanisms associated with GC-associated hypertension. It remains  uncertain  as  to  which  extent  the  underlying  disease  (for  example  as  a  consequence  of cardiomyopathy) and increases in weight as a consequence of vamorolone treatment contribute to small increases seen in SBP and DBP. Moreover, blood pressure measurements in the clinical trials were not sufficiently standardised. In addition, assessments of blood pressure in clinical trials with young children are known to be highly challenging. Studies VBP15-002/003/LTE and VBP15-004 collected single blood pressure measurements only, which could explain a high variability, which in turn hampers an accurate assessment of small changes in blood pressure over time. Hypertension will be further addressed as part of safety on long-term use in the RMP.

Although, some scientific literature supports vitamin D metabolism to be affected by glucocorticoids, thereby decreasing the synthesis of active vitamin D and impairing its biological action at the tissue

<div style=\"page-break-after: always\"></div>

level. (Mazziotti et al., 2018; Catalano et al., 2022), laboratory 25-Hydroxy-Vitamin D values lacked a clear decrease with vamorolone across studies and are thus not in support of the reports of some TEAEs in the clinical DMD studies. Shift analyses for 25-OH vitamin D in Pool 1 and Pool 3 do not indicate an increased incidence of shifts from normal to low during treatment with vamorolone.

It is known that metabolic clearance of glucocorticoids is decreased in hypothyroid patients and increased in  hyperthyroid  patients.  In  the  light  of  absence  of  clinical  data  of  an  effect  of  thyroid  function  on vamorolone clearance a warning in SmPC section 4.4 has been included.

## 3.6. Effects Table

Table 22: Effects table for vamorolone, indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients aged 4 years and older (data cut-off: 30 June 2022 for clinical studies except for ongoing study VBP15-006 (data cut-off 21 July 2023)).

| Effect                                                  | Short Description                         | Unit                                               | Vamorolone                                           | Placebo            | Prednis one 0.75 mg /kg   | Uncertainties/ Strength evidence                                 | of                 | Refere nces        |
|---------------------------------------------------------|-------------------------------------------|----------------------------------------------------|------------------------------------------------------|--------------------|---------------------------|------------------------------------------------------------------|--------------------|--------------------|
| Favourable Effects                                      | Favourable Effects                        | Favourable Effects                                 | Favourable Effects                                   | Favourable Effects | Favourable Effects        | Favourable Effects                                               | Favourable Effects | Favourable Effects |
| LSM change from baseline in TTSTAND velocity at week 24 | Primary endpoint                          | LSM change from baseline LSM difference (SE) 95%CI | Vam 6: 0.046 (0.014) 0.059 (0.019) 0.0218;0.0953     | -0.012 (0.0134)    |                           | Superiority vamorolone 6 mg/kg against placebo p= 0.0018         | of                 | (1)                |
| LSM change from baseline in TSTAND velocity at week 24  | First pre- specified secondary endpoint   | LSM change from baseline LSM difference (SE) 95%CI | Vam 2: 0.031 (0.013) 0.0430 0.0069;0.0791            | -0.012 (0.0134)    |                           | Superiority vamorolone 2 against placebo p= 0.0196               | of mg/kg           | (1)                |
| LSM change from baseline to week 24 in 6MWT             | Second pre- specified secondary endpoint  | LSM change from baseline LSM difference (SE) 95%CI | Vam 6: 24.57 (10.058) 35.936 (14.258) 7.9867:63.8851 | -11.367 (10.6082)  |                           | Superiority vamorolone 6 against placebo p= 0.0117               | of mg/kg           | (1)                |
| LSM change from baseline to week 24 in 6MWT distance    | Third pre- specified secondary endpoint   | LSM change from baseline LSM difference (SE) 95%CI | Vam 2: 24.979(10.035) 36.346 (14.332) 8.2538;64.4379 | -11.367 (10.6082)  |                           | Superiority vamorolone 2 agaianst placebo p= 0.0112              | of mg/kg           | (1)                |
| LSM change from baseline to week 24 in 6MWT distance    | Sixth pre- specified secondary endpoint   | LSM change from baseline LSM difference (SE) 95%CI | Vam 6: 24.57 (10.058) -19.552 (13.374) -45.767,6.663 |                    | 44.121 (9.644)            | Superiority vamorolone 6 Hierarchical ended before. (p = 0.1438) | of testing         | (1)                |
| LSM change from baseline to week 24 in 6MWT distance    | Seventh pre- specified secondary endpoint | LSM change from baseline LSM difference (SE) 95%CI | Vam 2: 24.979(10.035) -19.142 (13.800) -46.192;7.908 |                    | 44.121 (9.644)            | Superiority vamorolone 6 See above (p=0.1654)                    | of                 | (1)                |

<div style=\"page-break-after: always\"></div>

| Effect                                                   | Short Description                                  | Unit                                               | Vamorolone                                                           | Placebo              | Prednis one 0.75 mg /kg   | Uncertainties/ Strength evidence                                                                                                                                                                                                                                                                        | of                                         | Refere nces          |
|----------------------------------------------------------|----------------------------------------------------|----------------------------------------------------|----------------------------------------------------------------------|----------------------|---------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------|----------------------|
| LSM change from baseline to week 48 in TTSTAND velocity  | Pre-specified                                      | LSM change from baseline LSM difference (SE) 95%CI | Vam 6: 0.045 (0.014) Vam 2: -0.005 (0.014) 0.050(0.019) 0.0126;0.087 |                      |                           | Effects only can considered to maintained for up 48 weeks; uncontrolled design from Week 24 Week 48; lack of pre-defined non- inferiority margin; no formal statistical hypothesis testing planned (p=0.0099)                                                                                           | be be to to a                              | (4)                  |
| LSM change from baseline at month 12 in TTSTAND velocity | Pre-specified                                      | LSM change from baseline LSM difference (SE) 95%CI | Vam 6: 0.040 (0.011) -0.002 (0.018) -0.037,0.033                     |                      | 0.042 (0.015)             | Confidence limits were unadjusted limits Although the appear equivalent cannot be for methodological reasons. Hence, conclusion comparable efficacy can be given (p=0.9287)                                                                                                                             | results similar, efficacy concluded no of  |                      |
| LSM change from baseline at month 12 in TTSTAND velocity | Pre-specified                                      | LSM change from baseline LSM difference (SE) 95%CI | Vam 2: -0.003 (0.011) -0.045 (0.018) -0.0798,-0.0098                 |                      | 0.042 (0.015)             | Confidence were limits; results that Vam 2 inferior compared prednisone (p=0.0126)                                                                                                                                                                                                                      | limits unadjusted indicate has efficacy to |                      |
| Unfavourable Effects                                     | Unfavourable Effects                               | Unfavourable Effects                               | Unfavourable Effects                                                 | Unfavourable Effects | Unfavourable Effects      | Unfavourable Effects                                                                                                                                                                                                                                                                                    | Unfavourable Effects                       | Unfavourable Effects |
| Adrenal suppressio n                                     | Mean (SD) change in morning cortisol from baseline | µg/dL                                              | 6 mg/kg: -7.06 (3.028) 2 mg/kg: -3.58 (3.044)                        | 0.69 (2.769)         | -5.17 (2.890)             | VAM dependently leads an alteration of the HPA axis with suppression of endogenous cortisol and ACTH in the majority of subjects. Uncertainty: time to recovery of the HPA axis following discontinuation of VAM treatment and the potential long- term consequences of secondary adrenal insufficiency | dose- to                                   | (1)                  |
| Cushingoid features                                      | Number of patients with TEAEs                      | %                                                  | 6 mg/kg: 28.6 2 mg/kg: 6.7                                           | 0                    | 22.6                      | See suppression                                                                                                                                                                                                                                                                                         | adrenal                                    | (1)                  |

<div style=\"page-break-after: always\"></div>

| Effect                      | Short Description                              | Unit   | Vamorolone                                           | Placebo   | Prednis one 0.75 mg /kg   | Uncertainties/ Strength evidence                                                                                                                                                                                                                                                                                                                 | of                                          | Refere nces   |
|-----------------------------|------------------------------------------------|--------|------------------------------------------------------|-----------|---------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------|---------------|
| Weight gain                 | Number of patients with TEAEs                  | %      | 6 mg/kg: 17.9 2 mg/kg: 3.3                           | 6.9       | 9.7                       | Weight gain was more pronounced with VAM 6 mg/kg as compared to prednisone; it is uncertain to which extent the absence of growth inhibition of VAM attributes to weight gain; 10 patients with down-titration from 6 mg/kg to 2 mg/kg due to weight increased in VBP15- LTE; lack of controlled long-term data                                  |                                             | (1)           |
| Growth (height restriction) | Median change in height z- score from baseline | SD     | 6 mg/kg: 0.11 2 mg/kg: 0.07 0.13                     | 0.13      | - 0.10 -0.66 (predniso    | No controlled long- term data available                                                                                                                                                                                                                                                                                                          |                                             | (1) (3)       |
| Bone fractures              | Number of patients with TEAEs                  | %      | 0 6 mg/kg: 7.1 2 mg/kg: 2.1                          | 0 -       | 0 -                       | Uncertainties regarding vertebral fractures: no baseline lateral spine X-rays                                                                                                                                                                                                                                                                    |                                             | (1) (2)       |
| Vertebral fractures         |                                                |        | 12.8 (adjusted for 36 months)                        |           | 26.9 (predniso ne daily)  | readings were available. Uncertainty regarding bone age delay more than 1 year chronological after 30 months treatment. Uncertainty regarding inconsistent biomarker results. Uncertainty regarding a robustness issue with DXA measurement in VBP15-004. No scans beyond week 24. No controlled long- term data available TEAE irritability was | of vs. age of bone                          | (3)           |
| Behaviour problems          | Number of patients with TEAEs                  | %      | 6 mg/kg: 21.4 2 mg/kg: 16.7 6 mg/kg: 33.3 2 mg/kg: 0 | 13.8      | 32.3                      | more reported with 6 mg/kg compared prednisone vs. 3.2%); no reported in placebo and 2 group; The incidence higher in younger                                                                                                                                                                                                                    | frequently VAM to (10.7% TEAEs the mg/kg is | (1) (5)       |
| Gastro- intestinal symptoms | Number of patients with TEAEs                  | %      | 6 mg/kg: 28.6 2 mg/kg: 30                            | 27.6      | 25.8                      |                                                                                                                                                                                                                                                                                                                                                  | (1)                                         |               |

<div style=\"page-break-after: always\"></div>

| Effect                                                                           | Short Description                                                                                                | Unit               | Vamorolone                  |   Placebo |   Prednis one 0.75 mg /kg | Uncertainties/ Strength of evidence                                                                                                                                                                                                                                                                                                     | Refere nces   |
|----------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------|--------------------|-----------------------------|-----------|---------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------|
| Diabetic conditions (including changes in diabetes- related laboratory parameter | Number of patients with TEAEs                                                                                    | %                  | 6 mg/kg: 3.6 2 mg/kg: 0     |       3.4 |                       9.7 | No controlled long- term data available. Increases in fasting insulin without concomitant increase in fasting glucose and HbA1c indicative of                                                                                                                                                                                           | (1)           |
| Immuno suppressio n (i.e., infections grouped under the immune suppressio        | Number of patients with TEAEs                                                                                    | %                  | 6 mg/kg: 32.1 2 mg/kg: 43.3 |      44.8 |                      38.7 | Infections did not increase after switching from prednisone or placebo to vamorolone and were obviously not related to dose                                                                                                                                                                                                             | (1)           |
| n CMQ) Hypertensi on                                                             | Number of patients with TEAEs                                                                                    | %                  | 6 mg/kg: 0 2 mg/kg: 3.3     |       0   |                       3.2 | No effects on blood pressure in telemetered dogs; SBP and DBP already increased at baseline; increases in mean DBP and SBP during the first 6 months of treatment with VAM in Pool 1 (~5mmHg) and slight dose- dependency observed in Pool 3; however, measures were not standardised; known                                            | (1)           |
| Skin/ hair changes                                                               | Number of patients with TEAEs                                                                                    | %                  | 6 mg/kg: 3.6 2 mg/kg: 10    |       6.9 |                      12.9 |                                                                                                                                                                                                                                                                                                                                         | (1)           |
| Liver function                                                                   | Number of patients meeting treatment- emergent Hy's law criteria (ALT or AST > 3 x ULN and Total BILI > 2 × ULN) | Number of patients | 2                           |       0   |                       1   | ALT and AST not specific to assess hepatic function due the underlying disease (muscle loss); in a majority of subjects, bilirubin was already >2x ULN at baseline; a single patient remains suspect of DILI (diagnosed with acute hepatitis). 2 patients discontinued vamorolone as a consequence of hepatitis acute and ALT increased | (1)           |

## Abbreviations:

Notes: (1) Placebo- and active controlled Period 1 of study VBP15-004 (Pool 1); (2) All vamorolone treated safety population (Pool 3); (3) comparison of VBP15-LTE data and external FOR-DMD: (4) Study VBP15-004: Analysis based on the mITT - 2 population, defined as \"All randomised subjects who received at least one dose of study medication during Period 2 and had at least one post-baseline efficacy assessment during Period 2. (5) ongoing open-label study VBP15-006, cohort 2 to &lt;4 year old patients with DMD (cut-off 21 July 2023)

<div style=\"page-break-after: always\"></div>

## 3.7. Benefit-risk assessment and discussion

## 3.7.1. Importance of favourable and unfavourable effects

## Efficacy

In  the  pivotal  study,  Study  VBP15-004,  vamorolone  at  daily  doses  of  2  and  6  mg/kg  demonstrated convincing efficacy in the treatment of early ambulatory stage DMD patients between 4 to &lt;7 years of age at study entry when compared to placebo at 24-weeks.

Vamorolone produced clinically meaningful, statistically significant, and robust improvements in multiple measures of motor function, including TTSTAND and TTRW velocity, 6MWT distance and the NSAA score versus placebo. The improvements in motor function with vamorolone 6 mg/kg were overall similar to those seen with prednisone at Week 24 except for the 6MWT for which prednisone provided numerically better results. The improvements seen with vamorolone 2 mg/kg were overall slightly smaller than those seen with prednisone. Except for TTSTAND velocity, no clinically meaningful differences were seen in functional outcomes for vamorolone 2 mg/kg compared with vamorolone 6 mg/kg after 6 months of treatment.

Results  at  week  48  from  study  VBP15-004  (with  observed  cases  only)  suggest  that  the  effect  of vamorolone 6 mg/kg is maintained up to Week 48 as there was no decline across the relevant outcome parameters and the results were generally better than for the 2 mg/kg dosage. Significant decrease in several efficacy endpoints was observed with vamorolone 2 mg/kg between Week 24 and Week 48. Thus, maintenance  of  efficacy  for  the  2  mg/kg  dose  could  not  convincingly  be  demonstrated.  Additional analyses could not solve the uncertainties.

The pre-planned matched comparison of the vamorolone 6 mg/kg group to the continuous prednisone and deflazacort groups from study FOR-DMD (comparing different GCs and dosing regimens) at 1 year suggest  similar efficacy esp. to deflazacort, but equivalent efficacy cannot  be  concluded  for methodological reasons. However, the pre-specified comparison of vamorolone at the 2 mg/kg dosage to these comparators suggests inferior efficacy compared to both, i.e. prednisone and deflazacort.

No loss of efficacy was seen when subjects were switched from prednisone to vamorolone 6 mg/kg, whereas small but also inconsistent declines were seen after the switch from prednisone to vamorolone 2 mg/kg.

Generally, there should be an option to reduce the recommended 6 mg/kg dose to a lower dose in case of tolerability issues. This is assumed to be in line with clinical practice as physicians may change the dosage for  corticosteroids  individually  based  on  relevant  case  by  case  aspects.  Since  vamorolone  is intended  for  long-term  use  in  a  chronic  disease,  there  should  be  an  established  effect  on  relevant outcome parameters even for the lower dose. Since the 2 mg/kg dose could not convincingly maintain efficacy,  an  intermediate  dose  of  4 mg/kg  already  used  in  the  EAPs  has  been  proposed  to  mitigate tolerability issues. On the basis of the results from the new popPK model, that predicts a higher exposure for the ROS2 formulations compared to the ROS1 formulation across all dosages, the intermediate 4 mg/kg dose (ROS2 formulation) is expected to sufficiently maintain efficacy. Down-titration to the 4 mg/kg dose due to tolerability issues is therefore agreed with from efficacy perspective.

The 2 mg/kg dose is still considered adequate in case of moderate hepatic impairment as stated in the SmPC, section 4.2. In addition, even taking into account a certain loss of effect with this dose during maintenance treatment,  this  likewise  occurs  with  standard  steroid  treatment  regimens,  either  when lower  doses  are  administered  or  when  an  intermittent  course  regimen  is  applied,  and  this  is  also depending on age and the baseline disability status. Thus, partial efficacy of the 2 mg/kg dose should be acceptable in the context of the severity of the underlying disease.

<div style=\"page-break-after: always\"></div>

The proposed target population has now been restricted to DMD patients aged 4 years and over. While the main (active-controlled) study solely included patients aged 4 to &lt; 7 years, preliminary data from the uncontrolled study VBP15-006 on 2- &lt;4 year-old DMD patients have become available suggesting treatment  benefit  with  regard  to  gross-motor  function.  However,  due  to  methodological  issues,  the results should be interpreted with caution.

Based on the same pathomechanism with inflammation being present across all stages of the disease, extrapolation  of  efficacy  for  vamorolone  is  considered  possible.  Although,  data  on  corticosteroid treatment in boys with DMD are generally limited and scientific knowledge regarding the appropriate treatment duration is still evolving, corticosteroids are recommended in the decline phase and early nonambulatory phase of the disease. Studies have shown that steroid use after loss of ambulation in DMD was associated with delayed progression of important pulmonary, cardiac and upper extremity functional deficits  (McDonald  et  al,  2023).  In  addition,  it  is  recommended  to  continue  treatment  after  loss  of ambulation. Considering that the pharmacological mechanism that mediates efficacy of vamorolone in the  treatment  of  DMD  is  the  same  as  for  currently  used  corticosteroids,  extrapolation  of  these recommendations to vamorolone appears justified. In addition, very limited data in patients &gt;7 and up to 18 years suggest a similar safety profile in older compared to younger patients. Consequently, no upper age limit was included in the indication.

Recently, early corticosteroid treatment of boys with DMD has been recommended because inflammation and muscular degeneration is present from an early stage of the disease. In line with the knowledge about  symptom  onset  and  the  current  treatment  recommendations  to  start  treatment  early  for prolonging function, vamorolone could have been a treatment option already below the age of 4 years.

## Safety

Overall,  no  new  safety  issues  have  been  identified  with  vamorolone  treatment  as  compared  to conventional glucocorticoids. The limitations of the safety database of vamorolone regarding the lack of controlled comparative data with prednisone beyond 6 months, have been aimed to be addressed by long-term external comparison to the safety data of the FOR-DMD study covering aspects on growth and bone fractures for three different glucocorticoid regimens. While this comparison is generally considered acceptable  by  the  CHMP,  there  are  nonetheless  different  underlying  methods  or  sensitivities  in  the collection  of  safety  data  for  external  comparison  of  safety  variables  that  must  be  considered  when interpreting these data. Moreover, further long-term safety data for patients transitioning from a clinical study to an EAP have been provided during this procedure.

The  safety  profile  of  vamorolone  partly  differs  from  that  of  conventional  GCs.  Based  on  6 months controlled data, there are quantitative differences in favour of vamorolone on the one hand. On the other hand, there are safety issues for vamorolone for which the incidences are at least in the same magnitude as with prednisone or even increased.

Quantitative differences in the safety profile in favour of vamorolone over prednisone treatment in the controlled setting with positive trends up to 30 months of uncontrolled treatment and further supported by new emerging safety data from ongoing treatment of patients with vamorolone in EAPs were found for:

- effects on growth (i.e., the absence of a growth stunting effect of vamorolone), and

- effects of vamorolone on bone health outcomes, which are important given that there is an unmet medical need for DMD anti-inflammatory treatments lacking deleterious bone effects. While the disease itself predestines for long-bone fractures as a consequence of muscle atrophy, vertebral fractures are considered a direct side effect of long-term corticosteroid use (Parera et al., 2016). Vertebral fractures with vamorolone occurred less frequently as compared to prednisone and deflazacort treatment regimens based on an external comparison. However, assessment of the risk for fractures will need a longer follow-

<div style=\"page-break-after: always\"></div>

up  (&gt;3 years)  (Guglieri  et  al.,  2022),  which  weakens  the  significance  of  the  30 months  data  for vamorolone. Furthermore, lumbar spine BMD by DXA is recommended at diagnosis and annually in all patients to determine the overall bone health trajectory on serial measurements, which then informs on the frequency of spine radiography (Birnkrant et al., 2018). Serial measures of BMD by DXA have been generated in the pivotal study, but with some limitations (i.e., not all patients had such measures for all predefined time points, which was due to different reasons, including COVID restrictions). Nevertheless, available data do not point towards a decrease in LS-BMC and LS-BMD in vamorolone-treated subjects over 48 weeks of treatment, which could support that the risk for vertebral fractures is lower as for glucocorticoids. The risk for bone fractures will be further addressed post-marketing. Biomarkers of bone remodelling  are  valuable  in  assessing  treatment  compliance  and  in  the  response  or  failure  to  antiresorptive treatment in GC-induced osteoporosis but are not sufficient to predict bone loss and increase/ reduction  in  fracture  risk  (Devogelaer  et  al.,  2017).  Moreover,  a  major  prerequisite  for  using  bone turnover  markers  in  children  and  adolescents  is  sex-  and  age-specific  reference  curves  enabling calculation of z-scores, but these have neither been established (Rand et al., 2022) nor have they been presented for vamorolone. Evaluation of bone biomarkers in vamorolone - treated DMD patients is thus supportive information but can neither assess bone fragility nor predict future fracture risk (Bruckner et al. 2015). In summary, the totality of bone health evaluations based on 48 weeks of observation indicate that  bone  turnover  markers  as  well  as  lumbar  vertebral  bone  mineralisation  is  not  impaired  with vamorolone  as  compared  to  prednisone.  This  is  corroborated  by  the  fact  that  the  negative  effects observed  with  prednisone  during  the  first  6 months  of  treatment  are  reversed  after  switching  to vamorolone. However, neither bone turnover markers nor DXA results do allow to conclude on the risk for future fractures.

Absence of deleterious effects of vamorolone on hypertension, effects on lipid metabolism, and liver impairment during clinical studies with vamorolone needs to be confirmed in the long-term. The same applies  to  the  risk  for  infections  due  to  immunosuppression  based  on  the  differential  effects  of vamorolone  on  white  blood  cells,  especially  neutrophil  counts),  and  the  absence  of  cataracts  and glaucoma.

Aspects of the safety profile for vamorolone that are at least not better than for prednisone or even disfavour  vamorolone  6 mg/kg  over  prednisone  in  the  controlled  setting  and  similar  trends  during vamorolone treatment up to 30 months, and also supported by new emerging safety data from ongoing treatment of patients with vamorolone in EAPs:

- -Adrenal suppression: the totality of data indicate adrenal suppression to be more pronounced for vamorolone 6 mg/kg as for prednisone, and this was likewise observed for Cushingoid features, while these were rarely reported as clinically relevant. The duration of recovery from adrenal insufficiency after treatment cessation remains unknown, which sets the patients at risk for acute adrenal crisis during an unknown duration in a worst-case scenario. However, the risk is considered manageable with an adequate withdrawal regimen (for which evidenced-based guidelines are lacking; Bowden et al., 2019), specific warning regarding stress dosing regimens, and raising the awareness for symptoms of adrenal crisis in the product information, e.g. by means of a patient alert card.
- -Weight gain and increase in BMI were found to be directionally consistent, which implies that the increase in body weight and fat mass rather than increase in height is the driver. Dose reduction seems to mitigate the risk and is also included in section 4.2 of the SmPC. Moreover, dietary measures are recommended for patients at risk.
- -Increased fasting insulin levels (absence of increased fasting glucose and HbA1c values). The available long-term data at present do not indicate diabetogenic effects.

With regard to behaviour-related problems, a clear benefit of vamorolone over prednisone is difficult to be confirmed by the totality of data; while these were less frequently reported and not rated as clinically

<div style=\"page-break-after: always\"></div>

relevant for vamorolone as compared to prednisone in the reference population (4 to &lt;7 years of age), younger paediatric patients were found to be more susceptible to these events at the 6 mg/kg dose in an uncontrolled setting.

In the context of the overall safety data, the proposed dose reduction to 4 mg/kg or 2 mg/kg in case of tolerability issues while patients should be remained on the highest tolerable dose, is a conservative approach in order to minimise safety issues during treatment with vamorolone.

The safety profile has been determined in clinical studies in patients 4 to &lt;7 years of age. For patients beyond 7 years of age, extrapolation of clinical safety from the reference population studied in VBP15004 can be supported by the available clinical data from study VBP15-006, extension study VBP15-LTE, and patients being follow-up in EAPs.

## 3.7.2. Balance of benefits and risks

Short-term  efficacy  over  24  weeks  for  vamorolone  6  mg/kg  and  2  mg/kg  has  adequately  been demonstrated  in  ambulatory,  corticosteroid  naïve  ≥  4  to  &lt;7  years  old  DMD  patients. The  safety  of vamorolone in DMD patients aged 4 to &lt;7 years generally presents with findings qualitatively similar to conventional glucocorticoids, with quantitative differences, which are considered to be manageable with appropriate labelling in the product information and routine risk minimisation measures in the RMP. The short-term safety profile is considered established based on 6 months-controlled data in a rather limited number of patients, which of course precludes the detection of rare side effects.

The provided data indicate that the effect of the vamorolone 6 mg/kg dosage is maintained up to Week 48 and the results were generally better than for the 2 mg/kg dosage at Week 48. Data from an external comparison of vamorolone to prednisone and deflazacort at 1 year can only be interpreted to a limited extent for methodological reasons but are generally supportive of the maintenance of effect. Results across the efficacy outcome measures for the vamorolone 2 mg/kg dose were rather inconsistent with significant decrease in several efficacy endpoints between Week 24 and Week 48. Thus, maintenance of efficacy  for  the  2  mg/kg  dose  could  not  compellingly  be  shown.  No  loss  of  efficacy  was  seen  when subjects were switched from prednisone to vamorolone 6 mg/kg, whereas small declines were seen after the switch from prednisone to vamorolone 2 mg/kg.

The use of an intermediate dose of 4 mg/kg is expected to sufficiently maintain efficacy as indicated by further refinement of the updated popPK simulations, and it is a relevant dose for down-titration in case of  tolerability  issues.  Nevertheless,  even  if  maintenance  of  efficacy  for  vamorolone  could  not  be demonstrated for the 2 mg/kg dose, a small subset of patients might be in need for this dose due to safety issues not sufficiently be mitigated with the 4 mg/kg dose. Partial efficacy of the 2 mg/kg dose should therefore be accepted in the absence of treatment alternatives and given that up- and downtitration with standard GCs is common in clinical practice. This proceeding is also adequately reflected in the posology wording stating that patients should be maintained on the highest tolerable dose.

Currently available corticosteroids, esp. at high doses, are fraught with several serious side effects such as  stunted  growth,  impaired  bone  mineralisation,  accelerated  weight  gain,  diabetogenic  effects,  RR increase, infections, HPA suppression and changes in mood and behaviour.

Even though, there is a lack of controlled long-term safety data to confirm the absence of some of these glucocorticoid-specific  side  effects  with  longer  treatment  duration,  available  data  suggest  that vamorolone, a modified corticosteroid lacking transactivation properties, does not or at least to a lesser extent  than  prednisone  adversely  affect  growth  and  bone  health,  while  the  clinical  effects  on  blood pressure (no effects reported in animals) and glucose homeostasis (corroborated by pancreatic islet hypertrophy in animal studies), behavioural effects, increases in weight and suppression of the HPA axis

<div style=\"page-break-after: always\"></div>

do  not  allow  to  conclude  on  a  benefit  over  classic  GCs  at  present.  At  present,  long-term  safety observations are available for a median duration of exposure to vamorolone of 2.1 years for doses 2 6 mg/kg and up to a maximum of 4 years on top of the duration of exposure in the clinical studies.

The 6 mg/kg dose was shown to cause unwanted weight gain and HPA suppression and, when given as starting dose, behavioural issues in very young paediatric patients. While treatment with vamorolone should generally aimed at the highest tolerable dose, dose reductions might become necessary when tolerability/ safety issues occur, and this is reflected in the product information.

Adequate post-authorisation measures (i.e., by mean of a PASS study) have been provided to address remaining uncertainties.

Extrapolation of efficacy and safety data from the reference study population to DMD patients ≥7 years and over, including patients in the ambulatory declining and non-ambulatory phase of the disease, is supported by the same pharmacological mechanism of DMD, while the risks appear not different.

## 3.7.3. Additional considerations on the benefit-risk balance

Patients' perception of benefits and risks of a medicine may be different from the view of medical experts. That is why EMA engages with patients and their representatives at multiple stages of its activities and the  added  value  of  including  their  perspectives  in  the  evaluation  of  medicines  has  been  well demonstrated. To that effect, CHMP invited World Duchenne Organisation to share patients' perspectives on  behalf  of  its  patient/carer  members  with  respect  to  Agamree  (vamorolone)  in  the  treatment  of Duchenne Muscular Dystrophy. The following points are noted from the response from World Duchenne Organisation:

· standard treatments and how acceptable they are . Care considerations for DMD are published, last update 2018 Lancet (Birnkrant, 3 parts). Standard treatment includes use of steroids from 4-5 years on. ACE-inhibitors starting at 10 years (preventive) or earlier if needed. Betablockers and other cardiac medication when cardiac involvement (cardiomyopathy) becomes apparent. Use of prednisone is offlabel and deflazacort is only FDA-approved. In some countries Deflazacort is received through a namedpatient  procedure. A comparison between prednisone and deflazacort is published (For-DMD study). Given the side-effects (lower bone density, growth retardation/short stature, weight gain, behavioural issues,  cushingoid  appearance,  adrenal  suppression)  not  all  patients  start  or  continue  the  steroid treatment. Side effects are often underreported.

· Any aspects about the condition or its treatments that you feel are not well-understood or not sufficiently considered Treatment and drug development very much focussed on motor function, but  there  is  also  cardiac,  pulmonary,  behavioural,  and  smooth  muscle  involvement  (resulting  in  GI symptoms). Psychological issues are dominant in the daily lives of patients and their families.

· quality of life: several publications about QoL in DMD. Assistance in life/reimbursement plays a role in how well DMD patients can live their life; psychological issues are often not taken into account. For steroids, the above-mentioned side effects have a negative effect on QoL. Feeling and looking different because of the use of GCs in addition to the disease itself is troublesome for many patients.

· therapeutic/unmet medical needs . There is a high unmet need for a treatment with the same or better efficacy than GCs in slowing down the progression of the disease with less side effects.

· what  benefits  they  would  hope  for  in  new  medicines Slowing  down  or  even  stopping  the progression of the disease with preferable as little side effects as possible.

<div style=\"page-break-after: always\"></div>

· what level of side effects they would consider acceptable If improved efficacy compared to the current treatment, a vast majority of patients would accept similar side effects as when treated with prednisone or deflazacort.

· if there are large differences between groups of patients/carers about these aspects or if these views are generally similar across the condition . No large differences in patient perspectives. As mentioned above some families don't start their child on steroids or stop using it because of the (risk for) side effects.

## 3.8. Conclusions

The  overall  benefit/risk  balance  of  Agamree  is  positive,  subject  to  the  conditions  stated  in  section 'Recommendations'.

## 4. Recommendations

## Similarity with authorised orphan medicinal products

The CHMP by consensus is of the opinion that Agamree is not similar to Translarna within the meaning of Article 3 of Commission Regulation (EC) No. 847/2000.

## Outcome

Based on the CHMP review of data on quality, safety and efficacy, the CHMP considers by consensus that the  benefit-risk  balance  of  Agamree  is  favourable  in  the  following  indication(s):  the  treatment  of Duchenne muscular dystrophy (DMD) in patients aged 4 years and older.

The CHMP therefore recommends the granting of the marketing authorisation subject to the following conditions:

## Conditions or restrictions regarding supply and use

Medicinal product subject to restricted medical prescription.

## Other conditions and requirements of the marketing authorisation

- Periodic Safety Update Reports

The requirements for submission of periodic safety update reports for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal.

## Conditions or restrictions with regard to the safe and effective use of the medicinal product

- Risk Management Plan (RMP)

The marketing authorisation holder (MAH) shall perform the required pharmacovigilance activities and interventions detailed in the agreed RMP presented in Module 1.8.2 of the marketing authorisation and any agreed subsequent updates of the RMP.

An updated RMP should be submitted:

- At the request of the European Medicines Agency;
- Whenever the risk management system is modified, especially as the result of new information being received that may lead to a significant change to the benefit/risk profile or as the result of an important (pharmacovigilance or risk minimisation) milestone being reached.

<div style=\"page-break-after: always\"></div>

## · Additional risk minimisation measures

## Patient Alert Card

This patient is on long term treatment with Agamree (vamorolone), a dissociative corticosteroid for the chronic treatment of Duchenne Muscular Dystrophy, and therefore is physically dependent on daily steroid therapy as a critical medicine.

If this patient is unwell (excess fatigue, unexpected weakness, vomiting, diarrhea, dizziness or confusion), acute adrenal insufficiency or crisis must be taken into consideration.

## Conditions or restrictions with regard to the safe and effective use of the medicinal product to be implemented by the Member States

Not applicable.

## New Active Substance Status

Based on the CHMP review of the available data, the CHMP considers that vamorolone is to be qualified as a new active substance in itself as it is not a constituent of a medicinal product previously authorised within the European Union.